<SEC-DOCUMENT>0001558370-22-016850.txt : 20221108
<SEC-HEADER>0001558370-22-016850.hdr.sgml : 20221108
<ACCEPTANCE-DATETIME>20221108160300
ACCESSION NUMBER:		0001558370-22-016850
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221108
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		221368779

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>chrs-20220930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/8/2022 8:54:30 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: f14fbee3-a335-4e7a-b945-277db83c0358 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:chrs="http://www.coherus.com/20220930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" xs:nil="true" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Kb4GUTQev0Orv7RycLYxXg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" xs:nil="true" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_aENO8CqzWEi7pm9MYkUZ4w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ECF8NXIzLkyGuqG0mf7IJQ">77746895</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_1u4EHCP8NUmFYqPbh5RmvA">79013240</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_3rEZiFw3HE6ZvR_Z9ABgjg">77520244</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_euSITpJkbEmKgkSOWTbSZw">74984811</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityCentralIndexKey" id="Tc_xSTIKUQQe0aHLym0CfmFow_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:CurrentFiscalYearEndDate" id="Tc_gRicjeOIwUipHwNSjuOWYA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentFiscalYearFocus" id="Tc_rBO_tdPs30m9FhWOlBtteA_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentFiscalPeriodFocus" id="Tc_N8DwcJ49R0azT83uwa6z9g_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:AmendmentFlag" id="Tc_km_lNbZrvUerhxQadn0obg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_KJvqdFFSVUamaeho3x17Sg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_akGEym0pHU26fsiUnvvG6Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden__X7SCryzrEKB5UwqHX_2ew">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_o_UwxwCk6E-gu6vXZrueRQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_kpofWQWnEEeu3thsIH_a9g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_Z29eaBaajUGP3SId5ppCIw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_eQGquZC9vkOnHDFWp1UtUQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_-kJSaP2CeUiuU4iA32rAdg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_8Bz8Lkp8yEKjA2W9Sk2Upw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_Wa3cqRH1dUis1oQ1emvtGQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_bdIxfh13o0KisJnEyHBoSg">76930096</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_hoR0QtiyGUGfLjpvEN1Erw">77770593</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_Po6M_OUNuU6JSGR57SKfnQ">1.11</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_PTLiJ86BQ02BxxEIxmF4lA">0.49</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" sign="-" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_Km26HVskkUuB_voLJ-jedQ">3.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_co5ZJw0eiU-gfN_NI5P91g">3.22</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" name="chrs:MandatoryPrepaymentTerm" id="Hidden_zhRAFkTaEkWJkydvNPJsWQ">P10D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" id="Hidden_mJKNNF_1akSrcLTArm_qlw">4750000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="chrs-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eonw1mXuJUKOgVxQh1GSyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aJyitt-I006ugkqGquTXGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8V4HsE260kqaeuFD1bYwvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fkK5vNIN3kSwIqGaWNmteQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dHQDPExykagF_cy6siyDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_STiZudwhNUCxi022GQWjaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_IY-plOYV2EqQEJeaoZX88A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0hoMqPJyYUGnNJU59za1pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cb_X4L3p7EqqJH9nNd244g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h-ZTFPDr4EGbKfgG5ILwvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_eO8v2cr00kC45dIQYpWoLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w0nhYumrGkKrSb62bMeN2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iLCwIUmxe0y6CzAmEfiM4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zLA-RFtqoEew3-CZd0KOuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oFlUazjEnEWuN2MvAjRdcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gel7KLMwm06jHs-JrN3l4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ee2kjvAP4E6pnApIyvWmzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WH4pGIMYQk6BmQKSFzo65Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AHRLomthMUyUHM-nJtaJpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hLEdkaDzskaOra-KRKMpeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_xF3ZNwxQJkiLgijGJT1LhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q5iIlf1RGUq5nwYySyZq7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0AZ9AYU4JUiN7rdHxiI_4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28c3LpHdD0WZKehT5O6ONQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_f_HHaVH0CkK6RCmYXbR8_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KKNGL6SA9UeDBmazTlWOFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LYkuifxZg0OV34ZetlagUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_2wwQK9AUSwRjasJS_ULw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_14_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_iUGghFecu06NDEYjC7SfZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_14_2020_ThcS1SrdqkuYZeougINqKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_1qOFFGpSOkmstIVIX3zj7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_7jfBPaL450eXa1Y2g46z5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_84R_iMTr3kerbyr6upUqew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_FAORKnYJyESjSDSKaLODGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_lSeY1zTOCE6BV42943qNiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_Yibptfnp5UWmdGj-9kWtqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_ihiIu3McBkWodWSPBrrhmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:Chs2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_ETG3zuq6rEOjceZCC4QiRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lgVJdipFVkupB9l6dHBIsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_inJcJWO_YkiWXRyFQlnw4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3qhcXT0gtkypEYBUMeOpTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LqG5RoqoJEeZzKbXCggF-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_d9EHcCoTPk-AEH8jjwR_JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_yRUVgXSoDEydOBMMHjKAow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ghgoc7GaRUiVIJi-rnTZKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_2dIU4Wv5tE6Evkjk6He0eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_clg6kOzlW0-1bv2N8PSJDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_k4tZxvbaTESkkzwTRJUQcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B2ODLCj890aKQI7OAcmbTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1UFzj38Bbk-gQfCQaA9EHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_8yRk0_sXYUyHmkgGMlwvkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yBXFf2ogREGygqnskg8KNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R54yYimj30CJzK88nXK4mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xsaiQkMDeEurcwXQo7nNiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CR00ztb51Uqx2BIB8vBdNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ehG8basW0S3Sder5I7-Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiPDGwH4rUu0h2LujsdWDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mncLQiS1qE-Uskr7RtFgoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oIOC0Uy60EWaDKyAYFI7Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gKYdCCv6LE-IykKhJk4XGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_02uw6OI6VEef4Old7iSxSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6qmOksBoz0uXpji7uweM_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_eGmvrJ29CUKSMH_a7DSGFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_ProductOrServiceAxis_chrs_YusimryProductMember_JbvK-d-MGECmbZL_2UDv9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:YusimryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SjhD1IrJykmX9woy0w48cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_UyhokirZm0i2-644r14vMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_12_31_2021_y7OZ_vllI0mGatYYUEzb9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_ZdRhP2tlY0uSkxF4mWUkLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_gVgB94UeLkKTlxsG-jRXZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-07</xbrli:startDate><xbrli:endDate>2019-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_m-RRMH3z8UK2FguJb0RdSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaAndBLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Vahrp9O7ZE6CBtpYv1agDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaAndBLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nxmJVGXvoESV6WgNqF9pPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_FPqARq6mV0masUy1BsR29w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Iy6ly7BuYkCb3Hlrkpohpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_EPh9mQbc5E-s3ez_S3RVbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember_kdQLio7HLEqitGwRYsXFkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_qqqXHtfBs0OufPeCKnuFoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_1LbWHBCaeUiM3ttGuW95EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Ia8aHRxcikWcNmk3c7HDQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IviSwz1WNEmFo8vw--sRpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EiNpUK2b7k2PkIzqMYiCHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3156mbgj9UORepDGQ616-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4f86z1_gaUCyD4LR0zbwzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PEUy1iet8kGcmgswzbVqLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_MXAI7K0dnUqRQpnDD2bDzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__IeX3c6reEm-Apq48lU1Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aak9ct_niUi7Lq7sxeyMwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P30QcEujV0-5fFkIRIwjtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W4ZbE0h9nEqugpQqg-733w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vhI6ja0bQUKTRyCoU2x99g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_493Ej-l6IkadHd0s8Ev8iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rP5uVqxc9EqbTFWsU--suQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wzMkWYw-jkG5Z-S_a34Cdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fLEz9P6UwkuwqfzYcZElYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vv--ebqCnkqV5_hs0bFUXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7Ka18T27VkWuuzFhDZZuGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CnSVpPJZzU-M8zr97h3FzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JB1ySyU9gkuJVo799k_sDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Rq5_ejfD4E-zhmch0hzaXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OZ7xG5FttEWv9GoORmuT0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gcq3kr0aY0K5_CRVytES5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-GKhnbmx6EqrslRQyD5gVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zkV-yxWOFkCnW-ddikAq5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kn89hn5N_US1XfKr0SQ33Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VlaCc70eukKJoN2_W3ugDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h5ZptWvOE0uCY9Ybl5SojA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnYHy2xhCkCb9J7p4hkgRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Bc_irE1EYEa0-ZkdPtAZuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_twLiW2yaC0qy7WXGVse05g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_dEoY-sHSzUK02mdFlAWJzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lz0mTF4wV0GFylKh3m490w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_dED-Hyl570q2Gq2GdE_Mmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FSdT6Jp3yEaigOhy6sE_5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_Xt8hsRyWYUinCw6qBafEHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Aww4QNVaLk64YAzs3J9iFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yEOGTOZIeEWn5yVBWgq8Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_g1id0jQAJ0KFh6228c8jNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_kXWTWhXhFk2byCH1j93xkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_8AMDQ5u-0kqsUupldYB_uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_U4ZdZnH3fkC5viSWX3m83Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gkYrhJtFPkWcVDhkufdQuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_9008h6QJQk6ZQdJ45f6bfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wwwSCpIHT0qG7pxdRVzYHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_J1o7boGRZkedZZJHTOblEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XmTlwxSGn0m_uPHHGMPW9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_XYdisJOhq0qqXhF-fMCTHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5hmkNI6CL0Kpwf9YcrulMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1z-ozshyUUCySLmdDcUEPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ZH1LNjXzG0q7CAxQn1L9Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WaMcf-CWnEOlS3SaJTgvdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9qbE_7hJb0OAo7eMUGImJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cGIwu14pwEeco2TOLfoZWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_50U8Eql0mBG5Pu9OJs8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hXNe2mN_6kq827XHdcENIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_Qgwbc6x-6UChshllodc3Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_S_Q2ffeVKEC2FuV_r-0CyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_canvBDnSX0CAUr-ueKniXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_g3-gLMpZw0yYViaorsg8fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_r2ythOcrUUuTOM2mUeKjUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_5m_vF3mcb0iKQxtzWjcHZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_NTm60yerS06PfnGj4p8sbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_bfx-u6Wr1EqVZ6v_MBIiiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_FCwSTIPa0ECHMWQCuTIDsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_S3yaMtzKYEafjmMKoXco-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_KqBdumQ4qkSE2fcmpfAufA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_gnbxKpVogk6rFKwK3_goRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_vqkwbtvNdk6jZk0lQqoE8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iM8hqKoK6kGGORI4m24fvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-29</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bmA1J7_-g02NoTnD-cDbEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-04</xbrli:startDate><xbrli:endDate>2019-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_iHwIvN5laESr5Qc_H4fekA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SJkhVBwrA0SLA7eqmarAbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_76kJxJgZgEGENktd8re-Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_RXxIsuRCkkGGaNhY42HHGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_FgRJm8jDqkSf5ige14aHFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDCtyjQAwkKPEG_SutcvdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_287011mlzEmiZ0X0m6eNuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_AMgKdK-BQEurLZKKdbATnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_k-3RgBaCqUq-ucT3E9EGSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDVgIzSJCEyihHczolrtHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_-oXBZarHtkK0JSkSA05zDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_dj746ZuzZEuFlhD-iyPunw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_cD5KRETU-UOVx1YHhrwR2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_MTxWxPxnDkiqyDu_XrhHiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2022_To_8_2_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rAiEo9Y69EihH3kDtMl5ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_OptionExerciseFeeMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_uiPlNyA8AkK6KThMVOfv-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:OptionExerciseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-13</xbrli:startDate><xbrli:endDate>2020-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:BevacizumabLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-13</xbrli:startDate><xbrli:endDate>2020-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_Lph8a238DkeDMCSZPU71Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-04</xbrli:startDate><xbrli:endDate>2019-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w"><xbrli:measure>chrs:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_irYBJZf4GU-2pDQ3aghfCg"><xbrli:measure>chrs:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA"><xbrli:measure>chrs:product</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_093a8182_b87b_4e06_b857_c45f6d4d78a2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentType" id="Narr_4qC0r_i3Dkm29tw4qt-yYQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentQuarterlyReport" id="Narr_p90OjY0Kr0KReGGTJFpLdQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentPeriodEndDate" id="Narr_NB9yCNtFlUyQw0T-nLDx9g"><b style="font-weight:bold;">September 30, 2022</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:DocumentTransitionReport" id="Narr_5bUx9PHkBkuf80FODBSFzg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityFileNumber" id="Narr_6C2NywBVFkqtadJAnY4lLg"><b style="font-weight:bold;">001-36721</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityRegistrantName" id="Narr_GLnhdmA8N02eFhdcYMvKBw"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5eeecf53_145d_447a_9d9d_6302ec5014c7"></a><a id="Tc_L88eJlQCJEuWnSWiz-TA0A_1_0"></a><a id="Tc_8ifm96DGZEKmZdNUbeBInA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityIncorporationStateCountryCode" id="Tc_djhFJsDsWEKdbMNucZ34bQ_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityTaxIdentificationNumber" id="Tc_pj2bHdSYBEOJMZtXnLug9Q_0_2"><b style="font-size:9pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b><br /><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityAddressAddressLine1" id="Narr_ggOM0WHztECvfz3Eyxe33A"><b style="font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityAddressAddressLine2" id="Narr_Dnx1gexPS0mafVlExJGh7Q"><b style="font-weight:bold;">Suite&#160;600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityAddressCityOrTown" id="Narr_3YCO3fx6EU2pevb5gGMf6Q"><b style="font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityAddressStateOrProvince" id="Narr_nTA0AimnI0Gb3ZpgqsKfPg"><b style="font-weight:bold;">California</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityAddressPostalZipCode" id="Narr_7AXoNn_910iVvOyyR61XwQ"><b style="font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:CityAreaCode" id="Narr_X4yEye7xSEWMEPpp3sBAuA"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:LocalPhoneNumber" id="Narr_U-jgUhSl8UmA0XYh1DMFvw"><b style="font-weight:bold;">649-3530</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-indent:24.5pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9326331a_1949_4e18_8f64_ac3c3ea971d7"></a><a id="Tc_g2esNSQsVEKvAh7cNstH9g_0_0"></a><a id="Tc_Lp2uuyuDTkOBOf1z4D2vWg_0_1"></a><a id="Tc_-Awo_E9dKkqAWGWR3TC-_A_0_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:41.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:Security12bTitle" id="Tc_SdgYy_FsTEeA06DvDXwLpw_1_0"><span style="font-size:9pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:17.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:TradingSymbol" id="Tc_HrseCBlGGUC1MzJZLbceJw_1_1"><span style="font-size:9pt;">CHRS</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:41.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:SecurityExchangeName" id="Tc_0xHG47keWUqClXso-NFmzA_1_2"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityCurrentReportingStatus" id="Narr_vLhMhCnh_E6DAb_mReq_AA">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit). &#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityInteractiveDataCurrent" id="Narr_2vmW7Mp_C0eSgZINaq2_hA">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 2pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4f495eef_207c_4e39_a9df_15e1408c8d5b"></a><a id="Tc_tGO2yWStJEOUNPOiK30_vw_1_1"></a><a id="Tc_SU9dWTQxnU-tDrU2SCNUoA_1_3"></a><a id="Tc_NqYLfC_7x0iJftIfASQzSQ_1_4"></a><a id="Tc_iTSp_ihJDke14V7p7u3ACg_3_0"></a><a id="Tc_uoyjFbXxfEevidBD_DsnOA_3_1"></a><a id="Tc_FzER2CPBREqlKXiIjdOkiw_3_3"></a><a id="Tc_paqpXuTPn0O1C4ne1J5HRw_5_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityFilerCategory" id="Tc_9eBuxjqFsEWNjftxqvVB-A_1_0">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;">Non-accelerated filer</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntitySmallBusiness" id="Tc__Rr8K6eIEkm4P3zd99xS1g_3_4"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:59.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityEmergingGrowthCompany" id="Tc_FJh5bbAaG0uDyvtpWk7BLQ_5_4"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;<ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="dei:EntityShellCompany" id="Narr_l6yidhqzZkuqO-QcBCp3JA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">As of October 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_10_31_2022_Qgwbc6x-6UChshllodc3Yw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_pH4_pNrA-Ey_CxuDDTPOTg">77,777,938</ix:nonFraction> shares of the registrant&#8217;s common stock were outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:24.5pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3717de33_b1f3_4786_9b5f_f21875550296"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">COHERUS BIOSCIENCES,&#160;INC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FORM&#160;10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2022</p><a id="TOC"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.15pt 0pt 2.15pt 0pt;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.35%;border-bottom:1.0pt solid #000000;margin:0pt;padding:2.15pt 0.69pt 2.15pt 0.69pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">CAUTIONARY NOTE&#160;REGARDING FORWARD LOOKING STATEMENTS</span></a></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0.69pt 2.15pt 0.69pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">3 </p></th></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTI_729283"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#FINANCIALINFORMATION_522548"><b style="font-style:normal;font-weight:bold;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1_340806"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#UnauditedCondensedConsolidatedFinancialS"><span style="font-style:normal;font-weight:normal;">Unaudited Condensed Consolidated Financial Statements</span></a> </p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_68412"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations</span></a> </p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCompreh"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofStockho"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCashFlo"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#NotestoCondensedConsolidatedFinancialSta"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM2_265983"><b style="font-style:normal;font-weight:bold;">ITEM&#160;2</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ManagementsDiscussionandAnalysisofFinanc"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM3_924534"><b style="font-style:normal;font-weight:bold;">ITEM&#160;3</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#QuantitativeandQualitativeDisclosuresAbo"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM4_80244"><b style="font-style:normal;font-weight:bold;">ITEM&#160;4</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ControlsandProcedures_262474"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#PARTII_679735"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#OTHERINFORMATION_37114"><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM1LegalProceedings_470595"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1</b></a><b style="font-weight:bold;">.</b></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LegalProceedings_470595"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#Item1ARiskFactors"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1A.</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM2UnregisteredSalesofEquitySecurities"><b style="font-style:normal;font-weight:bold;">ITEM&#160;2</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM3DefaultsUponSeniorSecuritiesg_51029"><b style="font-style:normal;font-weight:bold;">ITEM&#160;3</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DefaultsUponSeniorSecuritiesg_51029"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM4MineSafetyDisclosures_660567"><b style="font-style:normal;font-weight:bold;">ITEM&#160;4</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MineSafetyDisclosures_660567"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM5OtherInformation_658170"><b style="font-style:normal;font-weight:bold;">ITEM&#160;5</b></a></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OtherInformation_658170"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ITEM6Exhibits_857545"><b style="font-style:normal;font-weight:bold;">ITEM&#160;6</b></a><b style="font-weight:bold;">.</b></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#ITEM6Exhibits_857545"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.8%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOEXHIBITS_387808"><span style="font-style:normal;font-weight:normal;">Exhibit&#160;Index</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_840188"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">106</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">UDENYCA&#174;, YUSIMRY&#8482; and CIMERLI&#8482;, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this Quarterly Report on Form 10-Q are, to the knowledge of Coherus, the property of their respective owners.</p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.35%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5eab7f8a_5cb2_405b_8434_74cbeff046a9"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">CAUTIONARY NOTE&#160;REGARDING FORWARD LOOKING STATEMENTS</span></p><a id="_Hlk98495238"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements </i><i style="font-style:italic;">regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</i><i style="font-style:italic;"> Any statements that are not statements of historical facts contained in this Quarterly Report on Form&#160;10-Q may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;attempt,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strive,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</i></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">whether we will be able to continue to maintain or increase sales for our products in the United States;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_cp_blt_1_167"></a><a id="_cp_text_1_168"></a><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">our expectations regarding our ability to develop and commercialize toripalimab, CHS-006 and our other product candidates in the United States and Canada, including whether the trial results, data package or biologics license application (&#8220;BLA&#8221;) for toripalimab will be sufficient to support regulatory approval</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">our ability to address comments raised in the complete response letter for the original BLA for toripalimab and timing of the review for the original BLA resubmission for toripalimab;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 48.5pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to receive marketing authorization for the on-body injector presentation of UDENYCA&#174;, including the timing of receiving such marketing authorization, if approved;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to maintain regulatory approval for our products and our ability to obtain and maintain regulatory approval of our product candidates, if and when approved;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding government and third-party payer coverage and reimbursement;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to manufacture our product candidates in conformity with regulatory requirements and to scale up manufacturing capacity of these products for commercial supply;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our reliance on third-party contract manufacturers to supply our product candidates for us;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding the potential market size and the size of the patient populations for our product candidates, if approved for commercial use;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations about making required future interest and principal payments as they become due in connection with our debt obligations;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our financial performance, including, but not limited to, projected future performance of our gross margins, research and development expenses and selling and general administrative expenses; </i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 48.5pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the implementation of strategic plans for our business, product and product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the initiation, timing, progress and results of future preclinical and clinical studies and our research and development programs;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</i></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding the scope or enforceability of third-party intellectual property rights, or the applicability of such rights to our product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the cost, timing and outcomes of litigation involving our products and product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our reliance on third-party contract research organizations to conduct clinical trials of our product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the benefits of the use of our product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the rate and degree of market acceptance of our current or any future product candidates;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to compete with companies currently producing competitor products, including Neulasta, Humira and Lucentis;</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">developments and projections relating to our competitors, our market opportunity and our industry; and</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_cp_blt_1_176"></a><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">t</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">he potential impact of COVID-19 and the continuation of the war in Ukraine on our business and prospects.</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part&#160;II, Item&#160;1A Risk Factors and discussed elsewhere in this Quarterly Report on Form 10-Q. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required under federal securities laws and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, publicly filed reports and similar sources.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0ddbdd32_6a40_4394_8dcc_4ed9fda9dd02"></a><a id="PARTI_729283"></a><a id="FINANCIALINFORMATION_522548"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I. FINANCIAL INFORMATION</p><a id="UnauditedCondensedConsolidatedFinancialS"></a><a id="ITEM1_340806"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 5pt 0pt;">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unaudited Condensed Consolidated Financial Statements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="CondensedConsolidatedBalanceSheets_68412"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6be522db_f95a_4b93_94c8_54dca55aa581"></a><a id="Tc_nML39lXq9EivYzogf4Sr7g_1_2"></a><a id="Tc_6GZW2Qd0R0CgNyhOMsiiQg_1_5"></a><a id="Tc_Bn6xONAy7EK9ytXxir52aQ_2_2"></a><a id="Tc_F6h-jnao0E2EJTkU2pcWhg_2_5"></a><a id="Tc_IhIo_ULBvk-3G__Zi3PbSg_3_0"></a><a id="Tc_dpnisX5kvUWI79Hv5iw1EQ_4_0"></a><a id="Tc_Psv16FS5iE2vTHCovLCN9w_5_0"></a><a id="Tc_hbTSmbOpUEOTEg9Pdj1wcg_5_2"></a><a id="Tc_aXK5nybPpk-LFryNFhGPOw_5_5"></a><a id="Tc_5EbP8T6zHUW4X82sAjJncA_6_0"></a><a id="Tc_btS4jrIankixxSmO8yYtmg_7_0"></a><a id="Tc_i4if73PWuku1O_LWsZrzMQ_8_0"></a><a id="Tc_dN2cjQ2dqE27erd1bKP2fA_9_0"></a><a id="Tc_RP8My8H_yU--4z_MpMR1Ew_10_0"></a><a id="Tc_YWVXj9g5tUiqXimwcW1voA_11_0"></a><a id="Tc_NQmJ6iojFU60trmTKKgbbA_12_0"></a><a id="Tc_HtxVQH3gZ06b5xLx2o4W0g_13_0"></a><a id="Tc_O7nGakBiiEOt78nFR_MFzA_14_0"></a><a id="Tc_Koz2T-mqw0qFa0NtEiegaw_15_0"></a><a id="Tc_W9ylCrV3wEa5B7U5z7Fiig_15_2"></a><a id="Tc_ZY7WaHRpqUGepF5SHaFECA_15_5"></a><a id="Tc_IerZYmkpZ0KYwmw-fZfQUw_16_0"></a><a id="Tc_3vyAKUwjr0mJhO11JIxvEQ_17_0"></a><a id="Tc_cNWjgXaRBUa_7CxIeb6IYw_18_0"></a><a id="Tc_6V26isoe8kWxAgjhNAQ-Hg_18_2"></a><a id="Tc_ZUjWsechvEO_DK2jgpwVUw_18_5"></a><a id="Tc_zvgR8lSH70muzlPT129tew_19_0"></a><a id="Tc_6QkgL_gNk0CK2Nmlg-73-g_20_0"></a><a id="Tc_ZScuTHGqLUeOy6T0aFyJSw_21_0"></a><a id="Tc_NZU3-Fl980S7tQkARpvpbA_22_0"></a><a id="Tc_bh7XqklaxUSwwFn-Q-lYOw_23_0"></a><a id="Tc_drRVh4NP-UmaH3ZSVca0vg_24_0"></a><a id="Tc_mTWHeqJ3YUSr6XCmJa9Xfg_25_0"></a><a id="Tc_dOM2qSiEiEGrPptPVUkf4Q_26_0"></a><a id="Tc_nuRJUoPmK0qnUp8Q1cBOWw_27_0"></a><a id="Tc_Z8WBjfjksUuYwXxxl17GJA_28_0"></a><a id="Tc_7CsL00fk_UmpQFTlvEYxvA_29_0"></a><a id="Tc_KyR7wZq3mU6_IANl6XeniA_30_0"></a><a id="Tc_RBBuXjSKdE-2hzSlsMij9w_31_0"></a><a id="Tc_wFOdBWBCuUWTybAAiviq5g_32_0"></a><a id="Tc_M3us2pSs7ECXlKHNzZqifw_33_0"></a><a id="Tc_NG25M6zkjEe9od5iUBUpsA_34_0"></a><a id="Tc_0Z0eCk3iNUe2Ky63MLvgqg_35_0"></a><a id="Tc_PL9oc6N2J02XG--he88DFw_35_2"></a><a id="Tc_bitMImh2oke5O_RFLi3E1w_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ISmhtGY6bEGsceNgd3nO-Q_5_3">286,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_K2iuZX1vP06oCB-hqetdJg_5_6">417,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_DD7DQG9g8kC4ohh5BPwdqA_6_3">91,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_eGYCkNcvtEaDl17tAAnvAQ_6_6">123,022</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_W3qzCjwelESS4C3rQNEBwQ_7_3">27,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_XOAAuA4FiEa35Dcx3u5lwA_7_6">37,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="3" id="Tc_DbevHgHZL0Cafzo5AA8DOQ_8_3">20,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="3" id="Tc_ZMU2Xk9N_UylMPfQaZ8c-w_8_6">13,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Other prepaid and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_vXbJQmdd7UeU8cswdT7Esg_9_3">21,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_NGyEZ1N3vEmaOeIVcd_z-Q_9_6">10,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ElJx4tv1OUaUQUcrUOBacQ_10_3">448,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_kRXjFU4CBUq7frNud0uA8w_10_6">602,323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_kJQCMjPDdkGFSroYI4qcrg_11_3">9,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_5HLJNrFHGUiVkld5s1mi-g_11_6">7,813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_taDrc5SbjkK3onHse-EwxA_12_3">77,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_o0alKKdR3k6Qu7YqzGpaYA_12_6">55,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_SfYn-YbFAEKOXZL8bCkZCQ_13_3">5,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_IeaM3FtgDkK2BDohrj_CsQ_13_6">3,563</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other assets, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_JvdkYGwlUU-CcDrDTE4QVA_14_3">9,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_zYyZL4lHzkOO3JsrnUHsiQ_14_6">10,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_2qa1HVzlkEWcs-LyLQwqgg_15_3">550,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_m3T3-rHyaECEDxUNrY_VtQ_15_6">679,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_13ThgZnA6Euy2FXFAde4XA_18_3">9,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_iGV8LRPLFEGUIvZVN8uDMA_18_6">16,159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued rebates, fees and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedRebatesFeesAndReserveCurrent" scale="3" id="Tc_xp6Fl8_Uw06lznHzQS78Xw_19_3">54,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedRebatesFeesAndReserveCurrent" scale="3" id="Tc_FGhDgT1-H02qcqAXfj-51g_19_6">79,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_xEiRZRvs1Eqh5Rr0w0Wciw_20_3">21,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Bw2Xta4pc0aDhzz5lAG3xQ_20_6">22,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_bhTb0jJZcUu3f86dScwmew_21_3">85,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_HoHp4Fcx2kOekU4RkWE9UQ_21_6">48,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_PZP3cKo3oEOMMn8r-dvqbg_22_3">171,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_oDWkgCRH3k-f_IobcjwpMQ_22_6">165,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Term loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoansPayableNoncurrent" scale="3" id="Tc_khumen12-0CDYRtwQqJ54A_23_3">245,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoansPayableNoncurrent" scale="3" id="Tc_zCE1iSFFY0-NEvxyX6N5EQ_23_6">75,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" scale="3" id="Tc_XOBPCiFO5Eex2X8Ra-NVAg_24_3">225,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" scale="3" id="Tc_odJKtEPAOkqikNGV1v_wCQ_24_6">332,767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_jwnYmF8vkk2tN4-FJDeBhw_25_3">6,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_2S29cTTNpEWsz-wQHKrG2A_25_6">7,251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_PcG5V3dd5UaohknZcKUqDA_26_3">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_rVlajgRVOkmtDmxWJ5FBeQ_26_6">750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_K7rk1Hr1yUeNcb6AjgfleQ_27_3">648,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Wea4Wgws9kSfGCiJnd6SSw_27_6">581,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Common stock (</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BVv8wKKFhkW9LDbCaCFQDg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6-65xeiPSUCuuDlKYtO5cg">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; shares authorized: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tkathzOtsk2WuYaQvMBFcw"><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_SwUGnugSpk--s_cZeu6QqQ">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;">; shares </span><span style="-sec-ix-hidden:Hidden_bdIxfh13o0KisJnEyHBoSg;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_hoR0QtiyGUGfLjpvEN1Erw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;">: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_uuepMVJBzE2m_wVFUy8zGA">77,770,593</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_e4nu94e0NkmuDGDSB--aRA">76,930,096</ix:nonFraction></span><span style="font-size:8pt;"> at September 30, 2022 and December 31, 2021, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_J6SPwTZW8kWODk4G8dQ1NA_30_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_lmb6VUX40kuxHiKxT11QWA_30_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_7g-RV3CiR0eV8-6K9Pp0IA_31_3">1,185,868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Ud4bcPa630KWU1CZItj5lg_31_6">1,147,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_T4qgnlXZCkm3xCraxVrJog_32_3">270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_hKpcfYrzuk-fT0MCVYiuzA_32_6">270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_muQTHM5Iw0O4DndR4i66Og_33_3">1,282,738</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_d3nZ9hV_vkmTqxzw3emWcg_33_6">1,049,854</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity (deficit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QqFhNyRlX0eqM_5F6LfybQ_34_3">97,133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nK9rDDK3hEe0TJuJiUJLTw_34_6">97,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities and stockholders&#8217; equity (deficit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_t5Ej7w0N40SB7Dvgp2ulQA_35_3">550,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ZgkxwSEuBEmrISJBrNS5_A_35_6">679,334</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:24.5pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_74e2bcc8_2d80_498d_8142_2f941b44c9c7"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_cf1e7100_1512_473d_9934_ceec88e0a3d6"></a><a id="Tc_9WBiHpD1jkqyEXtXzFKeQA_1_2"></a><a id="Tc_fuFhX4v3REKvQN52S3S6pw_1_8"></a><a id="Tc_CpH_eksc90-pk1SYmEFuiw_2_2"></a><a id="Tc_uqqbA7P170a13680kdNvDA_2_8"></a><a id="Tc_oXUXgYtD9kK2cFsrqMorQQ_3_2"></a><a id="Tc_GP4mupkaCEuDfk1du-rluQ_3_5"></a><a id="Tc_DV9COvR3HESWZUfkkIt91Q_3_8"></a><a id="Tc_ZnIYEeT92kmUJIAQ17XlHg_3_11"></a><a id="Tc_OSXAiQugdUuwgn2agNmxag_4_0"></a><a id="Tc_wqtXfhC9s06kZyohHE6n9Q_4_2"></a><a id="Tc_LoyAzXsh40i97yUqkMnHrA_4_5"></a><a id="Tc_HYrO1Y6kr0SBKT5wGrOmyA_4_8"></a><a id="Tc_Rn8P8vs3K0qIherZ2VdToQ_4_11"></a><a id="Tc_aPq4NaeGaUaDpYP7dEdq8A_5_0"></a><a id="Tc_4_vka6wQTESVesIHdVy6Jg_6_0"></a><a id="Tc_2KJ9fLupEEKY2EKHzOSBNg_7_0"></a><a id="Tc_AqbSP7RudUmOotVpiG-nQQ_8_0"></a><a id="Tc_oxcQuodv9k-CMU0KUxC-wg_9_0"></a><a id="Tc_akr-rUm79UuaLK2ewtqkjA_10_0"></a><a id="Tc_NynXRL-VsEKvX7KnLX_hDQ_11_0"></a><a id="Tc_2Trf7uvlUkKrippQeyht8w_12_0"></a><a id="Tc_xRtwDy4XrECr1hIB5HxAag_12_3"></a><a id="Tc_VItAUb6d20iVsvCYYTwEkQ_12_6"></a><a id="Tc_L-cl5d5uOkq3AeVPTyYKUA_12_12"></a><a id="Tc_1hlqW2McNU-sJEJiE_C9aw_13_0"></a><a id="Tc_SYQSizKIh06945dFd03oWw_14_0"></a><a id="Tc_ZtJIqYKHbUiB3feoN4KCiw_15_0"></a><a id="Tc_MnsylWg4I0uFDhg1DUZq7Q_15_3"></a><a id="Tc_CfdDCfB1302LE4jYBohTDw_15_6"></a><a id="Tc_ZUu-CxYnlkej0hUCSz6Geg_15_9"></a><a id="Tc_W-i12UwTik-UFNctIV79dw_15_12"></a><a id="Tc_YL-44dMtOEaKFmmv-pizGQ_16_0"></a><a id="Tc_j4i4XYCAz0a3UwUVJT8Fuw_16_2"></a><a id="Tc_kfh76x5RKEqdh3JRKszTIg_16_5"></a><a id="Tc_Wfjme8ra4kOFcgTfirbD5A_16_8"></a><a id="Tc_KvWYryZJKEe5snNaI1CL2g_16_11"></a><a id="Tc_T9ZcMpaIakiM3U4IU9IEFA_18_0"></a><a id="Tc__BpTTZoIB06ifC-jDJRIcw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5975723%;padding-left:0pt;padding-right:0pt;width:101.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_RPzsap8mNUeNAMR6c-NvWg_4_3">45,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_qLx8qoayBE6XbM4fxJGDYQ_4_6">82,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_fHgdrfHA-0-mxR1LNpdXgA_4_9">165,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_0bMwfRDW9U-WCMULSwXxWg_4_12">253,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_IRbY2FOOKk2RSli42-8pUQ_6_3">35,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_I_LxRcHfj0iVRc7odAp1dQ_6_6">21,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_6tnLkRTW8U-85tMePlDCpw_6_9">55,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_PUxiuW1RkEWcC4rKVEztqQ_6_12">45,487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Ak8_cEvbDEmQEJI0kIvWHg_7_3">45,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_eXwcryfXtkyll2ETlKL6jg_7_6">54,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_NiI3WphT602IpB-x5WUPRg_7_9">170,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8CSoxn6j1kqxYNPfBaUVkA_7_12">312,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_5JwApScTsEecbEFa4GhGVg_8_3">44,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_bRJBPM7At0SN4CJwA9xRdg_8_6">39,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_w2HiO_m470CnUfZJdnJUoQ_8_9">144,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_Oabbs6j2J0mq7UPoYdOK6g_8_12">119,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_rPhvo_BuHkiNvKW4anv-NA_9_3">125,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_1YSF1Gt5X0uj_Srd_Pfyxg_9_6">115,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_BaY5XV4Ock-nWbGwMepHOQ_9_9">371,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_TJXWCV9XaU-mUmZ_os2G9g_9_12">477,491</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_3WH0LqEZd0KjeHfYURNP5Q_10_3">80,449</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_j57WjCxjYUG9AwaA5_Vy7w_10_6">32,787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_AKamivPzbkmYX2FCyGJuAg_10_9">205,387</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_CF0tleJKVEe5Tpi6GtgRGQ_10_12">224,311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_lK8zhs5yGEeR45gW-5okxQ_11_3">7,540</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_6qAv6wG_QkaohCSoyKdYRg_11_6">5,771</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_SZdUsPdSrE2tfoZx8TuxiA_11_9">23,089</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_LP0fE0TGKECkaJ-WdDMcOw_11_12">17,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_4_n8xgn840-zgtNvUCU9jA_12_9">6,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_Fbj-C3aR6UeUhXlKiaFPrA_13_3">1,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_dQdWj_Tth0GRnKImLvg8Tw_13_6">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_Yjmag-C8gUuaRyMP9bjzDw_13_9">1,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_K6Ff7W1C9Eq6-IO0BYzSNA_13_12">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_5n1U_TgVnEy6Ot0z4ldQqg_14_3">86,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_Jb3OurDyA0StYnr6jlALmg_14_6">38,528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_oyQJLs6Ut0ibY6rkKVHtcA_14_9">232,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_bQpKs2mryUSL4CfmjEt4cA_14_12">241,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JFkEHU8Lu0S2p9jj_x7fgQ_16_3">86,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Jk7eyaK8sEutUn2XRLz1VA_16_6">38,528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eZHoRuVoCUGsOnyBbfJ-wg_16_9">232,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_81BYH_lkrUiEzYA4UBrp4w_16_12">241,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Po6M_OUNuU6JSGR57SKfnQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Wg0FJgdSeUCSCotKpnMr9g_18_3">1.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PTLiJ86BQ02BxxEIxmF4lA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Q99uO8jv80WtJqNwaeE-KA_18_6">0.49</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Km26HVskkUuB_voLJ-jedQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_z0NYSC8fyki0KQIyzKo-sQ_18_9">3.00</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_co5ZJw0eiU-gfN_NI5P91g;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_yGPqEnPe5E22URb9uaZlvg_18_12">3.22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Weighted-average number of shares used in computing basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Io2SXoWU6E-zUe5jcjNf1Q_20_3">77,746,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NzP3a1VPQkyzVTVjMpFY3g_20_6">79,013,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_53E6gmapIk627HKxv1QvZw_20_9">77,520,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_yrHZT_i62UKvtia9e0EBYQ_20_12">74,984,811</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:24.5pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e3558a29_ea57_432f_86fb_2fbc70a86364"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofCompreh"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Comprehensive Loss</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_b14b702f_21f3_4759_b4ed_3aaca0c873a9"></a><a id="Tc_YW6PXSrEJUCC2DvNhzObjw_1_2"></a><a id="Tc_IGZ9ryoEn0eZWJaBI6SkJw_1_8"></a><a id="Tc__aeoreWll0mEnK4jtaB9vw_2_2"></a><a id="Tc_WxzvhYbMdE6OhwTNX-ba9A_2_8"></a><a id="Tc_bZak2kKaC0yx4aJEor40GQ_3_2"></a><a id="Tc_5rI7OhNPf0eXfg0jTBW6-Q_3_5"></a><a id="Tc_7VbrYPGaK0C7k4PTfly8SQ_3_8"></a><a id="Tc_GmJZB7aHhEmzFG76zqE6Vg_3_11"></a><a id="Tc_6tYJLbK6vUybnk1jLE6kwA_4_0"></a><a id="Tc_5SmwgD46FUSL7AYhdRX4Aw_4_2"></a><a id="Tc_T5bQ7-gGVkau6pzpjYFjzw_4_5"></a><a id="Tc_tQz1OhMqHk2bNsN3g9hRKw_4_8"></a><a id="Tc_VZNQCiw01Ui3wKe5Go8Bdg_4_11"></a><a id="Tc__BXRLMxzT0uNXUStXrCNMA_5_0"></a><a id="Tc_YCKymH5tvk2vg0BhscfZyA_6_0"></a><a id="Tc_brzQMyu_akGWNdUI1lQQvg_6_3"></a><a id="Tc_8UlM-JbTQkCiVsK8BMYLaw_7_0"></a><a id="Tc_dxYDpy-UJEWARUNbTwSEZg_7_2"></a><a id="Tc_LB7o-1MqyE-f5wbmMZP-Gg_7_5"></a><a id="Tc_YDTRhgxXQE6yP2qseSKXwA_7_8"></a><a id="Tc_B9fYC1RfiUWfaNdmJ_EL8Q_7_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.14939117%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_g--9p0DkHkmf4V__6iIuSg_4_3">86,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1iVQgm3l4UOEIdAeURYzBQ_4_6">38,528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_58g9WO_cpUqcRvD51fMCzw_4_9">232,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HP4WZURAz0mPeikFXH8InQ_4_12">241,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Unrealized loss on available-for-sale securities, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_eA4aGgDAIUup8nXd_7ugYQ_6_6">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_JRfgNRix5UOCF0AUIZ4G5A_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_9xyTmgrHzkmBVOktpvvP8g_6_12">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_dR_595kxiEOxCawDsGJCTQ_7_3">86,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_vPpSWzlAdk-dBQiM487TSw_7_6">38,534</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_0tr19ZINSUaJZFbs1yC_Cg_7_9">232,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_hsWI20lXp0KsfTTYJHHBeQ_7_12">241,378</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:24.5pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cde4d37a_43f6_4811_84fb_6d8748e5377b"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofStockho"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_0372bbfa_04a2_49ea_82f5_159fea6ec133"></a><a id="Tc_opCIDNWY-0SFPiSrrGfxZw_1_10"></a><a id="Tc_VcxqbZeIZk23wyfiTRPoZQ_2_7"></a><a id="Tc_KCFgHxMUXUasOaWnpO8-ow_2_10"></a><a id="Tc_zIjkYjprv0OQMnF5WlB51w_2_16"></a><a id="Tc_Z9upLacSJEGVf8lZgM_VHQ_3_2"></a><a id="Tc_fmLuyNEsj0WF_SdezIHBgw_3_7"></a><a id="Tc_Bo3W6Ey6d0aT0WaBGYJcZA_3_10"></a><a id="Tc_KZe0Qr0ZHU64SHra6MTCaw_3_13"></a><a id="Tc_OdSNUDJJaUC2NoEVTIgcfQ_3_16"></a><a id="Tc_r4kl46ifWkW9uVSpHSeT6Q_4_2"></a><a id="Tc_Pq_-y79XmUKD6rX271egHw_4_5"></a><a id="Tc_AZHwA_vcI0GGf4sDzDFVtQ_4_7"></a><a id="Tc_D-THeAZWwkaYfpOOPWYmPQ_4_10"></a><a id="Tc_AJ6-BHnYN0GKb8VC4tVtDw_4_13"></a><a id="Tc_pCk5TEqPjUq9GnpygtUdgg_4_16"></a><a id="Tc_Ecsa3OV0F0OD0dJccalHeA_5_0"></a><a id="Tc_93Edgdet6kqBhaMmHvJECQ_5_4"></a><a id="Tc_FYBASx5x5EyV4PjNdjjdJA_5_7"></a><a id="Tc_LU4dUgUijEOfOqgQHJRhCg_5_10"></a><a id="Tc_Mz8zvX36mEOdqWre7hwAjg_5_13"></a><a id="Tc_Tgd18eoNRUm1kfxqXJzJzQ_5_16"></a><a id="Tc_DwWd5J-wP0qR5Bv03JczoA_6_0"></a><a id="Tc_JOWMxFWm10ymvZ-xUYcktQ_6_2"></a><a id="Tc_KDuADPtDo0mTLLSzrl31aA_6_5"></a><a id="Tc_eGkhOzKJ7k6UqKqPt3asqA_6_8"></a><a id="Tc_qbrPksmWnE-FXUGqtfJkDA_6_11"></a><a id="Tc_xJzjArDpYUqCK_N3frCYVQ_7_0"></a><a id="Tc_jHtAZSt_HUq9tgMP6m8lSA_7_5"></a><a id="Tc_wfeE0jHUhE-l1yYjsTHWaw_7_11"></a><a id="Tc_8kaDcdxaO06_uT7r6Devxw_7_14"></a><a id="Tc_my1o-NG8PkyPQOlKZZ-Iog_8_0"></a><a id="Tc_jM2VUFjX70G86Yv-5aoO6Q_8_5"></a><a id="Tc_s1WLbQyxZkGW8P8S_m2dIw_8_8"></a><a id="Tc_hrJ-VBKQX0GJb8K0jXViYA_8_11"></a><a id="Tc_wu8u_XIRFUWeRbXhQMxB2A_8_14"></a><a id="Tc_5Z9hd0j0XEGnKZZXX0M2qQ_8_17"></a><a id="Tc_Y8A6xkVv6Eqhg4U3S3AAVw_9_0"></a><a id="Tc_r8bRWwmnREi6u-AyuNyvbA_9_5"></a><a id="Tc_O37Vkjbx7USEYPYY1BiYaA_9_11"></a><a id="Tc_lo72bZBIBUSo-N-R3fkoPw_9_14"></a><a id="Tc_8ZIwvMIgzUmIDVsjuqtelg_10_0"></a><a id="Tc_4mpHBaY_7Eu7bwLyagxVVw_10_2"></a><a id="Tc_MWBUDYv9mUaUsrx4e_pEBA_10_5"></a><a id="Tc_BNCL_vMF3UyNYP2TkBV_PA_10_11"></a><a id="Tc_evxTGUmCVE-Qdc-QFVJjjA_10_14"></a><a id="Tc_nyu_IkGy8kihTA14XACpsQ_11_0"></a><a id="Tc_nnalp-2MTEezc9UZNv9dmw_11_2"></a><a id="Tc_88vbbyfqg0aEInxi_W91PA_11_5"></a><a id="Tc_BwVfLDl-fE2283Us3X6big_11_8"></a><a id="Tc_a8HSj19BY0ufSY9qq5rpAw_11_14"></a><a id="Tc_e_rg4N_pV0u2TQtn1MBHHw_12_0"></a><a id="Tc_f3Y7KHYUd0qmGJH0NMt-aQ_13_0"></a><a id="Tc_eQkSsY7kUES2wY7HWi8i1Q_13_2"></a><a id="Tc_qKVyVuI1RE-Z6kyVHS7qZw_13_5"></a><a id="Tc_c9sha4jbk0al-o6iPwLsXA_13_8"></a><a id="Tc_X3sdL-0wp0mEwEmJUrBvJA_13_11"></a><a id="Tc_CUywiRFYBEWOnAqcn4JCEQ_14_0"></a><a id="Tc_BCIr9-8vUE-PXTI1omGGpQ_14_5"></a><a id="Tc_eCGgUqXjJ0y5qlL_S5rlmA_14_11"></a><a id="Tc_YXSDapnVGkqZuBOi1cnZtg_14_14"></a><a id="Tc_y9Tw2Za1Bki8HhXK6xmqjw_15_0"></a><a id="Tc_XmZwvUJv90Wd-Pr8crtNgQ_15_5"></a><a id="Tc_B8gbHwP1tUKEyijsHXsqQg_15_8"></a><a id="Tc_UuooIgEa_U6C9Rr9FoSlwg_15_11"></a><a id="Tc_y-0_z8R8SkKFGRxV6EaAkg_15_14"></a><a id="Tc_FElHH85_l0mnOfkT15XKZA_15_17"></a><a id="Tc_pQW9UavvLEyFirm7UztH5w_16_0"></a><a id="Tc_nn-l9DBB3USY-4bu3lrWKA_16_5"></a><a id="Tc_KA-2TF9h5UW3aSXdqDnCNQ_16_11"></a><a id="Tc_UaC4_qXRAkWftbqIKJ8QUA_16_14"></a><a id="Tc_CX3i2NzPwkub0aVC3Fdw4Q_17_0"></a><a id="Tc_NsFDYd-uWUuMoKQoZCAAgg_17_5"></a><a id="Tc_gqK8pzZpi0Szrc1Nkh01tA_17_11"></a><a id="Tc_3btEFz15QEm_8cvvEkLqmA_17_14"></a><a id="Tc_34WxvRwzyE6Fkin96wL_iw_18_0"></a><a id="Tc_cgM3n38o40K5jgTxV0HGtA_18_2"></a><a id="Tc_Gy4abpwwMUO05R54RR4ZTw_18_5"></a><a id="Tc_tLn-0d57Mk6fyDChAS8Tig_18_11"></a><a id="Tc_PC_PmilNH0C0R0h-ImGFVQ_18_14"></a><a id="Tc_PXHwwrMg7Uy39nSTBSIWXw_19_0"></a><a id="Tc_u-ooSi-Kn0C7MLQFkpQMKg_19_2"></a><a id="Tc_U1TuQxZLgkCitjdN1Bw8VQ_19_5"></a><a id="Tc_ba3qmbafYkOglv4qp7Fvhg_19_8"></a><a id="Tc_H2h2_rzGLU6QFUwNflxhcw_19_14"></a><a id="Tc_dDbRAjgoIUO-S2CSs2HT0w_20_0"></a><a id="Tc_9axzIuZ5ekqMEonmkkEsmA_21_0"></a><a id="Tc__LrOVeiXSEi9egMikJMNFA_21_2"></a><a id="Tc_Nq6QmVHtkEyGzXAES4DDrQ_21_5"></a><a id="Tc_YUdMRV6oqES5foVZ58_wSA_21_8"></a><a id="Tc_MTjKax7wdEOMQ8-LzQFS2w_21_11"></a><a id="Tc__1DgWfgmIkWslJsozXiZvg_22_0"></a><a id="Tc_i5eXsdv67EugD8u3709Gmw_22_5"></a><a id="Tc_tD6iT58sokGTHC2gDxIofQ_22_11"></a><a id="Tc_G15UPaEYzkyJj0x_u9KeKQ_22_14"></a><a id="Tc_pMqLfVfXAEy3V76b5MeDFA_23_0"></a><a id="Tc_5SJJRrYseEa7nXGdF56yGw_23_5"></a><a id="Tc_CFNOVO5YMkOIFpj3cdwgOw_23_8"></a><a id="Tc_HiUfVADRK0uE7AEOHlygZw_23_11"></a><a id="Tc_xYTcamwgZk2R1DOcY9p62A_23_14"></a><a id="Tc_9u-w0dN6OEahy1qjsjluKA_23_17"></a><a id="Tc_vmStHHsSn06cQp5xKCUfvQ_24_0"></a><a id="Tc_ish8F3EHDkeD7sz-ulOIJw_24_5"></a><a id="Tc_xj9s2HkKtEu74HVKQeQM-w_24_11"></a><a id="Tc_-Z8XkdqKNkuicDW5cYeJuA_24_14"></a><a id="Tc_ohUPQ-M_QEebDS9HVHqbJQ_25_0"></a><a id="Tc_sKYpr5NK60SMN_YGl8eNHQ_25_2"></a><a id="Tc_l8SkuKy2O0-sUZvvW6DSUQ_25_5"></a><a id="Tc_Y3U9RP-IeEeHl9uUc0nofA_25_11"></a><a id="Tc_HYf5n37a80GbLsEfcuqOfQ_25_14"></a><a id="Tc_AI8otUif-EKbFSNbsKz3PA_26_0"></a><a id="Tc_x-RpVDPT4UO_Y-TmqVhnBg_26_4"></a><a id="Tc_p5xejcK_p0GeD6P3yGdh_A_26_7"></a><a id="Tc_7oLFPalsbEuvCBYPcQHzYw_26_10"></a><a id="Tc_6p3bLewjM0e9RG-3_nUn_g_26_13"></a><a id="Tc_QB17ofCO7U-qDuRt2NINJA_26_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;"> </span><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_gki8eLvm-k6zTJvQ9tL6Ow_5_2">76,930,096</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Za3Y-xEmTUmj7ezF8_nI8w_5_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iLCwIUmxe0y6CzAmEfiM4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hfhjZwIRg0q7zR7L9J_5Ng_5_8">1,147,843</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zLA-RFtqoEew3-CZd0KOuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7YMLENn-_EC9uvhlYliCRQ_5_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w0nhYumrGkKrSb62bMeN2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3beJcr6r_0Cy_ux2yVnnCA_5_14">1,049,854</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YAqmF8RFB0GwJaHe8ugcWQ_5_17">97,726</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oIOC0Uy60EWaDKyAYFI7Ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7Z2E18Vvj0Wul39GFgLNWw_6_14">96,084</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qJY-jwE2rUGldSV4f--HzA_6_17">96,084</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_z2hjpq-rSU2Fe-K_XWmung_7_2">102,632</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_co0Zlkw3aUGLdORKw2fGFw_7_8">544</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_iIRz4QIWA06r2sjUyLtcqw_7_17">544</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of restricted stock units (&quot;RSUs&quot;)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_r0dDwkbNXEmkoE7jYK8nNw_8_2">491,087</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_l6nsKd_0ZEWco9bquTJKig_9_2">185,644</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_cuX1PRI91U2cFyvY28kYLQ_9_8">2,658</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_ix-qlxp-eE-k21diAlrfSQ_9_17">2,658</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_RGNBEzgD5EiBHwLLzWnrvg_10_8">13,037</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_W5J0rE56oUWY6XrZwbqX8w_10_17">13,037</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Other comprehensive loss, net of tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R54yYimj30CJzK88nXK4mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_SKk4soc_Wkug-JwJKRmtwQ_11_11">2</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_EnFfMZEKL0WD8tzlfqoS-Q_11_17">2</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at March&#160;31,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_gi_r8NCRwkqWJbBPqCoeyQ_12_2">77,338,171</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_krxmslx1wUqwg2drsXtbrg_12_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cb_X4L3p7EqqJH9nNd244g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_j7J_MWWzYEKNhktCUJlsvg_12_8">1,158,766</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h-ZTFPDr4EGbKfgG5ILwvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6PsTjZ8QXUWFPztyYnsMcQ_12_11">272</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0hoMqPJyYUGnNJU59za1pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_WAJTBQ7Br0afT6c44b0F1Q_12_14">1,145,938</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_eO8v2cr00kC45dIQYpWoLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4V0u0SLUNkaHSuGhy6SI1g_12_17">12,563</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mncLQiS1qE-Uskr7RtFgoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0Jdr62_7R02Z4Cafo8J6bg_13_14">50,150</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3V3sFOdlk0eege4yo6XL5g_13_17">50,150</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_wpXm7_-DZ0Gk_KB4NdmJcA_14_2">4,499</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_zPAptWaZYECqJofQ3HdOsA_14_8">8</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_G-_udKvzFkSOnW_jQmUeHA_14_17">8</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_7fDoLS0NHkWEtXavbwFrug_15_2">173,867</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_0Pw6VGHrQUOG5SgXgmMdIg_16_2">58,771</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_bljk38zhKE--RpSEQ0Z0Jw_16_8">642</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_y3yq4rkQWUG70l_BWaojDg_16_17">642</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under the employee stock purchase plan (&quot;ESPP&quot;)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_GO92AYTL3Ei5CgDe7fP8oA_17_2">244,983</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_jBD00nNPykiFuN2hNGdEUg_17_8">1,655</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_KROKNMcIS0CZPWs5pwZbug_17_17">1,655</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MYHDXZBMIUyXj_FPWAqIoQ_18_8">13,935</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_jP3s9hLWqEmXhwropp5zhQ_18_17">13,935</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Other comprehensive gain, net of tax </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yBXFf2ogREGygqnskg8KNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_ncSjUwu0L0GBbU3f2ymu_Q_19_11">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_v-s_LMp3p0Cnnm5Oecxzkg_19_17">2</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at June&#160;30,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_qbREtfz_zUqMhUd-O8D6aQ_20_2">77,702,749</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CmaeRpPS2027G1QxjDc9Fg_20_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dHQDPExykagF_cy6siyDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wsSXn9t4eUigAmcZcI1-1A_20_8">1,173,722</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_STiZudwhNUCxi022GQWjaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kPTf9DO37EWXUt33Cye9XA_20_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fkK5vNIN3kSwIqGaWNmteQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QShgNGvJiUacZxSj1aBYMQ_20_14">1,196,088</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2022_IY-plOYV2EqQEJeaoZX88A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mc8GC6HkJkyz0-pclatDHg_20_17">22,629</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiPDGwH4rUu0h2LujsdWDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9c9ptv1U9UqX5qjaGZdqaQ_21_14">86,650</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_x5rQUnjFWE2LIEoXQZ7xBg_21_17">86,650</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_aV6DyqFXH0msen4BWqRohA_22_2">6,557</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_McheWmF9RESSdBZgN1Ev0g_22_8">79</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_198BV1ZBH0yk-PKwmA3pnA_22_17">79</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_eT1k3XsqTUuBcGjcKUbXEw_23_2">93,606</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_azd-qj1710ezinukwH-JFA_24_2">32,319</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_OdA33CNnWEKdrqUismV8rg_24_8">321</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_wiOGw9TNgEClyX1LC4pihw_24_17">321</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Tmd9OiV9-0apKl0ub-Bbfg_25_8">12,388</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_uFAVjSax_UGEBGOZ04BQVw_25_17">12,388</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:41.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at September&#160;30,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_TrM3Jw9bzEira5UsM4OP0Q_26_2">77,770,593</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_I6LlS69tuUG5lFv2UGepqw_26_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aJyitt-I006ugkqGquTXGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VGwr06qiiUmNV0rK3sIK8w_26_8">1,185,868</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8V4HsE260kqaeuFD1bYwvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kYidWCK28UyMhz2ec8qbqg_26_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eonw1mXuJUKOgVxQh1GSyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ol03f2OjCEC-GdtlP9qOdA_26_14">1,282,738</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_X7-Pm2qYfE6BlPlACcg2vg_26_17">97,133</ix:nonFraction>)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:219pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_06fd311c_2a2a_414b_882e_ca3a76dd8bca"></a><a id="Tc_xammCaDD4EGUGdsn4jJCkA_1_10"></a><a id="Tc_uubVj_nCq0WYcmfuim6oYg_2_7"></a><a id="Tc_uoXQSPTcFU2BeNsmIuNhpA_2_10"></a><a id="Tc_R4QvQJ4IWU6lFDAI9TpI9w_2_16"></a><a id="Tc_fFhosm8FbUesMirvHurPOw_3_2"></a><a id="Tc_9JyBLEwqpkKjpvLjgzBF2g_3_7"></a><a id="Tc_6nE5cA1Gwk2ZICzPOoVnQA_3_10"></a><a id="Tc_7fMywG1Nvky-s5j6UO2fJg_3_13"></a><a id="Tc_P9OWGQ3bBEmqqRFwRBntKA_3_16"></a><a id="Tc_IDJTIrGBwU-kXTVaaEMagQ_4_2"></a><a id="Tc_U3cHUhdhWUGqtNJzq0s1eQ_4_5"></a><a id="Tc_jGDjUDugHUOYCDbWIz5wZQ_4_7"></a><a id="Tc_fji1Hal52USqBkV-wB6DQw_4_10"></a><a id="Tc_9TmnDtqomkKaJCyJCTGtxA_4_13"></a><a id="Tc_y0i_EiYLCEGHV3zpuSrkDQ_4_16"></a><a id="Tc_HuzYgtH0DkijJFZ0zbpDoQ_5_0"></a><a id="Tc_OVZ5TP6vUk-zS1V_NVIZ8A_5_4"></a><a id="Tc_4NK__bYVqku2Rr7U1nuUsw_5_7"></a><a id="Tc_uHGiYeDENUOTPt3vEAGgMA_5_10"></a><a id="Tc_5mnNz2Kr_EmUFkwvZvnYzg_5_13"></a><a id="Tc_ZPuoSWQD5EeqROrPoMIrGA_5_16"></a><a id="Tc_mTu_afJBHk-3O8arTUOC2g_6_0"></a><a id="Tc_3eftt2HazEO8x6FLM9fTkQ_6_2"></a><a id="Tc_hAkXwbgW3ke-IZUDg_qePA_6_5"></a><a id="Tc_aj_h-qqXiUyTG1XcQtohRA_6_8"></a><a id="Tc_PbpiMUghL0WMR9vRIEhnLw_6_11"></a><a id="Tc_NHPUFI3SNUyVGNT3VE6NUQ_7_0"></a><a id="Tc_gzqzTixUh0a716xi6L752w_7_5"></a><a id="Tc_-4D-8fwb7EqiLnH0PFZKzQ_7_11"></a><a id="Tc_4IrovXXUNkGp9d0aMbLkfA_7_14"></a><a id="Tc_gF5EjTmiX0qQFtR9h0qhBQ_8_0"></a><a id="Tc_NsxwcGDWR0yaZWdp4Kb5KA_8_5"></a><a id="Tc_OBsVLRFd-kS_QYpqvMl8eQ_8_8"></a><a id="Tc_2c8WFE2x4kq6v99mEnXa9g_8_11"></a><a id="Tc_KPDh-tVjdk2knqHMqHiDow_8_14"></a><a id="Tc_mapoQGTMV0q2robzAj_sWA_8_17"></a><a id="Tc_QaleqSpwwE2X80INSU49tg_9_0"></a><a id="Tc_QJ792C9qjEycsrix5Cwwrg_9_5"></a><a id="Tc_1P3Tn8KIykW1RhMmTgYtzg_9_11"></a><a id="Tc_fMYumc_iREGRlBOVXM_UEQ_9_14"></a><a id="Tc_Y77GBKoQvki51R3x4nrjfw_10_0"></a><a id="Tc_dHthRfFWyk-wTpveitgiVQ_10_2"></a><a id="Tc_vWUHkyjtekigGo6ycetnxw_10_5"></a><a id="Tc_qHekvkLWRkuHUJ0tfIYzRg_10_11"></a><a id="Tc_HLw6Sw3gXUGFbNtFEDe10Q_10_14"></a><a id="Tc_XJrHGu_ZkUqeF4bIX3Bgfg_11_0"></a><a id="Tc_cSmXRgCSjU6G_pbmFgqJsw_11_2"></a><a id="Tc__LCjkhFmBkCa_j9opvaKWQ_11_5"></a><a id="Tc_BdJNCvmOvEGHVt-WELA6bg_11_8"></a><a id="Tc_-zcvCHt480-riTrrhmcABA_11_14"></a><a id="Tc_uuTVjgu8PUSfNyW0BH3LuQ_12_0"></a><a id="Tc_sj1PAxeVt0iZ_oOIw0GgPw_13_0"></a><a id="Tc_OJqN-E9s10CvCeVNb8qPZw_13_2"></a><a id="Tc_nr5VylsiwUuMu-l5gfYt1w_13_5"></a><a id="Tc_voIBNjFl7U6oWUwB0yEVaw_13_8"></a><a id="Tc_Mu7lEHszLUKSMYpIx0nk5g_13_11"></a><a id="Tc_Zc8423xGM0awILnTzg8S0A_14_0"></a><a id="Tc__SpmHRA2-Uuif0hisfX1xA_14_5"></a><a id="Tc_q3KVUqXwfEmgBjs2kXqBPA_14_11"></a><a id="Tc_2-8-2OSFKkys1CDKgnEc8Q_14_14"></a><a id="Tc_SUue5gqcy0eJ8pN5PO2NrQ_15_0"></a><a id="Tc_XL0HfgmlG0OLHBBVbso23g_15_5"></a><a id="Tc_eCBolXucN064w98reW_sHQ_15_8"></a><a id="Tc_YhhzKEJW4kCIPtnvsHIOjQ_15_11"></a><a id="Tc_aPs0vnxUk0qsf2t3FIZHqw_15_14"></a><a id="Tc_3SPYa4ppD0-dT2rF0dGBCw_15_17"></a><a id="Tc_BUQ2MqI7gkiSQx3BGlQ91g_16_0"></a><a id="Tc_YIin86OdQUaWc-1P6xEhhw_16_11"></a><a id="Tc_osKcXGl1JECLJtobM76d3Q_16_14"></a><a id="Tc___MozBFMVEut4eH6QcriIw_17_0"></a><a id="Tc_00FB3JHeek2Xnp3-6397eg_17_5"></a><a id="Tc_m-GS_r6R4k-twxOznDjUbw_17_11"></a><a id="Tc_FpUtJwJNqE2EY8mQB-b1xQ_17_14"></a><a id="Tc_k373JWhAfUuG8bT7gCdF2Q_18_0"></a><a id="Tc_qYH_ifv3a0mv5fZ26zvs5Q_18_2"></a><a id="Tc_By6M48DlFE-12p1ZX_GY0Q_18_5"></a><a id="Tc_T27yayUP-0yFVFapC0At6A_18_11"></a><a id="Tc_tKIDjhPeakqAN3KbqqnXMQ_18_14"></a><a id="Tc_xE9KNYoUk0iy__DBY4veqw_19_0"></a><a id="Tc_yDIeHc8Cv0GbMmwUEF-i-g_19_2"></a><a id="Tc_EX5tiQrvOEuHWguEwKmuEg_19_5"></a><a id="Tc_36F6ht-rv0WcgAACUceDIQ_19_8"></a><a id="Tc_Mx82lUvRoEuxi5-abpvMjg_19_14"></a><a id="Tc_UZl5I2o8UkGITjnU5EQ5-g_20_0"></a><a id="Tc_6qA-lpavjUq2k0_WKzyH4Q_21_0"></a><a id="Tc_Jo-hlv2isU2kbl8l4WqfJA_21_2"></a><a id="Tc_Q6CjBI7PMk-sYls3ofDG-w_21_5"></a><a id="Tc_Q7U9y8rMB0WiXCmx3pF0GQ_21_8"></a><a id="Tc_uEdhPdGfGkmftF5FxaEXSw_21_11"></a><a id="Tc_MB0ntPedk0SGdmyzc5Yfeg_22_0"></a><a id="Tc_PacV5cNUJEOa3GhCvbUpdw_22_5"></a><a id="Tc_z6FL-bOHj0Ga52FMqhlbtA_22_11"></a><a id="Tc_Wl-abNo5F0O6EDMrr3zmCA_22_14"></a><a id="Tc_8s_UlntnfE64vclqGZWqFQ_23_0"></a><a id="Tc_ggBG-QLKc0KKImENOmlCWA_23_5"></a><a id="Tc_fmOc_JOxx0Kf065j7zP9jA_23_8"></a><a id="Tc_Oo1oqj8rJEuje0koaZdn2Q_23_11"></a><a id="Tc_Q3--sgpXtUeW0qMNu15PkQ_23_14"></a><a id="Tc_FH6JHpJsXECOkezmhu0lVA_23_17"></a><a id="Tc_rHpyZKm0kkyWfSc-e1mnnA_24_0"></a><a id="Tc_HXCRdV_UokeeZQsu-2V-0A_24_2"></a><a id="Tc_l65KxRwEuUSTAGiePOk01w_24_5"></a><a id="Tc_T7yuyOzN-UuV2OocXpuWRQ_24_11"></a><a id="Tc_yNX0NAftDkqshBsxf5nzEg_24_14"></a><a id="Tc_q2Tj1Oi0ZUu1nYwx3IPUdA_25_0"></a><a id="Tc_8yfya81jU0CZ5XmhzvoYIg_25_2"></a><a id="Tc_kVmR1Nl7iE6MetE2MIbeJg_25_5"></a><a id="Tc_pUm6qHjYk0eWwTOy4gd-Zw_25_8"></a><a id="Tc_sDH2-xsNfkuA2TnwaYKIRQ_25_14"></a><a id="Tc_zaFyucgQM0CrWUNEm1iNMg_26_0"></a><a id="Tc_pYVwI3QhRUut44meQsPOmA_26_4"></a><a id="Tc_xFyaqu_SVUaTUi0y6lGVPg_26_7"></a><a id="Tc_zqhbpWx3MUas1iI0J3FQjw_26_10"></a><a id="Tc_bHFgGDAvHEaNPzWDi0Ukag_26_13"></a><a id="Tc_agSGs9C77km-w1IOqweNxA_26_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> </span><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_Qpl3CztXhkO7wshlKYtGvA_5_2">72,513,348</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UMMgS8kkQEO4h1MsXiV-BQ_5_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LYkuifxZg0OV34ZetlagUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sbS0P16fQEG4NMHkEaaOkg_5_8">1,043,991</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_2wwQK9AUSwRjasJS_ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zuUjQkR84kih-UNUIUETgg_5_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KKNGL6SA9UeDBmazTlWOFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Xywcgx5QuEugdw0ZkIpGrw_5_14">762,754</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_h2Q5qfLtokiVDz_7Idw_Tg_5_17">280,974</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6qmOksBoz0uXpji7uweM_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Ho2R6HY2REWFmDZ0PHR9Gg_6_14">172,947</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_H9YbyhbJ2kSgE6TbBwNlCg_6_17">172,947</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_0YCnWxLB7UqpwUFwyy8zyA_7_2">451,883</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc__rCBcfBgWk-WucgDbjbEng_7_8">4,429</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_cjLLbLa_nkyifC1gWqq33Q_7_17">4,429</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_O7dSl4siW0yceAWwr0l4jA_8_2">252,846</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_hzLuEx4IF0OyIN19DaB-zw_9_2">95,169</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_CGE0GvbpxUKByuaGSfwi4g_9_8">1,730</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_T35KmaQVxEGpi_1KDBWKKA_9_17">1,730</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bu363KDpAk2lsDLh-ce_VA_10_8">16,982</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_08wDOxuivkyAJ8106ZnwMQ_10_17">16,982</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Other comprehensive loss, net of tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ehG8basW0S3Sder5I7-Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_cll1W1AusEOHcxitwdARVA_11_11">37</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_aO9wuyTZckqoXrwkjJN6yw_11_17">37</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Balances at March&#160;31,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_U2-keWw-pk-O76gytVMFlg_12_2">73,122,908</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9V_w883p40eyh5kXTJCGbQ_12_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0AZ9AYU4JUiN7rdHxiI_4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_I822HlASw0uLdxwYnXxDXA_12_8">1,063,672</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28c3LpHdD0WZKehT5O6ONQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_iLOFSfTapkCVXRrEvOtkzg_12_11">307</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q5iIlf1RGUq5nwYySyZq7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NXRZNRllL0WOuY0Yt_F8Hw_12_14">935,701</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2021_f_HHaVH0CkK6RCmYXbR8_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_g3XpJg3JTECfzTvZN5GFKg_12_17">127,671</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_02uw6OI6VEef4Old7iSxSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_TnA-d2940Ei-QcjqeTrw9Q_13_14">29,900</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1fslAWVbREuJH4FlFUTBJg_13_17">29,900</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_kPM-BLROLE2D3eOcNW5JHg_14_2">686,145</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_RTO42nrqb0irsloQn3ss6A_14_8">4,009</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_BqscKpROR02EvVcvT74GNw_14_17">4,009</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_84buSQhS1Uai6-YF1TSL_g_15_2">9,334</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock to Shanghai Junshi Biosciences Ltd. (&quot;Junshi Biosciences&quot;), net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_elX9JvgGO0qQhbEBZU28OQ_16_2">2,491,988</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_TnQUZrKo3kmS5ZOGbteE-Q_16_8">40,903</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_KPNkTAEzl0WyaACtlnm68w_16_17">40,903</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock under the ESPP</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_y2jtsB6vikG4e7VqljkbCw_17_2">154,325</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Rzqgko16tk-YcL76iRiqlQ_17_8">1,985</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_ZDGlOzdIe0ud3TMSwjbpaA_17_17">1,985</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3LEwXhR9gECry70vgmUu6A_18_8">11,512</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-hdef4LXw0mW38PR5daGpg_18_17">11,512</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Other comprehensive gain, net of tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CR00ztb51Uqx2BIB8vBdNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_4frVS5bqtkSuyP1pwS-U8w_19_11">40</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_lOs34OLqq0SZJ0kGMohCmQ_19_17">40</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Balances at June&#160;30,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_MgXyTJb0ZEujCWOyI0TGow_20_2">76,464,700</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RxOw4arQAUGzjMh3AR0X2g_20_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AHRLomthMUyUHM-nJtaJpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3ThiwduNAUWnndy9P8SHiw_20_8">1,122,081</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hLEdkaDzskaOra-KRKMpeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ye5AkA6du0uxUagwdV4vVQ_20_11">267</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WH4pGIMYQk6BmQKSFzo65Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ILnBEiWLa0OQvGygxlG1gA_20_14">965,601</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_6_30_2021_xF3ZNwxQJkiLgijGJT1LhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_q58yWaOJeUqDJ5z-Pe0bQA_20_17">156,220</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gKYdCCv6LE-IykKhJk4XGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_kgsM-1TQ70yoQ3vIBpxY6A_21_14">38,528</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xzEfze1-NEqKXBL7Kd91RQ_21_17">38,528</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_vrd_TNzv5U2UPJv63soSNQ_22_2">116,246</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_pMj_-tqSqk-B37kA2nDwBQ_22_8">1,288</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_t1HVmx5ho02BJPugl1ch9w_22_17">1,288</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_3oi7zIWAOU6H8GoDleLU3w_23_2">2,333</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_gyvFGqPBB0a6Lt1nMaK5vg_24_8">11,786</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ONqDj-7EZUS75hvuJFpxTg_24_17">11,786</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Other comprehensive loss, net of tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xsaiQkMDeEurcwXQo7nNiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_zSApSON68kuZKDVhL1OYkw_25_11">6</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_AjpXf8hFokudoGBWmmZuEQ_25_17">6</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Balances at September&#160;30,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_eEkU2TjQTUa4LYFFtZnf5Q_26_2">76,583,279</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bGbIJyihNkS3qp9Q_esq5Q_26_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gel7KLMwm06jHs-JrN3l4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NWwCEblOlU-fR7I3blvEjg_26_8">1,135,155</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ee2kjvAP4E6pnApIyvWmzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FDDPzqJzcUy7gDqSJ69HXQ_26_11">273</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oFlUazjEnEWuN2MvAjRdcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IKQymB3adUGpxXMmBAN5hw_26_14">1,004,129</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_exwicoPfS0yt3Yaml1Yw3Q_26_17">130,760</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_db2a21fa_cf7d_4106_ad09_356cc03f97f9"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofCashFlo"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b850b476_1351_4202_800a_f0e4f5b149b1"></a><a id="Tc_52DsUump4EW7X4qjgUHE2Q_1_2"></a><a id="Tc_11_qJr5m3EO79akpPx9hjg_2_2"></a><a id="Tc_pOsgn5aTjkmuxNLcMxedwQ_3_2"></a><a id="Tc_gQjSKlOdiEafX7Fk6Bm0Qg_3_5"></a><a id="Tc_cNPX9bezRE636CoARI60Zw_4_0"></a><a id="Tc_Ek2VF814PkiOV_3YxhrZ2w_5_0"></a><a id="Tc_Rt76UFZ4zki1O-dHlTX3Lg_5_2"></a><a id="Tc_Wt_DeRtXtk6EehRMP54WcQ_5_5"></a><a id="Tc_PYl9S_hzikWP3A0QOT9BBA_6_0"></a><a id="Tc_ey5aGQDfA06jgUxJheu-fw_7_0"></a><a id="Tc_m0EDDF7ntEqkeiJZDlMpSQ_8_0"></a><a id="Tc_oulXOtrmVEKwCxK2WPbunA_9_0"></a><a id="Tc_2TLwJHu1jUmyf-VdUGgrmA_9_3"></a><a id="Tc_XJZZF5bqvkmCARjmPlD-BA_10_0"></a><a id="Tc_IsHHVs0P0EGTCXMirtY1Ng_11_0"></a><a id="Tc_qFqdhXyTs0C0pAIKd_Bv_A_12_0"></a><a id="Tc_tT9PmTlvck-IsUPpXMCE7g_13_0"></a><a id="Tc_UxyZlB4T9EeOJhjohLiYdg_13_6"></a><a id="Tc_iiPfFDbT4EiMw3w7n5ur8Q_14_0"></a><a id="Tc_7Bl1hHWb2EGxfnQq-N1L2Q_15_0"></a><a id="Tc_ttNUS1L02kmri1OOjTwwUA_16_0"></a><a id="Tc_wMHGzrB-ykCyP853JfsIVw_17_0"></a><a id="Tc_sVD0LtYxaEeUE9lVT1Ragg_18_0"></a><a id="Tc_YglntVdXyUa26BelbjKr-A_19_0"></a><a id="Tc_CFpdMQj7P0WoaLgdZvVHlA_20_0"></a><a id="Tc_BBEnWsw2RUuxLVjZmPjtmA_21_0"></a><a id="Tc_ezNe0Tg8q0qqfuzIIw_Tsg_22_0"></a><a id="Tc_lz_EPVI5PE-Lld0T87dRjg_23_0"></a><a id="Tc_u7mCuX1T-Umn7qu_YZ_u9A_24_0"></a><a id="Tc_G0rd9FfG0UC9bvYYdq7Wrw_26_0"></a><a id="Tc_4JZZScI0hUO36fXQe8ckXw_27_0"></a><a id="Tc_d__VpfxaHUiWGw0H0qS38w_28_0"></a><a id="Tc_pBRa3PvPi0y2w6iMGdjXvg_28_3"></a><a id="Tc_q43ODAat8063-5iyOglRdQ_29_0"></a><a id="Tc_w9VfaaO1oUuTF7NznzW6rw_29_3"></a><a id="Tc_bfMc0FIrIkOLkjvYBOGB7A_30_0"></a><a id="Tc_iMRRjd-2pU2iEmBj9rHtJg_31_0"></a><a id="Tc_DeccGZhVvEae-s6dnzpsiw_33_0"></a><a id="Tc_UCutoBfiokeOgGsx6f6pSg_34_0"></a><a id="Tc_PDttZHOFlEqGo7qEfcKU0A_34_6"></a><a id="Tc_aSQ_5FLHzE2yeIK29iTzWA_35_0"></a><a id="Tc_kQlmVVMQKkqXBvbwmJm4Uw_35_3"></a><a id="Tc__QYo4HxOZkKwx6he4bubkA_36_0"></a><a id="Tc_N00-pC2G6E6AgcW9kMptqg_37_0"></a><a id="Tc_aylz8Y6y0kODLZYTIVN-8g_38_0"></a><a id="Tc_ps32S3FCL0ecZdtex_rEZA_39_0"></a><a id="Tc_XUhHLEwEIUq_OQRMq93IlQ_39_6"></a><a id="Tc_UiB64eLYyUSl_XawDNdYhw_40_0"></a><a id="Tc_zcrOrhkuVEKl6pCIPr87xQ_40_6"></a><a id="Tc_GIQX5s_jH0iv0qDvGm_Z9w_41_0"></a><a id="Tc_0i7fopMXGkeZN6TUFLIuLw_42_0"></a><a id="Tc_fE16qoYdQkiUk2O0Qvr2Kg_44_0"></a><a id="Tc_daCnZn5_bkGxzpkU0aBitw_45_0"></a><a id="Tc_4u8lpyLJk0-pfDZRD0BBDw_46_0"></a><a id="Tc_21aIT3jOE02ECRQ90A7dOw_46_2"></a><a id="Tc_upSkNL4AJ0O1FXSpzBGJJA_46_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_frnSGG8VSEqCU3r1lrsLvg_5_3">232,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_nfwATkj9-USdM3-BP6Cvsw_5_6">241,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_e72Gt4VU2EmhagKbyMBlSw_7_3">2,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_QpOSS6Kn-UeXHkt7603vAw_7_6">2,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_eusNcPBFP0SayBT1E4Bpqg_8_3">39,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_sBxEfaOkkUugIgVwSErisg_8_6">40,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Write-off of prepaid manufacturing services related to the termination of CHS-2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnContractTermination" sign="-" scale="3" id="Tc_0n7jon13u0ui8i8y9OYt8A_9_6">3,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Inventory reserves and write offs, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_FMImtTMFWkGA4kpdMrZ5Qw_10_3">26,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_Pmr39xVUMk69luqA8oUk8Q_10_6">5,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest expense from amortization of debt discount &amp; issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_fCfS8fD2m02nv7dv5RFcbg_11_3">5,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_JF89PfqQT06yWz9hzDWR0A_11_6">3,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Upfront and option payments to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_g1I7YJ0PiEGFxNbfGmVQcg_12_3">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_7HsEoGhDtEii6bwFxjVNlw_12_6">136,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_7fmuO2NW-0OSsIqOemSpOQ_13_3">6,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Other non-cash adjustments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:OtherNoncashAdjustments" scale="3" id="Tc_8zHHmFEFpE-cKHY6NVbinw_14_3">1,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:OtherNoncashAdjustments" scale="3" id="Tc_5UZ9-aOmukOFYeP7i1lM7w_14_6">2,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Trade receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="3" id="Tc_8AtuLeDqVUeX0eeSH3F2-g_16_3">31,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="3" id="Tc__OWfC4s-hEaj7CwxZXb0sw_16_6">20,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_-s1PuZjwuEaGP4f1BJOC7w_17_3">37,556</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_EecjZ4w6kUqzjdGCtoSr0A_17_6">2,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Prepaid manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_zU8FbVun7E2I2VL0uOOzkA_18_3">6,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_NKS4v9xECkuCkWm2PVh_Vg_18_6">2,884</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Other prepaid, current and non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_wSVrPYrWTk-N8x8cBFDumA_19_3">12,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_8olT3PeN9kG5rHMw9hAC8w_19_6">4,590</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_i9ZVzThQOUaEbwKjmgIPMw_20_3">6,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_B_JT2lLG30WdOnENkjUw9Q_20_6">30,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued rebates, fees and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve" sign="-" scale="3" id="Tc_0ZXxTLltGUCdC_8g5_160g_21_3">25,006</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve" scale="3" id="Tc_MuzGc-Du6kmvjrvcVooj4Q_21_6">3,215</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedCompensation" sign="-" scale="3" id="Tc_XQ0r6FHOcUSnsLne0cSiOA_22_3">623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedCompensation" sign="-" scale="3" id="Tc_4P0FSw4EYEqFIRvo5O9LkA_22_6">3,451</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued and other current and non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_eoubDXVmAUSnb-NCBUhYgw_23_3">32,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_ZQ5ij2yUNEqYIOqHp8u_EQ_23_6">16,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash (used in) provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_DhXxrpOqyEaB_jiywLKP5w_24_3">141,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_1s0EZ7oa8kehc95lxzYiPw_24_6">14,890</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_vk4yf0k4Y0igF3PVWP8r8Q_27_3">1,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Z1_81HqC8EWJXJoLr0bNwA_27_6">821</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Purchases of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_NpkpS3_CJUuoGWCCDngB6A_28_6">171,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from maturities of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_krgqpG4OWk-LmG8fQvYsdw_29_6">62,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Upfront and option payments to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" scale="3" id="Tc_7B6Ly50nQk2v-mmhlGz80g_30_3">35,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" scale="3" id="Tc_R96mAMxrFkG14X6TQcVT1Q_30_6">136,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Bms8J25DwkitjqOYCbZYTA_31_3">36,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_4hVUn0LAFku-ihvew06rDA_31_6">245,900</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="Tc_10LiTMRykU2AghGodHLBOw_34_3">240,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_IcJgQhCVG0y0o3sODkejdQ_35_6">40,903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_Kr2OOon6UUWzTJWVQygsJA_36_3">631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_sEie6ce9e0KHuFqVRl59rQ_36_6">9,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from purchase under the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_2MlsHc8m70mFSLm2CJY2AA_37_3">1,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_8TC9be3CkESq2Uq6l8vQ3w_37_6">1,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Taxes paid related to net share settlement of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_SDqchBNLsESzJZ3jhPnAuQ_38_3">3,621</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_K4eNvgtf0kSbjyf1H5lN_A_38_6">1,730</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Repayment of 2022 Convertible Notes and premiums</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_iT1Pufsmbk-tp1p1RToxJA_39_3">109,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Repayment of 2025 Term Loan, premiums and exit fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_Q2bZlvhL40eMoC7RxdA1qQ_40_3">81,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Other financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_ESt3hOX_S0mHYeaq6zUwDw_41_3">861</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_kgEcBBgYWUiq0adJssM6dg_41_6">492</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_rEGwGkCZDUaqcBw-Lw4U5w_42_3">47,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_PZqyeiq7uEyjmH4wdc_ddw_42_6">50,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc__s7OZwQoeUW_T5PxOU1b4w_44_3">130,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_hebJPenCEUerXXJvhvNdag_44_6">180,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_XL11D0RZx02UpB-LWxEVtA_45_3">417,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_38yl_hRPeEy4WkYzRr4OpQ_45_6">541,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_7V5s4j3-i0avo_5OQfeW3g_46_3">287,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ftGgTmrs2kSPSkW92F0ZBA_46_6">360,980</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:24.5pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_d8twu95RB0emhLBqLsvV0w" continuedAt="Tb_d8twu95RB0emhLBqLsvV0w_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Coherus BioSciences,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Coherus&#8221;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and commercialization of its portfolio of United States Food and Drug Administration (&#8220;FDA&#8221;)-approved biosimilars. The Company&#8217;s strategy is to develop and commercialize innovative cancer treatments funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA <span style="background:#ffffff;">(pegfilgrastim-cbqv)</span>, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. The FDA approved YUSIMRY&#8482; <span style="background:#ffffff;">(adalimumab-aqvh) </span>in December 2021, which the Company plans to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie Inc. (&#8220;AbbVie&#8221;). On August 2, 2022, the FDA approved CIMERLI&#8482; <span style="background:#ffffff;">(ranibizumab-eqrn)</span>, a Lucentis biosimilar, and commercial launch commenced on October 3, 2022 in the United States.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company&#8217;s product pipeline comprises&#160;the following <ix:nonFraction unitRef="Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="0" format="ixt-sec:numwordsen" name="chrs:ProductPipelineNumberOfDrugCandidates" scale="0" id="Narr_4jRqGRJVn0yDCLCuszwpiw">three</ix:nonFraction> product candidates: toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly-owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. In May 2022, the Company discontinued development of its bevacizumab (Avastin) biosimilar product candidate from Innovent Biologics (Suzhou) Co., Ltd. (&#8220;Innovent&#8221;). In October 2022, the Company discontinued development of its preclinical immuno-oncology program, CHS-3318, an antibody targeting CCR8, in order to focus on external molecules targeting CCR8.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_DDLF6bl8Bk-6H4kaS19uEA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals, that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with U.S.&#160;GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full&#160;year or any subsequent interim period.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;) filed with the SEC.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:UseOfEstimates" id="Tb_Ykaqw1pkLUWOtmBSN6swLw" continuedAt="Tb_Ykaqw1pkLUWOtmBSN6swLw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9cd6f5ee_6a6c_4a51_8f3f_37c0d242ca08"></a><a id="Tc_LvO4yqHVzkqGgVPPutZnUw_2_0"></a><a id="Tc_1UqPGHpJqEqCS1ZgVjUDCA_2_2"></a><a id="Tc_Us58Sv4kbUqqEuBWWdzVJQ_3_0"></a><a id="Tc_Oaee-VrC60OzCSMwTrsUCw_3_2"></a><a id="Tc_PGGxnOioQEyunu_8wBw7YA_3_5"></a><a id="Tc_XJ8IMiALbE-rNUYRFpbQcA_4_0"></a><a id="Tc_Wy4QWzmaQEC3QwcqX9fvzg_4_2"></a><a id="Tc_84fNHCBbF0KWIhYjVLCXuA_4_5"></a><a id="Tc_ObhCaQwsiUCZ0NabVNVYpQ_5_0"></a><a id="Tc_LRR_n_lH5EyqSt2Q-R98Tg_6_0"></a><a id="Tc_0e6M6LwBDka3k8t2-qCUHA_6_2"></a><a id="Tc_nz3oK8Zoa0KJ34ZTFTTFag_6_5"></a><a id="Tc_rzgn7m562UaELgUGxnQ4mg_8_2"></a><a id="Tc_aM1fLu1K-k2A-jjpTeX-Cg_9_0"></a><a id="Tc_40a4vJjOL0CBKBvekUV_LQ_9_2"></a><a id="Tc_T6bAOxix0UmeAiWxOqK-SQ_9_5"></a><a id="Tc_JvmAVG-ROEOcq7khmrdazg_10_0"></a><a id="Tc_-kSXl92Ea0qPkEdqBRH_Lw_10_2"></a><a id="Tc_xVm9swVMXku2HJIK-EDL2g_10_5"></a><a id="Tc_2EV4KMdt0E-HOJl0qRdqNQ_11_0"></a><a id="Tc_JP5HMR2cv0-zoCPz0R05bw_12_0"></a><a id="Tc_RvC9kgKzFkef3zYAecBI-w_12_2"></a><a id="Tc_qgwXGMvG_E6Hm6AanalqNQ_12_5"></a><ix:continuation id="Tb_d8twu95RB0emhLBqLsvV0w_cont1" continuedAt="Tb_d8twu95RB0emhLBqLsvV0w_cont2"><ix:continuation id="Tb_Ykaqw1pkLUWOtmBSN6swLw_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_fGSTpzoh2ke-mMMKjC68mA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_ZOVCHZkDR0-9KlLFu09zEA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_aPh5m0Xx-USJyptPODCH5w_4_3">417,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_bvN_PitZ_ESMeIOAL5MpVQ_4_6">541,158</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_G3Our49_kEm2UStVOMGStw_5_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_S4e85_gXDUuQIc8TDZM_TQ_5_6">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ajzfLNI4u0qHJLJemYybng_6_3">417,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__Km-RlYVOUii7Hlf-BNSHg_6_6">541,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_pPRW7Jg2YUOHCVxfMoPpqA_10_3">286,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_GF_wm_oPIUm147y0M7C45g_10_6">360,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_9SduIG_R0kKbG10ykBty4Q_11_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_8sKL31I-Vkq4iMgpWUsQKg_11_6">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_D0EfH0TV206OyBhges3Kfw_12_3">287,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5c61DeDYSkSbSbWVHfbPlQ_12_6">360,980</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.</p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_txqJZcaquUe-ipvYfLLMkA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Investments in marketable securities primarily consist of corporate debt obligations and commercial paper. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limit its exposure to any single issuer. All investments in debt marketable securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. There were <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecurities" scale="3" id="Narr_nr39YOs2dUmn69V8XhecVQ"><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecurities" scale="3" id="Narr_jUgoafykYUKqyD9Tdn5VLA">no</ix:nonFraction></ix:nonFraction> investments in marketable securities as of September 30, 2022 or December 31, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses on available-for-sale securities are included in other income, net, based on the specific identification method.</p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_oZSO_nIsmUCbWpwQHCxl6Q" continuedAt="Tb_oZSO_nIsmUCbWpwQHCxl6Q_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_d8twu95RB0emhLBqLsvV0w_cont2"><ix:continuation id="Tb_oZSO_nIsmUCbWpwQHCxl6Q_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2022 and December 31, 2021.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_B8DkrRwvYUmsuzqhLQgjUw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-weight:normal;">The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_fb03d24b_5b88_4c28_a45e_c69c2211e9ec"></a><a id="Tc_TO8gD8vIbkeUWUNbIXJyFw_1_2"></a><a id="Tc_WgZtcMAOm0y4USvHrj4SNw_1_8"></a><a id="Tc_lVKw6xG990yLwAHIeDWU1Q_2_2"></a><a id="Tc_ePxN9G12VE-Fh-BTHNvkXQ_2_5"></a><a id="Tc_KDow4SY3T0eavj6Bder2Ow_2_8"></a><a id="Tc_JGyzE9vsiUOa4qy89E3rfw_2_11"></a><a id="Tc_OfBQBxTNvEaAxwDEYHUVJw_3_0"></a><a id="Tc_bLotJd20x0Wd_nIRg7olzg_3_3"></a><a id="Tc_P0bG-akEHEOjdlfmFz-AlQ_3_6"></a><a id="Tc_18rFPOmI7UOFSdPf3kO_Iw_3_9"></a><a id="Tc_PXDau6kPZUevmALYDvsWVg_3_12"></a><a id="Tc_RRFFnOULaUW8f4aV_HFmOA_4_0"></a><a id="Tc_kBrRi-kFpEGkW803mB-CLA_4_3"></a><a id="Tc_2sedLGHwvUykoP5zxp4xwg_4_6"></a><a id="Tc_CGAMBMc9E0a3K7RBgz1Obg_4_9"></a><a id="Tc_EMzB8KQccEGPuRxsbFwXtg_4_12"></a><a id="Tc_QJaCBxaAckqwYIvlakVGyQ_5_0"></a><a id="Tc_pJx3NP9sLUqtPAd1Ps1DRg_5_3"></a><a id="Tc_q1671lvcS0CeeBzVirVX4Q_5_6"></a><a id="Tc_NtbAe-EEBE2q95wh0DFlOA_5_9"></a><a id="Tc_cvRDdlosDE2xGQJHc_YTQQ_5_12"></a><a id="_2de59c64_6d56_44b8_ac83_c56e4e56194e"></a><a id="Tc_hPDXIDk-7UuGjBC7ePgBLg_1_2"></a><a id="Tc_CxMYgmtIjEm3TstPeZMr7w_2_2"></a><a id="Tc_PLo7R5043kuCbYyKAl-D7Q_2_8"></a><a id="Tc_bbdQl96lUEuHOWB5KSf3uQ_3_2"></a><a id="Tc_eNxOCj40tk2sphqkDB6_vg_3_8"></a><a id="Tc_4J18axb750exUAF-TNAVMg_4_2"></a><a id="Tc_nWr-EJxB10OCulEN4WamWA_4_8"></a><a id="Tc_j5pUK4ju1kqXmDYNhRqEeA_5_0"></a><a id="Tc_hszcOr0xBUO7usE-z2R-AA_5_2"></a><a id="Tc_DTJHmLBncUCPG5Pxb-lCBA_5_5"></a><a id="Tc_2gTerWjRDEijHba0ZQLc2Q_5_8"></a><a id="Tc_DYemiSLI6Uqvdq1eV7vyWg_5_11"></a><a id="Tc_AKo7qCtYH0GTSb0PS7FSXw_6_0"></a><a id="Tc_1EXP71Ayv0C2LAX2DqLjHQ_6_2"></a><a id="Tc_PFQlPG-QgUajz7pVgO7ZQw_6_5"></a><a id="Tc_Nx6Cup5dZ0aZEkhnyp23Zw_6_8"></a><a id="Tc_ShLgrAj_wEWvOm_6LhiboQ_6_11"></a><a id="Tc_3V3uB4AtCUKH30fJZmrdFw_7_0"></a><a id="Tc_xQmQ8CtjGkW_l_mq2OzCXw_8_0"></a><a id="Tc_AQmzs8yHzUSQWUmbKWxYTQ_9_0"></a><a id="Tc_d-C5f8htnkOnAK1PWYNHsg_10_0"></a><a id="Tc_iRLP_dl4Zk-sIxLKOgr3nA_11_0"></a><a id="Tc_Uyd-rdrBkEiIt5UG28qE2Q_11_2"></a><a id="Tc_tLqVgVyFUU-3XXsF4m6XMA_11_5"></a><a id="Tc_FP2CQZ_GpEueoKGr6T5VXA_11_8"></a><a id="Tc_GKvWOZadLkKUV4awFF9f-g_11_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_Z4pGZAvaaUuFF0JY81qYSQ" continuedAt="Tb_Z4pGZAvaaUuFF0JY81qYSQ_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company recorded net revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_bcLvvX1mQkCwHOprntRvTw">45.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_f-1qg3HoykS8lLBP6EvySg">165.7</ix:nonFraction> million during the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_a4MDO_gIQE6oT4ennfW0rw">82.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_MtpiQt0g-Umb10vKvbjljA">253.2</ix:nonFraction> million during the three and nine months ended September 30, 2021, respectively.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Tb_2U1tMbmx_kKHWcJLXyzPSQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Gross revenues by significant customer as a percentage of total gross revenues are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5203018%;padding-left:0pt;padding-right:0pt;width:101.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_EMjAmcNvJU-kOgmkkZZeiA_3_2">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_MXAI7K0dnUqRQpnDD2bDzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_AwX9x64lmEyOSW6RnAxQzw_3_5">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3156mbgj9UORepDGQ616-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_qaGdmyboL0eqwhpr1DhVDg_3_8">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P30QcEujV0-5fFkIRIwjtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_J8X4nfKkqUuZVZ91ebm51A_3_11">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">AmeriSource-Bergen Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EiNpUK2b7k2PkIzqMYiCHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_ccwSbVBd_Eu2L_bQStXe3A_4_2">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aak9ct_niUi7Lq7sxeyMwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_KWS_4BfEP0WCmvbFeBapNw_4_5">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PEUy1iet8kGcmgswzbVqLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_umA9ArISd0qgjypuZ8vaAg_4_8">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vhI6ja0bQUKTRyCoU2x99g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_mSCQvhngSkWMQDhGJcihuw_4_11">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IviSwz1WNEmFo8vw--sRpQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_gN2wzr2rY0ufCZqXTPTP-g_5_2">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__IeX3c6reEm-Apq48lU1Ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_jA6h1pZRcUeY5JanahuaLQ_5_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4f86z1_gaUCyD4LR0zbwzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_R2VVJ0bvaUChdc6dHGpcUQ_5_8">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W4ZbE0h9nEqugpQqg-733w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_rIgUTBCvZkajA2pmcE48Uw_5_11">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Sales Discounts and Allowances</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" id="Tb_RY1_V707M06DHmPJHUVkbw" continuedAt="Tb_RY1_V707M06DHmPJHUVkbw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_NTm60yerS06PfnGj4p8sbg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_9eGXMpEYLkqRanNM6RhLyA_6_3">29,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_r2ythOcrUUuTOM2mUeKjUQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_6mGS0KUgIU-uHMhMWdwkxQ_6_6">54,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_5m_vF3mcb0iKQxtzWjcHZQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_dFeRu-c9fEaY-4dzJ5JJVA_6_9">26,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_CXL4KlLti0GN2Yimf0QuAw_6_12">109,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_HU43DKMTikOOw25Avd4ZPQ_8_3">321,056</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_plLuvqAV_EiANFytHQkypw_8_6">50,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ElaV8kpJ8EmrqFAsPU40mw_8_9">54,967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_8ES3zh4DqEGE0w9uP0pLPg_8_12">426,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_elNZ7l4QyEOQTlnTmhZ9vA_9_3">2,055</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_vkCJyKsjfkOBch3nV0VV0A_9_6">5,064</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_EJdMOZQWqEiK-gURDY0SPQ_9_9">181</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_TXU-e5sGgEWTY-49RVoJvw_9_12">7,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_J_v-Gvr6iE2BcXgzJKW7Bw_10_3">320,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_jjpJGnO8bESpk_Q4RMvu9g_10_6">64,869</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_3cOerRNfHUKareFEFPeLmA_10_9">61,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_g0Fnby9jcUCOiM8zvmNt9g_10_12">446,720</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_g3-gLMpZw0yYViaorsg8fw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_COEwT1P0nUWM4MrXUewFJA_11_3">28,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_S_Q2ffeVKEC2FuV_r-0CyQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_y15NTGNESEeslOkjdIwWTw_11_6">35,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_canvBDnSX0CAUr-ueKniXA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_lYGvtDN310SEvjQpYNppLA_11_9">19,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ZncGRNOE9EuYWg07gthi9g_11_12">82,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d8abf526_58d4_4c59_8e73_5e5387579062"></a><a id="Tc_pZxAAKr7SEKnjxlmZjYHaQ_1_2"></a><a id="Tc_Ht9vULIVw0ibDuZfj8d2Xg_2_2"></a><a id="Tc_7N9m5xM_AE6IIzWeKu4IOg_2_8"></a><a id="Tc_ttZNZd12d0uj8XlMc1J2cg_3_2"></a><a id="Tc_68TGKvjWFkyRjQht7cBFaw_3_8"></a><a id="Tc_JLEZ4QYhQUa4FdFoFkJtBQ_4_2"></a><a id="Tc_O5i2jZw0JUybzX5qjwVzbw_4_8"></a><a id="Tc_kQtwg0K4REm_-XpuIpPrgQ_5_0"></a><a id="Tc_eopqsLBCxkO4uJw0p2IhaQ_5_2"></a><a id="Tc_BlrALk5g1kGFc_9B-MzGew_5_5"></a><a id="Tc_s2r08dGUWEaoUMDK6g67Pw_5_8"></a><a id="Tc_VIUawPjpiEa1sCB9Tka3dA_5_11"></a><a id="Tc_UV__7sYmfkK4-3mk3SJTyw_6_0"></a><a id="Tc_R96m88KGeEulR60XelO7Wg_6_2"></a><a id="Tc_ZlpmzegxT0WS1CJLGnAzQg_6_5"></a><a id="Tc_xyVOq6mN1EGpKoDwMo6FLQ_6_8"></a><a id="Tc_M6lfVW6xcUiUj2ZTQidlIQ_6_11"></a><a id="Tc_kYJKdq7CF0S4iOnxBvoZVg_7_0"></a><a id="Tc_XumdJHEcdEy76k5fyqQebg_8_0"></a><a id="Tc_zeZqQLguP0u6MvXpVDKBRQ_9_0"></a><a id="Tc_xl1T-3NLYkCbPYkHBnTITw_10_0"></a><a id="Tc_7vtKz4dtYEichCpzj8W8Fg_11_0"></a><a id="Tc_jKANoxaOXkyiqksgHmQeBw_11_2"></a><a id="Tc_SHu2hGhRDEqBo8ChhJDypA_11_5"></a><a id="Tc_ozzqZl98U0yel4GwoAg5Ng_11_8"></a><a id="Tc_izYUBWVLpkyGZXH6pCDoqA_11_11"></a><ix:continuation id="Tb_Z4pGZAvaaUuFF0JY81qYSQ_cont1"><ix:continuation id="Tb_RY1_V707M06DHmPJHUVkbw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_vqkwbtvNdk6jZk0lQqoE8w" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_lVZgkq-YZk62hKCWC1xYEg_6_3">40,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_KqBdumQ4qkSE2fcmpfAufA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_qKwaPDpCSEGvZXtBN7-75w_6_6">54,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_gnbxKpVogk6rFKwK3_goRQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_OkykCr--w0qDZM42DE6nRw_6_9">28,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_bahNhCGKN0y7qGnQJIl_KA_6_12">123,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_wqsX_mPcLkacDuX70sKHtw_8_3">356,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_1RFGKBmndUunjrs0_lYQgg_8_6">90,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_GibhBik-XkuLElMuAXgMtA_8_9">73,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_YqDFKHJUuk2liEM_I2OFGQ_8_12">520,917</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_J6SvidAO30uM3MEB5pEIlQ_9_3">2,859</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_2M-wEpRDVUSs9F8aG6AtxA_9_6">2,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_t9UQOaUm80ClfQaR7U9Ymw_9_9">3,035</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_4LIZiaggCUi8Dr31l8iLZw_9_12">8,715</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_8Rqp4jOZPUmpx4EzjdQjmg_10_3">362,241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_4M-TIqIXtEm3Gwuxp56lWw_10_6">78,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_XR1jR2Y4a0eF0p69LCccww_10_9">75,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_xjZ3wk2wlEW_Md_pC2XySw_10_12">516,557</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_S3yaMtzKYEafjmMKoXco-w" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_muPQCFP-E0e0mq2dwGepdg_11_3">32,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_bfx-u6Wr1EqVZ6v_MBIiiA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_qDwb34SqfEOMcYgjzE-Ayg_11_6">63,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_FCwSTIPa0ECHMWQCuTIDsg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_W90HVEwNYEaLxRXFPezR4A_11_9">23,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_t7c3LAGvZkWQquEQCckumw_11_12">119,043</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities in the accompanying unaudited condensed consolidated balance sheets.</span> </p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_53e80839_b575_4936_b737_5dd64c8985a5"></a><a id="_53e80839_b575_4936_b737_5dd64c8985a5_2"></a><a id="_53e80839_b575_4936_b737_5dd64c8985a5_3"></a><a id="_6eb533cb_24dd_4fd8_94a4_80d38f6817b0"></a><a id="_6eb533cb_24dd_4fd8_94a4_80d38f6817b0_2"></a><a id="_6eb533cb_24dd_4fd8_94a4_80d38f6817b0_3"></a><a id="_1beae587_e001_4d51_bcbb_46a7e03039c8"></a><a id="_1beae587_e001_4d51_bcbb_46a7e03039c8_2"></a><a id="_1beae587_e001_4d51_bcbb_46a7e03039c8_3"></a><a id="_b0e07af2_2fb7_4a86_a443_bb0dbf46ad54"></a><a id="_b0e07af2_2fb7_4a86_a443_bb0dbf46ad54_2"></a><a id="_b0e07af2_2fb7_4a86_a443_bb0dbf46ad54_3"></a><a id="_48e46c06_29d7_462a_8c79_b8edcfb69ef9"></a><a id="_48e46c06_29d7_462a_8c79_b8edcfb69ef9_2"></a><a id="_48e46c06_29d7_462a_8c79_b8edcfb69ef9_3"></a><a id="_e4d43622_a261_46e0_b303_4262bff62aad"></a><a id="Tc_f-hayjeb1kmCD0bCpK1LWw_1_2"></a><a id="Tc_3xTbEMjPc0a3ewzJ_7aAug_2_2"></a><a id="Tc_-X2ZOONCFkejf81Zwsnitg_3_0"></a><a id="Tc_HwYgf7cEBEimky3ex1dhFg_3_2"></a><a id="Tc_Eb0Di-5rJkm3IgAXbiUwgw_3_5"></a><a id="Tc_MT9uZ0no_kysADJtbBpXmA_3_8"></a><a id="Tc_qgSY_oz7r029HPPQetaOfA_3_11"></a><a id="Tc_3F3xNvhbxUahkMRHatFJyA_4_0"></a><a id="Tc_cla24HhpdU6dkQiOb9y3og_5_0"></a><a id="Tc_5L6zrFE2QkitpyrCRnRRJQ_5_2"></a><a id="Tc_jAexqkS7O0KaGln7Mq5EDA_5_5"></a><a id="Tc_8PNR0xPwt0GHYy3EYAOA3w_5_8"></a><a id="Tc_Jjs8xeswEUucAak0_ph1BA_5_11"></a><a id="Tc_26nNMJiUrEWvXA82ASKCmw_6_0"></a><a id="Tc_kQbgl-CxPE6qGpkuAm_8NA_7_0"></a><a id="Tc_uYVxexn97EK0nILTLo_R2w_7_2"></a><a id="Tc_Pcld9cJEvEi2bfiJyN-f4A_7_5"></a><a id="Tc_Ysj4vep2uEWt7ox2DzcLCA_7_8"></a><a id="Tc_0tlQ9tC4RkOqpLCKLBmo7g_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_CcSJRDmRj0aR_aRlVAlnDw" continuedAt="Tb_CcSJRDmRj0aR_aRlVAlnDw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The fair values of financial instruments are classified into one of the following categories:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Where quoted prices are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds that are included in cash and cash equivalents, and restricted cash.</span> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="6" id="Narr_r6x-hbvLjE22nNbp5KWtdQ"><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="6" id="Narr_aEP-oHd0v0iybK67WoJV_Q">no</ix:nonFraction></ix:nonFraction> transfers between Level 1, Level 2 and Level 3 during the periods presented.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_NiA4AHpbeU6rNC7pruKdGw" continuedAt="Tb_NiA4AHpbeU6rNC7pruKdGw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wzMkWYw-jkG5Z-S_a34Cdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_lu_jNl7xM0qh7jTs_YmaXQ_5_3">286,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rP5uVqxc9EqbTFWsU--suQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4bJk6BdvnkSqqbB6WOCd-g_5_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_493Ej-l6IkadHd0s8Ev8iQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_qR8510MA7EuzIiN57XxWfw_5_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CnSVpPJZzU-M8zr97h3FzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ERd4STGECkiv-6AxPE9E7g_5_12">286,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7Ka18T27VkWuuzFhDZZuGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Nn-bmKFNskWo2mNyb6gBLw_6_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vv--ebqCnkqV5_hs0bFUXA" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_04qw2_M0oUOU-Kw_4u5GGA_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fLEz9P6UwkuwqfzYcZElYA" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_bv654wWC_EqTKiTHJhtX2w_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gcq3kr0aY0K5_CRVytES5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_tHHN5tg1Zk63tzK5MOUq4w_6_12">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OZ7xG5FttEWv9GoORmuT0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_KHAAZw4Nn0W9mMdXg7SaPQ_7_3">287,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Rq5_ejfD4E-zhmch0hzaXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_v8OZw2mGh0CBqRQ6s9fcCg_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JB1ySyU9gkuJVo799k_sDQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_l4pfqXb2t0erT4a0fWRvsQ_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_urBwu9TfakKWHu4-f9eB6w_7_12">287,245</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fab97571_eabf_44a6_9837_6410ac9472e6"></a><a id="Tc_rYrGs7qbd0KeOdzEae0epA_1_2"></a><a id="Tc_f9yK-Os7hkmBJVA3oFwv5w_2_2"></a><a id="Tc_FWJ09gNEAEuktc4_XjBzlg_3_0"></a><a id="Tc_J9O0PW3O_km0onwNN16OIg_3_2"></a><a id="Tc_MpzFaLJC4kGf_C8dK8kRUQ_3_5"></a><a id="Tc_J7ygC0VJZESaOxAYG2qPKQ_3_8"></a><a id="Tc_PSSckankNki3fUG8tnqL3Q_3_11"></a><a id="Tc_9TeP7-L5L06nnnnOFCSUzA_4_0"></a><a id="Tc_VUh1WjPJiEybgrsajef9HA_5_0"></a><a id="Tc_EREaJhru_UO9GxqCrEWjXg_5_2"></a><a id="Tc_RXmrqzi4-EKapYR-h0CYkA_5_5"></a><a id="Tc_kPsKS_iF1UqAIth9vs8nmw_5_6"></a><a id="Tc_B35jHvzyxEeA1nYk3uNnSw_5_8"></a><a id="Tc_ZfcDIanKekC2nyE5IC4cJQ_5_9"></a><a id="Tc_juFn30fmtECpKalisnsm6w_5_11"></a><a id="Tc_gWbKORH9VUmWRfzBb-Jrog_6_0"></a><a id="Tc_SoJRvCqo0keDpogQvF7OEw_6_6"></a><a id="Tc_qPoQxkEQAUWyh4vcUv0vWg_6_9"></a><a id="Tc_wCmRk-8XDEm1FG-MceyssQ_7_0"></a><a id="Tc_WaVXqt6a-EKc8DVsxnrGfg_7_2"></a><a id="Tc_5QcoMVHHI0e68gA5RAnoeA_7_5"></a><a id="Tc_OzaoyAq_ekypy3D-Grll6A_7_6"></a><a id="Tc_5Q8cb2Fdd0mXiVbnzTId9Q_7_8"></a><a id="Tc_D0e_ycqM0U26SLb5w9VGEw_7_9"></a><a id="Tc_M_7-gjQePkiokYj0d4RXRA_7_11"></a><ix:continuation id="Tb_CcSJRDmRj0aR_aRlVAlnDw_cont1"><ix:continuation id="Tb_NiA4AHpbeU6rNC7pruKdGw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-GKhnbmx6EqrslRQyD5gVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ipkwzPMU8kOKI_8XMTPVoA_5_3">417,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kn89hn5N_US1XfKr0SQ33Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_nIRejwbFaUic0ISy0RQi0Q_5_12">417,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zkV-yxWOFkCnW-ddikAq5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_na0N20oQDESj4llOJjJ4iA_6_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h5ZptWvOE0uCY9Ybl5SojA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_m_MmvTiDD0CjO7_W89PLnw_6_12">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VlaCc70eukKJoN2_W3ugDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_YlmWeOn_UUqm4mNpqh8w9w_7_3">417,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnYHy2xhCkCb9J7p4hkgRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_hoCtmyU2wkGk2d3GPaMbVw_7_12">417,605</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_66575261_72d6_4cdd_9d34_2faed557c020"></a><a id="Tc_kmpRE7LkXkKys2Zbf7ZJ0Q_1_2"></a><a id="Tc_QZnbuJxwhkqRjSt2dqnmYg_1_5"></a><a id="Tc_DBP-EMlb_E6fkKgFr5eMkA_2_0"></a><a id="Tc_DgdtTmRCB0WmT-OTOl-m3Q_2_2"></a><a id="Tc_PSYF_J4Gr0CL8V5cx8g5YQ_2_5"></a><a id="Tc_mAbWFQcHIkOC-_Jc77aKnA_3_0"></a><a id="Tc_EMThbqRiKEKmGfBToz33Kg_3_2"></a><a id="Tc_Dt20Dpkp2UiUJWPG-1ajYg_3_5"></a><a id="Tc_jSK-6lwca02meXRNAvHYyw_4_0"></a><a id="Tc_kcQ_JVENRU-JmpUIEE23XA_5_0"></a><a id="Tc_T3s_UzL1RkuoWl0jLemwSA_6_0"></a><a id="Tc_ttlaUkzmGUqga7Ahunolow_6_2"></a><a id="Tc_kRgNLeApPEqANeNoI649Tg_6_5"></a><a id="Tc_PGn8kUNAFUmE6bIamMVTLg_1_2"></a><a id="Tc_3zbSTl-lqE-vbvB-_-CyOQ_1_5"></a><a id="Tc_-jirkkrLj0GS_xzrd6D2qg_2_0"></a><a id="Tc_v4hG3UCt80iQDyurQa_tNA_2_2"></a><a id="Tc_6UoSNZx7Nk-ajnFkvO7OyQ_2_5"></a><a id="Tc_HH4zhd5gz0-HPaa3QzEQDg_3_0"></a><a id="Tc_Q5Px-NksJkq3DieIvMXEVQ_3_2"></a><a id="Tc_gpiwRws9VUqQOxY4e_Gp6A_3_5"></a><a id="Tc_RN-TQn3LTECklZdKRkgBLg_4_0"></a><a id="Tc_KjplF1YpYUuHOqbjTRWENw_5_0"></a><a id="Tc_BbmYo9L1w02TKKxybrn_FA_5_2"></a><a id="Tc_6k2geWCHo0e_-IXRsVnifQ_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_ade33Wli902o9NYCu4gXEQ" continuedAt="Tb_ade33Wli902o9NYCu4gXEQ_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="chrs:ScheduleOfInventoryTableTextBlock" id="Tb_I-WXVlNjtkyd3_Z2ZT6QXg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_SHmDGbVStEeG8SXbkQuSuA_3_3">10,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_4xcKvIQ1mUSwdDmO9Lr7Cw_3_6">4,870</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_PSVs5q7NF0m_XMqHAA-5EA_4_3">77,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc__Ook4Gln60a5FYJWGLKG-A_4_6">65,117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_nQ784kTN3kGJ0Xc9Ket2qA_5_3">17,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_uUYdULZDNkKxnVOLtaxQ8g_5_6">23,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="Tc_qZbUJ3HrPEWESRj8XGUhig_6_3">105,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="Tc_nxh1hGdkH0q10TWMtkBHnA_6_6">93,252</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During the third quarter of 2022 and 2021, the Company recorded write-downs of inventory of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_XLNap-_BM0S25dihIZKcEw">26.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_I9O_bUd9s0WxOIJToWt8_w">5.2</ix:nonFraction> million, respectively, in cost of goods sold in the condensed consolidated statements of operations. The write-down during the third quarter of 2022 was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration, which increased net loss by $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-5" format="ixt:numdotdecimal" name="chrs:EstimatedIncreaseDecreaseInNetIncomeLoss" scale="6" id="Narr_4SrdoH92fU6rEFnzuXl0kA"><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:EstimatedIncreaseDecreaseInNetIncomeLoss" scale="6" id="Narr_XdBHyDSXC0aVEJkCkIzY7g">26.0</ix:nonFraction></ix:nonFraction> million and basic and diluted net loss per share by $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="2" format="ixt:numdotdecimal" name="chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" scale="0" id="Narr_PM1J_BKJ30-J8Li5wOobLQ">0.33</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="2" format="ixt:numdotdecimal" name="chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" scale="0" id="Narr__iA7ewMImEuscDRr7-wknA">0.34</ix:nonFraction> per share for the three- and nine-month periods ended September 30, 2022, respectively. The inventory write-down during the third quarter of 2021 was for inventory that did not meet acceptance criteria. Inventory reserves were $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="Narr_KfeXNCYoL0m6QKBrc-tp_A">26.0</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="Narr_QKeUZ7ZRUEe-mVFTrmIy0w">0.2</ix:nonFraction> million as of September 30, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company began capitalizing YUSIMRY inventory in the second quarter of 2022 and had $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_ProductOrServiceAxis_chrs_YusimryProductMember_JbvK-d-MGECmbZL_2UDv9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="Narr_UctsxIulpUuR3QqzKlg7UA">24.6</ix:nonFraction> million of such inventory recognized on the condensed consolidated balance sheets at September 30, 2022. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current on the condensed consolidated balance sheets. As of September 30, 2022 and December 31, 2021, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following tables presents the inventory balance sheet classifications:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="chrs:ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" id="Group_oehF2OA_jE6nCZ1pDDJiBQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Qu-zh5vtB0enpMZtbRWL1Q_3_3">27,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_V8h95cVH1E-76-xEj22KjA_3_6">37,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_30wgIp6A2UWUoY6yWf0JAw_4_3">77,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_KO8k68u31kq_m0xaMuJ2tQ_4_6">55,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:InventoryCurrentAndNoncurrent" scale="3" id="Tc_SWM1VWWvxUSJziu-GQvyow_5_3">105,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:InventoryCurrentAndNoncurrent" scale="3" id="Tc_vATGsAznn0eT4SY1CwrAZA_5_6">93,252</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Prepaid manufacturing of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="6" id="Narr_CxM4BkQ1FkiRQLpQ_RuAsA">20.6</ix:nonFraction> million as of September 30, 2022 includes prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForManufacturingServices" scale="6" id="Narr_g4yXP8_hUEysCTPdec4K2g">16.6</ix:nonFraction> million to contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing services for our products, which the Company expects to be converted into inventory within the next twelve months; and prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" scale="6" id="Narr_0ndJstbNgUm0eRr1QuAW6Q">4.0</ix:nonFraction> million to various CMOs for research </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ade33Wli902o9NYCu4gXEQ_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">and development pipeline programs. Prepaid manufacturing of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="6" id="Narr_b1NJx2-OnUmZ28crsGDW8w">13.7</ix:nonFraction> million as of December 31, 2021 included prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForManufacturingServices" scale="6" id="Narr_cFxeMI4KykKQUUHZtegHVA">8.3</ix:nonFraction> million to a CMO for manufacturing services for UDENYCA; and prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" scale="6" id="Narr_Ooskb1SFWk2UqGRFj_byFw">5.4</ix:nonFraction> million to various CMOs for research and development pipeline programs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea&#174; as part of a realignment of research and development resources toward other development programs. As a result, during the quarter ended March 31, 2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_ihiIu3McBkWodWSPBrrhmg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_WTvWTBrkSkuSiJcWpyvEPw">11.5</ix:nonFraction> million within research and development expenses on its condensed consolidated statement of operations, which included an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnContractTermination" sign="-" scale="6" id="Narr_pi2Ft4WyXUqmj4sb9B4IqQ">3.2</ix:nonFraction> million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_12_31_2021_y7OZ_vllI0mGatYYUEzb9A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnContractTermination" scale="0" id="Narr_gg41X0oMXUGM00mJklPkWw"><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnContractTermination" scale="0" id="Narr_hlFdlwk8X0uHzrG3daakmg">No</ix:nonFraction></ix:nonFraction> material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b875d317_87a8_4cc1_b16d_163694a8d782"></a><a id="Tc_RCN57tVMz06R5gO_h2pr3Q_1_2"></a><a id="Tc_a4UNjht8tUyFznn1Aos7QA_1_5"></a><a id="Tc_zaDQ9trvX0qgVOzs-WK9Wg_2_0"></a><a id="Tc_VcqYzUkOjUS1zoOYlqO8jQ_2_2"></a><a id="Tc_eEb_MZGtj0mUSQy3EagAZw_2_5"></a><a id="Tc_MRaZswm9aECQp_HpIKm_8Q_3_0"></a><a id="Tc_qkfeMv9IQU6_-_xdvnM63w_3_2"></a><a id="Tc_zHdFPLWl6UiHIeKrqFccQA_3_5"></a><a id="Tc_zCTex6P6BESIMOcSizf2sw_4_0"></a><a id="Tc_S3vOdDbl7ESsOP92WCFfNw_5_0"></a><a id="Tc_-H-S_ljO7U6riZ8ytU4rEw_6_0"></a><a id="Tc_j3sjxxs-gkOE6JAgEcUDPQ_7_0"></a><a id="Tc_ju3zP5pX-EOuTarOx58DOw_8_0"></a><a id="Tc_46IXG6novkWOgHrucbxVNA_9_0"></a><a id="Tc_mqSqv223jkyMpcHRD0cj5w_10_0"></a><a id="Tc_xAy5jR43tUq4Ld5dCOKmYw_11_0"></a><a id="Tc_lVzmCXEou0S430gwZQluag_11_2"></a><a id="Tc_AGyvHaLl_EyegdRjzS6BSg_11_5"></a><a id="_6bf8482e_b06d_4610_be32_5647d7294ab7"></a><a id="Tc_rep3gA-2FUaf9dnoVwHuww_1_2"></a><a id="Tc_LxvCrhmXtE2vrWC1fXvTHw_1_5"></a><a id="Tc_A6YN57q6n0Si6ubcmmICFQ_2_0"></a><a id="Tc_n2Tk9w_2LE6THn572ckZYw_2_2"></a><a id="Tc_YK7sIY5j_UG6oVMl3q3v2w_2_5"></a><a id="Tc_xifXL9hRuUGPYg_Va7yp1w_3_0"></a><a id="Tc_iCZ41Up060GEc5tIyfSWHg_3_2"></a><a id="Tc_bOTEzs4Z6kaE83GsQmvQmg_3_5"></a><a id="Tc_nw7527dSpESOgDIgVB6uSA_4_0"></a><a id="Tc_wuH7OVLBjEqnuqVhC25HAg_5_0"></a><a id="Tc_e_VH6jj_tkmlnDPyjFoUQQ_6_0"></a><a id="Tc_-DusvmGZaki30xVuVHMYHQ_7_0"></a><a id="Tc_6X62YhBeAU2ONpvMKTesxw_7_2"></a><a id="Tc_qUTPGOhJnUW3pXqGTewpyw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_6sEg06ZG4U2vHkj6hDXIrg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Balance Sheet Components</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_cAICcqMvkUeaMiIa_jpIfQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_inJcJWO_YkiWXRyFQlnw4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_EvoZ3bBXbEO6fqdWmoD8XQ_3_3">12,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_2dIU4Wv5tE6Evkjk6He0eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_wDXFBc9vsk6Fbiax4aBH_w_3_6">11,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ghgoc7GaRUiVIJi-rnTZKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc__GCtQjzq30qPliUDzDZtDA_4_3">3,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_8yRk0_sXYUyHmkgGMlwvkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_nUN3hNUALUSz9ayJpv5xSg_4_6">3,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_d9EHcCoTPk-AEH8jjwR_JQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_-ED5RPpOQkOLTuxKiOQTHQ_5_3">1,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B2ODLCj890aKQI7OAcmbTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_GRy8_BOnoUaZMveKrrG01g_5_6">1,129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LqG5RoqoJEeZzKbXCggF-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_ZxUtUYEekUyENBcJmVfJ4w_6_3">6,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_k4tZxvbaTESkkzwTRJUQcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_d-HUckoJkkWCMtp_yysuWQ_6_6">5,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3qhcXT0gtkypEYBUMeOpTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_iMVeN0dGg0ur8uydq8CSSg_7_3">4,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_clg6kOzlW0-1bv2N8PSJDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_lmzPxEJHEUCfzNlCrxwt8g_7_6">2,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_yRUVgXSoDEydOBMMHjKAow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_4Deuujn-Y0GMwz6b-2e8EQ_8_3">845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1UFzj38Bbk-gQfCQaA9EHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_aNhDw5yEY0uia9SLl3Y4GA_8_6">388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_XJBxqIjEJkKndqWGTf-mKw_9_3">28,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_bRXtTbXaf0SxzwElydEwTQ_9_6">24,662</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_58cfxSk-NEmCvBo4QaQ0Fg_10_3">19,319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_ACGg_hyJ_UOGIUYKeCmRIw_10_6">16,849</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_LLspQ0NhX0GHii6HAmJ1Gw_11_3">9,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_twxoXKHYIUmdJFXZJ-_BiA_11_6">7,813</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;">Depreciation and amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_yNnVu9UsIEuOneNJYNmInA">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_8tPNjCXT90WPTqsaCHwqGQ">2.6</ix:nonFraction> million&#160;for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_xkQoyTotW0-y_cuB8YuIKQ">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_sjsws-xi0k6pbvoK3Q9JWA">2.6</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.<span style="color:#ff0000;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Current Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_8OzdxdY4QkewRzGpk-fwUQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" scale="3" id="Tc_ji7S4eZEbEuTswo2UziMKw_3_3">51,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" scale="3" id="Tc_dDdnB3y9KUaNe8PD-ad6ng_3_6">30,541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued co-development costs payable to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences" scale="3" id="Tc_C_vGGH6qs0ibxMaonqpnbw_4_3">17,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences" scale="3" id="Tc_R6vWjTudJECDPAezl0BwJQ_4_6">1,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="chrs:LeaseLiabilitiesOperatingAndFinancing" scale="3" id="Tc_mqKS_uCqT0-OiWKLwRsflg_5_3">4,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="chrs:LeaseLiabilitiesOperatingAndFinancing" scale="3" id="Tc_H8FFU9TWL0e7fch281cesw_5_6">3,492</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_yrhCNHKM4kCUVVLvxzdAjg_6_3">12,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_5psQTG7AgkSJ0Xz16wruxg_6_6">12,168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ppGAAnHjYUuEPfYa33bOrw_7_3">85,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_WOlaZOJMsECAU65oBSQqtw_7_6">48,127</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk86751062"></a><a id="_Hlk106783636"></a><a id="_Hlk78976492"></a><a id="_Hlk106719049"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_yMqhl7DFg0ilFCQEhiG2cw" continuedAt="Tb_yMqhl7DFg0ilFCQEhiG2cw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Collaborations and Other Arrangements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Junshi Biosciences </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the &#8220;Collaboration Agreement&#8221;) with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#8217; anti-PD-1 antibody, in the United States and Canada. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the terms of the Collaboration Agreement, the Company paid&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_VG-QQcb_7U6UnncjAiCkug">150.0</ix:nonFraction> million&#160;upfront for exclusive rights to toripalimab in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to <ix:nonFraction unitRef="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA" decimals="INF" format="ixt-sec:numwordsen" name="chrs:CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" scale="0" id="Narr_LTyZesAsb02umQGc9BR4CQ">two</ix:nonFraction> undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of toripalimab in the United States and Canada. The Company will be obligated to pay Junshi Biosciences a <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ" decimals="2" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales" scale="-2" id="Narr_a4xBZxc8qUe1ZJ_vw29Wqg">20</ix:nonFraction>% royalty on net sales of toripalimab and up to an aggregate&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_k-3RgBaCqUq-ucT3E9EGSg" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementThresholdRoyaltyPayments" scale="6" id="Narr_k4G20Ol4mU2V-Cek-UNwgw">380.0</ix:nonFraction> million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In March 2022, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_3_1_2022_To_3_31_2022_-oXBZarHtkK0JSkSA05zDg" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementOptionExerciseFeePerProgram" scale="6" id="Narr_JUMkpcpdPE6_vLLzxRXfKg">35.0</ix:nonFraction> million for the exercise of its option to license CHS-006. The Company will lead further development of CHS-006 and will be responsible for the associated development costs as set forth in the Collaboration Agreement. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay an additional option exercise fee of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_dj746ZuzZEuFlhD-iyPunw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementOptionExerciseFeePerProgram" scale="6" id="Narr_kB8WpjOX3k2XwSeMV-6c4w">35.0</ix:nonFraction> million. Additionally, for each exercised option, the Company will be obligated to pay Junshi Biosciences an <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA" decimals="2" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" scale="-2" id="Narr_5GzFO-o74EW_KwG8zW5I1A">18</ix:nonFraction>% royalty on net sales, up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDVgIzSJCEyihHczolrtHA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" scale="6" id="Narr_-9xshifxjUuts_kMQxYdeA">85.0</ix:nonFraction> million&#160;for the achievement of certain regulatory approvals, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_cD5KRETU-UOVx1YHhrwR2A" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" scale="6" id="Narr_HQGtQPDLO0aR-e-ruA9sSA">170.0</ix:nonFraction> million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of toripalimab and the other licensed compounds, including CHS-006, and will pay for a portion of these co-development activities up to a maximum of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA" decimals="-5" format="ixt:numdotdecimal" name="chrs:MaximumAmountPaidCoDevelopmentActivities" scale="6" id="Narr_ofLpt1G7dEGs3FH-IL08eQ">25.0</ix:nonFraction> million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for toripalimab and other licensed compounds and will reimburse Junshi Biosciences for such costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_1qOFFGpSOkmstIVIX3zj7Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_-72Hn-bcSkGbw1gDtg7xSQ">7.6</ix:nonFraction> million in the third quarter of 2022 and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_7jfBPaL450eXa1Y2g46z5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_1YSpYo7DDECKViPfIlHwnA">67.6</ix:nonFraction> million in the nine months ended September 30, 2022, inclusive of the $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_FgRJm8jDqkSf5ige14aHFw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_kkF0Ox__-0mhbWzFe_rYkA">35.0</ix:nonFraction> million option fee incurred in the first quarter, and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_84R_iMTr3kerbyr6upUqew" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_SJxkY6i_WkWKbu4-j5eJmA">15.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_lSeY1zTOCE6BV42943qNiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_u2NZJAGjD0KI2mXhlvCnkQ">173.6</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively. The first quarter of 2021 included $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_287011mlzEmiZ0X0m6eNuQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_NMIUgg3A70KtFetn7aPg2g">145.0</ix:nonFraction> million for the upfront payment for the exclusive rights to toripalimab and the second quarter of 2021 included a credit of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDCtyjQAwkKPEG_SutcvdQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_ahMeTOPRNEajZxEXiboKjw">9.0</ix:nonFraction> million for the discount for lack of marketability (&#8220;DLOM&#8221;), discussed below. Accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022 included $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_MTxWxPxnDkiqyDu_XrhHiw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts" scale="6" id="Narr_6nNsTnAGQ0m93tDB9sAb6Q">17.5</ix:nonFraction> million related to the co-development, regulatory and technology transfer costs related to these programs. The Company entered into a right of first negotiation agreement with Junshi Biosciences and paid a fee of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_AMgKdK-BQEurLZKKdbATnw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_SGxiPeuB9U-6wAKfW3ie-g">5.0</ix:nonFraction> million which was fully expensed as research and development expense in the fourth quarter of 2020. The right of first negotiation fee was fully credited against the total upfront license fee obligation under the Collaboration Agreement. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Junshi Biosciences. The additional milestone payments, option fee for the IL-2 cytokine&#160;and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA" decimals="0" format="ixt:numdotdecimal" name="chrs:StockPurchaseAgreementSharesAgreedToBeIssued" scale="0" id="Narr_O9_j65Xm8kGmiKsUD3H4jQ">2,491,988</ix:nonFraction> unregistered shares of its common stock to Junshi Biosciences, at a price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_wUXO1sTam0mcWhwFoAdM_g">20.06</ix:nonFraction>, for an aggregate value of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA" decimals="-5" format="ixt:numdotdecimal" name="chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue" scale="6" id="Narr__4nhjuELPEya_uorMphXHw">50.0</ix:nonFraction> million cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences is not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the&#160;<ix:nonNumeric contextRef="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iM8hqKoK6kGGORI4m24fvw" format="ixt-sec:durwordsen" name="chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" id="Narr_lSQ4oxtyX0WYrTgWbRQIhw">two-year</ix:nonNumeric> period </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk78976367"></a><a id="_Hlk78976406"></a><ix:continuation id="Tb_yMqhl7DFg0ilFCQEhiG2cw_cont1" continuedAt="Tb_yMqhl7DFg0ilFCQEhiG2cw_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#8220;Finnerty&#8221; and &#8220;Asian put&#8221; valuation models and determined the fair value for the DLOM was $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA" decimals="-5" format="ixt:numdotdecimal" name="chrs:FairValueForDiscountForLackOfMarketability" scale="6" id="Narr_lru5z3CQGE-DwGbEsHM_2Q">9.0</ix:nonFraction> million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the condensed consolidated statement of operations for the three months ending June 30, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Innovent&#160;Biologics (Suzhou) Co., Ltd. </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:8.2pt;"></span>On January&#160;13, 2020, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) with Innovent for the development and commercialization of a biosimilar version of bevacizumab (Avastin) in any dosage form and presentations (&#8220;bevacizumab Licensed Product&#8221;) in the United States and Canada (the &#8220;Territory&#8221;). Under the License Agreement, Innovent granted to the Company an exclusive, royalty-bearing license to develop and commercialize the bevacizumab Licensed Product in the field of treatment, prevention or amelioration of any human diseases and conditions as included in the label of Avastin. Under the License Agreement, the Company also acquired an option to develop and commercialize Innovent&#8217;s biosimilar version of rituximab (Rituxan&#174;) in any dosage form and presentations (the &#8220;rituximab Licensed Product&#8221; and together with the bevacizumab Licensed Product, the &#8220;Innovent Licensed Products&#8221;) in the Territory.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the License Agreement, the Company committed to pay Innovent a $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_7BAAp7AzFUi5t7RIgh1cKQ">5.0</ix:nonFraction> million upfront payment and an aggregate of up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" scale="6" id="Narr_EqHrQEZRTU6-_VjBNAa-xA">40.0</ix:nonFraction>&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the bevacizumab Licensed Product and, if the Company&#8217;s option was exercised, an aggregate of up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_OptionExerciseFeeMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_uiPlNyA8AkK6KThMVOfv-Q" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" scale="6" id="Narr_7KIezKnTxkOYct-d8TB1vg">40.0</ix:nonFraction>&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the rituximab Licensed Product. The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. During the three and nine months ended September 30, 2022, the Company&#8217;s research and development expense related to bevacizumab Licensed Product development activities directly with Innovent was immaterial. <span style="background:#ffffff;">During the three and nine months ended September 30, 2021, the Company recognized research and development expense of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_FAORKnYJyESjSDSKaLODGw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_hIaUBpZhjEu2jYaUbaHmnA">0.5</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_Yibptfnp5UWmdGj-9kWtqw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_O9pYChuNWES7_rSClbGNjA">1.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million, respectively, related to bevacizumab Licensed Product development activities directly with Innovent. </span>As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Innovent.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On May 3, 2022, the Company provided notice of termination of the License Agreement to Innovent pursuant to Section 13.6 of the License Agreement. In connection therewith, the Company has discontinued development of the bevacizumab Licensed Product.<span style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Bioeq</b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;">On November&#160;4, 2019, the Company entered into a license agreement with Bioeq AG (&#8220;Bioeq&#8221;) (the &#8220;Bioeq License Agreement&#8221;) for the commercialization of CIMERLI, a biosimilar version of ranibizumab (Lucentis), in certain dosage forms in both a vial and pre-filled syringe presentation (the &#8220;Bioeq Licensed Products&#8221;). Under the Bioeq License Agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. The Bioeq License Agreement&#8217;s initial term continues in effect for <ix:nonNumeric contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ" format="ixt-sec:durwordsen" name="chrs:InitialTermOfAgreement" id="Narr_Vhp0q5C8c0yiYEmbzULXcw">ten years</ix:nonNumeric>&#160;after the first commercial sale of a Bioeq Licensed Product in the United States which occurred on October 3, 2022 and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq License Agreement and a manufacturing and supply agreement between the Company and Bioeq dated as of September 29, 2022 (the &#8220;Bioeq Manufacturing Agreement&#8221;) and will remain in force until the first to occur of the following: (1) the termination of the Bioeq License Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yMqhl7DFg0ilFCQEhiG2cw_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Under the Bioeq License Agreement, the Company must use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company must commit certain post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;">The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA" decimals="-6" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_dQtmLy_WwkehJmpF-vltTQ">10</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA" decimals="-5" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_CEmQUTSYtUenCz8KZNAs4A">11.1</ix:nonFraction>&#160;million), which was recorded as research and development expense in the Company&#8217;s consolidated statement of operations in 2019. The terms of the Bioeq License Agreement include an aggregate of up to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA" contextRef="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_Lph8a238DkeDMCSZPU71Og" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" scale="6" id="Narr_qem1UGDAbEC_CskC-YnpEw">12.5</ix:nonFraction>&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA" contextRef="Duration_8_2_2022_To_8_2_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rAiEo9Y69EihH3kDtMl5ug" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" scale="6" id="Narr_gr5naIStnES7qhNcE2zV4w">2.5</ix:nonFraction> million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA which occurred on August 2, 2022 and certain other criteria which were satisfied in October 2022. The obligation to pay this milestone was recorded in accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022. The Company will share a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low to mid&#160;<ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ" decimals="2" format="ixt-sec:numwordsen" name="chrs:PercentageOfGrossProfitsOnSales" scale="-2" id="Narr_lOI8Mpq1_E-g_7rFt5KuPw">fifty</ix:nonFraction>&#160;percent range. The remaining milestone payments and royalties are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved or when royalties are incurred.  </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_1ccb8a6c_fcbf_4c2a_a594_faf0087b6f36"></a><a id="Tc_aQwtNMMVT0SxzHiTtAn2_A_1_1"></a><a id="Tc_VkuaDKETBkuN8rDcgDqGtQ_2_0"></a><a id="Tc_7P0xIhvEVkKbn_JImR8drw_2_1"></a><a id="Tc_Vm40Aw4vxUiM2YbMJLYTsg_2_5"></a><a id="Tc_CX7XdP7F_U2ggzfcc25fmQ_2_7"></a><a id="Tc_bRRrcz2Edkq6oNNAG0QqGA_2_10"></a><a id="Tc_CKzMzhoCl0uLW6MLfrQP_w_2_13"></a><a id="Tc_dTnqAEI8XUeZ1KoQI9jdgw_3_0"></a><a id="Tc_sdqcXOO1zEuKfIu_ZzHDvg_4_0"></a><a id="Tc_NC0ajvBSCUqpXMMRQBdV1w_4_1"></a><a id="Tc_jk_3xOW-lEeZmmDUucxlAA_4_4"></a><a id="Tc_o_4d86UF4k6-V2unH8kIMg_4_7"></a><a id="Tc_Hi7RuNZZ0027kZEo30RQ4A_4_10"></a><a id="Tc_qywKd1uL5km0HdS8jYTufw_4_13"></a><a id="Tc_v-HKeCCTi0Ktvak-4hjMVw_5_0"></a><a id="Tc_vFXAutlwkUWsx1ROc0VxSQ_5_1"></a><a id="Tc_rZ1O-wtVHk6bDmBjw1yBLA_5_4"></a><a id="Tc_WP8-udBykkSsoiiv91-eYw_5_7"></a><a id="Tc_j0w9nPdBZESFROKM1-zj1w_5_10"></a><a id="Tc_FyEN7FBroUaAl3fj9n2iCA_5_13"></a><a id="Tc_OTCuqvhPG0ewVy2qXUN0Cg_7_1"></a><a id="Tc_IFzSD6Z-80a5Q9cBF75ykw_8_0"></a><a id="Tc_7kawxA07ME-a5WipfZ8JBA_8_1"></a><a id="Tc_eimc5lBHxUCDGGeZEBsM0g_8_4"></a><a id="Tc_Tu5oMlcDL0-saNDOvRCjcQ_8_7"></a><a id="Tc_pYHKuo6Z20qd11MTDhzZWQ_8_10"></a><a id="Tc_meSnd0dlFUCaN9i463JaqQ_8_13"></a><a id="Tc_L_m33T4llEGVBlhcm25tSQ_9_0"></a><a id="Tc_C_hSylWt3k-M5UHhGOFepA_10_0"></a><a id="Tc_ih6gNyEnPkKHSIPhzYEK2A_10_1"></a><a id="Tc_NL8lKPoNyE-s0Mfr3Xyptw_10_4"></a><a id="Tc_h2R-e0xWgEi4RlB1u5bG4w_10_7"></a><a id="Tc_TtphByyRok-FvQ1obN1S6g_10_10"></a><a id="Tc_NE4w4rNS9EaFJ9p6Xi0qAQ_10_13"></a><a id="Tc_uHoc31n_40Gdim-5rSQfeQ_11_0"></a><a id="Tc_B5zcPyo1aEqoxywopXRdDQ_11_1"></a><a id="Tc_9YsAiXU-o0qXZsoG1ij58g_11_4"></a><a id="Tc_6pm7bBFCXEyh2x0cHpE1FQ_11_7"></a><a id="Tc_Z8EpeO8v_0y07Tbc_oxN7g_11_10"></a><a id="Tc_ypRWb9NfPUuyxv-v1YJlYQ_11_13"></a><a id="Tc_umIQWiBB0U-eHso13AIaAA_12_0"></a><a id="Tc_Evmer8N1C0SV1NBSaj7heg_12_1"></a><a id="Tc_s_FnJwa1sE21RgcD4V69iA_12_4"></a><a id="Tc_4TwLzjUtRUKRbIHNpL6x3g_12_7"></a><a id="Tc_f7GLP4e3c0WE5KwPgk-oQQ_12_10"></a><a id="Tc_JjXFzaJK3UGPzvqiKgMTWw_12_13"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_ranbE7plx0Gi7ib0js3lSA" continuedAt="Tb_ranbE7plx0Gi7ib0js3lSA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt Obligations</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="Tb_JyUER1LECU-3R_q3GsKSIQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 9pt 0pt;">A summary of the Company&#8217;s debt obligations, including level within the fair value hierarchy (see Note 3), is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_Otgz4GSGFkCAG6blm1e_VA_4_2">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" sign="-" scale="3" id="Tc_iLwpkTzjg0eAcCgmZwyaYg_4_5">4,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_SucPvTMg6E-DOh-JYXnkXQ_4_8">245,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_k1F5sWr00Eq1AYxINJenIA_4_11">245,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_L3_F7WIGBkmTE42O2WEN2g_5_2">230,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" sign="-" scale="3" id="Tc_AGWniHgp_06IgwVVctBJ8A_5_5">4,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_-83CaLAteUCCOvRbgaawDw_5_8">225,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_Xk8wFd_7HEyLQY5-Gc0abQ_5_11">175,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Exit Fee, Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_eOOKtGddQ0yv5EOiJStQIA_10_2">230,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" sign="-" scale="3" id="Tc_Vqrz49xHOku5sIPlusw0zQ_10_5">5,712</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_fuxyRdIfdECGGJQz-dckVA_10_8">224,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_lvukmfD_uUupzrKIZbwqJA_10_11">271,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_SqXdT_GETEKrdVqK-4weLQ_11_2">109,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" sign="-" scale="3" id="Tc_WrCVtdF6O06ganl7ieQomA_11_5">521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_9h6NQuDiPUW4PU1K-PS-gA_11_8">108,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_XKdzR-sAd066bAnlPlhB2g_11_11">108,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 3</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025 Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_njLxf4lTJ0m8PmyFnjVtlg_12_2">75,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_K7ho3ac4bUCZ3ii9M7wnCA_12_5">513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_RM63L4TviUO2zhAyd-2xzw_12_8">75,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_jQVn0qkneU6_Xuh5eWOXVg_12_11">75,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month LIBOR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2027 Term Loans </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company entered into a loan agreement (including as subsequently amended, the &#8220;Loan Agreement&#8221;) with BioPharma Credit, PLC, (as the &#8220;Collateral Agent&#8221;), BPCR Limited Partnership (as a &#8220;Lender&#8221;), and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#8220;Lender&#8221;) that provides for a senior secured term loan facility of up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_4Dem1FxmC06LtE-OUORmJQ">300.0</ix:nonFraction> million to be funded in <ix:nonFraction unitRef="Unit_Standard_tranche_irYBJZf4GU-2pDQ3aghfCg" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w" decimals="INF" format="ixt-sec:numwordsen" name="chrs:DebtInstrumentNumberOfTranches" scale="0" id="Narr_U0q2mu_PGk2-x2fm0XiVgw">four</ix:nonFraction> committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_qqqXHtfBs0OufPeCKnuFoQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_AWA4KvZRdUK8q3mRrxf8rw">100.0</ix:nonFraction> million (the &#8220;Tranche A Loan&#8221;) that was funded on January 5, 2022 (the &#8220;Tranche A Closing Date&#8221;); (ii) a Tranche B Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_y3NUpqMtykOfPkCBXVXGwg">100.0</ix:nonFraction> million (the &#8220;Tranche B Loan&#8221;) that was funded on March 31, 2022; (iii) a Tranche C Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember_kdQLio7HLEqitGwRYsXFkA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_etf0v29ry0yPQ5Fou4nXOQ">50.0</ix:nonFraction> </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ranbE7plx0Gi7ib0js3lSA_cont1" continuedAt="Tb_ranbE7plx0Gi7ib0js3lSA_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">million (the &#8220;Tranche C Loan&#8221;) to be funded at the Company&#8217;s option between April 1, 2022 and March 17, 2023, subject to certain conditions including the first FDA approval of a BLA for the Company&#8217;s product candidate toripalimab in the United States; and (iv) a Tranche D Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_AUukf7jhKUan3koVylcb5w">50.0</ix:nonFraction> million that was funded on September 14, 2022 (the &#8220;Tranche D Loan&#8221; and, together with the Tranche A Loan, the Tranche B Loan, and the Tranche C Loan, the &#8220;2027 Term Loans&#8221;). The Company has the right to request an uncommitted additional facility amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_FPqARq6mV0masUy1BsR29w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_JH1BCdeiUEKsNg5oFVi4Ow">100.0</ix:nonFraction> million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#8217;s 2026 Convertible Notes is greater than $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nxmJVGXvoESV6WgNqF9pPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_h6EHC9-hBk-yQ0n5nsKrbw">50.0</ix:nonFraction> million on October 1, 2025. The 2027 Term Loans bear interest at <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_FPjdu0G0fkuq2cELi3vxqQ">8.25</ix:nonFraction>% plus three-month LIBOR per annum with a LIBOR floor of <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_1LbWHBCaeUiM3ttGuW95EQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_qvmmgT7SE0uDc6N4BGsXgg">1.0</ix:nonFraction>%; the interest rate for the third quarter of 2022 was <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_7_1_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaAndBLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Vahrp9O7ZE6CBtpYv1agDA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_ayEHhhz-OUiBXlJ7SxkDJA">10.54</ix:nonFraction>% for Tranches A and B and <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_m-RRMH3z8UK2FguJb0RdSg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_9KYDwuHbNkm0RZrNxjvFiA">11.73</ix:nonFraction>% for Tranche D. In the event of the cessation of LIBOR, the benchmark governing the interest rate will be replaced with a rate based on the secured overnight financing rate published by the Federal Reserve Bank of New York as described in the Loan Agreement. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in <ix:nonFraction unitRef="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg" decimals="INF" format="ixt-sec:numwordsen" name="chrs:DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" scale="0" id="Narr_9KqKhyN1U022M8XXx0RbZA">five</ix:nonFraction> equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#8217;s tangible and intangible assets and property, including intellectual property.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were and will be used to fund the Company&#8217;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the Company&#8217;s $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Iy6ly7BuYkCb3Hlrkpohpw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_jdlGixV1fUWMnLNVMLKpng">75.0</ix:nonFraction> million aggregate principal credit agreement with affiliates of Healthcare Royalty Partners (the &#8220;2025 Term Loan&#8221;), as well as all associated costs and expenses pursuant to which a payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_ETG3zuq6rEOjceZCC4QiRg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_XvBuFQaz_kyJxvClBkwnxg">81.9</ix:nonFraction>&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the Company&#8217;s $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_EPh9mQbc5E-s3ez_S3RVbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_rWg9wGORTk6lDhDIdEo3Sg">100.0</ix:nonFraction> million aggregate principal amount <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_43U5YRzDxkmwNw6aXFGqPw">8.2</ix:nonFraction>% Convertible Senior Notes (the&#160;&#8220;2022 Convertible Notes&#8221;), as well as all associated costs and expenses pursuant to which a payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lgVJdipFVkupB9l6dHBIsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_5h02lbUnQ0mvcKoMIqDyBg">111.1</ix:nonFraction> million was outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes affirmative covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that begins at $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodOne" scale="6" id="Narr_daqLY4br_Uu1fyoZNNWJWw">200.0</ix:nonFraction>&#160;million for the quarter ending March 31, 2022, increases to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodTwo" scale="6" id="Narr_SPYuYeOWfkihAF9Ur1NELw">210.0</ix:nonFraction>&#160;million for the quarter ended March 31, 2024, increases to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodThree" scale="6" id="Narr_8v9BXzxk7Uq6beSnEiyh7g">230.0</ix:nonFraction> million for the quarter ending June 30, 2024, increases to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodFour" scale="6" id="Narr_ng7GZA6gvU-JHhn_LOj6CA">270.0</ix:nonFraction> million for the quarter ending September 30, 2024, and increases to $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodFive" scale="6" id="Narr_us6GpnuKeEOkM40KUQzCEg">300.0</ix:nonFraction>&#160;million for the quarter ended December 31, 2024 and thereafter. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, <span style="background:#ffffff;">make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#8217;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#8217;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;</span><span style="-sec-ix-hidden:Hidden_zhRAFkTaEkWJkydvNPJsWQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">&#160;business days.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b408494f_075c_4c06_9ee7_c6deb7cc4029"></a><a id="Tc_FmQdY4Q-ekmp3uC-2zr2tQ_1_2"></a><a id="Tc_wnjpPBkwYUSR0qlwEGdt5g_1_5"></a><a id="Tc_M0LfMUoOmUWMs5aO0d0zbQ_2_2"></a><a id="Tc_q1cStgJMpUGKIPX67ss0-Q_2_5"></a><a id="Tc_MT9qC9lQHU2Q2GGQu2U_hA_3_0"></a><a id="Tc_V-UaxpYlFEO9yIn4bwYmrg_3_2"></a><a id="Tc_22L_onCWKUqIc7nEK5UIuQ_3_5"></a><a id="Tc_Jv40NUUvLUClnxuWFGXLmQ_4_0"></a><a id="Tc_Rm1ZkLJuxEqhu8S7XoqKGA_4_2"></a><a id="Tc_NbGJfxIg00W2TN3ONeSJIA_4_5"></a><a id="Tc_iYJ6HXn_OEuqo5tCK6jSeA_5_0"></a><a id="Tc_-kAmejy9GUexpD89-kmw6g_6_0"></a><a id="Tc_U3slAGlUVUW005txoNVZOg_6_2"></a><a id="Tc_iAfwbiS7-0SRFYdOb4ltfw_6_5"></a><a id="_a9b4aa33_7e63_42c2_8529_59152d4ef480"></a><a id="Tc_5aaF37cxAkGHCEoMcLqe4w_1_0"></a><a id="Tc_zgxNtBzEnketXQitzdtoNw_2_0"></a><a id="Tc_nBnfxMlblk6nNUkpSXiH4g_2_2"></a><a id="Tc_02JF4yH23kSvmFJaYl3qCw_3_0"></a><a id="Tc_T98ZXwVygUqXj07TjUykkQ_4_0"></a><a id="Tc_d_EX7xGcQ0W3XL3tXDzcng_5_0"></a><a id="Tc_dOmeobT4Vkahhlas3_jJyg_6_0"></a><a id="Tc_te3XBJ0nEUe6lKEcrsUlaw_7_0"></a><a id="Tc_YoPD2bWIF0SIoXDOC41GlQ_8_0"></a><a id="Tc_rqhr9cGOrkGWvQ8pg3u-hA_9_0"></a><a id="Tc_nXARsXJJVU2ML-sSriQfpQ_10_0"></a><a id="Tc_7FY764brf0y1M0VDdVtH9A_11_0"></a><a id="Tc_urivb7nN9kybDeTSjnpCsg_11_2"></a><ix:continuation id="Tb_ranbE7plx0Gi7ib0js3lSA_cont2" continuedAt="Tb_ranbE7plx0Gi7ib0js3lSA_cont3"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of Tranche A, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_RXxIsuRCkkGGaNhY42HHGg" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_2yva7gvzIEODPPzcQOiuSQ">7.8</ix:nonFraction> million&#160;in debt discounts and issuance costs<span style="color:#ff0000;"> </span>of which $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_2RaxJRT63k2XFAEZM5Yvog">6.8</ix:nonFraction> million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_76kJxJgZgEGENktd8re-Jg" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_JGEZVTp3o0WyHwbngsnkAg">2.3</ix:nonFraction> million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. Until unfunded tranches are drawn, the associated debt discounts and issuance costs are deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_FqUKSzDWTEKYQwtv9cQS_w">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_9jJAb2nN8UmquR7D6scuyg">0.5</ix:nonFraction> million, respectively,&#160;in debt issuance costs. As of September 30, 2022, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_ZdRhP2tlY0uSkxF4mWUkLw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_emlz_GgFC0y2gLYMQXJlFQ">4.8</ix:nonFraction> million will be amortized using the effective interest rate over the remaining term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_iHwIvN5laESr5Qc_H4fekA" format="ixt-sec:duryear" name="chrs:DebtInstrumentRemainingTerm" id="Narr_ymHhzqmBu0-594aeHEwDPw">4.3</ix:nonNumeric> years. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_AJFX04q7aUWIUWpurdzLyQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2027 Term Loans:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_N-8IhEaz2EigU2lMeehoBg_4_3">5,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_Ju3uikaP4k61RRfujIadBQ_4_6">12,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_7jqVKXgr2Ei4vYSRWEEvTA_5_3">622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_xHF7jkmy40WPvKiPm-2wFw_5_6">4,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_akiiEE5byk-bFyzSpLflxw_6_3">6,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_FKsFnmYgYEe2_fiD9NhvuA_6_6">16,699</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_qoaklaNpUUu1f9gA9R-WFQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2027 Term Loans as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="Tc_gjYqjpVdP0KJXndrEfR13Q_2_3">6,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_iLXt1yfS9EaHuI-ujtx-RQ_3_3">27,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_D59vqe5YlEilwzdr3FTQog_4_3">27,402</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_DfOV11BamEC3tMPsFzGWCA_5_3">27,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" scale="3" id="Tc_JNqwO9tkZkmPbXqFCn4IFQ_6_3">269,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_bPv-nt1PUkGTRPUUfVc5Lg_7_3">358,094</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_gzpR56HRoEq-yFu5MjSUQw_8_3">108,094</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoanGross" scale="3" id="Tc_r-wKsVY5qUmT6FLakT7FYQ_9_3">250,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_CswlqvZsR02Rz70YCXOE_g_10_3">4,754</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_CpUjExLrQUWWpP4_yWBbnA_11_3">245,246</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zXE2eF-YdUe7uHR5cDAcqQ">1.5</ix:nonFraction>%</b><b style="font-weight:bold;"> Convertible Senior Subordinated Notes due 2026</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company issued and sold $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_qq-UG2Ry506tWzrqVo_Obw">230.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Phv-XsBT4EWLy3tsBOvyug">1.5</ix:nonFraction>% Convertible Senior Subordinated notes due 2026 (the &#8220;2026 Convertible Notes&#8221;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="Narr_C70tNvrFYkOoqqemb2TEyw">222.2</ix:nonFraction> million after deducting initial purchasers&#8217; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#8217;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and <span style="background:#ffffff;">structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables</span>. <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q" name="us-gaap:DebtInstrumentInterestRateTerms" id="Narr_yllf-PmAUkyE8uGCLm8Crw">The 2026 Convertible Notes accrue interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ldheLSp01kODQ__2ikiRjA">1.5</ix:nonFraction>% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020</ix:nonNumeric>, and will mature on <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr__-evxVnINU6A-SojGfaNKw">April 15, 2026</ix:nonNumeric>, unless earlier repurchased or converted.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#8217;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. Since inception, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ranbE7plx0Gi7ib0js3lSA_cont3" continuedAt="Tb_ranbE7plx0Gi7ib0js3lSA_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">the conversion price has been <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="4" format="ixt:numdotdecimal" name="chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" scale="0" id="Narr_h3ueFOxIrk-cdk230WWV4g">51.9224</ix:nonFraction> shares of common stock per $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ" decimals="0" format="ixt:numdotdecimal" name="chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" scale="0" id="Narr_NvIqma5-HEKAC2QYcDWDBQ">1,000</ix:nonFraction> principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q" decimals="2" format="ixt:numdotdecimal" name="chrs:EquivalentToConversionPricePerCommonShare" scale="0" id="Narr_hfEJTyxAT0epFNiiXYPkbQ">19.26</ix:nonFraction> per share of common stock. The initial conversion price represents a premium of approximately <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageOfPremiumOnConvertibleNote" scale="-2" id="Narr_h3gRwxxvekqCYXI8-taDLQ">30.0</ix:nonFraction>% over the last reported sale of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_4_14_2020_ThcS1SrdqkuYZeougINqKA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_o4wLlTcuW0iWoYcIXmMTPA">14.815</ix:nonFraction> per share of the Company&#8217;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#8220;make-whole fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#8217;s election before maturity. If a &#8220;fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The 2026 Convertible Notes have customary provisions relating to the occurrence of &#8220;events of default&#8221; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg" name="us-gaap:DebtInstrumentCovenantCompliance" id="Narr_qAMGiRivYkmE7MCcjp-UdA">As of September 30, 2022, the Company was in full compliance with these covenants and there were <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bmA1J7_-g02NoTnD-cDbEw" decimals="0" format="ixt-sec:numwordsen" name="chrs:NumberOfEventsInDefault" scale="0" id="Narr_r4B9nsZyP0qlatM_VpSd2g">no</ix:nonFraction> events of default under the 2026 Convertible Notes.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the features embedded in the 2026 Convertible Notes&#160;under the relevant accounting rules and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability on the condensed consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capped Call Transactions</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with the pricing of the 2026 Convertible Notes, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g" decimals="-5" format="ixt:numdotdecimal" name="chrs:PaymentForCappedCallTransactions" scale="6" id="Narr_NU1OwdCtRUiYqkpPayLhRg">18.2</ix:nonFraction> million to enter into privately negotiated capped call transactions with one or a combination of the initial purchasers, their respective affiliates and other financial institutions (the &#8220;option counterparties&#8221;). The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g" decimals="4" format="ixt:numdotdecimal" name="chrs:CapPriceOfCapCallTransactions" scale="0" id="Narr_pK28cN1h_EGAEZzA7hkP8Q">25.9263</ix:nonFraction> per share, which represents a premium of approximately <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g" decimals="2" format="ixt:numdotdecimal" name="chrs:PercentageOfCapPriceCappedCallTransactions" scale="-2" id="Narr_22bA5LKKD0mT8l9-3bBpRA">75.0</ix:nonFraction>% over the last reported sale price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_4_14_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_iUGghFecu06NDEYjC7SfZg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4i3LrH4nWEqN_krSQFQzsQ">14.815</ix:nonFraction> per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and classified as equity instruments; thus, they are recorded as a reduction to additional paid-in capital on the condensed consolidated balance sheets. The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">If the 2026 Convertible Notes were converted on September 30, 2022, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Ia8aHRxcikWcNmk3c7HDQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="Narr_Eu7CwJXEKkCrCQybuT6wKg">114.8</ix:nonFraction> million based on the Company&#8217;s closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_8eMBIezfSE6z-vkdnq838g">9.61</ix:nonFraction>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:9pt 0pt 0pt 0pt;">The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="Narr_qS832gScc0GQHsdYbtcJ6A">0.9</ix:nonFraction> million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA" format="ixt-sec:durwordsen" name="chrs:DebtInstrumentContractualTerm" id="Narr_KnVyUue0BEaumIrTqxpWGQ">six-year</ix:nonNumeric> contractual term of the notes using </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ef16fb31_d6b7_4c02_9fc4_6ac1e0a44ea5"></a><a id="Tc_hEuI4gU1OEaE4YQCLPHSVw_1_2"></a><a id="Tc_iFwPolq2aUKDEwENm001YA_1_8"></a><a id="Tc_iOPN3_CijkC1tzsU_NAXxQ_2_2"></a><a id="Tc_NKPs3Qc8SES5SzubApR58A_2_8"></a><a id="Tc_qtPaaRrLl0S7-Vyn2u3-Ng_3_0"></a><a id="Tc_p1ocY_-_wk6WUFk2OK0mIQ_3_2"></a><a id="Tc_ElKHLxhQC0Kha-AOZY-R5g_3_5"></a><a id="Tc_g9aKSckZVU6WaoxwDFrNyw_3_8"></a><a id="Tc_StIL1QmZ50eyfwR5BEQH5A_3_11"></a><a id="Tc_khHnphvCIk6CAiDjgyaRfQ_4_0"></a><a id="Tc_42Kx3063z0OX0GNd1cQ6Ww_4_2"></a><a id="Tc_2HNCe4bXM0a86T7ehPY0Ig_4_5"></a><a id="Tc_G_fnB3mavESIpSrCoTqF3w_4_8"></a><a id="Tc_FHNEBPMQD0ahfMVSetzoMw_4_11"></a><a id="Tc_s7l43eIx6UaA1Z5wFZkPEA_5_0"></a><a id="Tc_dOa26CRS3U2WxnBhM-2mzQ_6_0"></a><a id="Tc_4Rk13kSTS0K8_Rcp6njNiA_6_2"></a><a id="Tc_pXLBsE64gES1gvYsgwp6Cw_6_5"></a><a id="Tc_ptjmX6cyBEmihu5GZsQMQQ_6_8"></a><a id="Tc_Up199Yl9SEK4t4CB6y9kCw_6_11"></a><a id="_4a81a2a9_5348_4ed9_8f31_39306d4d3366"></a><a id="Tc_uFqUZWJ9DkypyibJ8wqcPw_1_0"></a><a id="Tc_Udr637kagkOqane8Wqh1cw_2_0"></a><a id="Tc_WweanqU030CKtLW2X9aCJA_2_2"></a><a id="Tc_O-HJ7NlO8k6ANIJZ-ee9uA_3_0"></a><a id="Tc_micdNSOMkE2_9ytT7b9b1Q_4_0"></a><a id="Tc_npwrzy_k6UCBa6fVXvBlrw_5_0"></a><a id="Tc_HquLCbKFj0ueXmqAQfxmvw_6_0"></a><a id="Tc_CUPspuJJZkSYIpI4pPeqsQ_7_0"></a><a id="Tc_3Sc4f12v20-YMpZ3_T5nNw_8_0"></a><a id="Tc_ltlxkV82CU-AhHuI631dXw_9_0"></a><a id="Tc_WioGDtV9dE2pxRb5GvmSsA_10_0"></a><a id="Tc_ZjVdB4kb8EyrEToepzSfJA_11_0"></a><a id="Tc_-HGvUau6bUGOxU1IwOV8Aw_11_2"></a><a id="_01fbf270_f940_4ffe_bee1_b037b50cf16f"></a><a id="Tc_vPHFcBceBEO6UDxEEGN98Q_1_2"></a><a id="Tc_qja7u5EhO0unQ5ES4PXFNw_1_8"></a><a id="Tc_gigkXqxKs0S6J0m0kHcN4A_2_2"></a><a id="Tc_a-_hxlTFMkmFKLbu-dSKFQ_2_8"></a><a id="Tc_SLnQFpemuUWPVeK_eLNCBA_3_0"></a><a id="Tc_EDazx78imU28jgmlQdmvJw_3_2"></a><a id="Tc_f16j9PtUq0W6mSe6XwtDYQ_3_5"></a><a id="Tc_ZaS2BoSxJEKwztJMP7L7Rg_3_8"></a><a id="Tc_SGBddQOKGkiatRg7jkss8w_3_11"></a><a id="Tc_3ZXu8RXKQU62OcKUFxMoiA_4_0"></a><a id="Tc_8mGzMTrLPUCpVaf5tXclRg_4_2"></a><a id="Tc_PwJLL6B51EuwvZXFxNq4Jg_4_3"></a><a id="Tc_skFb1SjRzkWHWHjOifGf9w_4_5"></a><a id="Tc_byzRBvCHhkOt-gsCzoQ1lQ_4_8"></a><a id="Tc_uyrnSgo2c0-XsuKC8WIA4g_4_11"></a><a id="Tc_5FmKeZiJXkSoS6qf5VLr7g_5_0"></a><a id="Tc_mqw8vl6fJk2pSyOpmQ9TCg_5_3"></a><a id="Tc_BX9GBrFJqk2ZTcjgEHiVgw_6_0"></a><a id="Tc_UG-65_MbRUGDLaXruESQhA_6_2"></a><a id="Tc_DU4udLcx5UG8qATN8X1n8w_6_3"></a><a id="Tc_9t780yx7Dk20fxM7fnccag_6_5"></a><a id="Tc_KIhTZwnVS0CFkEcdoSp9dw_6_8"></a><a id="Tc_La-8VKGjLk6bQZkzSOaL3g_6_11"></a><ix:continuation id="Tb_ranbE7plx0Gi7ib0js3lSA_cont4" continuedAt="Tb_ranbE7plx0Gi7ib0js3lSA_cont5"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the effective interest rate method. The remaining unamortized debt discount and debt offering costs related to the Company&#8217;s 2026 Convertible Notes&#160;of <span style="-sec-ix-hidden:Hidden_mJKNNF_1akSrcLTArm_qlw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.7</span></span> million as of September 30, 2022, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_iSApamJ8mEaioWfyeVs7bg">2.1</ix:nonFraction>% for the 2026 Convertible Notes.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_xEhN3LB-rES1JCabPV8MNA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;">The following table presents the components of interest expense related to 2026 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_TU-TdkpOp0WLV7PFJ0abZg_4_3">863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_U7VTnqdhaUimGCozYgEpHA_4_6">862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_-F8iBpPCyUyePy3uPCv24g_4_9">2,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc__Jtj5-u8B0SQeOtkQw_c7w_4_12">2,587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_ryYH_ALHrEW8RDvjYa60yg_5_3">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_GgXIJX3xSka1X45AhoSLwQ_5_6">316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_jIWpczcyc0uOqalmd2mkDQ_5_9">962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_NoFx5mj0EkmwrA4YmzZXjw_5_12">942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_AG5r8jzO5kGXje3VGVHvzA_6_3">1,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_2r-Cu16F2UOPzBMekPR1MQ_6_6">1,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_0skM80LbHEGvqVZgfIq_jA_6_9">3,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_TMDxpFMgN0acyyOnub-fMA_6_12">3,529</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_BACf8bTLRkK7wi23XcgMdQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="Tc_QiTZYPCXwUqvNoHkj0366A_2_3">1,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_Z8sF4x6nDUmvX4RAESJ0pg_3_3">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_soDidgudd0ix67mzN6fzEQ_4_3">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_v4Xqeut47k-9d7iftT8rYw_5_3">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" scale="3" id="Tc_SrO552YK-U2bRRHPj3tXdQ_6_3">231,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_CXYBYXAgX0WwHRn5lG1Zfg_7_3">243,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_fm6iQSggK0GDW1IAYJL0ig_8_3">13,800</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ConvertibleNotesPrincipalAmount" scale="3" id="Tc_8oAmEKnSPkmpDZ0QntE8Dg_9_3">230,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_VpqMBfTuXE2Q5r3G9sGnuQ_10_3">4,750</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_IB2Low8lIUezDkWefHWF5w_11_3">225,250</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_oLdM9LhJ2Uq0LzFOoakWdQ">8.2</ix:nonFraction>% Convertible Notes due 2022 </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">On February&#160;29, 2016, the Company issued and sold $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_VepU_nxJW0WWmeoeZIc9rg">100.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_eg4PnPPvLkeb7dmAEnzT3Q">8.2</ix:nonFraction>% Convertible Senior Notes. The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company. <ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q" name="us-gaap:DebtInstrumentInterestRateTerms" id="Narr_7tOEmqAzX0-Q9pAkdSCcjg">The 2022 Convertible Notes&#160;bore interest at a fixed coupon rate of <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_OqF7FuEngUCUgYLAEJVe1Q">8.2</ix:nonFraction>% per annum payable quarterly in arrears on March&#160;31, June&#160;30, September&#160;30 and December&#160;31 of each&#160;year, since March&#160;31, 2016</ix:nonNumeric>, and matured on <ix:nonNumeric contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_oFd6qVgazE2Vmo9ZiHdc-g">March&#160;31, 2022</ix:nonNumeric>. The 2022 Convertible Notes&#160;also had a premium of <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ" decimals="2" format="ixt:numdotdecimal" name="chrs:PercentageOfPremiumOnConvertibleNote" scale="-2" id="Narr_bMNfgCNEukyX7iQF-tw9Rw">9</ix:nonFraction>% of the principal amount which was payable when the 2022 Convertible Notes&#160;matured or were repurchased or redeemed by the Company.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Company fully repaid the 2022 Convertible Notes, and a<span style="background:#ffffff;">s a result had </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ConvertibleNotesPayable" scale="6" id="Narr_ADdKYukTtUuAb4fI8GaYmQ">no</ix:nonFraction></span><span style="background:#ffffff;"> continuing obligations associated with them thereafter</span>. The payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_m4gNrG_ymkC11FeBIglj2Q">111.1</ix:nonFraction> million included the repayment of the entire outstanding principal amount, the <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg" decimals="2" format="ixt:numdotdecimal" name="chrs:PercentageOfPremiumOnConvertibleNote" scale="-2" id="Narr__TaD-SH-Y0qqN1pF_a6axg">9</ix:nonFraction>% premium of the outstanding principal amount and accrued and unpaid interest. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_UyhokirZm0i2-644r14vMg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_FnF-_Z32JEGrTVBSyzyr9Q" continuedAt="Tb_FnF-_Z32JEGrTVBSyzyr9Q_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2022 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_-bdGByOTkk-hSsRHDdksSQ_4_6">2,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_zssuObOazEu2IN01R6EF7Q_4_9">2,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_ynECuyiiF02A2HsHEpp9wg_4_12">6,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_3UZU89F1UUK35T_q_TF07Q_5_6">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc__7nS_5iTqk-Crc34ChvAaQ_5_9">521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_H2o8GpD5_UaU06RFnEAs0g_5_12">1,457</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_vClOfaQBxUecY1okHJGYJA_6_6">2,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_Wrt8g7o5AkuOsnCEdDZTvw_6_9">2,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_BGOwHePIpUiYIYZolvipKQ_6_12">7,607</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_de1074e3_f47a_4b81_b439_fc2ecefbd8c1"></a><a id="Tc_F7k_jN-HdU2phZ-RLCWqog_1_2"></a><a id="Tc_gZlR0GZcvEy_dDlN7abp3Q_1_8"></a><a id="Tc_jTijM-Fl3EaBEJRVP3DXFg_2_2"></a><a id="Tc_crjSSkl_EkWEEIvvpETu4Q_2_8"></a><a id="Tc_dnv_l2bk9Uu385xyupZLtg_3_0"></a><a id="Tc_9G9_x0v6sU-S8-gBxUAVFg_3_2"></a><a id="Tc_0zbmiVwKn0eV7muKCA1YLA_3_5"></a><a id="Tc_BqPRywlJbUGgG6w7HP4j8w_3_8"></a><a id="Tc_44IIRy5qrUaFPV5rHfP_Ww_3_11"></a><a id="Tc_0hgw-VTrqkSJcXXalBpawg_4_0"></a><a id="Tc_5PqU2kWdOkmky5nwwRwncQ_4_2"></a><a id="Tc_KdUX5gKH80aqt29DVkw65w_4_3"></a><a id="Tc_S7KWPUL7h0mQkBnxbsbjfg_4_5"></a><a id="Tc_-0Hzp623h02cXZI6HoXahw_4_8"></a><a id="Tc_Nnnl4klJTkyY3HG5B468sw_4_11"></a><a id="Tc_EVeOpsX3p0aoycp91GJMKg_5_0"></a><a id="Tc_2PHp0drtxUqeHFlTthQgOA_5_3"></a><a id="Tc_RCNBWTyEMUq65Ebkzw5Zrw_6_0"></a><a id="Tc_rcOwUlz5FU289P-p1RO4ug_6_2"></a><a id="Tc_EB3k6LmJ_E-BW-FJ3vMLOQ_6_3"></a><a id="Tc_Z8ANFOEpSk6AXQ1Fr34CXA_6_5"></a><a id="Tc_Tz9L4mbo5k-Ud2sfS0DcHg_6_8"></a><a id="Tc_07NCAM3JuEiG6kgBeoBtBA_6_11"></a><ix:continuation id="Tb_ranbE7plx0Gi7ib0js3lSA_cont5"><ix:continuation id="Tb_FnF-_Z32JEGrTVBSyzyr9Q_cont1"></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">2025 Term Loan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">On January&#160;7, 2019, the Company entered into a credit agreement with affiliates of Healthcare Royalty Partners. The 2025 Term Loan consisted of a <ix:nonNumeric contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_gVgB94UeLkKTlxsG-jRXZg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_vOKujek3L0y0TiunAfXmXg">six-year</ix:nonNumeric> term loan facility for an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_013WYEaIFEeLduU4RVB9pQ">75.0</ix:nonFraction> million (the &#8220;Borrowings&#8221;). Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at&#160;<ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_3o8tH3TKVEWimP0KP3lYHQ">6.75</ix:nonFraction>%&#160;per annum plus three-month LIBOR. Interest was payable quarterly in arrears.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on the </span>third anniversary of the 2025 Term Loan Closing Date, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_BzSPj7QMBUiTvLZBvtYxeA">81.9</ix:nonFraction> million included principal repayment in full, accrued interest, a <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SJkhVBwrA0SLA7eqmarAbg" decimals="3" format="ixt:numdotdecimal" name="chrs:DebtInstrumentPrepaymentPercentage" scale="-2" id="Narr_W-vlV-u-20mIg6K0rqYEag">5.0</ix:nonFraction>% prepayment premium fee of the Borrowings principal amount, and an exit fee of <ix:nonFraction unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" scale="-2" id="Narr_tqIc8-augkKNZBW6Rwe7Lw">4.0</ix:nonFraction>% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the payoff of the 2025 Term Loan totaled $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_P2DaE6YyYUyLCiVW9r9TZA">6.2</ix:nonFraction> million and was recorded in loss on debt extinguishment in the condensed consolidated statement of operations for the nine months ended September 30, 2022. As of September 30, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_eGmvrJ29CUKSMH_a7DSGFw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="Narr_1sGWaNWqGkq4OdudW_Fvvw">no</ix:nonFraction> continuing obligations associated with the 2025 Term Loan.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SjhD1IrJykmX9woy0w48cg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_g21J7syCmU24b-ejR-FfXw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2025 Term Loan: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_d3tI6jY_rEOy1apb0cRKWQ_4_6">1,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_pItZIN1yD0KTOqRQOIbvhw_4_9">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_Fzbw4RyQ9UWjVefn3f5KRg_4_12">5,261</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_ayCpfnXnOkGIM-wlCQJOCw_5_6">273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_RjNqz4J3iUajOp9hHAuYhw_5_9">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_6V3KmNdFDUSdV014GJ77UQ_5_12">751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_BmDTzGujjEWTLZ9zOlL_Sw_6_6">2,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_j417iohuqkuLRO5VJcElQg_6_9">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_hJ1jmaEkoEKec0lYimC4-w_6_12">6,012</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#00ff00;">&#8203;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#00ff00;">&#8203;</span></p><a id="_a15a0fdc_558e_4d3a_ba8f_09a32fc1223f"></a><a id="Tc_3DrEb3_yq0yBmbc50Qrotw_1_0"></a><a id="Tc_VvontM0lvUOEL62WNV8keg_2_0"></a><a id="Tc_22brs9bQ9UacyXJiCPh1Tw_2_2"></a><a id="Tc_bAhXStTbwkC-V5t13bNpTg_3_0"></a><a id="Tc_3cI2ylepqEOV3AcsQsgcaA_4_0"></a><a id="Tc_ww2Yopo_KUCJmS1AgJ150g_5_0"></a><a id="Tc_Sap_kUq7yk-5KWi9Pi_TmQ_6_0"></a><a id="Tc_Sfoyfquq8EazjLMcRgXK0w_7_0"></a><a id="Tc_1lhu42aE90ewaXWuNckXiw_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_rN7epk7AUES2V1KpnHRb7w" continuedAt="Tb_rN7epk7AUES2V1KpnHRb7w_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Purchase Commitments   </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of September 30, 2022, the Company&#8217;s contractual obligations under the terms of the agreements are as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:LongTermPurchaseCommitmentTextBlock" id="Tb_366qgrYoJk-bhCqC1GreXw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Years ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Remainder of 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="Tc_NVSVjJZa2EeqbBfEOqqexA_2_3">9,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="3" id="Tc_9Gh4Ag0J-kGLLkHb7ZAFHg_3_3">28,740</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInSecondYear" scale="3" id="Tc_a8cQcvgl3EWFs2yKxTFO8g_4_3">911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInThirdYear" scale="3" id="Tc_HmHY30HdaEOmzXho08pgOQ_5_3">911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInFourthYear" scale="3" id="Tc_DCE1VF5fdkiV63QRGP0eWg_6_3">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="3" id="Tc__yq0NRrnvk6RiT9IbQJe_g_7_3">40,218</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are generally cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rN7epk7AUES2V1KpnHRb7w_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Guarantees and Indemnifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Legal Proceedings and Other Claims</b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">The Company is a party to various legal proceedings and other claims that arise in the ordinary, routine course of business and that have not been fully resolved. The most significant of these are described below. The outcome of such legal proceedings and other claims is inherently uncertain. Accruals are recognized for such legal proceedings and other claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. The Company did not have any accruals related to such matters on the condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#8220;Zinc&#8221;) asserting Zinc was entitled to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" scale="6" id="Narr_Si_vyQObSE-CVzmrn_H5ng">14</ix:nonFraction> million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company is unable to reasonably estimate the amount or range of loss that may be incurred, if any, in connection with this matter. At this time, the Company has not made an accrual in connection with this matter.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Other than the matter in connection with the demand letter described in this Note 8, there are no material pending legal proceedings or other claims, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries&#8217; property is subject.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7402bde5_b5ad_4789_8d64_e78450354c57"></a><a id="Tc_ht21xHOXkkiqVDSvmjL5yw_1_2"></a><a id="Tc_BG47SFGh_UK6s22aWaKyng_1_8"></a><a id="Tc__rN19A74EUGq6MAmDZh5mA_2_2"></a><a id="Tc_pS5mVg12C0erH7JTi1IPwA_2_8"></a><a id="Tc_9tNJQCcnlkKYoY-8_dkOWQ_3_0"></a><a id="Tc_sGY75dOBB0C7P0XcIfajKQ_3_2"></a><a id="Tc_r0asYaqbWU-wuoAVVVW-rg_3_5"></a><a id="Tc_lC5Q5jTWNU-qt-rpCM9WeA_3_8"></a><a id="Tc_r6Ktl88pbUmOt1KUhtSdbw_3_11"></a><a id="Tc_EXLp8ChdOE6UK6jCDX_8JQ_4_0"></a><a id="Tc_3URIb_G9dU2NHaDm4RGcig_4_2"></a><a id="Tc_PbIF3kQVmEO1yXkO2p1Z5w_4_5"></a><a id="Tc_jy3ZLULA3USpM3FJWdkEqw_4_8"></a><a id="Tc_gd2cTCEsO0iEolY7D9n0ZQ_4_11"></a><a id="Tc_6uJtmD0CrESgrAVP1K0p1Q_5_0"></a><a id="Tc_jJX2kXiQXUqNAhyGRW1WHA_6_0"></a><a id="Tc_bGyCY2wx_0eLtWB-k5i0XQ_7_0"></a><a id="Tc_DO1a09ipNUmqaAHudkRfUw_7_2"></a><a id="Tc_viXduQLdZ0G5vchkjUc53w_7_5"></a><a id="Tc_nCKI7F0dFUeyNEWAW9eIJg_7_8"></a><a id="Tc_FyjbQnb0E06MTaR5FvaTcw_7_11"></a><a id="Tc_saMKBP5JVEirTnLGfALAdQ_9_0"></a><a id="Tc_xfCsXQt4j02QF8dBNHH6Aw_9_2"></a><a id="Tc_1eEO-lsQy0WRDUMecoOSGg_9_5"></a><a id="Tc_y2YdFjTwuEaToDrmZ9N4mg_9_8"></a><a id="Tc_rKxY6dawTkSgR96Cqq6a_Q_9_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_9TqgzzbBVkSZJcQSbcFOtA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the classification of stock-based compensation expense in the Company&#8217;s condensed consolidated statements of operations related to options and restricted stock units granted to employees and nonemployees:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_Xv6JBvhkMUi5FA2MPnAvXQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XmTlwxSGn0m_uPHHGMPW9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_VVlDJtVo_UaGzbnn5b3Zhw_4_3">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9qbE_7hJb0OAo7eMUGImJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_oH8sXoEUjUW0ysPb8OPRbw_4_6">394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1z-ozshyUUCySLmdDcUEPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_1O8DexTOFkWMrQ7CpLmJVQ_4_9">555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hXNe2mN_6kq827XHdcENIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_r7kbByQalUOekRFZczpgsQ_4_12">896</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_J1o7boGRZkedZZJHTOblEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Kr5Mthne8EK0q6wCXK63ug_5_3">5,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WaMcf-CWnEOlS3SaJTgvdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TNIBH83hUkiS2G4qBettNA_5_6">4,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5hmkNI6CL0Kpwf9YcrulMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IEUEPAF8y0SYImGH7GYi6w_5_9">14,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_50U8Eql0mBG5Pu9OJs8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-CdSK2VKiEy3LxEXV04twA_5_12">14,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wwwSCpIHT0qG7pxdRVzYHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Fzt5X_LsDUa0SZ7yjAebIA_6_3">6,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ZH1LNjXzG0q7CAxQn1L9Tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NzZ7abnJZk6mtwWyLSfBqw_6_6">7,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_XYdisJOhq0qqXhF-fMCTHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_QsTGFh-7pE6Ta8Gw3uVqdw_6_9">23,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cGIwu14pwEeco2TOLfoZWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Jue68wOlm0Sunc_j5EZ2_A_6_12">24,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_LwtzcMzHCUeeGS5Vcg6Xlg_7_3">12,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0DXFLQ93EE6o_A8xyyL4eg_7_6">11,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_stGAM_UjN0WPjnxBXR9hiA_7_9">39,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_agwtojqk5E2Ju7YnIyv-oQ_7_12">40,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_6Ym_9DTQEkOcTRJ2zFOzfA_9_3">290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_NrT6t99Nd0WNiZAkyfD3Lw_9_6">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_ZeT9L2pUr0mtOcVOu2XMoA_9_9">904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_MiNpDVcKoEC1B1zRfkzKUw_9_12">758</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:6pt;"></div></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk101945576"></a><a id="_c4b41874_7b10_4ce6_bc6b_4e42288da3ec"></a><a id="Tc_iSKvFDrd0EOJB6DgSaiFaw_1_2"></a><a id="Tc_ETUzEbMeQ0WdOLNEJjHn7w_1_6"></a><a id="Tc_4Sc0F1sArUy9FvMU41MKlQ_2_2"></a><a id="Tc_42BzDcrdQ0K0xPX4TUuDng_2_6"></a><a id="Tc_QUhl89DHOUqg5PU1ylLCvQ_3_2"></a><a id="Tc_tLSA4As2-0SAChdceyEXBA_3_4"></a><a id="Tc_gMXHju6p4EylSB_Q2rTwFg_3_6"></a><a id="Tc_kJGEVgIz0kGxawAOsKOICg_3_8"></a><a id="Tc_lcBKZiS2tUa8oG6NJB3PbQ_4_0"></a><a id="Tc_Lv85WgPwPkq8dFalZ1bhlA_5_0"></a><a id="Tc_-Isbef38306W5tK7DGW9sg_6_0"></a><a id="Tc_uXJ8WFDOjkqYqetsyLJ6mg_6_2"></a><a id="Tc_nxese3BleUy1He8wPXV2IA_7_0"></a><a id="Tc_mheQD8WfWUq6v2u_M_iuCA_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Ju5uKuFPHU69gb-6o8tVug" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;Net Loss Per Share</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_cYASZ11jR0G4ilbNCXSleg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_dEoY-sHSzUK02mdFlAWJzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__93dHk2GdkC8le36gbY0EA_4_2">22,535,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_kXWTWhXhFk2byCH1j93xkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wOtcxas_q0icbieMDtykVQ_4_4">19,543,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_Xt8hsRyWYUinCw6qBafEHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2SAhnbhb8ECfABm3If0FLQ_4_6">22,267,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_9008h6QJQk6ZQdJ45f6bfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2g93G0HbwEON7-YMZMv4cw_4_8">19,847,917</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_twLiW2yaC0qy7WXGVse05g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WT6s5SH400aQxnerUFmdng_5_2">2,305,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_g1id0jQAJ0KFh6228c8jNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ge0wdEb2REGJZGZaeSXAng_5_4">1,916,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FSdT6Jp3yEaigOhy6sE_5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5Xf4AwTSM0em4YNdAo5HhQ_5_6">2,401,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gkYrhJtFPkWcVDhkufdQuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gqTyRUWLpUWFyYZ0ipF2CA_5_8">1,812,799</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yEOGTOZIeEWn5yVBWgq8Iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vufCa4_ZZUG0xyFZUsLTHA_6_4">4,473,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_dED-Hyl570q2Gq2GdE_Mmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LUwyvCGSUUSm9I-4X_rbQA_6_6">1,442,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_U4ZdZnH3fkC5viSWX3m83Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_nBAL0_yEQkaPENG7hb0y7Q_6_8">4,473,871</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Bc_irE1EYEa0-ZkdPtAZuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qnw3R5i7U0WQoOIQYpYMFA_7_2">11,942,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Aww4QNVaLk64YAzs3J9iFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_HgNG4MWdyE-1IMnipaJCdg_7_4">11,942,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lz0mTF4wV0GFylKh3m490w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KZbikrYHtUOfEiukYcGipw_7_6">11,942,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_8AMDQ5u-0kqsUupldYB_uA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GRL4H3kk40aY8iR495J5Og_7_8">11,942,152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_efHu2d2cw0KXBgdxt1rypw_8_2">36,783,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_JbFlLxILkkeqdH_kwimFUg_8_4">37,875,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wzmJqwdXS0imkgt-NqmrDA_8_6">38,052,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TUb-_3tnZUeIIqUx9wMYJA_8_8">38,076,739</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_UwOcmbDVakmDKTZA3L9oMA" continuedAt="Tb_UwOcmbDVakmDKTZA3L9oMA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;Related Party Transactions</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consulting services</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board of Directors. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 (See Note 6). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_sEJjuKrdO0WbrQfw1Pgzsg">65,000</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Xo49SJP-KkixiwfQaxkFeQ">17.60</ix:nonFraction> per share to Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences. During the first quarter of 2021, the Company recognized non-cash </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_dQAxXLUxQEaw5vMRS0Gj2g"></a><a id="_ec4b5bfc_7775_4588_92c5_8994ebe4bcf0"></a><ix:continuation id="Tb_UwOcmbDVakmDKTZA3L9oMA_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_pgPhPnaDwUKDXEozULlleA">0.8</ix:nonFraction> million and consulting service expense of $<ix:nonFraction unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_nt3nEVs0zkeDmpdaTCfrlg">0.2</ix:nonFraction> million related to these services. There have been no subsequent material related party expenses. Total liabilities recognized on the condensed consolidated balance sheets with respect to these services were immaterial as of September 30, 2022 and December 31, 2021. </p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_83d94e0c_37bc_43dd_9303_2db08ab8ea48"></a><a id="ManagementsDiscussionandAnalysisofFinanc"></a><a id="ITEM2_265983"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The interim financial statements included in this Quarterly Report on Form&#160;10-Q and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the&#160;year ended December&#160;31, 2021, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contained in the</i> 2021 Form 10-K<i style="font-style:italic;">. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. These forward-looking statements are subject to risks and uncertainties, including those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part&#160;II&#160;&#8211; Other Information, Item&#160;1A below and elsewhere in this report, that could cause actual results to differ materially from historical results or anticipated results.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of our portfolio of FDA-approved biosimilars. Our strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of our diversified portfolio of FDA-approved therapeutics.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our commercial portfolio includes three FDA-approved biosimilar biologics. Our first product, UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor (&#8220;G-CSF&#8221;), was launched commercially in the United States in January&#160;2019. Our second product, CIMERLI (ranibizumab-eqrn), was approved by the FDA in August 2022 as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The FDA also granted CIMERLI 12 months of interchangeability exclusivity. We launched CIMERLI commercially in the United States on October 3, 2022. In December 2021, the FDA-approved YUSIMRY (adalimumab-aqvh), formerly CHS-1420, our Humira (adalimumab) biosimilar product, which we plan to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In addition to our three FDA-approved biosimilar biologics, we also have an original biologic license application submitted under Section 351(a) of the Public Health Service Act (&#8220;original BLA&#8221;) under review by the FDA for toripalimab. Toripalimab is being developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2 by binding to the FG loop on the PD-1, and for enhanced PD-1 receptor internalization (endocytosis function). We believe blocking PD-1 interactions with PD-L1 and PD-L2 have the potential to promote the immune system&#8217;s ability to attack and kill tumor cells. The original BLA for toripalimab seeks FDA approval for the use of toripalimab in combination with gemcitabine and cisplatin for first-line treatment of adults with metastatic or recurrent locally advanced <span style="background:#ffffff;">nasopharyngeal carcinoma (&#8220;NPC&#8221;), and for use as a monotherapy in the second- or later-line treatment of patients with recurrent unresectable or metastatic NPC that have progressed on or after a platinum-containing chemotherapy</span>. On April 29, 2022, we received a complete response letter (&#8220;CRL&#8221;) from the FDA for the original BLA for toripalimab requesting certain manufacturing process changes that we and Junshi Biosciences believe are readily addressable. On July 6, 2022, we announced that the FDA accepted the resubmission of the original BLA for toripalimab. The FDA has set a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) action date for December 23, 2022. We are still working with the FDA to set a date for a required inspection in China. We plan to launch toripalimab in the United States in the first quarter of 2023, if approved by the December 23, 2022 PDUFA action date. In May 2022, we discontinued development of CHS-305, an Avastin biosimilar candidate. We have built an experienced and robust oncology market access, key account management and medical affairs capability in the United States, supporting the successful commercialization of UDENYCA. We expect to leverage these capabilities as we build and launch our immuno-oncology franchise.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We primarily operate in the United States and partner with companies that operate in other countries. We have no material direct exposure to Russia and Ukraine; however, we are monitoring any broader economic impact from Russia&#8217;s invasion of Ukraine and the ongoing war between the two nations, including heightened risk of cyberattacks, increased prices of fuel and other commodities, and potential impacts to our partners&#8217; supply chains.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Business Update </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Tranche D Loan </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">In January 2022, we entered into the 2027 Term Loans which provide for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches. The Tranche D Loan of the 2027 Term Loans funded an aggregate principal amount of $50.0 million on September 14, 2022, in connection with the FDA approval of the BLA for CIMERLI. The principal amount outstanding on our 2027 Term Loans is $250.0 million as of September 30, 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CIMERLI &#8211; Genentech Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">On June 22, 2022, we entered into a license agreement with Genentech, Inc. (&#8220;Genentech&#8221;) and our partner Bioeq (the &#8220;Genentech Agreement&#8221;). Under the agreement, Genentech granted us and Bioeq a non-exclusive, royalty-bearing, license under certain of its patent rights to commercially launch and sell CIMERLI in the United States which started on the launch date on October 3, 2022. Pursuant to the terms of the Genentech Agreement, the royalty is a low single-digit percentage of net sales of CIMERLI that must be paid through December 13, 2023. In addition, we obtained the right to make non-binding offers to sell and engage in manufacturing and stockpiling activities during specified time periods prior to the launch date pursuant to the terms of the Genentech Agreement. The term of the Genentech Agreement will expire when all of the valid claims in the patent rights licensed under the agreement expire. The agreement may be terminated by either party if a party materially breaches one or more of its material obligations, subject to customary cure period. If we, Bioeq or either party&#8217;s respective affiliates initiate, participate, or assist any other person in bringing or prosecuting any challenge to the validity of any patent rights licensed under the Genentech Agreement, Genentech may terminate the licenses granted under such licensed patent rights or terminate the Genentech Agreement in its entirety, unless we, Bioeq, or the applicable affiliates withdraw all such challenges or stop assisting in any such challenges. Genentech may also terminate the agreement in the event of our insolvency.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Products and Product Candidates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our portfolio includes the following products and product candidates:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Oncology </span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">UDENYCA is a biosimilar to Neulasta, a long-acting G-CSF. We launched UDENYCA commercially in the United States in January&#160;2019 following approval by the FDA in November 2018. In the first nine months of 2022, we recorded $165.7 million of net revenue, primarily from sales of UDENYCA. In addition to the currently marketed pre-filled syringe (&#8220;PFS&#8221;) presentation, we are also developing additional presentations of UDENYCA, such as a proprietary </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">on-body injector (&#8220;OBI&#8221;)</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. In October 2021, we announced positive results from a randomized, open-label, crossover study assessing the pharmacokinetic and pharmacodynamic bioequivalence of UDENYCA administered via OBI compared to our currently marketed UDENYCA PFS. We are planning a 2023 launch of UDENYCA OBI, if approved by the FDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Toripalimab is being developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2 by binding to the FG loop on the PD-1, and for enhanced PD-1 receptor internalization (endocytosis function). We believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune system&#8217;s ability to attack and kill tumor cells. More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted by our partner Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49.5pt;">Together with Junshi Biosciences, in the third quarter of 2021 we completed the submission of the original BLA for toripalimab to the FDA seeking approval for the use of toripalimab in combination with gemcitabine and cisplatin for first-line treatment of adults with metastatic or recurrent locally advanced <span style="background:#ffffff;">NPC</span>, and for use </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49.5pt;">as a monotherapy in the second- or later-line treatment of patients with recurrent unresectable or metastatic NPC that have progressed on or after a platinum-containing chemotherapy. The FDA issued a CRL for the original BLA for toripalimab requesting certain manufacturing process changes. On July 6, 2022, we announced that the FDA accepted the resubmission of the original BLA for toripalimab. The FDA has set a PDUFA action date for December 23, 2022. We are still working with the FDA to set a date for a required inspection in China. We plan to launch toripalimab in the United States in the first quarter of 2023, if approved by the December 23, 2022 PDUFA action date. We believe there is potentially a high unmet need in NPC based on the current FDA-approved treatment alternatives and the lack of any approved immunotherapies. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49.5pt;">The FDA has granted Breakthrough Therapy designation to toripalimab for the treatment of patients with recurrent or metastatic NPC with disease progression on or after platinum-containing chemotherapy and for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the first-line treatment of recurrent or metastatic NPC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-006 is an investigational recombinant humanized IgG4&#954; monoclonal antibody designed to act specifically against human TIGIT that we are developing in collaboration with Junshi Biosciences. A number of third-party preclinical and clinical studies have demonstrated that activation of the TIGIT pathway could be a crucial underlying mechanism for tumor immune evasion and resistance to PD-1 blockade therapy in some tumor types. Combination of TIGIT and PD-1/PD-L1 antibodies showed a synergistic potential to enhance antitumor response, to overcome anti-PD-1 resistance and possibly broaden the cancer patient population that can benefit from immunotherapy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49.5pt;">A dose escalation, dose expansion clinical trial (clinicaltrials.gov identifier# NCT05061628) evaluating the safety, tolerability and pharmacokinetic properties of CHS-006 as monotherapy and in combination with PD-1 inhibitor toripalimab in patients with advanced solid tumors is ongoing in China. The FDA has allowed clinical trials for CHS-006 to proceed in the United States under an IND, and we plan to advance toripalimab in combination with CHS-006 in a clinical trial in North America later in 2022 or early 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are pursuing an early-stage development candidate designed to improve anti-PD-1 clinical benefit by transforming an unfavorable tumor microenvironment (&#8220;TME&#8221;) to a more favorable TME. We expect to submit an IND to the FDA in 2023 for CHS-1000, an antibody targeting ILT4.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immunology</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">YUSIMRY (adalimumab-aqvh), is a biosimilar of Humira, a monoclonal antibody that can bind to </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">tumor necrosis factor (&quot;TNF&quot;)</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. YUSIMRY provides certain therapeutic benefits for treatment of patients with certain inflammatory diseases characterized by increased production of TNF in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#8217;s disease, psoriasis and ulcerative colitis. </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">In December 2021, the FDA approved YUSIMRY, which we plan to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie. We are developing high-concentration formulations of YUSIMRY.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ophthalmology </span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CIMERLI </span><span style="color:#0a0a0a;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">(ranibizumab-eqrn)</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, formerly known as CHS-201, is a Lucentis biosimilar</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. In November 2019, we entered into a license agreement with Bioeq for the commercialization of CIMERLI, a biosimilar version of ranibizumab (Lucentis) in certain dosage forms in both a vial and PFS presentation. Under this agreement, Bioeq granted to us an exclusive royalty-bearing license to commercialize CIMERLI in the field of ophthalmology (and any other approved labelled indication) in the United States. </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 49.5pt;"><span style="color:#0a0a0a;background:#ffffff;">On August 2, 2022, the FDA approved CIMERLI (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The FDA also granted CIMERLI 12 months of interchangeability exclusivity. On October 3, 2022, we launched CIMERLI commercially in the United States in both 0.3 mg and 0.5 mg dosage forms.</span> CIMERLI achieved leading biosimilar market share within the first four weeks of launch. The launch of CIMERLI builds on the success we demonstrated with UDENYCA, our first product, that also rapidly overtook a large, first-to-market competitor. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Discontinued Product Candidates</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In January 2020, we entered into a license agreement with Innovent for the development and commercialization of a biosimilar version of bevacizumab (Avastin) in any dosage form and presentations in the United States and Canada. On May 3, 2022, we provided notice of termination of the License Agreement to Innovent pursuant to Section 13.6 of the License Agreement to discontinue development of CHS-305, a bevacizumab (Avastin) biosimilar candidate, </span><span style="font-weight:normal;">because regulatory approval of the licensed product could not be reasonably obtained within the agreed time period</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we discontinued development of our preclinical immuno-oncology program, CHS-3318, an antibody targeting CCR8, in order to focus on external molecules targeting CCR8.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;">License Agreement with Junshi Biosciences </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:22.5pt;background:#ffffff;margin:0pt;">On February 1, 2021, we entered into an Exclusive License and Commercialization Agreement with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#8217; anti-PD-1 antibody, in the United States and Canada. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:22.5pt;background:#ffffff;margin:0pt;">Under the terms of the Collaboration Agreement, we obtained exclusive rights to toripalimab in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. We will have the right to conduct all commercial activities of toripalimab in the United States and Canada. We will be obligated to pay Junshi Biosciences a 20% royalty on net sales of toripalimab and up to an aggregate&#160;$380.0 million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><a id="_Hlk106699310"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:22.5pt;background:#ffffff;margin:0pt;">In March 2022, we paid $35.0 million for the exercise of our option to license CHS-006. We will lead further development of CHS-006 and be responsible for the associated development costs as set forth in the Collaboration Agreement. If we exercise our remaining option for the IL-2 cytokine, we will be obligated to pay an additional option exercise fee of&#160;$35.0 million. Additionally, for each exercised option, we will be obligated to pay Junshi Biosciences an 18% royalty on net sales, up to $85.0 million&#160;for the achievement of certain regulatory approvals, and up to&#160;$170.0 million&#160;for attainment of certain sales thresholds. Under the Collaboration Agreement, we retain the right to collaborate in the development of toripalimab and the other licensed compounds, including CHS-006, and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, we are responsible for certain associated regulatory and technology transfer costs for toripalimab and other licensed compounds and will reimburse Junshi Biosciences for such costs. We recognized research and development expense of $7.6 million in the third quarter of 2022 and $67.6 million in the nine months ended September 30, 2022, inclusive of the $35.0 million option fee in the first quarter. Research and development expense was $15.4 million and $173.6 million for the three and nine months ended September 30, 2021, respectively; the nine months ended September 30, 2021 included $136.0 million for the upfront payment for the exclusive rights to toripalimab. Accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022 included $17.5 million related to the co-development, regulatory and technology transfer costs related to these programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, we did not have any outstanding milestone or royalty payment obligations to Junshi Biosciences. The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded when it is probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Update</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As a result of the&#160;COVID-19&#160;pandemic, we have experienced and may continue to experience disruptions that could severely impact our business, clinical trials and preclinical studies. See &#8220;Risk Factors &#8211; Risks Related to COVID-19.&#8221; These and other factors arising from the COVID-19 pandemic could result in us not being able to maintain UDENYCA&#8217;s market position or increase its penetration against all Neulasta&#8217;s dosage forms and could result in our inability to meet development or regulatory milestones for our product candidates, each of which would harm our business, financial condition, results of operations and growth. Although cases and deaths from the COVID-19 pandemic have generally declined in the United States recently, spread of COVID-19 in China recently resulted in a protracted lockdown covering all of Shanghai where our partner Junshi Biosciences has its headquarters. The spread of COVID-19 in China may impact the timeline to manufacture toripalimab and the FDA has communicated to us the COVID-19 pandemic will impact the FDA&#8217;s ability to conduct foreign inspections of our partner&#8217;s manufacturing facilities in China. Until the COVID-19 pandemic is controlled, we expect it may continue to adversely impact our sales growth. In addition, the spread of more contagious and/or deadly variants, such as the omicron subvariant BA.2, could cause the COVID-19 pandemic to last longer than expected and could result in the reinstatement of restrictive orders that could disrupt our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">While the long-term economic impact and the duration of&#160;the COVID-19&#160;pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and our convertible notes. In addition, a recession, market correction or depression resulting from the spread of&#160;COVID-19&#160;could materially affect our business and the value of our notes and our common stock.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our first FDA-approved product, UDENYCA, was approved in November&#160;2018, and we initiated United States sales of UDENYCA on January&#160;3, 2019. In December 2021, the FDA approved YUSIMRY, which we plan to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie. On August 2, 2022, the FDA approved CIMERLI, which we launched on October 3, 2022. Net revenues, primarily from sales of UDENYCA, were $45.4 million and $82.5 million </span>during the three months ended September 30, 2022 and 2021<span style="background:#ffffff;">, respectively, and $165.7 million and $253.2 million during the nine months ended September 30, 2022 and 2021, respectively. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="background:#ffffff;">Cost of goods sold consists primarily of third-party manufacturing, distribution, and certain overhead costs. During the third quarter of 2022, we recorded an inventory write-down of $26.0 million for inventory at risk of expiration. Prior to the second quarter of 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021. On May&#160;2, 2019, we settled a trade secret action brought by </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Amgen&#160;Inc. and Amgen USA&#160;Inc. (collectively &#8220;Amgen&#8221;)<span style="background:#ffffff;">. As a result, cost of goods sold reflects a mid-single digit royalty on net product revenue, which began July&#160;1, 2019 and continues for five years from then. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Research and development expense represents costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. We currently track research and development costs incurred on a product candidate basis only for external research and development expenses. Our external research and development expense consists primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expense incurred under agreements with consultants, third-party contract research organizations (&#8220;CROs&#8221;), and investigative sites where a substantial portion of our preclinical studies and all of our clinical trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with manufacturing process development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">upfront and certain milestone payments related to licensing and collaboration agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Internal costs are associated with activities performed by our research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expense, which includes salaries, benefits and stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The largest component of our total operating expense has historically been our investment in research and development activities, including the licensing and collaboration costs, clinical development and manufacturing process development of our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Products manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. For all the periods presented, we expensed manufacturing costs as incurred as research and development expense for products that had not been approved. UDENYCA and YUSIMRY received regulatory approval in November 2018 and December 2021, respectively. In the second quarter of 2022, we began to capitalize YUSIMRY costs and had $24.6 million in inventory recognized on the condensed consolidated balance sheet at September 30, 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming. Furthermore, in the past, we have entered into collaborations with third parties to participate in the development and commercialization of our product candidates, and we may enter into additional collaborations in the future. In situations in which third parties have substantial influence over the development activities for product candidates, the estimated completion dates are not fully under our control. For example, our partners in licensed territories may exert considerable influence on the regulatory filing process globally. Therefore, we cannot forecast with any degree of certainty the duration and completion costs of these or other current or future clinical trials of our product candidates. We may never succeed in achieving regulatory approval for any of our pipeline product candidates. In addition, we may enter into other collaboration arrangements for our other product candidates, which could affect our development plans or capital requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expense consists primarily of personnel costs, allocated facilities costs and other expense for outside professional services, including legal, insurance, human resources, outside marketing, advertising, audit and accounting services, as well as costs associated with supporting the commercialization of UDENYCA including certain legal disputes and establishing commercial capabilities. Personnel costs consist of salaries, benefits and stock-based compensation.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and debt issuance costs associated with our debt agreements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Loss on Debt Extinguishment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Loss on debt extinguishment consists of losses incurred related to the early repayment of debt obligations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comparison of Three and Nine months ended September 30, 2022 and 2021</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="white-space:pre-wrap;">Revenue  </i></p><a id="_fe482cdc_f432_4d4e_b8ce_647656df0819"></a><a id="_6284515b_e2ef_49f3_aa2a_5c3263a34861"></a><a id="_49a9899f_c2a4_41ac_8b4d_f90df6f76a27"></a><a id="_da1bcd72_9944_4987_972c_fa2081446817"></a><a id="_ae48c141_dab2_4a98_9e3e_bb57d2ae3d21"></a><a id="_a8704a5f_f80c_4d8d_b2ae_83f041bb58ab"></a><a id="_6498e684_a0cf_40a4_8a4c_5c8c2cb165b8"></a><a id="_d6d25e36_c289_4a38_9edb_d78d393e3b41"></a><a id="_dd3547dd_76d9_4d45_919e_e3702b16e10b"></a><a id="_bcf96a52_2243_4822_9377_57fb667007e1"></a><a id="_0ae570fb_b7fe_4ccb_a5da_21ee37953d84"></a><a id="_987c8eab_ca43_474c_b1c4_484a27f99808"></a><a id="_07938534_269a_47a4_b946_4dcf7580bf14"></a><a id="_d5b2181d_22ba_4e18_9be0_ccd1bac0f04d"></a><a id="_144e87f3_8c9f_46c4_aa1f_e5eec11442c2"></a><a id="_7481bde3_1d74_461e_9cec_2e59d544bae7"></a><a id="_570302c0_50ef_4316_9792_9a2c795e911b"></a><a id="_7643f3d3_d07a_4e2d_a1b1_3613e4be96db"></a><a id="_02218fdc_080a_4808_9522_453b3099d90e"></a><a id="_79470286_5594_445a_b72c_b4ce5fcdc979"></a><a id="_3bbf537e_9df1_4929_9f54_45a5a5dde772"></a><a id="_c358ba9f_25b5_43e5_a97d_591c717eeaa8"></a><a id="_1de1a958_076e_40d0_b491_4c8704d30eb3"></a><a id="_e5715815_d711_4a4a_a4c6_819242be85dc"></a><a id="_7ffa18e5_bfb8_467f_9520_34316bf6ef49"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,424</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,503</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,079)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 165,690</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 253,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (87,490)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk117275297"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The decrease in net revenue for the three and nine months ended September 30, 2022 compared to the same periods in the prior year was primarily due to decrease in the number of UDENYCA units sold and a reduction in the average net selling price per unit resulting from competition and lower patient enrollment. <span style="background:#ffffff;">Our&#160;net revenue and market penetration&#160;may&#160;continue to be adversely impacted by pricing trends and competitive dynamics in the overall pegfilgrastim market. </span>In addition, the COVID-19 pandemic has negatively impacted the pre-filled syringe pegfilgrastim market due to&#160;preferences to administer medication at home.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We expect our net revenue to decrease during the remainder of 2022 as compared to the same period in the previous year as a result of increased competition for UDENYCA, with the potential for such decreases to be slightly offset by net revenues from CIMERLI, which launched in early October of 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="white-space:pre-wrap;">Cost of Goods Sold  </i></p><a id="_d59bcec7_cdaa_4bd9_9dde_5ccdf37cdd45"></a><a id="_713c607c_a90b_44a8_814e_9da65d620e96"></a><a id="_0b47c3bf_b3d5_4c1f_895d_4a2123c282dd"></a><a id="_237343f2_4d13_47d9_a6bd_200ee2a7cd7a"></a><a id="_c9b3d5ca_4ec6_43aa_9715_5ceb9b63b93d"></a><a id="_22a251cb_6c75_499b_a05e_be562c29623c"></a><a id="_b7a7061b_bfec_40f0_9454_04057f3bcf91"></a><a id="_9ea8f31a_3737_42ed_95cc_a2935c9dd501"></a><a id="_f772f1f6_48b2_44cf_8582_791aaaf91c36"></a><a id="_acf6a482_a54e_44ea_99ff_f0f13a00de4a"></a><a id="_6e5760a1_0d8a_4a52_a480_12008b53cd05"></a><a id="_578cccb3_f869_49c3_869d_ecfd0f62ea6b"></a><a id="_808a3da4_47a2_40a0_9f6d_19456392409f"></a><a id="_1c14d5f1_f3b4_4d16_9b45_c1389e93438e"></a><a id="_0f2fcc21_5d8d_4b66_a58a_c6d76a69554f"></a><a id="_9ebe7c9c_69f3_4c00_b95f_f245ef1c7f09"></a><a id="_1c6340ec_ba7f_4872_910e_eb26c1a49ea6"></a><a id="_9c6ce690_bd0b_44b2_9238_dc1e215789ee"></a><a id="_efd7276a_4d58_4d1f_8cf8_735fe332eb75"></a><a id="_733f406e_4877_46f0_a809_7ada4ce77cae"></a><a id="_3f7d6844_58f2_4cfe_81ef_4e43ad9bcdd8"></a><a id="_823d9f4f_fac5_4657_9bbe_36b4364df53d"></a><a id="_334e9359_2d96_46bf_ac17_5ed1cb09d679"></a><a id="_617fa4e9_fb4b_4a73_a8c4_f6c7b40fe9d1"></a><a id="_cf094cdf_38bb_49b9_b2b1_82d0051ed6e2"></a><a id="_518a5b7c_1917_443f_86c3_6e3121a0f906"></a><a id="_6c1e8934_d25e_46fb_ad24_b1e602e50072"></a><a id="_ff34c1f4_0904_4137_85ea_d73c8c741dd1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:37.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,234</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,954</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,881</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,487</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,394</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 74</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The increase in cost of goods sold for the three and nine months ended September 30, 2022 compared to the same periods in the prior year resulted from the $26.0 million <span style="background:#ffffff;">write-down in the third quarter of 2022 of inventory at risk of expiration compared to the $5.2 million write-off of inventory in the third quarter of 2021 for inventory that did not meet acceptance criteria. The increase was partially offset by </span>decreases in the number of <span style="background:#ffffff;">UDENYCA units sold as well as</span> lower royalty costs of $1.9 million and $4.4 million <span style="background:#ffffff;">for the three and nine months ended September 30, 2022, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">respectively. </span>In addition, a portion of the costs of producing UDENYCA sold through the first quarter of 2021 was expensed as research and development prior to the FDA approval of UDENYCA and, therefore, was not reflected in the cost of goods sold. During the first quarter of 2021, the UDENYCA inventory with no inventory value was fully utilized, and since then cost of goods sold fully reflects per unit acquisition cost of UDENYCA. <span style="background:#ffffff;">The cost basis of product sold that was expensed prior to approval was $3.3 million in the first quarter of 2021.&#160;Had such inventories been valued at acquisition cost, it would have resulted in corresponding increases in cost of goods sold and corresponding decreases in gross margin.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We expect our gross margin for the full year 2022 to be lower than the full year 2021, as a result of declining net realized price per unit of UDENYCA sold, the impact of the third quarter of 2022 write-down of $26.0 million of inventory at risk of expiration and higher average annual costs per unit of UDENYCA sold<span style="background:#ffffff;"> primarily due to the transition in the first quarter of 2021 from inventory with manufacturing costs that were partly recognized as research and development expenses prior to the regulatory approval of UDENYCA. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expense </p><a id="_0722da10_2a08_449b_87e0_6f05d86b49c6"></a><a id="_eda6cc4d_262f_4511_af21_085efb8eaab2"></a><a id="_3da2bf78_f20d_4012_b3c8_6dcf65e65800"></a><a id="_926d445f_3c59_452f_b201_49d1f2a841c6"></a><a id="_4dc1d172_1e5f_4055_9005_67ce3d56bcfe"></a><a id="_23124954_d8d2_401e_94b2_5990629a9701"></a><a id="_cef45392_70c6_4b11_ac1f_e031ccec6fb0"></a><a id="_1239e12b_e307_4618_a7ea_2f60e5ef3950"></a><a id="_03ef2327_7adc_49e1_9c3a_fea5b994fdc6"></a><a id="_a34848c1_a15b_4f53_8094_9aa965899b74"></a><a id="_5feaaf4c_73a9_4a17_ac37_5d28a0cce55e"></a><a id="_264af7a1_194d_46cd_9905_5c03df9c2fa5"></a><a id="_caf518ee_d370_4639_ba25_3f098ef3ea43"></a><a id="_00c568e9_bfc8_4635_8659_5c7262c086d1"></a><a id="_c3759bbc_bfca_4ce2_9fe6_647e0d5a59f4"></a><a id="_8ebef255_ac33_4ed8_b71a_6ce02b38344a"></a><a id="_50e49eda_dc47_4ca8_b4ae_73b41488d6b7"></a><a id="_df46bf78_5310_471a_bf44_ba74a6f1f0c8"></a><a id="_5a2f0603_02cf_4bc7_9542_9e89cf12b589"></a><a id="_989ce254_ae5e_414b_99dd_5e85836022a1"></a><a id="_ffba6825_9fa6_401d_882e_5fe2c51e782c"></a><a id="_3fa3571b_e4b1_41e8_8b16_f08ec0ecceb7"></a><a id="_22d818cd_8056_4fb6_8bcb_1de059accf8f"></a><a id="_1f27eaaf_bf63_4e9a_ae2b_6b00169798c2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,808</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,085</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,277)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 170,336</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 312,343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (142,007)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The decrease in research and development expense in the three months ended September 30, 2022 was primarily due to: </p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">a decrease of $6.5 million in co-development costs for toripalimab and CHS-006;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">a decrease of $3.4 million&#160;related to the development of additional presentations of UDENYCA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $1.7 million in costs for the development of bevacizumab (Avastin</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">)</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> biosimilar, a former product candidate which we discontinued development in May 2022. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The decrease was partially offset by:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $2.7 </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">million related to the development of YUSIMRY mainly due to higher costs in the current year associated with FDA pre-approval inspections and scaling up process performance qualification production run</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">s; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.3 </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">million in stock-based compensation expense mainly related to the acceleration of awards to a certain individual and additional expense related to equity awards granted since the third quarter of 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The decrease in research and development expense in the nine months ended September 30, 2022 was primarily due to:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">higher license fees in the first nine months of 2021, including $145.0 million in expense pursuant to the Collaboration Agreement with Junshi Biosciences in February 2021, which was partially offset by a $9.0 million credit related to the fair value of the DLOM on the common shares purchased under the Stock Purchase Agreement, as compared to the first nine months of 2022 which included an upfront payment of $35.0 million to exercise our option to license CHS-006, a TIGIT-targeted antibody, in the United States and Canada; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">a decrease of $13.6 million&#160;related to the development of additional presentations of UDENYCA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">a decrease of $11.5 million in costs related to CHS-2020 due to the discontinuation of its development in the first quarter of 2021; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $8.0 million in costs for the development of bevacizumab (Avastin</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">)</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> biosimilar, a former product candidate which we discontinued development in May 2022; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $7.6 </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">million related to the development of YUSIMRY mainly due to higher costs in the prior year associated with FDA pre-approval inspections and scaling up process performance qualification production run</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">s. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The decrease was partially offset by an increase of $1.1 <span style="background:#ffffff;">million in personnel and consulting costs to advance our research and development programs.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expense for the full year 2022 to be lower than the prior year because 2021 included $136.0 million of expense for the upfront license with Junshi Biosciences.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><a id="_b96ac4c3_93eb_4409_8fbe_c29b41d93331"></a><a id="_fcbd61a8_8a04_44a7_b0f8_a8d665272be0"></a><a id="_ee97cdbf_f937_46f2_85d7_35f22f5dff65"></a><a id="_57391c01_4aaa_4107_b23c_b85c1b5a402a"></a><a id="_7433bb5a_4a44_481e_aa11_19e56fb0360e"></a><a id="_552eb232_9410_4362_8174_7cdf8f3ed65b"></a><a id="_e205b285_d3ca_4274_9622_421d669ed916"></a><a id="_c1b862ad_f77e_4638_b2cc_21d28767dbd3"></a><a id="_bfe92f0e_c881_46d2_a73c_bfd2156a4a6d"></a><a id="_6d141768_fc6d_4a76_b600_c04dccaff958"></a><a id="_5270b24a_e955_43d9_bbeb_88624c1fe838"></a><a id="_5b9262eb_eeb6_4553_a05b_4485ea817df9"></a><a id="_c2bdd905_605c_4356_920c_001d2f057289"></a><a id="_e7a0446e_3f61_40ff_9b0f_b724c63e04af"></a><a id="_e963704f_3236_4f39_8ac1_8242ae6ce018"></a><a id="_43bb7258_bfcb_4bf8_a94e_3881f0ab8b57"></a><a id="_015956fa_43a0_4b60_bb02_944183c3d20a"></a><a id="_8c4fb4da_88e2_458e_a044_b0ffb9f2df60"></a><a id="_6c32d1a2_d8ed_4e76_8d45_24bfcacfa2bd"></a><a id="_41948d37_bcea_4261_b0f2_ed27b28cf07a"></a><a id="_20d315c0_06dd_4dbf_8bde_ec0d17abe827"></a><a id="_41b82126_1c94_45ae_9fbc_c46d55977160"></a><a id="_0731d665_12c6_4fc4_9e24_0e3541b3c592"></a><a id="_527c5524_b685_4556_bbd2_4199a5a78d37"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39,925</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,906</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144,860</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119,661</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,199</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The increase in selling, general and administrative expense for the three months ended September 30, 2022 was primarily due to <span style="background:#ffffff;">an increase of $4.0 million for personnel, consulting, professional services, marketing, advertising and other expenses resulting from an increase in sales force and related commercial functions to support our product sales.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The increase in selling, general and administrative expense for the nine months ended September 30, 2022 was primarily due to the following: &#160;</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">an increase of $21.4 million for personnel, consulting, professional services, marketing, advertising and other expenses resulting from an increase in sales force and related commercial functions to support our product sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">an increase of $2.5 million in facilities, supplies and materials and other infrastructure related expenses to support our commercial infrastructure for our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">an increase of $2.4 million in travel expenses as a result of curtailed travel in 2021 due to COVID-19.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The increase in selling, general and administrative expense for the nine months ended September 30, 2022 was partially offset by a decrease of $1.1 million in stock-based compensation expense resulting from the grant of fully vested stock options to certain employees and consultants upon the execution of the Collaboration Agreement with Junshi Biosciences in 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We expect our selling, general and administrative expense in the fourth quarter of 2022 to be higher than in the same period in 2021, as a result of increased commercial headcount and activities to support the launch of CIMERLI which occurred on October 3, 2022 and expenses incurred in connection with preparation activities for the planned launch of YUSIMRY in 2023. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt;">Interest Expense</p><a id="_b621bb87_3342_4b5d_be97_3cf69fea6bef"></a><a id="_20b8f928_d295_4332_930e_84ec0cb8bed0"></a><a id="_7ea8b577_0953_4c01_8f91_9d97437ab028"></a><a id="_2d5f9d3b_6307_4281_b886_5203a26db98b"></a><a id="_d44b250f_a1c9_4315_ab67_45848d0dee25"></a><a id="_ff7e0149_0662_4b63_b02e_794c50fa33e1"></a><a id="_b195c5ea_2859_43f1_aebe_4b37bcad8f5a"></a><a id="_3a122194_56e5_4ad2_9c70_879bd53ab7c3"></a><a id="_d1fa611f_edf0_41ee_824c_d186dbf448bd"></a><a id="_b567c9d3_02f5_45b6_b510_c476ded0a7f6"></a><a id="_628ceb30_ae1b_4163_a6e5_3aaf8e1ea080"></a><a id="_756a7f30_b3a1_45b3_8004_00b230a849f0"></a><a id="_f9fb1a60_8158_426b_8e12_9527f8704e1d"></a><a id="_27159dbc_6306_4962_a820_1d72ba70dff6"></a><a id="_7c551cf3_d2b3_4949_a74d_37c8b3ef209d"></a><a id="_4cf6d13d_0cdd_4270_be61_f27bf456ba77"></a><a id="_2e0bf276_0918_4532_9277_4cdc5081300c"></a><a id="_3e4a7f9c_5a2e_4c81_856d_2bffa3a4a05a"></a><a id="_f7dcc2da_ea43_4a40_951a_1be48d483811"></a><a id="_31e49997_f6d6_4b62_933c_f6cbf0460de5"></a><a id="_12c27c69_feaa_47e0_8f5c_f7f1f89e580d"></a><a id="_aac33610_e98a_4c17_b42a_349d01664d68"></a><a id="_80700076_3e00_4a1f_8e3f_862ad50801f7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,771</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,769</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,089</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,166</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,923</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The increase in interest expense for the three months ended September 30, 2022 was primarily due to the third quarter of 2022 having a higher average outstanding debt balance with a higher weighted-average interest rate than the third quarter of 2021. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The increase in interest expense for the nine months ended September 30, 2022 was due to $3.6 million of interest expense in the nine months of 2022 related to the 2027 Term Loan discount and debt issuance costs that was allocated to unfunded tranches and then amortized over the respective commitment periods for the tranches, including $2.3 million allocated to Tranche B that was fully amortized in the first quarter of 2022. In addition, the first nine months of 2022 had a higher average outstanding debt balance and interest rate hikes in the U.S. in 2022 has led to a higher weighted-average interest rate in the first nine months of 2022 as compared to the first nine months of 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our 2027 Term Loans have a variable interest rate component that resets the first day of every quarter and resulted in a 10.54% interest rate for Tranches A and B applicable for the third quarter of 2022 which increased to 12.00% on October 1, 2022. As a result of the higher interest rate and the $50.0 million in additional borrowings drawn through the Tranche D Loan in September 2022, we expect higher interest expense in the fourth quarter than the third quarter of 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss on debt extinguishment<i style="color:#ff0000;"> </i></p><a id="_9aa779bc_d5bf_42ef_ab4f_4de2b081b8e7"></a><a id="_16740254_1c5a_4c57_a23b_8f5b622b4a1a"></a><a id="_a7965f53_50db_41b3_a10e_3c06e9263648"></a><a id="_f35697c3_b4db_4d9e_90e7_089bb7d5040a"></a><a id="_12778b12_c9d9_4e25_94bb_7d65b80d5053"></a><a id="_ed9d123e_572b_428c_a58c_79cc8da9e6b2"></a><a id="_664007e3_2a26_423c_bf3e_350a44d17be3"></a><a id="_e2db6f3d_ae6f_437a_87e7_08e0acb544ad"></a><a id="_79a48888_800c_47c9_b5cd_704f540ec225"></a><a id="_20331414_6a65_4263_b197_e9a2e46922d9"></a><a id="_008f5c68_c71e_4cd0_8d1c_50a2b8b4a48c"></a><a id="_66ee073e_c40a_447c_9175_f6abc4f3f16c"></a><a id="_2e247297_e335_4c12_a082_645940587145"></a><a id="_ed3d8bcf_b281_49ee_884f_59f948783f37"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,222</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="background:#ffffff;">The $6.2 million loss on debt extinguishment recorded in the nine months ended September 30, 2022 resulted from voluntarily prepaying all amounts outstanding under the 2025 Term Loan in January 2022. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Certain relevant measures of our liquidity and capital resources are summarized as follows:</p><a id="_d468f479_1f3b_41c6_9701_d196058f9d3d"></a><a id="_a4a4ff63_9a54_4eab_9de7_0f797df2fb35"></a><a id="_9f6d53a2_2174_445b_b8bc_bc3d114ce83b"></a><a id="_8bd24860_4049_4a2a_ac9b_b82067aeafd3"></a><a id="_fed71194_e5fa_4cff_a175_831382c322bd"></a><a id="_8ce07374_a3d1_4eb2_b600_956b37eaa030"></a><a id="_15c94d23_f34c_48f6_9ff8_d710a1e3c444"></a><a id="_5d6476c4_1e35_415a_8638_83ab255c9b94"></a><a id="_908e8ff5_2c02_4750_9e7f_f6b884203d7b"></a><a id="_0ee8df23_daa4_401a_a541_aa94f35dc479"></a><a id="_5fc2e6c3_9462_416c_9774_3b95daee16ec"></a><a id="_0abeb6b7_a0e4_4314_862b_68dcb0be8f06"></a><a id="_0c9d8ede_9c30_44b0_9f89_998e38ad0f4c"></a><a id="_1efe6742_7e61_4890_9f5a_56972853f675"></a><a id="_ad9c9951_8d42_4962_85a5_1a9469f093c2"></a><a id="_507654ea_b2e6_4fb6_a060_e2e6c0d81eba"></a><a id="_d00cfceb_7802_4f10_bf73_a375fe20f033"></a><a id="_e8004530_2e8b_4f96_8c45_1d54f55de2fc"></a><a id="_2dece31d_88f0_424f_ad2b_62aeee587b12"></a><a id="_66967606_0fd1_4d4f_828d_44f09142b7e4"></a><a id="_bf5d6910_193c_4865_b6b2_55278b97c989"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       Total Cash, cash equivalents and marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 286,805</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 417,195</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Debt obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       2027 Term Loans</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 245,246</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       2025 Term Loan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75,513</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       2022 Convertible Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 108,479</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       2026 Convertible Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 225,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 224,288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">            Total debt obligations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 470,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 408,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The 2027 Term Loans were entered into during the first nine months of 2022 in connection with the payoff and refinancing of existing debt facilities. See below for further discussion and </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Note 7. Debt Obligations in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Although we were profitable in 2020 and 2019, due to our research and development expenditures and declines in revenue beginning in 2021, we have generated significant operating losses in all other years since our inception, including the three and nine months ended September 30, 2022. We have funded our operations primarily through sales of our common stock, issuance and incurrence of convertible and term debt and sales of UDENYCA.</span> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, we had an accumulated deficit of $1.3 billion and cash, cash equivalents, and marketable securities of $286.8 million. We believe that our available cash, cash equivalents, marketable securities, cash collected from product sales and additional funding available under the 2027 Term Loan Agreement will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve&#160;months following our financial statement issuance date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional agreements with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated research and development activities, and on-going and future licensing and collaboration obligations. We may need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, if they are successful, the terms and conditions of such financing will be favorable. Our future funding requirements will depend on many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">cash proceeds from product sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing, distributing and marketing our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical supplies and any products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any other collaborative, licensing and other arrangements that we have established or may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales, profit sharing or royalties, if any, from any product candidates that are approved in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of our clinical trials, preclinical testing and other related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products or technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of general economic conditions on our business, including but not limited to increased interest rates and high inflation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of the impact from the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">For further discussion of risks related to our financial condition and capital requirements, please see &#8220;Risk Factors&#8212; Risks Related to Our Financial Condition and Capital Requirements.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing arrangements</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2027 Term Loans</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In January 2022, we entered into the 2027 Term Loans which provide for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $100.0 million that was funded on January 5, 2022; (ii) a Tranche B Loan in an aggregate principal amount of $100.0 million that was funded on March 31, 2022, in connection with the full repayment of our 2022 Convertible Notes due in March 2022; (iii) a Tranche C Loan in an aggregate principal amount of $50.0 million to be funded at our option between April 1, 2022 and March 17, 2023, subject to certain conditions including the first FDA approval of a BLA for our product candidate CHS-007 (toripalimab) in the United States; and (iv) a Tranche D Loan in an aggregate principal amount of $50.0 million that was funded on September 14, 2022. We have the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) January 5, 2027; or (ii) October 15, 2025, if the outstanding aggregate principal amount of our 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans bear interest at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.00%. In the event of the cessation of LIBOR, the benchmark governing the interest rate will be replaced with a rate based on the secured overnight financing rate published by the Federal Reserve Bank of New York as described in the 2027 Term Loans agreement. Interest is payable quarterly in arrears. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In January 2022, we paid to the Lenders of the 2027 Term Loans $6.0 million for a funding fee equal to 2.00% of the Lenders&#8217; total committed amount to fund all four tranches. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the 2027 Term Loans agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were and will be used to fund our general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to voluntarily repay in full all amounts outstanding under the 2025 Term Loan, as well as all associated costs and expenses; and proceeds of the Tranche B Loan were drawn in connection with the full repayment of our 2022 Convertible Notes due in March 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2025 Term Loan</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the carrying amount of our $75.0 million aggregate principal 2025 Term Loan was $75.5 million. In January 2022, the Company used proceeds from a separate borrowing, Tranche A Loan of the 2027 Term Loans, to voluntarily prepay all amounts outstanding under the 2025 Term Loan, pursuant to the $81.9&#160;million payoff amount which included all costs and fees.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2022 Convertible Notes </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the carrying amount of our $100.0 million aggregate principal amount convertible senior notes due March 31, 2022 was $108.5 million, inclusive of a 9% premium due at maturity or redemption, if not earlier converted. During the first quarter 2022, we fully repaid these notes, and in connection with the repayment, drew $100.0 million from the Tranche B Loan of the 2027 Term Loans. Excluding accrued interest, the payoff amount of the 2022 Convertible Notes was $109.0 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2026 Convertible Notes </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">As of September 30, 2022, the carrying amount of our $230.0 million aggregate principal amount convertible senior subordinated notes due 2026 was $225.3 million. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, and will mature on April 15, 2026, unless earlier repurchased or converted at the option of holders. Since inception, the conversion price has been 51.9224 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.815 per share of our common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. The 2026 Convertible Notes are not redeemable at our election before maturity<span style="background:#ffffff;">. &#160;If the 2026 Convertible Notes were converted on September 30, 2022, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $114.8 million based on the Company&#8217;s closing stock price of $9.61.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with the pricing of the 2026 Convertible Notes, we entered into privately negotiated capped call transactions with certain of the initial purchasers of the 2026 Convertible Notes and other financial institutions. Since inception, the cap price has been $25.93 per share, which represents a premium of approximately 75.0% over the last reported sale price of the Company&#8217;s common stock of $14.815 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Milestones &#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We have obligations to make future payments to third parties that become due and payable upon the achievement of certain development, regulatory and commercial milestones (such as clinical trial achievements, the filing of a BLA, approval by the FDA or product launch). These milestone payments and other similar fees are contingent upon future events and therefore are only recorded when it becomes probable that a milestone will be achieved or other applicable criteria will be met. As of September 30, 2022, the &#8364;2.5 million milestone to Bioeq related to the FDA approval of the CIMERLI Section 351(k) BLA milestone was determined to be probable of becoming due and payable and thus accrued in other current liabilities on the condensed consolidated balance sheet. Because the achievement of other milestones had not reached the threshold for recognition as of September 30, 2022, such contingencies were not recorded in our financial statements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;">The following presents a summary of our active partnerships and collaborations that have contingent regulatory and sales milestones:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_24798ba0_c1df_4f42_957d_a6693c7dd9ef"></a><a id="_f18ef4d8_005e_4d7f_99ac_d881dc2c4a1b"></a><a id="_004ade39_16ac_465b_af63_ccc00838e033"></a><a id="_0cb05e2a_db0a_42a2_a53d_811985cd96fd"></a><a id="_06c7b317_5fb6_4f77_bda5_058d71a9feca"></a><a id="_cabd74f7_d939_497b_a905_6001911ce0a7"></a><a id="_eaa01085_3276_4035_9136_940ea2acc7c4"></a><a id="_d5a65551_9820_44dc_a72e_195ab24d7649"></a><a id="_1c02ee9b_cf5b_40b0_be0f_3cdfef53342b"></a><a id="_277cd44f_2d34_4ea5_98c3_d74957c63854"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Counterparty</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Potential Aggregate Milestone Amounts</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.04%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Toripalimab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$380.0 million<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:24.04%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CHS-006 anti-TIGIT antibody</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$255.0 million <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:24.04%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bioeq</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CIMERLI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8364;12.5 million <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA issued a CRL for the original BLA we had submitted for toripalimab requesting a quality process change that we and Junshi Biosciences believe is readily addressable. On July 6, 2022, we announced that the FDA accepted the resubmission of the original BLA for toripalimab. The FDA has set a PDUFA action date for December 23, 2022. If such regulatory approval is achieved, we will be required to pay Junshi Biosciences a milestone payment of $25.0 million. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pon the initiation of a qualifying clinical trial that contains the optioned TIGIT molecule,</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> we will be required to pay Junshi Biosciences a milestone payment of $20.0 million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(3)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The &#8364;12.5 million potential aggregate milestone amount includes a &#8364;2.5 million milestone amount related to the FDA approval of the CIMERLI Section 351(k) BLA, which occurred on August 2, 2022, and certain other criteria, that were satisfied in October 2022.&#160; </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The obligation to pay this &#8364;2.5 million milestone amount was recorded in accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Commitments</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs for preclinical research studies and clinical trials, research supplies and other services and products for operating purposes.&#160;We have also entered into agreements with several CMOs for the manufacture and clinical drug supply of our commercial and product candidates.<span style="background:#ffffff;"> Our non-cancelable purchase commitments as of September 30, 2022 were $40.2 million, as outlined in Note 8. Commitments and Contingencies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There have been no significant changes to our leases or contingent payment to InteKrin stockholders during the nine months ended September 30, 2022, as compared to the discussion in the 2021 Form 10-K. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Summary Statement of Cash Flows </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the periods presented<b style="font-weight:bold;">:</b></p><a id="_bd277b22_bb17_45f9_b631_d0128bf745bc"></a><a id="_36aecab8_d6c1_41a7_8524_3ce4eb5f8790"></a><a id="_a6f64359_4c18_44dc_9cce_6d2b3c2f2e60"></a><a id="_0e367d32_53be_4812_8e69_88121fbe08c3"></a><a id="_9eb2cc16_a35e_41f1_99b9_a7c250b3dccb"></a><a id="_5288051e_1145_4032_8d54_5bc3343fb442"></a><a id="_eb97a305_94ac_46dd_bcb7_9ab4230a8819"></a><a id="_00006c58_a7a7_4c6f_aef9_bddc3542e3e9"></a><a id="_41127708_575d_420d_8a7a_68ceacfeb15b"></a><a id="_473d3341_c3ad_4a58_8a8d_78211eef4b7f"></a><a id="_276d5d30_79e9_474b_830d_5a2777a46273"></a><a id="_bc847172_73f2_4b0f_937f_c1b5aa3ca486"></a><a id="_d4c8d171_d30b_4bc0_8a2c_2960bde4d191"></a><a id="_64228895_c075_4fcb_8fc6_b1c325aa2447"></a><a id="_2675ed2f_aad2_4ef7_82fd_7130833f27ba"></a><a id="_338350f3_be17_49a1_8b98_777390ebe4ae"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (141,171)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,890</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,952)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (245,900)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,733</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,392</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (130,390)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (180,618)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash (used in) provided by operating activities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities was $141.2 million for the nine months ended September 30, 2022, which was primarily due to the following: </p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">net loss of $232.9 million;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a net increase in inventory of $37.6</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">million, excluding the $26.0 million inventory write-down in the third quarter of 2022 for inventory at risk of expiration, primarily due to production of YUSIMRY inventory in anticipation of that product&#8217;s planned July 2023 launch and continuing to maintain adequate supplies of our other products to meet future demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in accrued rebates, fees and reserves of $25.0 million as a result of lower </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">UDENYCA</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> sales</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in other prepaid, current and non-current assets of $12.5 million primarily due to timing of clinical services and payments for insurance, software implementation costs, debt issuance fees, and other services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in prepaid manufacturing of $7.0 million primarily due to </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">prepaid contract manufacturing related to our research and development programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in accounts payable of $6.1 million primarily</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;due to the&#160;timing of receiving and processing invoices from our vendors.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The cash used in operating activities for the nine months ended September 30, 2022 was partially offset by the following: </p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the reclassification of cash flows associated with the license fee payment </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">of $35.0 million to </span><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise our option to </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">license CHS-006 to investing activities in the condensed consolidated statement of cash flows</span><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in accrued and other current and non-current liabilities of $32.3 million </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">primarily due to amounts accrued to Junshi Biosciences and Bioeq pursuant to the Collaboration Agreement and </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bioeq License Agreement, respectively, as well as </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">contract manufacturing accruals,&#160;clinical and regulatory accruals related to our research and development programs and other accrued liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in trade receivables of $31.8 million primarily due to lower revenue in 2022 and the</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> timing of payments from our customers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">non-cash charges related to stock-based compensation of $39.0 million, write-down of inventory at risk of expiration of $26.0 million, loss on debt extinguishment of $6.2 million, non-cash interest expense from amortization of debt discount and issuance costs of $5.6 million, depreciation and amortization of property and equipment of $2.6 million, and other non-cash adjustments of $1.8 million.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash provided by operating activities was $14.9 million for the nine months ended September 30, 2021, which was primarily due to the following:</span> </p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the reclassification of cash flows associated with the license fee payment to Junshi </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Biosciences of $145.0 million pursuant to the Collaboration Agreement,</span><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> partially offset by a </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$9.0 million adjustment related to the fair value of the DLOM on our common stock purchased by Junshi </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Biosciences</span><span style="color:#212529;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">, to investing activities in the condensed consolidated statement of cash flows to provide better alignment between the cash flows and the underlying nature of the transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in accounts payable of $30.5 million primarily</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;due to the&#160;timing of receiving and processing invoices from our vendors and amounts payable to Junshi Biosciences pursuant to the Collaboration Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in trade receivables of $20.7 million primarily due to the</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> timing of payments from our customers and lower revenue in 2021; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in accrued and other current and non-current liabilities of $16.5 million </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">primarily due to clinical, regulatory and manufacturing accruals related to our research and development programs, partially offset by lower contract manufacturing accruals for UDENCYA;</span></td></tr></table><a id="_Hlk114153984"></a><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in accrued rebates, fees and reserves of $3.2 million as a result of higher rebates per unit and timing of rebate payments</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in inventory of $2.9 </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span><span style="color:#242424;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> primarily driven by inventory depletion due to the timing of our manufacturing campaign for UDENYCA that planned for a level of sales of UDENYCA that were not achieved</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">non-cash charges related to stock-based compensation of $40.4 million, a $5.2 million write-off of inventory that did not meet our acceptance criteria, write-off of prepaid manufacturing services of $3.2 million related to the termination of CHS-2020 development, non-cash interest expense from amortization of debt discount and issuance costs of $3.2 million, depreciation and amortization of property and equipment of $2.6 million, and other non-cash adjustments of $2.7 million.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.5pt;">The cash provided by operating activities was partially offset by the following:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">net loss of $241.4 million;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in other prepaid, current and non-current assets of $4.6 million primarily due to timing of clinical services and payments for interest, insurance and other services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease in accrued compensation of $3.5 million </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">primarily&#160;due to the payment of 2020 employee bonuses, which was partially offset by an increase in ESPP contributions and the additional bonus accrual for the nine months ended September 30, 2021; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in prepaid manufacturing services of $2.9 million primarily due to increased prepaid contract manufacturing related to our research and development programs partially offset by lower prepaid commercial manufacturing services.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash used in investing activities of $37.0 million for the nine months ended September 30, 2022 was primarily due to the option fee payment of $35.0 million </span>to license CHS-006<span style="background:#ffffff;"> from Junshi Biosciences and purchases of property and equipment of $2.0 million.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities of $245.9 million for the nine months ended September 30, 2021 was primarily due to the &#160;upfront license fee of $145.0 million to Junshi Biosciences pursuant to the Collaboration Agreement, partially offset by a $9.0 million adjustment related to the fair value of the DLOM on our common stock purchased by Junshi Biosciences, purchases of investments in marketable securities of $171.8 million and purchases of property and equipment of $0.8 million, partially offset by proceeds from maturities of investments in marketable securities of $62.7 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities of $47.7 million for the nine months ended September 30, 2022 was primarily due to proceeds of $240.7 million under the 2027 Term Loans, net of debt discount and issuance costs and $1.7 million proceeds from purchase under the ESPP. These were partially offset by fully repaying $109.0 million on the 2022 Convertible Notes and $81.8 million on the 2025 Term Loan (excluding interest which is accounted for as an operating activity), and $3.6 million in tax payments related to net share settlement of RSUs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities of $50.4 million for the nine months ended September 30, 2021 was primarily due to $50.0 million of gross proceeds from issuance of our common stock to Junshi Biosciences partially offset by a credit of $9.0 million related to the fair value of the DLOM on the common stock purchased by Junshi Biosciences, $9.7 million proceeds from the exercise of stock options, and <span style="background:#ffffff;">$2.0 million proceeds from purchases under the ESPP, </span>partially offset by $1.7 million in tax payments related to net share settlement of RSUs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates<span style="display:inline-block;width:23.76pt;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of our condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expense incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There have been no significant changes to our critical accounting estimates during the nine months ended September 30, 2022, as compared to the critical accounting estimates described in our 2021 Form 10-K. We believe that the critical accounting estimates discussed in the 2021 Form 10-K are meaningful to understanding our historical and future performance, as these estimates relate to the more significant areas involving management&#8217;s judgments and assumptions. During the third quarter of 2022, we recorded an inventory write-down of $26.0 million for inventory at risk of expiration (see Note 4. Inventory in the Notes to Condensed Consolidated Financial Statements contained in Part 1, Item 1 of this Quarterly Report on Form 10-Q).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements <span style="display:inline-block;width:27pt;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">For a description of the impact of recent accounting pronouncements, see Note 1. Organization and Summary of Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cabebee1_dd7d_4ab8_b11a_f413a7879c4d"></a><a id="QuantitativeandQualitativeDisclosuresAbo"></a><a id="ITEM3_924534"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk<span style="display:inline-block;width:13.43pt;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">As of September 30, 2022, we had cash and cash equivalents of $286.8 million. A portion of our cash equivalents, which are in money market funds, may be subject to interest rate risk and could fall in value if market interest rates increase. However, because our cash equivalents are primarily short-term in duration, we believe that our exposure to interest rate risk on these investments is not significant and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We are exposed to interest rate risk with respect to variable rate debt. As of September 30, 2022, we had $250.0 million principal outstanding on our 2027 Term Loans that bears interest at a rate equal to the 3-month LIBOR, subject to a 1% floor, plus 8.25% per year. We are monitoring risks from potential future interest rate increases. We currently do not hedge our variable interest rate debt. The interest rate for our variable rate debt during the quarter ended September 30, 2022 ranged between 10.54% to 11.73%, and the interest rate during the fourth quarter of 2022 will be 12.00% based on the 3-month LIBOR on October 1, 2022. A hypothetical 100 basis point increase in the interest rate on our variable rate debt could result in up to a $2.5 million increase in the annual interest expense as of September 30, 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">All of our sales and most of our inventory purchases are denominated in U.S. dollars. We have exposure to the exchange rate between the U.S. Dollar and the Euro because we make purchases of CIMERLI inventory from our partner Bioeq that are denominated in the Euro and we are therefore subject to fluctuations due to changes in foreign currency exchange rates. Accordingly, fluctuations in the exchange rate between the U.S. Dollar and the Euro may impact our condensed consolidated statements of operations. We currently do not hedge foreign currency exposure related to fluctuations in the exchange rate between the U.S. Dollar and the Euro. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_99f27f0f_8125_4698_a114_6d473548a8f0"></a><a id="ControlsandProcedures_262474"></a><a id="ITEM4_80244"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluation of Effectiveness of Disclosure Controls and Procedures</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We carried out an evaluation, under the supervision of our Chief Executive Officer and our Chief Financial Officer, and evaluated the effectiveness of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. Based on that evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were, in design and operation, effective.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer, principal financial officer and principal accounting officer, as appropriate, to allow for timely decisions regarding required disclosure.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to correct any material deficiencies that we may discover. Our goal is to ensure that our management has timely access to material information that could affect our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to modify our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting<span style="font-style:italic;">.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We substantially completed the implementation of our new Enterprise Resource Planning (&#8220;ERP&#8221;) system in August 2022. The implementation of that ERP system is expected to, among other things, upgrade a number of business, operational and financial processes as well as decrease the number of manual processes previously required. Except for the implementation of the new ERP system, there were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations on Effectiveness of Controls and Procedures</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8efeb9d7_a78f_46e3_82c7_b0002eae262d"></a><a id="PARTII_679735"></a><a id="OTHERINFORMATION_37114"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II&#160;&#8211; OTHER INFORMATION</p><a id="ITEM1LegalProceedings_470595"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings<b style="font-weight:bold;white-space:pre-wrap;">   </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The information called for by this Item is incorporated herein by reference to the information set forth in Note 8. Commitments and Contingencies in the Notes to Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</p><a id="_926c2edc_a176_4921_822b_5e41985e2bf6"></a><a id="Item_1A"></a><a id="Item1ARiskFactors"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:55.45pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:18pt;text-align:justify;"><b style="font-weight:bold;">Ite</b><b style="font-weight:bold;">m&#160;1A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:18pt;text-align:justify;"><span style="font-style:italic;font-weight:bold;">Risk Factors</span><span style="display:inline-block;width:3.28pt;"></span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Item1ARiskFactors_350560"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risk Factor</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Summary</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 0pt 0pt;"><i style="font-style:italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q, </i><i style="font-style:italic;">including our financial statements and related notes thereto, </i><i style="font-style:italic;">before making investment decisions regarding our common stock.</i></p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited history of profitability</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, which we have not maintained and may not achieve again, and only two products that have been approved and marketed, with multiple products either approved and not yet marketed or not approved and still in development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The applicability of clinical data generated outside the United States, particularly from a single country such as China, is subject to FDA concurrence for its suitability in supporting product approvals in the United States. If the FDA or comparable regulatory agencies do not accept data from such trials, our development plans will be delayed, which could materially harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national and/or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business, financial condition, results of operations and growth could be harmed by the effects of the COVID-19 pandemic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">As we have in-licensed development and/or commercial rights to toripalimab and CHS-006, we rely on prior and ongoing preclinical, clinical, regulatory and manufacturing expertise of our collaborators in order to advance these product candidates through regulatory approvals in the United States and other licensed territories.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct foreign inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our biosimilar products or our biosimilar product candidates, if approved, face significant competition from the reference products and from other biosimilar products or pharmaceuticals approved for the same indication as </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the originator products. Toripalimab and CHS-006, if approved, face significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The future commercial success of toripalimab, CHS-006 and any other immuno-oncology products, if approved, will depend on our ability to successfully transition our company&#8217;s clinical, commercial, manufacturing, regulatory, marketing and general historical focus on biosimilars to a new strategy to build a leading immuno-oncology franchise funded with cash generated by our commercial biosimilar business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If an improved version of an originator product, such as Neulasta, Humira or Lucentis, is developed or if the market for the originator product significantly declines, sales or potential sales of our biosimilar product candidates may suffer. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare reform measures, including the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to a multitude of manufacturing risks. Any adverse developments affecting the manufacturing operations of our product candidates and presentations could substantially increase our costs and limit supply for our product candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The continuation of the war between Russia and Ukraine may exacerbate certain risks we face.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;">Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:normal;">Investing in the common stock of a biopharmaceutical company, including one with significant international partnerships and multiple products in development, is a highly speculative undertaking and involves a substantial degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing the Company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;">We have a limited history of profitability</span><span style="font-family:'Calibri','Helvetica','sans-serif';">, which we have not maintained and may not achieve again, and only two products that have been approved and marketed, with multiple products either approved and not yet marketed or not approved and still in development.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We incurred net losses in each year from our inception in September 2010 through December&#160;31, 2018, including a net loss of $287.1 million in 2021 and $232.9 million for the nine months ended September 30, 2022. However, while we did generate net income of $132.2 million and $89.8 million in 2020 and 2019, respectively, it is uncertain that we will be profitable in future periods as research and development is expensive and risky. The amount of our future net losses or net income will depend, in part, on the amount of our future expenditures offset by the amount of future product sales, including sales of our current products or any other products that may receive regulatory approval. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">For example, as of September 30, 2022, we had an accumulated deficit of $1.3 billion. The losses and accumulated deficit were primarily due to the substantial investments we made to identify, develop or license our product candidates, including conducting, among other things, analytical characterization, process development and manufacturing, formulation and clinical studies and providing general and administrative support for these operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk106783503"></a><a id="_Hlk106782865"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We anticipate we will incur certain development and pre-commercial expenses for toripalimab, the anti-PD-1 antibody we licensed from Junshi Biosciences in 2021, and have agreed to pay up to $85.0 million for the achievement of certain regulatory approvals and up to $170.0 million for the attainment of certain sales thresholds. Advancing this and our other product candidates through clinical development will be expensive and could result in us continuing to experience future net losses.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">For YUSIMRY, which is approved but not yet marketed, and for CIMERLI, which is approved and recently launched, and if we obtain regulatory approval to market any other biosimilar product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payers, and adequate market share for our product candidates which include all product candidates for which we obtained commercial rights, in those markets. However, even if additional product candidates in addition to our current products gain regulatory approval and are commercialized, we may not remain profitable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our expenses will increase substantially if and as we: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">further develop our sales, marketing and distribution infrastructure for our current products and develop such infrastructure for new products once they are launched;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize any of our product candidates for which we may obtain marketing approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">make upfront, milestone, royalty or other payments under any license agreements; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our nonclinical and clinical development of our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate additional nonclinical, clinical or other studies for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expand the scope of our current clinical studies for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advance our programs into more expensive clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">change or add contract manufacturers, clinical research service providers, testing laboratories, device suppliers, legal service providers or other vendors or suppliers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, assess, acquire and/or develop other product candidates or products that may be complementary to our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to create, maintain, protect and expand our intellectual property portfolio; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">engage legal counsel and technical experts to help us evaluate and avoid infringing any valid and enforceable intellectual property rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in litigation, including patent litigation, and Inter Partes Review (&#8220;IPR&#8221;) proceedings with originator companies or others that may hold patents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to attract and retain skilled personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">experience any delays or encounter issues with any of the above, including but not limited to failed studies, conflicting results, safety issues, manufacturing delays, litigation or regulatory challenges that may require longer follow-up of existing studies, additional major studies or additional supportive studies or analyses in order to pursue marketing approval. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 49pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Further, the net loss or net income we achieve may fluctuate significantly from quarter-to-quarter and year-to-year such that a period-to-period comparison of our results of operations may not be a good indication of our future performance quarter-to-quarter and year-to-year due to factors including the timing of clinical trials, any litigation that we may initiate or that may be initiated against us as well as any settlements or judgments from such litigation, the execution of collaboration, licensing or other agreements and the timing of any payments we make or receive thereunder.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We continue to be dependent on the ability to raise funds. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization efforts or other operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of September 30, 2022, our cash and cash equivalents were $286.8 million. We expect that our existing cash and cash equivalents and cash collected from our product sales will be sufficient to fund our current operations for the foreseeable future. We have financed our operations primarily through the sale of equity securities, convertible notes, credit facilities, license agreements and through recent product sales of our products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">However, our operating or investing plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to successfully commercialize our products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of any clinical studies, nonclinical testing and other related activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical drug supplies and establishing commercial supplies, of our product candidates and any products that we may develop; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing sales, marketing and distribution capabilities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any licensing or other arrangements to acquire intellectual property rights that we may establish, including any milestone and royalty payments thereunder; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of conversion in common shares or repayment in cash of our convertible debt, or the timing of repayment in cash, whether due or not, of our long-term debt; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of any litigation that we may file against third parties or that may be filed against us by third parties. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute the share ownership of our existing stockholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as those contained in our Loan Agreement, including limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. For more information on our restrictive covenants please read the Loan Agreement referenced as Exhibit 10.31 to our 2021 Annual Report on Form 10-K. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we are unable to obtain funding on a timely basis or at all, stay profitable or increase our net profits, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our financial condition and results of operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50&#160;percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period), such corporation&#8217;s ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;) and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and may experience ownership changes in the future (some of which changes are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Launch and Commercialization of our Products and our Product Candidates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The applicability of clinical data generated outside the United States, particularly from a single country such as China, is subject to FDA concurrence for its suitability in supporting approval in the United States. If the FDA or comparable regulatory agencies do not accept data from such trials, our development plans may be delayed, which could materially harm our business.</span><span style="color:#ff0000;font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Certain clinical trials supporting our regulatory strategies were conducted outside the United States in foreign countries such as China, and we or our collaborators in the future may choose to conduct one or more clinical trials or a portion of such clinical trials for our product candidates outside the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (&#8220;GCP&#8221;) regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We have a limited operating history in an emerging regulatory environment on which to assess our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We are a biopharmaceutical company with a limited operating history in an emerging regulatory environment of biosimilar products. Although we have received upfront payments, milestone and other contingent payments and/or funding for development from some of our collaboration and license agreements, our only approved products include UDENYCA, YUSIMRY and CIMERLI which are approved for commercialization in the United States, and we have no products approved in any other territories.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our ability to generate meaningful revenue and remain profitable depends on our ability, alone or with strategic collaboration partners, to successfully market and sell our products, and to complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of our product pipeline candidates, which include: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">toripalimab;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-006;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional presentations of UDENYCA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-1000.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 49pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We may not be able to continue to generate meaningful revenue from product sales, as this depends heavily on our success in many areas, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to successfully commercialize UDENYCA product presentations and CIMERLI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully launch and commercialize YUSIMRY;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competing against numerous current and future pegfilgrastim and adalimumab products with significant market share; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare providers, payers, and patients adopting our products and product candidates once approved and launched;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to procure and commercialize our in-licensed biosimilar candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining additional regulatory and marketing approvals for product candidates for which we complete clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining adequate third-party coverage and reimbursements for our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of our products and product candidates as viable treatment options; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">completing nonclinical and clinical development of our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and testing of our product formulations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a sustainable and scalable manufacturing process for our products and any approved product candidates and establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our products our product candidates, if approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, assessing and developing (or acquiring/in-licensing on favorable terms) new product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">defending against any litigation including patent or trade secret infringement lawsuits, that may be filed against us, or achieving successful outcomes of IPR petitions that we have filed, or may in the future file, against third parties.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs to commercialize any such product. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medical Agency (the &#8220;EMA&#8221;), other regulatory agencies, domestic or foreign, or by any unfavorable outcomes in intellectual property litigation filed against us, to change our manufacturing processes or assays or to perform clinical, nonclinical or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining additional regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the number of biosimilar or immuno-oncology competitors in such markets, the accepted price for the product, the ability to get reimbursement at any price, the nature and degree of competition from originators and other biosimilar or immuno-oncology companies (including competition from large pharmaceutical companies entering the biosimilar market or possessing large established positions in the immuno-oncology market that may be able to gain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">advantages in the sale of biosimilar or immuno-oncology products based on brand recognition and/or existing relationships with customers and payers) and whether we own (or have partnered with companies owning) the commercial rights for that territory. If the market for our products and product candidates (or our share of that market) is not as significant as we expect, the indication approved by regulatory authorities is narrower than we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are unable to successfully complete development and obtain additional regulatory approval for our products, our business may suffer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national and/or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance. </span><span style="font-style:italic;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Even with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products or product candidates, if approved, will depend in part on the medical community, patients and third-party payers accepting our products and product candidates as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payers and others in the medical community. The degree of market acceptance of our newly launched product CIMERLI or any of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of the product, as demonstrated in clinical studies, and potential advantages over competing treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects and any limitations or warnings contained in a product&#8217;s approved labeling; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which approval is granted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for our immuno-oncology product candidates, our ability to compete in a competitive immuno-oncology market that may differ from the biosimilar market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inclusion, in either parity or better position, on commonly accepted clinical guidelines or pathways that influence prescribing patterns and/or affect reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for our biosimilar product candidates, the possibility that a competitor may achieve interchangeability and we may not; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience, ease of administration and any real or perceived benefit from administration at home as opposed to in the clinic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">policies and practices governing the naming of biosimilar product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence of the disease or condition for which the product is approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment, particularly in relation to competing treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support and timing of market introduction of competitive products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which the product is approved for inclusion on formularies of hospitals, integrated delivery networks and managed care organizations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which third-party payers (including government and national/regional commercial plans) provide adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the price at which we sell our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential impact of the IRA on the pharmaceutical industry and the market for biosimilars;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the actions taken by current and future competitors to delay, restrict or block customer usage of the product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain compliance with regulatory requirements. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Market acceptance of any future product candidates, if approved, will not be fully known until after they are launched and may be negatively affected by a potential poor safety experience and the track record of other biosimilar and immuno-oncology products and product candidates. Further, continued market acceptance of UDENYCA and CIMERLI, and the market acceptance of YUSIMRY, once launched, any future product candidates that may be approved, depends on our efforts to educate the medical community and third-party payers on the benefits of our products and product candidates and will require significant resources from us and we have significantly less resources compared to large, well-funded pharmaceutical entities. Given the resource disparity, our outreach may have little success or may never be successful. If our products or any future product candidates that are approved fail to achieve an adequate level of acceptance by physicians, patients, third-party payers and others in the medical community, we will not be able to generate sufficient revenue to sustain profitability.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The future commercial success of toripalimab, CHS-006 and any other immuno-oncology product candidates, if approved, will depend on our ability to successfully transition our company&#8217;s clinical, commercial, manufacturing, regulatory, marketing and general historical focus on biosimilars to a new strategy to build a leading immuno-oncology franchise funded with cash generated by our commercial biosimilar business. We may have little or no success making this strategic transition if there is difficulty hiring and retaining employees with expertise in both biosimilar and immuno-oncology products, managing our licensing relationship with our partner for toripalimab and CHS-006, regulatory differences between biosimilars and immuno-oncology products and other factors.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-style:italic;"> </span><span style="font-weight:normal;">Our acquisition of toripalimab and CHS-006</span> <span style="font-weight:normal;">represented a significant strategic shift for our company from a historical focus on biosimilars to a new strategy to build a leading immuno-oncology franchise funded with cash generated by our commercial biosimilar business. Pivoting in this manner requires hiring and retaining new employees with expertise across multiple therapeutic areas, particularly immuno-oncology, in a highly competitive global market for talent. In addition, our strategic transition requires us to rely heavily on our licensing relationship with Junshi Biosciences, our partner for toripalimab. A bilateral relationship involves significant risks, including those discussed below in the Risk Factor titled &#8220;we are dependent on Junshi Biosciences, Bioeq and Orox Pharmaceuticals B.V. (&#8220;Orox&#8221;) for the commercialization of our product candidates in certain markets and we intend to seek additional commercialization partners for major markets, and the failure to commercialize in those markets could have a material adverse effect on our business and operating results.&#8221; We have managed in a highly complex regulatory environment for biosimilars in the past where approval from the FDA primarily requires a demonstration that our product shows biosimilarity with the reference product. However, with our strategic shift to operating in both the biosimilar and immuno-oncological spaces, we must still maintain regulatory expertise within the biosimilar area while also building capabilities in the immuno-oncology market. FDA regulation of immuno-oncology product candidates like toripalimab is different than for biosimilars because we must demonstrate the safety, purity and efficacy of the product candidate to the satisfaction of the FDA rather than relying on the safety and efficacy data of the reference product and demonstrate biosimilarity. This process of generating acceptable safety and efficacy data from clinical trials represents a relatively new approach for our company, so it involves more execution risk for us than for biosimilars where we have many years of experience advancing product candidates. If we fail to successfully manage the transition of our focus on biosimilars to our new strategy to build a leading immuno-oncology franchise funded with cash generated by our commercial biosimilar business, it will materially and adversely affect our financial results.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">The third-party coverage and reimbursement status of our products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Pricing, coverage and reimbursement of our products, or any of our product candidates, if approved, may not be adequate to support our commercial infrastructure. The prices required to successfully compete may not continue to be sufficient to recover our development and manufacturing costs, and as a result, we may not be profitable in the future. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and commercial payers are essential to enable provider/patient access to our products and our patient support services must be sufficiently scaled to meet the needs of patients receiving our products. Sales will depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations or reimbursed by government authorities, private health insurers and other third-party payers. If coverage and reimbursement are not available, or are available only to limited levels, or become unavailable, we may not be able to successfully commercialize our products or any of our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be adequate to allow us to establish or maintain pricing sufficient to realize a return on our investment. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payers, including private and governmental payers such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older or those who are disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state to state, covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental payers develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict what third-party payers will decide with respect to the coverage and reimbursement for any newly approved product. In addition, in the United States, no uniform policy of coverage and reimbursement for biologics exists among third-party payers. Therefore, coverage and reimbursement for biologics can differ significantly from payer to payer. As a result, the process for obtaining favorable coverage determinations often is time-consuming and costly and may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Effective January 2019, the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) assigned a product specific Q-Code to UDENYCA, which is necessary to allow UDENYCA to have its own reimbursement rate with Medicare or other third-party payers. However, reimbursement is not guaranteed and rates may vary based on product life cycle, site of care, type of payer, coverage decisions, and provider contracts. Furthermore, while payers have adopted the Q-Code assigned by CMS for UDENYCA, there remains uncertainty as to whether such payers will continue to cover and pay providers for the administration and use of the product with each patient or may favor a competing product. If our products or any of our future product candidates, are not covered or adequately reimbursed by third-party payers, including Medicare, then the cost of the relevant product may be absorbed by healthcare providers or charged to patients. If this is the case, our expectations of the pricing we expect to achieve for such product and the related potential revenue, may be significantly diminished.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Outside of the United States, pharmaceutical businesses are generally subject to extensive governmental price controls and other market regulations. We believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Increasing efforts by governmental and third-party payers in the United States and abroad to control healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or any of our product candidates. While cost containment practices generally benefit biosimilars, severe cost containment practices may adversely affect our product sales. Furthermore, the impact of the IRA on our business and the pharmaceutical industry generally is currently unknown. We expect to experience pricing pressures in connection with the sale of our products and any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our products and our product candidates, even If approved, will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any new drug application (&#8220;NDA&#8221;), original BLA submitted under Section 351(a) of the Public Health Service Act (&#8220;PHSA&#8221;) (&#8220;original BLA&#8221;), biosimilar application (&#8220;Section 351(k) BLA&#8221;) or Marketing Authorization Application (&#8220;MAA&#8221;). Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any regulatory approvals that we or our collaboration partners receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse events and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased costs to assure compliance. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. If our product candidates are approved, we must submit new or supplemental applications and obtain approval for certain changes to the approved products, product labeling or manufacturing process. We or our collaboration partners could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval is obtained via an accelerated biosimilar approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other possibilities: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a product recall. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States, China or other foreign countries.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct foreign inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:12pt 0pt 0pt 0pt;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&#160;For example, over the last several years, the United States government has periodically shut down and certain regulatory agencies, such as the&#160;FDA, had to furlough critical&#160;FDA&#160;employees and stop critical activities.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA postponed most inspections of foreign and domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA began conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities in circumstances where the FDA determines that such remote evaluation would be appropriate based on mission needs and travel limitations. In July 2021, the FDA resumed standard inspectional operations of domestic facilities. Since that time, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if they continue in regions such as China, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including in China </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">where we partner with Junshi Biosciences for toripalimab, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. For example, in the CRL we received from the FDA for toripalimab, the FDA indicated that the review period for the resubmission of the original BLA for toripalimab would be impacted by travel restrictions and closures occurring in China as a result of the COVID-19 pandemic. While the FDA provided an initial estimate of such timing impacts, the ultimate delay could be substantially more for reasons outside of our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Risks Related to COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;">Our business, financial condition, results of operations and growth could continue to be harmed by the effects of the COVID-19 pandemic and other viral pandemics.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">We are subject to risks related to public health crises such as the global pandemic associated with&#160;the COVID-19 pandemic.&#160;As a result of the&#160;COVID-19&#160;outbreak, we have experienced and may continue to experience disruptions that could severely impact our business, competitive position, clinical trials and preclinical studies, including, but not limited to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased sales of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with Neulasta Onpro&#174; during the period of time when the UDENYCA on-body injector is not approved and is not commercially available if a large number of patients demonstrate a preference to administer medication at home due to COVID-19, other viral pandemics, convenience or other factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain or expand the commercial use of our products due to, among other factors, healthcare providers, payers and patients not utilizing or adopting our products due to resources being strained or otherwise focused on the COVID-19 pandemic and our sales team efficacy in selling our products being limited due to such strained resources or other factors such as travel restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fewer individuals undertaking or completing cancer treatments, or participating in clinical trials, whether due to contracting COVID-19, self-isolating or quarantining to lower the risk of contracting COVID-19 or being unable to access care as a result of healthcare providers tending to COVID-19 patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contract manufacturers and logistics providers not being able to maintain adequate (in amount and quality) supply to support the commercial sale of our products or the clinical development of our product candidates due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays and difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, as well as delays or difficulties in enrolling patients or maintaining enrolled patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by foreign, federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact regulatory review and approval timelines; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on our employee resources, and those of our business partners, that would otherwise be focused on the conduct of our business in all aspects, including because of sickness or fear of sickness of employees or their families; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">negative impact from government orders, quarantines and similar government orders and restrictions.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">These and other factors arising from the COVID-19 pandemic could result in us not being able to maintain UDENYCA&#8217;s market position or increase its penetration against all of Neulasta&#8217;s dosage forms, achieve a successful launch </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">of new products, and could result in our inability to meet development milestones for our product candidates, each of which would harm our business, financial condition, results of operations and growth. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Numerous state and local jurisdictions have imposed, and others in the future may impose,&#160;&#8220;shelter-in-place&#8221;&#160;orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of&#160;COVID-19.&#160;Multiple times in 2021, the governor of California, where our headquarters and laboratory facilities are located, issued&#160;a &#8220;shelter-in-place&#8221; order restricting&#160;non-essential&#160;activities, travel and business operations for an indefinite period of time, subject to certain exceptions for necessary activities. Such orders or restrictions have resulted in our headquarters closing for certain periods, slowdowns and delays, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our operations. In addition, there was a lockdown order in all of Shanghai, China in April and May 2022, where our partner Junshi Biosciences has its headquarters. Such orders or restrictions may continue or be re-instated, as the case may be, thereby causing additional negative impact on our operations. Further, because the full rollout of COVID-19 vaccines and booster doses has suffered from reluctance from eligible individuals to be fully inoculated, the COVID-19 pandemic may last longer than expected and could result in additional outbreaks that prompt additional closings. In addition, the spread of more contagious and deadly variants, such as the Delta variant and the omicron variant, could cause the COVID-19 pandemic to last longer or be more severe than expected. We have no ability to predict the future spread of severe and deadly pandemics that could disrupt our business and materially impact our financial position.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">While the long-term economic impact and the duration of&#160;the COVID-19&#160;pandemic or other viral pandemics may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and our notes. In addition, a recession, further market correction or depression resulting from the spread of&#160;COVID-19&#160;could materially affect our business and the value of our notes and our common stock.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Competitive Activity</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our biosimilar products or our biosimilar product candidates, if approved, face significant competition from the reference products and from other biosimilar products or pharmaceuticals approved for the same indication as the originator products. Toripalimab and CHS-006, if approved, face significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We operate in highly competitive pharmaceutical markets. Successful competitors in the pharmaceutical market have demonstrated the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as an ability to effectively commercialize, market and promote approved products. Numerous companies, universities and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with those that we are developing. Many of these potential competitors are large, experienced multinational pharmaceutical and biotechnology companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, legal, governmental affairs, manufacturing, personnel, marketing resources, and the benefits of mergers and acquisitions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">UDENYCA faces competition in the United States from Amgen, Mylan N.V. (with partner Viatris / Biocon), Sandoz International GmbH (&#8220;Sandoz&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), and may face competition from Amneal Pharmaceuticals, Inc. (&#8220;Amneal&#8221;) and Fresenius Medical Care AG &amp; Co. KGaA (&#8220;Fresenius&#8221;), companies that have pegfilgrastim biosimilars that were recently approved by the FDA.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">CIMERLI, our ranibizumab (Lucentis) biosimilar product licensed from Bioeq, faces competition in the United States from Genentech (the manufacturer of Lucentis), Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;), and Biogen Inc., among others. Xbrane Biopharma AB (&#8220;Xbrane&#8221;) (in collaboration with STADA Arzneimittel AG and Bausch &amp; Lomb Incorporated) has also disclosed the development of a Lucentis biosimilar candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Similarly, YUSIMRY may face competition from AbbVie (the manufacturer of Humira) as well as manufacturers of Humira biosimilars such as Pfizer, Boehringer Ingelheim GmbH (&#8220;Boehringer Ingelheim&#8221;), Amgen, Sandoz, Alvotech and Samsung Bioepis. Boehringer Ingelheim&#8217;s biosimilar was approved as interchangeable of Humira which means that pharmacists may provide it instead of Humira without a specific prescription. There is no guarantee that YUSIMRY will be approved as interchangeable. There are a number of adalimumab biosimilar products that have been approved by the FDA in the United States, and Fujifilm Kyowa Kirin Biologics Co., Ltd. and Fresenius have each received approvals for Humira biosimilars. As a result of continued expected competition from Humira and a large number of potential adalimumab (Humira) biosimilar competitors, we may not be able to achieve substantial topline sales for YUSIMRY in the United States when we launch it as planned in July 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Toripalimab and CHS-006 may face competition from Merck &amp; Company, Inc. (&#8220;Merck&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Novartis International AG (&#8220;Novartis&#8221;), AstraZeneca plc (&#8220;AstraZeneca&#8221;), Pfizer, Eli Lilly and Company (&#8220;Eli Lilly&#8221;), Regeneron, EQRx, Inc. and others who currently commercialize PD-1/PD-L1 blocking antibodies or are developing such compounds for commercialization in the United States. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">These companies may also have greater brand recognition and more experience in conducting preclinical testing and clinical trials of product candidates, obtaining FDA and other regulatory approvals of products and marketing and commercializing products once approved. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, many manufacturers of originator products have increasingly used legislative, regulatory and other means, such as litigation, to delay regulatory approval and to seek to restrict competition from manufacturers of biosimilars. These efforts may include or have included: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">settling, or refusing to settle, patent lawsuits with biosimilar companies, resulting in such patents remaining an obstacle for biosimilar approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">submitting Citizen Petitions to request the FDA Commissioner to take administrative action with respect to prospective and submitted biosimilar applications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">appealing denials of Citizen Petitions in United States federal district courts and seeking injunctive relief to reverse approval of biosimilar applications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restricting access to reference brand products for equivalence and biosimilarity testing that interferes with timely biosimilar development plans; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attempting to influence potential market share by conducting medical education with physicians, payers, regulators and patients claiming that biosimilar products are too complex for biosimilar approval or are too dissimilar from originator products to be trusted as safe and effective alternatives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing payer market access tactics that benefit their brands at the expense of biosimilars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking state law restrictions on the substitution of biosimilar products at the pharmacy without the intervention of a physician or through other restrictive means such as excessive recordkeeping requirements or patient and physician notification; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking federal or state regulatory restrictions on the use of the same non-proprietary name as the reference brand product for a biosimilar or interchangeable biologic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking changes to the United States Pharmacopeia, an industry recognized compilation of drug and biologic standards; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining new patents covering existing products or processes, which could extend patent exclusivity for a number of years or otherwise delay the launch of biosimilars; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">influencing legislatures so that they attach special patent extension amendments to unrelated federal legislation. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products and our product candidates, if approved, could face price competition from other products or biosimilars of the same reference products for the same indication. This price competition could exceed our capacity to respond, detrimentally affecting our market share and revenue as well as adversely affecting the overall financial health and attractiveness of the market for the biosimilar.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Competitors in the biosimilar market have the ability to compete on price through PBMs, payers and their third-party administrators, IDNs and hospitals who exert downward pricing pressure on our price offerings. It is possible our biosimilar competitors&#8217; compliance with price discounting demands in exchange for market share or volume requirements could exceed our capacity to respond in kind and reduce market prices beyond our expectations. There could be similar price competition in the immuno-oncology market that could adversely affect our results in the future. Such practices may limit our ability to increase market share and may also impact profitability.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, less costly, easier to administer or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop; they may also obtain patent protection that could block our products; and they may obtain regulatory approval, product commercialization and market penetration earlier than we do. Our competitors may have products that are easier to administer than our products, which could adversely affect our results, such as due to the observed trend that a large number of patients demonstrate a preference to administer medication at home due to COVID-19 or other factors. Biosimilar or immuno-oncology product candidates developed by our competitors may render our potential product candidates uneconomical, less desirable or obsolete, and we may not be successful in marketing our product candidates against competitors. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If other biosimilars of ranibizumab (Lucentis) or adalimumab (Humira), are approved and successfully commercialized before our product candidates and products for these originator products, our business would suffer. If other competitors to toripalimab are approved and successfully commercialized before our product candidates and products for these originator products, our business would suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Approvals have already been obtained and we expect additional companies to continue to seek approval to manufacture and market biosimilar versions of Lucentis or Humira. Similarly, there are a number of companies that currently commercialize PD-1/PD-L1 blocking antibodies or are developing such compounds for commercialization in the United States. If other biosimilars of these branded biologics are approved and successfully commercialized before our biosimilar products and product candidates and if other competitors to toripalimab are successfully commercialized before our product candidates, we may never achieve meaningful market share for these products, our revenue would be reduced and, as a result, our business, prospects and financial condition could suffer. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If an improved version of an originator product, such as Neulasta, Humira or Lucentis, is developed or if the market for the originator product significantly declines, sales or potential sales of our biosimilar products and product candidates may suffer. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Originator companies may develop improved versions of a reference product as part of a life cycle extension strategy and may obtain regulatory approval of the improved version under a new or supplemental BLA submitted to the applicable regulatory authority. Should the originator company succeed in obtaining an approval of an improved biologic product, it may capture a significant share of the collective reference product market in the applicable jurisdiction and significantly reduce the market for the reference product and thereby the potential size of the market for our biosimilar products and product candidates. In addition, the improved product may be protected by additional patent rights that may subject our follow-on biosimilar to claims of infringement. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Biologic reference products may also face competition as technological advances are made that may offer patients a more convenient form of administration or increased efficacy or as new products are introduced. External developments such as the COVID-19 pandemic can also result in changing preferences for convenient forms of administration of products that may impact our business. As new products are approved that compete with the reference product to our biosimilar product candidates, sales of the reference originator product may be adversely impacted or rendered obsolete. If the market for the reference product is impacted, we may lose significant market share or experience limited market potential for our approved biosimilar products or product candidates, and the value of our product pipeline could be negatively impacted. As a result of the above factors, our business, prospects and financial condition<b style="font-weight:bold;"> </b>could suffer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates for which we intend to seek approval as original biologic products may face competition sooner than anticipated.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our development of novel biologic product candidates, such as toripalimab, subjects us to additional risks relating to biosimilar competition. In particular, under the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We believe that any of our future product candidates approved under an original BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:18pt 0pt 12pt 0pt;">Risks Related to Our Ability to Hire and Retain Highly Qualified Personnel </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, product development and scientific personnel, our business will suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We are highly dependent on the principal members of our management and scientific and technical staff. The loss of service of any of our management or key scientific and technical staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, product development and scientific personnel. If we are not able to retain our management, particularly our President and Chief Executive Officer, Mr.&#160;Lanfear, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We will need to expand and effectively manage our managerial, scientific, operational, financial, commercial and other resources in order to successfully pursue our product development and commercialization efforts. Our success also depends on our continued ability to attract, retain and motivate highly qualified management and technical personnel. We may not be able to attract or retain qualified management and scientific and product development personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly those located in the San Francisco Bay Area. We also use equity compensation as a part of a comprehensive compensation package for our personnel and to the extent our stock price declines significantly due to a variety of factors outside of our control, our equity compensation packages may not provide the retention and motivation incentive that we believe it should. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We will need to expand our organization, particularly due to the transition of our strategy from a biosimilars business to a company using cash flows from our commercial biosimilars portfolio to fund our immuno-oncology pipeline, and we may experience difficulties in managing this transition and associated growth, which could disrupt our operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of September 30, 2022, we had 376 employees. As our development and commercialization plans and strategies develop and evolve with our new corporate focus, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources, particularly those with expertise in immuno-oncology. Further, as we develop and build our immuno-oncology platform, such work could further divert internal resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities, including building our immuno-oncology platform. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Reliance on Third Parties</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">comply with cGMP, GCP, and Good Laboratory Practices (&#8220;GLP&#8221;), which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections or remote regulatory assessments (&#8220;RRAs&#8221;) of study sponsors, principal investigators, study sites and other contractors. If we, any of our CROs, service providers or investigators fail to comply with applicable regulations or GCPs, the data generated in our nonclinical and clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. There can be no assurance that upon inspection or conclusion of an RRA by a given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must be conducted with product generated under cGMP regulations. Failure to comply by any of the participating parties or ourselves with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process. Moreover, our business may be implicated if our CRO or any other participating parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, a transition period is necessary when a new CRO commences work, which can materially impact our ability to meet our desired clinical development timelines. Though we strive to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We rely on third parties, and in some cases a single third party, to manufacture nonclinical, clinical and commercial drug supplies of our product candidates and to store critical components of our product candidates for us. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product candidates or fail to do so at acceptable quality levels or prices. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We do not currently have the infrastructure or capability internally to manufacture supplies of our product candidates for use in our nonclinical and clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on third-party manufacturers to manufacture and supply us with our product candidates for our preclinical and clinical studies as well as to establish commercial supplies of our product candidates. Successfully transferring complicated manufacturing techniques to contract manufacturing organizations and scaling up these techniques for commercial quantities is time consuming and we may not be able to achieve such transfer or do so in a timely manner. Moreover, the availability of contract manufacturing services for protein-based therapeutics is highly variable and there are periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce our product candidates on a timely basis or on commercially viable terms. Although we will plan accordingly and generally do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any significant delay or discontinuation in the supply of a product candidate for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">approval of our product candidates, which could harm our business and results of operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third-party manufacturers may not be able to comply with cGMP or similar regulatory requirements outside the United States. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or any other product candidates or products that we may develop. Any failure or refusal to supply the components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If any of our product candidates are approved, in order to produce the quantities necessary to meet anticipated market demand, any contract manufacturer that we engage may need to increase manufacturing capacity. If we are unable to build and stock our product candidates in sufficient quantities to meet the requirements for the launch of these candidates or to meet future demand, our revenue and gross margins could be adversely affected. Although we believe that we will not have any material supply issues, we cannot be certain that we will be able to obtain long-term supply arrangements for our product candidates or materials used to produce them on acceptable terms, if at all. If we are unable to arrange for third-party manufacturing, or to do so on commercially reasonable terms, we may not be able to complete development of our product candidates or market them. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are dependent on Junshi Biosciences, Bioeq and Orox for the commercialization of our product candidates in certain markets and we intend to seek additional commercialization partners for major markets, and the failure to commercialize in those markets could have a material adverse effect on our business and operating results. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have an exclusive license from Junshi Biosciences to develop and commercialize toripalimab and CHS-006 in the United States and Canada. We have an exclusive license from Bioeq to commercialize CIMERLI in the United States. Our licensors are responsible for supplying us with drug substance and final drug products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our exclusive licensee, Orox, is responsible for commercialization of certain of our products and product candidates, including UDENYCA and YUSIMRY in certain Caribbean and Latin American countries (excluding Brazil, and in the case of UDENYCA, also excluding Argentina). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our licenses with Junshi Biosciences, Bioeq, Orox, or other future license or collaboration agreements, may not be successful. Factors that may affect the success of our licenses and collaborations include, but are not limited to, the following:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail to provide sufficient amounts of commercial products, including because of import restrictions, or they may be ineffective in doing so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail regulatory inspections or RRAs which may preclude or delay the delivery of commercial products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail to exercise commercially reasonable efforts to market and sell our products in their respective licensed jurisdictions or they may be ineffective in doing so; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may incur financial, legal or other difficulties that force them to limit or reduce their participation in our joint projects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may terminate their licenses or collaborations with us, which could make it difficult for us to attract new partners and/or adversely affect perception of us in the business and financial communities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may choose to pursue alternative, higher priority programs, which could affect their commitment to us. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Moreover, any disputes with our licensees and collaboration partners will substantially divert the attention of our senior management from other business activities and will require us to incur substantial costs associated with litigation or arbitration proceedings. If we cannot maintain successful license and collaboration arrangements, our business, financial condition and operating results may be adversely affected.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Manufacturing and Supply Chain </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our products. Any adverse developments affecting the manufacturing operations of our product candidates could substantially increase our costs and limit supply for our product candidates. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product loss due to contamination, equipment failure or improper installation or operation of equipment or vendor or operator error; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">equipment failures, labor shortages, natural disasters, power failures and numerous other factors associated with the manufacturing facilities in which our product candidates are produced, and potentially exacerbated by climate change; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of supply chains for critical and specialized raw materials, delays in regulatory inspections of manufacturing and testing facilities, and reduced manufacturing capacities created by global events such as the COVID-19 pandemic and the ongoing conflict in Ukraine. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We reduced production yields, product defects and other supply disruptions. For example, we have experienced failures with respect to the manufacturing of certain lots of each of our product candidates resulting in delays prior to our taking corrective action. Additionally, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any adverse developments affecting manufacturing operations for our product candidates, including due to sudden or long-term changes in weather patterns, may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for products that are manufactured in reliance on a forecast that proves to be inaccurate because we do not sell as many units as forecasted. For example, during the third quarter of 2022, we recorded a $26.0 million write-down of inventory that was at risk of expiration. Although we believe that the assumptions that we use in estimating inventory write-downs are reasonable, if actual market conditions are less favorable than our projections, then additional write-downs of inventory may be required in the future, which could materially and adversely impact our financial results. In addition to such write-offs, we may also have to incur charges and expenses related to firm purchase commitments or for product candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">We currently engage single suppliers for manufacture, clinical trial services, formulation development and product testing of our product candidates. The loss of any of these suppliers or vendors could materially and adversely affect our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">For our products and our product candidates, we currently engage a distinct&#160;vendor or service provider for each of the principal activities supporting our manufacture and development of these products, such as manufacture of the biological substance present in each of the products, manufacture of the final filled and finished presentation of these products, as well as laboratory testing, formulation development and clinical testing of these products.&#160;For example, in December 2015, we entered into a strategic manufacturing agreement with KBI Biopharma for long-term commercial manufacturing of UDENYCA. Because we currently have engaged a limited number of back-up suppliers or vendors for these single-sourced services, and although we believe that there are alternate sources that could fulfill these activities, we cannot assure you that identifying and establishing relationships with alternate suppliers and vendors would not result in significant delay in the development of our product candidates. Additional delays or cost increases could occur due to the direct or indirect effects of the COVID-19 pandemic and the ongoing conflict in Ukraine.&#160;Additionally, we may not be able to enter into arrangements with alternative service providers&#160;on commercially reasonable terms or at all.&#160;A delay in the development of our product candidates, or having to enter into a new agreement with a different third party on less favorable terms than we have with our current suppliers, could have a material adverse impact on our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We and our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We, our collaboration partners, or our contract manufacturers must supply all necessary documentation in support of a Section 351(k) BLA, original BLA, NDA or MAA on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our contract manufacturers may have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our collaboration partners and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The regulatory authorities also may, at any time following approval of a product for sale, inspect, audit or initiate an RRA of the manufacturing facilities of our collaboration partners and third-party contractors. If any such inspection, audit or RRA identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection, audit or RRA, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we, our collaboration partners or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate, withdrawal of an approval or suspension of production. As a result, our business, financial condition and results of operations may be materially harmed. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a BLA supplement, NDA supplement or MAA variation or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">These factors could cause us to incur additional costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The structure of complex proteins used in protein-based therapeutics is inherently variable and highly dependent on the processes and conditions used to manufacture them. If we are unable to develop manufacturing processes that achieve a requisite degree of biosimilarity to the originator drug, and within a range of variability considered acceptable by regulatory authorities, we may not be able to obtain regulatory approval for our biosimilar products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Protein-based therapeutics are inherently heterogeneous and their structures are highly dependent on the production process and conditions. Products from one production facility can differ within an acceptable range from those produced in another facility. Similarly, physicochemical differences can also exist among different lots produced within a single facility. The physicochemical complexity and size of biologic therapeutics create significant technical and scientific challenges in the context of their replication as biosimilar products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The inherent variability in protein structure from one production lot to another is a fundamental consideration with respect to establishing biosimilarity to an originator product to support regulatory approval requirements. For example, the glycosylation of the protein, meaning the manner in which sugar molecules are attached to the protein backbone of a therapeutic protein when it is produced in a living cell, is critical to therapeutic efficacy, half-life, efficacy and even safety of the therapeutic and is therefore a key consideration for biosimilarity. Defining and understanding the variability of an originator molecule in order to match its glycosylation profile requires significant skill in cell biology, protein purification and analytical protein chemistry. Furthermore, manufacturing proteins with reliable and consistent glycosylation profiles at scale is challenging and highly dependent on the skill of the cell biologist and process scientist. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There are extraordinary technical challenges in developing complex protein-based therapeutics that not only must achieve an acceptable degree of similarity to the originator molecule in terms of characteristics such as the unique glycosylation pattern, but also the ability to develop manufacturing processes that can replicate the necessary structural characteristics within an acceptable range of variability sufficient to satisfy regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Given the challenges caused by the inherent variability in protein production, we may not be successful in developing our biosimilar products if regulators conclude that we have not achieved a sufficient level of biosimilarity to the originator product, or that the processes we use are unable to generate our products within an acceptable range of variability. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Adverse Events </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As with most pharmaceutical products, use of our products or our product candidates could be associated with side effects or adverse events, which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates may be observed at any time, including in clinical trials or when a product is commercialized. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our studies could reveal a high and unacceptable severity and prevalence of side effects such as toxicity or other safety issues and could require us or our collaboration partners to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. In such an event, we may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our product candidates, which we have not planned or anticipated or our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any other regulatory agency in a timely manner, if ever, which could harm our business, prospects and financial condition. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, product quality characteristics have been shown to be sensitive to changes in process conditions, manufacturing techniques, equipment or sites and other such related considerations, hence any manufacturing process changes we implement prior to or after regulatory approval could impact product safety and efficacy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Drug-related side effects could affect patient recruitment for clinical trials, the ability of enrolled patients to complete our studies or result in potential product liability claims. We currently carry product liability insurance and we are required to maintain product liability insurance pursuant to certain of our license agreements. We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we receive approval for our product candidates, regulatory agencies including the FDA and foreign regulatory agencies, regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Adverse events involving an originator product, or other biosimilars of such originator product, may negatively affect our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In the event that use of an originator product, or other biosimilar for such originator product, results in unanticipated side effects or other adverse events, it is likely that our biosimilar product candidate will be viewed comparably and may become subject to the same scrutiny and regulatory sanctions as the originator product or other biosimilar, as applicable. Accordingly, we may become subject to regulatory supervisions, clinical holds, product recalls or other regulatory actions for matters outside of our control that affect the originator product, or other biosimilar, as applicable, if and until we are able to demonstrate to the satisfaction of our regulators that our biosimilar product candidate is not subject to the same issues leading to the regulatory action as the originator product or other biosimilar, as applicable. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our commercial success depends in large part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. The companies that originated the products for which we intend to introduce biosimilar versions, such as Amgen, AbbVie and Genentech, as well as other competitors (including other companies developing biosimilars) have developed, and are continuing to develop, worldwide patent portfolios of varying sizes and breadth, many of which are in fields relating to our business, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. We are aware of third-party patents or patent applications with claims, for example, to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. While we have conducted freedom to operate analyses with respect to our products and our product candidates, including our in-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">licensed biosimilar candidates, as well as our pipeline candidates, we cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents covering our product candidates. With respect to products we are evaluating for inclusion in our future product pipeline, our freedom to operate analyses, including our research on the timing of potentially relevant patent expirations, are ongoing. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There may also be patent applications that have been filed but not published and if such applications issue as patents, they could be asserted against us. For example, in most cases, a patent filed today would not become known to industry participants for at least 18 months given patent rules applicable in most jurisdictions, which do not require publication of patent applications until 18 months after filing. Moreover, some United States patents may issue without any prior publication in cases where the patent applicant does not also make a foreign filing. We may also face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. In addition, coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid and/or unenforceable, and we may not be able to do this. Proving that a patent is invalid or unenforceable is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Also in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial monetary damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on commercially acceptable terms or at all. If, as a result of patent infringement claims or to avoid potential claims, we choose or are required to seek licenses from third parties, these licenses may not be available on acceptable terms or at all. Even if we are able to obtain a license, the license may obligate us to pay substantial license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would likely involve substantial litigation expense and would likely be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may, in addition to being blocked from the market, have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On May 10, 2017, Amgen Inc. and Amgen Manufacturing Inc. filed an action against us in the United States District Court for the District of Delaware alleging infringement of one or more claims of Amgen&#8217;s US patent 8,273,707 (the &#8220;&#8216;707 patent&#8221;) under 35 U.S.C. &#167; 271. The complaint seeks injunctive relief, monetary damages and attorney fees. On December&#160;7, 2017, the United States Magistrate Judge issued under seal a Report and Recommendation to the District Court recommending that the District Court grant, with prejudice, our pending motion to dismiss Amgen&#8217;s complaint for failure to state a claim pursuant to Federal Rule of Civil Procedure 12(b)(6). On March 26, 2018, Judge Stark of the District Court adopted the United States Magistrate Judge&#8217;s Report and Recommendation to grant our motion pursuant to Federal Rule of Civil Procedure 12(b)(6) to dismiss with prejudice the patent infringement complaint alleging </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">infringement of the &#8216;707 patent on the grounds that such complaint failed to state a claim upon which relief may be granted. In May 2018, Amgen filed a Notice of Appeal in the United States Court of Appeals for the Federal Circuit. Amgen and Coherus filed briefs in this matter and oral argument was held on May 8, 2019. On July 29, 2019, the Federal Circuit issued a precedential opinion affirming the District Court&#8217;s judgment in our favor. The Federal Circuit held that the doctrine of prosecution history estoppel barred Amgen from succeeding on its infringement claim and affirmed the District Court&#8217;s dismissal. In a Joint Status Report, dated September 20, 2019, Amgen stated that it does not intend to further appeal the Federal Circuit&#8217;s decision. On October 11, 2019, we filed a Motion for Attorneys&#8217; Fees with the District Court. Amgen filed its Answering Brief in Opposition on November 8, 2019. On November 22, 2019, we filed our Reply Brief with the District Court. On November 30, 2020, the District Court issued an order denying the Company&#8217;s motion.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On January 24, 2019, we entered into settlement and license agreements with AbbVie, that grant us global, royalty-bearing, non-exclusive license rights under AbbVie&#8217;s intellectual property to commercialize CHS-1420, our proposed adalimumab (Humira) biosimilar. The global settlements resolve all pending disputes between the parties related to CHS-1420. Under the United States settlement, our license period in the United States commences on July 1, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, IPR, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. An unfavorable outcome in any such proceeding could require us to cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties may submit applications for patent term extensions in the United States or other jurisdictions where similar extensions are available and/or Supplementary Protection Certificates in the E.U. states (including Switzerland) seeking to extend certain patent protection, which, if approved, may interfere with or delay the launch of one or more of our products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Patent litigation and other proceedings may fail, and even if successful, may result in substantial costs and distract our management and other employees. The companies that originated the products for which we intend to introduce biosimilar versions, as well as other competitors (including other biosimilar companies) may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We do not know whether any of our pending patent applications will result in the issuance of any patents or whether the rights granted under any patents issuing from these applications will prevent any of our competitors from marketing similar products that may be competitive with our own. Moreover, even if we do obtain issued patents, they will not guarantee us the right to use our patented technology for commercialization of our product candidates. Third parties may have blocking patents that could prevent us from commercializing our own products, even if our products use or embody our own, patented inventions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The validity and enforceability of patents are generally uncertain and involve complex legal and factual questions. Any patents that may issue on our pending applications may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing products similar to ours. Furthermore, our competitors may develop similar or alternative technologies not covered by any patents that may issue to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">For technologies for which we do not seek patent protection, we may rely on trade secrets to protect our proprietary position. However, trade secrets are difficult to protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, advisors, contractors or collaborators. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, advisors, contractors and collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits or IPR proceedings to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We may discover that competitors are infringing our issued patents. Expensive and time-consuming litigation may be required to abate such infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone involved in the prosecution of the patent withheld relevant or material information related to the patentability of the invention from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if we cannot obtain a license from the prevailing party on commercially reasonable terms. Third parties may request an IPR of our patents in the USPTO. An unfavorable decision may result in the revocation of our patent or a limitation to the scope of the claims of our patents. Our defense of litigation, interference or IPR proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during any litigation we initiate to enforce our patents. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We employ individuals, retain independent contractors and consultants and members on our board of directors or scientific advisory board who were previously employed at universities or other pharmaceutical companies, including our competitors or potential competitors. For example, our Chief Executive Officer, Dennis&#160;M. Lanfear is a former employee of Amgen. Mr.&#160;Lanfear was employed at Amgen during periods when Amgen&#8217;s operations included the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">development and commercialization of Neulasta. Senior members of our commercial team and medical affairs team who will be responsible for any launch of additional presentations of UDENYCA formerly held positions at Amgen. Our board of directors and scientific advisory board include members who were former employees of Genentech, Amgen and Abbott Laboratories. Although we have procedures in place to try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On March 3, 2017, Amgen filed an action against us, KBI Biopharma, our employee Howard S. Weiser and Does 1-20 in the Superior Court of the State of California, County of Ventura. The complaint, which was amended, alleged that we engaged in unfair competition and improperly solicited and hired certain former Amgen employees in order to acquire and access trade secrets and other confidential information belonging to Amgen. The complaint, as amended, sought injunctive relief and monetary damages. On May 2, 2019, we and Amgen settled the trade secret action brought by Amgen. The details of the settlement are confidential, but the Company will continue to market UDENYCA and began paying a mid-single digit royalty to Amgen for five years starting on July 1, 2019.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We are a party to certain non-exclusive intellectual property license agreements with certain vendors (pertaining to mammalian cell lines), with Genentech (pertaining to Genentech&#8217;s intellectual property related to CIMERLI) and with AbbVie (pertaining to AbbVie&#8217;s intellectual property related to YUSIMRY) that are important to our business, and we expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the license or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In the event we breach any of our obligations related to such agreements, we may incur significant liability to our licensing partners. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patents and other rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and that could have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We currently have rights to certain intellectual property, through licenses from third parties and under patent applications that we own, to develop our product candidates. Because we may find that our programs require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we are unable to successfully obtain required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to market our products in the United States may be significantly delayed or prevented by the BPCIA patent dispute resolution mechanism. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The BPCIA created an elaborate and complex patent dispute resolution mechanism for biosimilars that, if we choose to implement it, could prevent us from launching our product candidates in the United States or could substantially delay such launches. However, even if we elect not to implement this mechanism, the launch of our products in the United States could still be prevented or substantially delayed by intellectual property disputes with originator companies that market the reference products on which our biosimilar products are based.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The BPCIA establishes a patent disclosure and briefing process between the biosimilar applicant and the originator that is demanding and time-sensitive. While certain aspects of this process are still being tested in the federal courts, the United States Supreme Court, as discussed further below, ruled in 2017 that this process is not mandatory, such that a biosimilar applicant may elect to engage in this process, but is not required to do so. The following is an overview of the patent exchange and patent briefing procedures established by the BPCIA for biosimilar applicants that elect to employ them: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosure of the Biosimilar Application. Within 20 days after the FDA publishes a notice that its application has been accepted for review, a Section 351(k) biosimilar applicant may elect to provide a copy of its application to the originator if it chooses to engage in the BPCIA patent exchange mechanism. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of Pertinent Patents. Within 60 days of the date of receipt of the application the originator must identify patents owned or controlled by the originator, which it believes could be asserted against the biosimilar applicant. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Statement by the Biosimilar Applicant. Following the receipt of the originator&#8217;s patent list, the biosimilar applicant must state either that it will not market its product until the relevant patents have expired or alternatively provide its arguments that the patents are invalid, unenforceable or would not be infringed by the proposed biosimilar product candidate. The biosimilar applicant may also provide the originator with a list of patents it believes the brand-name firm could assert against the reference product. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Statement by the Originator. In the event the biosimilar applicant has asserted that the patents are invalid, unenforceable or would not be infringed by the proposed follow-on product, the originator must provide the biosimilar applicant with a response within 60 days. The response must provide the legal and factual basis of the opinion that such patent will be infringed by the commercial marketing of the proposed biosimilar. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent Resolution Negotiations. If the originator provides its detailed views that the proposed biosimilar would infringe valid and enforceable patents, then the parties are required to engage in good faith negotiations to identify which of the discussed patents will be the subject of a patent infringement action. If the parties agree on the patents to be litigated, the brand-name firm must bring an action for patent infringement within 30 days. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Simultaneous Exchange of Patents. If those negotiations do not result in an agreement within 15 days, then the biosimilar applicant must notify the originator of how many patents (but not the identity of those patents) that it wishes to litigate. Within five days, the parties are then required to exchange lists identifying the patents to be litigated. The number of patents identified by the originator may not exceed the number provided by the biosimilar applicant. However, if the biosimilar applicant previously indicated that no patents should be litigated, then the originator may identify one patent. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Commencement of Patent Litigation. The originator must then commence patent infringement litigation within 30 days. That litigation will involve all of the patents on the originator&#8217;s list and all of the patents on the follow-on applicant&#8217;s list. The follow-on applicant must then notify the FDA of the litigation. The FDA must then publish a notice of the litigation in the Federal Register. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Notice of Commercial Marketing. The BPCIA requires the biosimilar applicant to provide notice to the originator 180 days in advance of its first commercial marketing of its proposed follow-on biologic. The originator is allowed to seek a preliminary injunction blocking such marketing based upon any patents that either party had preliminarily identified but were not subject to the initial phase of patent litigation. The litigants are required to &#8220;reasonably cooperate to expedite such further discovery as is needed&#8221; with respect to the preliminary injunction motion. The federal courts have not yet settled the issue as to when, or under what circumstances, the biosimilar applicant must provide the 180-day notice of commercial marketing provided in the BPCIA.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On June 12, 2017, the Supreme Court issued its decision in <i style="font-style:italic;">Amgen v. Sandoz</i>, holding that (i) the &#8220;patent dance&#8221; is optional; and (ii) the 180-day pre-marketing notification may be given either before or after receiving FDA approval of the biosimilar product. The Supreme Court declined to rule whether a state injunctive remedy may be available to the originator and remanded that question to the Federal Circuit for further consideration. On December 14, 2017, the Federal Circuit decided that state law claims are preempted by the BPCIA on both field and conflict grounds. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">A significant legal risk for a biosimilar applicant that pursues regulatory approval under the Section 351(k) regulatory approval route and also elects to engage in the above-described BPCIA patent exchange mechanism, is that the process could result in the initiation of patent infringement litigation prior to FDA approval of a Section 351(k) application, and such litigation could result in blocking the market entry of the biosimilar product. However, even if biosimilar applicants opt out of the BPCIA patent exchange process, originators will still have the right to assert patent infringement as a basis to enjoin a biosimilar product launch. Thus, whether or not we engage in the BPCIA patent exchange process, there is risk that patent infringement litigation initiated by originators could prevent us indefinitely from launching our biosimilar products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The legal and strategic considerations weighing for or against a decision to voluntarily engage in the BPCIA patent exchange process are complex and will differ on a product-by-product basis. If we decide to engage in the BPCIA patent exchange process, preparing for and conducting the patent exchange, briefing and negotiation process outlined above will require extraordinarily sophisticated legal counseling and extensive planning, all under extremely tight deadlines. Moreover, it may be difficult for us to secure or retain such legal support if large, well-funded originators have already </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">entered into engagements with highly qualified law firms or if the most highly qualified law firms choose not to represent biosimilar applicants due to their long-standing relationships with originators. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">Under the complex, and uncertain rules of the BPCIA patent provisions, coupled with the inherent uncertainty surrounding the legal interpretation of any originator patents that might be asserted against us in this new process, we see substantial risk that the BPCIA process may significantly delay or defeat our ability to market our products in the United States, or may result in us incurring substantial legal settlement costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Discovery and Development of Our Product Candidates </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We invested substantially all of our efforts and financial resources to identify, acquire and develop our product candidates. Our future success is dependent on our ability to develop, obtain regulatory approval for, and then commercialize and obtain adequate third-party coverage and reimbursement for one or more of our product candidates. We currently have three approved products: UDENYCA, CIMERLI and YUSIMRY. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Our product candidates are in varying stages of development and will require additional clinical development, management of nonclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supplies, commercial organization and significant marketing efforts before we generate any revenue from product sales. For example, YUSIMRY received FDA approval but we still will not launch it until July 2023 due to our settlement agreement with AbbVie, and the FDA has set a PDUFA action date for December 23, 2022 for the toripalimab original BLA. Other than certain PK bridging studies, we have not initiated phase 3 clinical trials for other product candidates in our pipeline. It may be some time before we file for market approval with the relevant regulatory agencies for these product candidates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we and our existing or future collaboration partners do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We, together with our collaboration partners, generally plan to seek regulatory approval to commercialize our product candidates in the United States, the E.U., and additional foreign countries where we or our partners have commercial rights. To obtain regulatory approval, we and our collaboration partners must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, and pricing and distribution of our product candidates. Even if we and our collaboration partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we and our collaboration partners are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and the regulatory approval requirements for biosimilars are evolving. If we and our collaboration partners are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, marketing, distribution, post-approval monitoring and reporting and export and import of biologic and biosimilar products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, by the EMA and EEA Competent Authorities in the European Economic Area (&#8220;EEA&#8221;), and by other regulatory authorities in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">other countries, where regulations differ from country to country. Neither we nor any existing or future collaboration partners are permitted to market our product candidates in the United States until we and our collaboration partners receive approval from the FDA, or in the EEA until we and our collaboration partners receive EC or EEA Competent Authority approvals. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The time required to develop new products or obtain approval for new products by the FDA and comparable foreign authorities is unpredictable, may take many years following the completion of clinical studies and depends upon numerous factors. Further, applications to the Human Genetic Resources Administration of China (HGRAC) required for any activities, including development activities and data sharing with our partners in China, may result in product development delays. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. For example, in 2020 during FDA&#8217;s review of Bioeq&#8217;s Section 351(k) BLA for CIMERLI, the FDA requested that Bioeq submit additional manufacturing data for the equipment in its new location, leading Bioeq to withdraw its Section 351(k) BLA for this candidate in order to provide the requested data and to resubmit the application thereafter. Neither we nor any collaboration partner has obtained regulatory approval for any of our product candidates, other than UDENYCA, which has received approval from the FDA and EMA, YUSIMRY and CIMERLI, which have received approval from the FDA, and toripalimab, which is approved for use in China only, and it is possible that none of our other current or future product candidates will ever obtain additional regulatory approvals.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an original BLA, an NDA, a Section 351(k) BLA, a biosimilar marketing authorization under Article 6 of Regulation (EC) No.&#160;726/2004 and/or Article 10(4) of Directive 2001/83/EC in the EEA or other submission or to obtain regulatory approval in the United States, the EEA or elsewhere; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may determine that the population studied in the clinical program may not be sufficiently broad or representative to assure safety and efficacy in the full population for which we seek approval, or that conclusions of clinical trials conducted in a single country or region outside the United States may not be generalizable to the patient population in the United States; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from analytical and bioanalytical studies, nonclinical studies or clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of our collaborators or third-party manufacturers with which we contract for clinical and commercial supplies; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">This approval process, as well as the unpredictability of the results of clinical studies, may result in our failure to obtain regulatory approval to market any of our product candidates, which would significantly harm our business. Any delays in the commencement or completion of clinical testing could significantly impact our product development costs and could result in the need for additional financing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Toripalimab may not be approved in a timely manner or at all by regulatory agencies. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On April 29, 2022, the FDA issued a CRL in response to our original BLA for toripalimab. The letter identified certain issues, including a request for a quality process change. On July 6, 2022, we announced that the FDA accepted the resubmission of the original BLA for toripalimab. The FDA has set a PDUFA action date for December 23, 2022. Even though the FDA accepted our resubmission of the BLA for toripalimab, there is no guarantee that the FDA will conclude that the information in that resubmission will be sufficient to support approval and we may fail to obtain regulatory approval in the United States for toripalimab. Additionally, certain factors beyond our control, such as the COVID-19 pandemic, may impact the timeliness of the regulatory reviews of our submissions or any applications for approval.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not able to demonstrate biosimilarity of our biosimilar product candidates to the satisfaction of regulatory authorities, we will not obtain regulatory approval for commercial sale of our biosimilar product candidates and our future results of operations would be adversely affected. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our future results of operations depend, to a significant degree, on our ability to obtain regulatory approval for and to commercialize our proposed biosimilar products. To obtain regulatory approval for the commercial sale of these product candidates, we will be required to demonstrate to the satisfaction of regulatory authorities, among other things, that our proposed biosimilar products are highly similar to biological reference products already licensed by the regulatory authority pursuant to marketing applications, notwithstanding minor differences in clinically inactive components, and that they have no clinically meaningful differences as compared to the marketed biological products in terms of the safety, purity and potency of the products. Each individual jurisdiction may apply different criteria to assess biosimilarity, based on a preponderance of the evidence<b style="font-weight:bold;"> </b>that can be interpreted subjectively in some cases. In the EEA, the similar nature of a biosimilar and a reference product is demonstrated by comprehensive comparability studies covering quality, biological activity, safety and efficacy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">It is uncertain if regulatory authorities will grant the full originator label to biosimilar product candidates when they are approved. For example, an infliximab (Remicade) biosimilar molecule was approved in Europe and in the United States for the full originator label but received a much narrower originator label when initially approved in Canada. That infliximab biosimilar only received full label extension in Canada in 2016 after providing additional clinical data. A similar outcome could occur with respect to our product candidates and there is no guarantee that our product candidates will receive a full originator label even after the provision of additional clinical data. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In the event that regulatory authorities require us to conduct additional clinical trials or other lengthy processes, the commercialization of our proposed biosimilar products could be delayed or prevented. Delays in the commercialization of or the inability to obtain regulatory approval for these products could adversely affect our operating results by restricting or significantly delaying our introduction of new biosimilars. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Clinical drug development involves a lengthy and expensive process and we may encounter substantial delays in our clinical studies or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we or our collaboration partners, or both we and our collaboration partners, as the case may be, must conduct clinical studies to demonstrate the safety and efficacy of the product candidates in humans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies. There is a high failure rate for product candidates proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical studies. A&#160;number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">notwithstanding promising results in earlier studies. Nonclinical and clinical data are also often susceptible to varying interpretations and analyses. We do not know whether any clinical studies we may conduct for our product candidates will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval. Furthermore, biosimilar clinical studies must use originator products as comparators, and such supplies may not be available on a timely basis to support such trials.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to generate sufficient preclinical, toxicology or other </span><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> or </span><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> data to support the initiation of human clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on study design; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining required institutional review board (&#8220;IRB&#8221;) approval at each clinical study site; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory agencies, after review of an investigational new drug application (&#8220;IND&#8221;) or amendment or equivalent application or amendment, or an inspection of our clinical study operations or study sites or as a result of adverse events reported during a clinical trial; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in recruiting suitable patients to participate in our clinical studies sponsored by us or our partners; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty collaborating with patient groups and investigators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by our CROs, other third parties or us to adhere to clinical study requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to perform in accordance with the FDA&#8217;s good clinical practices requirements or applicable regulatory guidelines in other countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in patients completing participation in a study or return for post-treatment follow-up, or patients dropping out of a study; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical studies of our product candidates being greater than we anticipate; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding or regulators requiring us to conduct additional clinical studies or abandon product development programs; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in manufacturing, testing, releasing, validating or importing/exporting and/or distributing sufficient stable quantities of our product candidates and originator products for use in clinical studies or the inability to do any of the foregoing. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, or conducting our planned clinical trials. Any inability to successfully complete nonclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">additional studies to bridge our modified product candidates to earlier versions. For example, we altered the manufacturing processes for CHS-1420 and will need to provide data to the FDA and foreign regulatory authorities demonstrating that the change in manufacturing process has not changed the product candidate. If we are unable to make that demonstration to the FDA or comparable foreign regulatory authorities, we could face significant delays or fail to obtain regulatory approval to market the product, which could significantly harm our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The development, manufacture and commercialization of biosimilar products under various global regulatory pathways pose unique risks. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We and our collaboration partners intend to pursue market authorization globally. In the United States, an abbreviated pathway for approval of biosimilar products was established by the BPCIA, enacted on March&#160;23, 2010, as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;). The BPCIA established this abbreviated pathway under Section 351(k) of the PHSA. Subsequent to the enactment of the BPCIA, the FDA issued guidance documents regarding the demonstration of biosimilarity and interchangeability as well as the submission and review of biosimilar applications. Moreover, market acceptance of biosimilar products in the United States is unclear. Numerous states are considering or have already enacted laws that regulate or restrict the substitution by state pharmacies of biosimilars for originator products already licensed by the FDA. Market success of biosimilar products will depend on demonstrating to patients, physicians, payers and relevant authorities that such products are similar in quality, safety and efficacy as compared to the reference product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We will continue to analyze and incorporate into our biosimilar development plans any final regulations issued by the FDA, pharmacy substitution policies enacted by state governments and other applicable requirements established by relevant authorities. The costs of development and approval, along with the probability of success for our biosimilar product candidates, will be dependent upon the application of any laws and regulations issued by the relevant regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Biosimilar products may also be subject to extensive originator-controlled patent portfolios and patent infringement litigation, which may delay and could prevent the commercial launch of a product. Moreover, the BPCIA prohibits the FDA from accepting an application for a biosimilar candidate to a reference product within four years of the reference product&#8217;s licensure by the FDA. In addition, the BPCIA provides innovative biologics with 12&#160;years of exclusivity from the date of their licensure, during which time the FDA cannot approve any application for a biosimilar candidate to the reference product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under current E.U. regulations, an application for regulatory approval of a biosimilar drug cannot be submitted in the E.U. until expiration of an eight-year data exclusivity period for the reference (originator) product, measured from the date of the reference product&#8217;s initial marketing authorization. Furthermore, once approved, the biosimilar cannot be marketed until expiration of a ten-year period following the initial marketing authorization of the reference product, such ten-year period being extendible to 11 years if the reference product received approval of an additional therapeutic indication, within the first eight years following its initial marketing authorization, representing a significant clinical benefit in comparison with existing therapies. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In Europe, the approval of a biosimilar for marketing is based on an opinion issued by the EMA and a decision issued by the EC. Therefore, the marketing approval will cover the entire EEA. However, substitution of a biosimilar for the originator is a decision that is made at the national level. Additionally, a number of countries do not permit the automatic substitution of biosimilars for the originator product. Therefore, even if we obtain marketing approval for the entire EEA, we may not receive substitution in one or more European nations, thereby restricting our ability to market our products in those jurisdictions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Other regions, including Canada, Japan and South Korea, also have their own legislation outlining a regulatory pathway for the approval of biosimilars. In some cases other countries have either adopted European guidance (Singapore and Malaysia) or are following guidance issued by the World Health Organization (Cuba and Brazil). While </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">there is overlap in the regulatory requirements across regions, there are also some areas of non-overlap. Additionally, we cannot predict whether countries that we may wish to market in which do not yet have an established or tested regulatory framework could decide to issue regulations or guidance and/or adopt a more conservative viewpoint than other regions. Therefore, it is possible that even if we obtain agreement from one health authority to an accelerated or optimized development plan, we will need to defer to the most conservative view to ensure global harmonization of the development plan. Also, for regions where regulatory authorities do not yet have sufficient experience in the review and approval of a biosimilar product, these authorities may rely on the approval from another region (e.g., the United States or the E.U.), which could delay our approval in that region. Finally, it is possible that some countries will not approve a biosimilar without clinical data from their population or may require that the biosimilar product be manufactured within their region, or some countries may require both. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If other biosimilars of pegfilgrastim (Neulasta) or adalimumab (Humira), are determined to be interchangeable and our biosimilar products and product candidates for these originator products are not, our business could suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The FDA or other relevant regulatory authorities may determine that a proposed biosimilar product is &#8220;interchangeable&#8221; with a reference product, meaning that the biosimilar product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, if the application includes sufficient information to show that the product is biosimilar to the reference product and that it can be expected to produce the same clinical result as the reference product in any given patient. If the biosimilar product may be administered more than once to a patient, the applicant must demonstrate that the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar product candidate and the reference product is not greater than the risk of using the reference product without such alternation or switch. To make a final determination of interchangeability, regulatory authorities may require additional confirmatory information beyond what we plan to initially submit in our applications for approval, such as more in-depth analytical characterization, animal testing or further clinical studies. Provision of sufficient information for approval may prove difficult and expensive. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot predict whether any of our biosimilar products and product candidates will meet regulatory authority requirements for approval not only as a biosimilar product but also as an interchangeable product in any jurisdiction. Furthermore, legislation governing interchangeability could differ by jurisdiction on a state or national level worldwide. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The labelling of &#8220;interchangeability&#8221; is important because, in the United States for example, the first biosimilar determined to be interchangeable with a particular reference, or originator, product for any condition of use is eligible for a period of market exclusivity that delays an FDA determination that a second or subsequent biosimilar product is interchangeable with that originator product for any condition of use until the earlier of: (1)&#160;one year after the first commercial marketing of the first interchangeable product; (2)&#160;18 months after resolution of a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3)&#160;42 months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4)&#160;18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42&#160;U.S.C.&#160;&#167;&#160;262(l)(6). Thus, a determination that another company&#8217;s product is interchangeable with the originator biologic before we obtain approval of our corresponding biosimilar product candidates may delay the potential determination that our products are interchangeable with the originator product, which could materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Failure to obtain regulatory approval in any targeted regulatory jurisdiction would prevent us from marketing our products to a larger patient population and reduce our commercial opportunities.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We are marketing UDENYCA in the United States, and subject to product approvals and relevant patent and settlement agreement expirations, we intend to market our other biosimilar products in the United States and outside the United States on our own or with future collaboration partners. We entered into a distribution agreement with our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">licensee Orox for the commercialization of biosimilar versions of etanercept (Enbrel) (for which we discontinued development), rituximab (Rituxan), adalimumab (Humira) and pegfilgrastim (Neulasta) in certain Caribbean and Latin American countries. We intend to market our biosimilar product candidates in the United States and may seek to partner commercially all biosimilars outside the United States. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In order to market our products in the E.U., the United States and other jurisdictions, we and our collaboration partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The EMA is responsible for the centralized procedure for the regulation and approval of human medicines. This procedure results in a single marketing authorization that is valid in all E.U. countries, as well as in Iceland, Liechtenstein and Norway. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and we may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We or our collaboration partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. Failure to obtain these approvals would materially and adversely affect our business, financial condition and results of operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify, develop or commercialize additional product candidates. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing product candidates, the success of our business also depends upon our ability to identify, develop and commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our development efforts may fail to yield additional product candidates suitable for clinical development and commercialization for a number of reasons, including but not limited to the following: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be successful in identifying potential product candidates that pass our strict screening criteria; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to overcome technological hurdles to development or a product candidate may not be capable of producing commercial quantities at an acceptable cost or at all; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may not succeed in nonclinical or clinical testing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential product candidates may fail to show sufficient biosimilarity to originator molecules; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our product candidates obsolete or less attractive or the market for a product candidate may change such that a product candidate may not justify further development. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs or we may not be able to identify, develop or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Compliance with Applicable Laws</b> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Healthcare reform measures, including the IRA, may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA, was passed, which substantially changed the way health care is financed by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">both governmental and private insurers and has impacted and continues to impact the United States pharmaceutical industry. The ACA, among other things, modified the average manufacturer price (&#8220;AMP&#8221;) definition under the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) for drugs that are inhaled, infused, instilled, implanted or injected and not generally distributed through the retail channel; expanded rebate payments under the MDRP to include utilization by individuals enrolled in Medicaid managed care organizations; added a provision to increase the Medicaid rebate for line extension drugs; established annual fees and taxes on manufacturers of certain branded prescription drugs; expanded the entities eligible for discounts under the Public Health Service 340B drug pricing program; and established the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include the American Rescue Plan Act of 2021, which eliminates the statutory cap on the Medicaid drug rebate, currently set at 100% of a drug&#8217;s AMP, beginning January 1, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Most significantly, on August 16, 2022, President Biden signed the IRA into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. &#160;Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). &#160;The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. In particular, if a product becomes subject to the IRA negotiation provision and related price cap, that may significantly alter the economic rationale for developing and commercializing a biosimilar.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The cost of prescription pharmaceuticals in the United States is likely to remain the subject of considerable discussion. There have been several Congressional inquiries and proposed and enacted legislation designed to, among other things, reform government program reimbursement methodologies. The likelihood of implementation of these and other reform initiatives is uncertain. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Individual states in the United States have also proposed and enacted legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures, such as a single reimbursement code for biosimilar products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In the E.U., similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the E.U. or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the E.U., including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than E.U., law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most E.U. member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing E.U. and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and E.U., reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We may be subject, directly or indirectly, to federal and state healthcare laws, including fraud and abuse, false claims and physician payment transparency laws. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our operations are directly or indirectly through our customers subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws impact, among other things, sales, marketing and education programs. The laws that may affect our ability to operate include: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or in return for the purchase, recommendation, order or furnishing of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented claims for payment from Medicare, Medicaid or other third-party payers that are false or fraudulent and which may apply to entities that provide coding and billing advice to customers. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician &#8220;sunshine&#8221; requirements under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services information related to payments and other transfers of value made by such manufacturers to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors, and certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives)), and teaching hospitals and ownership and investment interests held by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Efforts to ensure that our operations and business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"></span>We participate in governmental programs that impose drug price reporting, payment, and other compliance obligations on pharmaceutical manufacturers. Medicaid is a joint federal and state program that is for low income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Medicare Part B reimburses physicians who administer our products. Under the MDRP, as a condition of having federal funds available for our covered outpatient drugs under Medicaid and under Medicare Part B, we must enter into, and have entered into, an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we are required to report on a monthly and quarterly basis to CMS, the federal agency that administers the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">MDRP and Medicare programs. For the MDRP, these data include the AMP for each drug and, in the case of innovator products, the Best Price, which represents the lowest price available from us to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. In connection with Medicare Part B, we must provide CMS with Average Sales Price (&#8220;ASP&#8221;) information on a quarterly basis. CMS uses this information to compute Medicare Part B payment rates, which consist of ASP plus a specified percentage. If we become aware that our MDRP submissions for a prior period were incorrect or have changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. Pursuant to the IRA, the AMP and ASP figures we report will also be used to compute rebates under Medicare Part D and Medicare Part B triggered by price increases that outpace inflation. If we fail to provide information timely or are found to have knowingly submitted false information to CMS, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;) and requires us to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered drugs when used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs when used in an inpatient setting.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, a pharmaceutical manufacturer must also participate in U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA FSS program, we must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers for the untimely, inaccurate, or incomplete reporting of drug pricing information or for otherwise failing to comply with drug price transparency </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">requirements. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or underage in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of ASP, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS or other governmental agencies to be incomplete or incorrect.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Common Stock </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The market price of our common stock may be highly volatile, and purchasers of our common stock could incur substantial losses. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The market price of our common stock has been highly volatile since our Initial Public Offering (&#8220;IPO&#8221;) and the intraday sales price per share has ranged from $5.60 to $38.10 per share during the period from November 6, 2014 through September 30, 2022 and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q and others such as: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the Covid-19 pandemic and other viral pandemics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in preclinical or clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain additional funding; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in filing an IND, NDA, BLA, Section 351(k) BLA or other regulatory submission for any of our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory agency&#8217;s review of that IND, NDA, BLA, Section 351(k) BLA or other regulatory submission; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of limited market sizes or pricing for our products and product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-marketing safety issues relating to our product candidates or biosimilars generally; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to maintain our existing strategic collaborations or enter into new collaborations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in the implementation of the shift in our clinical, commercial, manufacturing, regulatory, marketing and general historical focus on biosimilars to a new strategy to build a leading immuno-oncology franchise funded with cash generated by our commercial biosimilar business; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we may provide to the public; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial projections of the investment community; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">lawsuits, including but not limited to complaints initiated by stockholders, customers and collaboration partners, and litigation filed by us or filed against us pertaining to patent infringement or other violations of intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcomes of any citizen petitions filed by parties seeking to restrict or limit the approval of biosimilar products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions, including rising interest rates and inflation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of patents to third parties that could prevent our ability to commercialize our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reductions in the prices of originator products that could reduce the overall market opportunity for our product candidates intended as biosimilars to such originator products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in biosimilar regulatory requirements that could make it more difficult for us to develop our product candidates. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of September 30, 2022, our executive officers, directors, five percent stockholders and their affiliates beneficially owned 61.8% of our voting stock (assuming no exercise of outstanding options or conversion of our outstanding convertible notes). These stockholders have the ability to influence us through their ownership positions, which may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our financial condition, our ability to raise additional capital to fund our operations, our ability to operate our business, our ability to react to changes in the economy or our industry and our ability to pay our debts and could divert our cash flow from operations for debt payments.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our leverage and debt service obligations could adversely impact our business, including by:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impairing our ability to generate cash sufficient to pay interest or principal, including periodic principal payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increasing our vulnerability to general adverse economic and industry conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring the dedication of a portion of our cash flow from operations to service our debt, thereby reducing the amount of our cash flow available for other purposes, including funds for clinical development or to pursue future business opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to sell debt or equity securities or to sell some of our core assets, possibly on unfavorable terms, to meet payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limiting our flexibility in planning for, or reacting to, changes in our business and the industries in which we compete; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">placing us at a possible competitive disadvantage with less leveraged competitors and competitors that may have better access to capital resources.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Any of the foregoing factors could have negative consequences on our financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">This indebtedness could be due sooner upon the triggering of certain covenants in our debt agreements and or upon the occurrence of an event of default. If and when our indebtedness becomes due, if we do not have sufficient cash or access to capital to pay such indebtedness, we will default on our obligations which will adversely harm our business. We also recently entered into a Loan Agreement that contains affirmative and negative covenants that restrict our operations, including, among other restrictions, the requirement to maintain minimum trailing twelve-month net sales in an amount that begins at $200 million in the first quarter of 2022 and increases to $210 million for the quarter ended March 30, 2024 and increases to be as much as $300 million for the quarter ended December 31, 2024. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict our ability to incur liens, incur additional indebtedness, make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">If our existing stockholders sell or indicate an intention to sell substantial amounts of our common stock in the public market the market price of our common stock could decline. As of September 30, 2022, there were 77.8 million shares of our common stock outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In addition, as of September 30, 2022, 30.0 million shares of common stock that are either subject to outstanding options and restricted stock units or reserved for future issuance under our equity incentive plans were eligible or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule&#160;144 and Rule&#160;701 under the Securities Act. If these additional shares of common stock are sold or if it is perceived that they will be sold in the public market, the market price of our common stock could decline. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans and convertible notes, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have needed and anticipate we will need additional capital in the future to continue our planned operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. Similar to prior financing transactions, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. In addition, if we raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Pursuant to our 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2014 Plan will be increased by (i)&#160;the number of shares pursuant to outstanding awards under the 2010 Plan that are forfeited or lapse unexercised and which following the effective date are not issued under the 2010 Plan and (ii)&#160;an annual increase on the first day of each fiscal year beginning in 2015 and ending in 2024, equal to 4% of the shares of stock outstanding as of the last day of the preceding fiscal year, or such smaller number of shares as determined by our board of directors. Pursuant to our 2014 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), eligible employees are able to acquire shares of our common stock at a discount to the prevailing market price, and an aggregate of 320,000&#160;shares are initially available for issuance under the ESPP. The number of shares available for issuance under the ESPP will automatically increase on the first day of each fiscal year beginning in 2015 and ending in 2024, equal to 1% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year or such smaller number of shares as determined by our board of directors. If our board of directors elects to increase the number of shares available for future grant under the 2014 Plan or the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall<b style="font-weight:bold;">. </b>Pursuant to our 2016 Employment Commencement Incentive Plan (the &#8220;2016 Plan&#8221;), our management is authorized to grant stock options and other equity-based awards to our new employees. The 2016 Plan is designed to comply with the inducement exemption contained in Nasdaq&#8217;s Rule 5635(c)(4), which provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director, or following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entering into employment with us. As of September 30, 2022, we reserved for future issuance under the 2016 Plan a total of 0.6 million shares of common stock for new employees. The 2016 Plan does not provide for any annual increases in the number of shares available.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In April 2020, we issued and sold $230.0 million aggregate principal amount of our 1.5% senior convertible notes due April 2026 (the &#8220;2026 Convertible Notes&#8221;). The holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the second scheduled trading day immediately before April 15, 2026. Upon conversion of the 2026 Convertible Notes by a holder, the holder will receive shares of our common stock, together, if applicable, with cash in lieu of any fractional share. The initial conversion rate is 51.9224 shares of common stock per $1,000 principal amount of convertible notes, which is equivalent to an initial conversion price of approximately $19.26 per share, and is subject to adjustment in certain events.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation of their stock. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">create a classified board of directors whose members serve staggered three-year terms; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">specify that special meetings of our stockholders can be called only by our corporate secretary pursuant to a resolution adopted by a majority of our board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors other than nominations made by or at the direction of the board of directors or a committee of the board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our directors may be removed only for cause or without cause by the holders of 66&#160;2/3% of the voting power of all then outstanding shares of voting stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">specify that no stockholder is permitted to cumulate votes at any election of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">require holders of 66&#160;2/3% of the voting power of all then outstanding shares of voting stock to amend specified provisions of our amended and restated certificate of incorporation except for the provision making it possible for our board of directors to issue &#8220;blank check&#8221; preferred stock, and amended and restated bylaws. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">These provisions, alone or together, could delay, deter or prevent hostile takeovers and changes in control or changes in our management. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Investors&#8217; expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance (or &#8220;ESG&#8221;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We also face significant costs from complying with new ESG regulations, for example, the SEC&#8217;s proposed climate disclosure rule would result in significant costs of compliance if it is approved in December 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchange or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaboration partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Our corporate headquarters and laboratory are located in the San Francisco Bay Area and in Southern California (Camarillo), respectively. These locations have in the past experienced severe earthquakes and other natural disasters. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaboration partners and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure (such as the manufacturing facilities of our third-party contract manufacturers) or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The continuation of the war in Ukraine may exacerbate certain risks we face.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Russia&#8217;s invasion of Ukraine in February 2022 and the global response, including the imposition of sanctions by the United States and other countries, could create or exacerbate risks facing our business. We have evaluated our operations and partner contracts, and we currently do not expect the outbreak to directly have a significant effect on our financial condition or results of operations. However, if the war in Ukraine persists, escalates or expands, risks that we have identified in this Quarterly Report on Form 10-Q may be materially increased. For example, if our supply arrangements or clinical operations are disrupted due to expanded sanctions or involvement of countries where we have operations or relationships, our business could be materially disrupted. Further, the use of cyberattacks could expand as part of the ongoing conflict, which could adversely affect our ability to maintain or enhance our cyber security measures. These and other risks are described more fully in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">So called &#8220;submarine&#8221; patents may be granted to our competitors that may significantly alter our launch timing expectations, reduce our projected market size, cause us to modify our product or process or block us from the market altogether. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The term &#8220;submarine&#8221; patent has been used in the pharmaceutical industry and in other industries to denote a patent issuing from an application that was not published, publicly known or available prior to its grant. Submarine patents add substantial risk and uncertainty to our business. Submarine patents may issue to our competitors covering our biosimilar product candidates or our pipeline candidates and thereby cause significant market entry delay, defeat our ability to market our products or cause us to abandon development and/or commercialization of a molecule. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Examples of submarine patents include Brockhaus, et al., United States patents 8,063,182 and 8,163,522 (controlled by Amgen), which are directed to the fusion protein in Enbrel. On July 1, 2020, the United States Court of Appeals for the Federal Circuit issued a decision that affirmed the lower court&#8217;s decision upholding the validity of these patents. As a result, we discontinued the development of CHS-0214 (our etanercept (Enbrel) biosimilar candidate). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The issuance of one or more submarine patents may harm our business by causing substantial delays in our ability to introduce a biosimilar candidate into the United States market. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which might adversely affect our ability to develop and market our products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or pipeline molecules. We may incorrectly determine that our products are not covered by a third-party patent. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Many patents may cover a marketed product, including but not limited to the composition of the product, methods of use, formulations, cell line constructs, vectors, growth media, production processes and purification processes. The identification of all patents and their expiration dates relevant to the production and sale of an originator product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates, resulting in loss of any potential competitive advantage our patents may have otherwise afforded us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. Our ability to enjoy any competitive advantages afforded by our own intellectual property depends in large part on our ability to obtain and maintain patents and other intellectual property protection in the United States and in other countries with respect to various proprietary elements of our product candidates, such as, for example, our product formulations and processes for manufacturing our products and our ability to maintain and control the confidentiality of our trade secrets and confidential information critical to our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk110416334"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our products that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no guarantee that any patent application we file will result in an issued patent having claims that protect our products. Additionally, while the basic requirements for patentability are similar across jurisdictions, each jurisdiction has its own specific requirements for patentability. We cannot guarantee that we will obtain identical or similar patent protection covering our products in all jurisdictions where we file patent applications. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The patent positions of biopharmaceutical companies generally are highly uncertain and involve complex legal and factual questions. As a result, the patent applications that we own or license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries for many reasons. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, considered or cited during patent prosecution, which can be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patent claims being narrowed, found unenforceable or invalidated. Our patents and patent applications, even if they are unchallenged, may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competitors from using the technologies claimed in any patents issued to us, which may have an adverse impact on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In addition, changes to United States patent laws provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March 15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to prevent competitive products using our proprietary technology. Further, because patent applications in the United States and most other countries are confidential for a period of time, typically for 18 months after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013 or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications claiming the same invention are filed by different parties. A third party that files a patent application in the USPTO before we do, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to &#8220;first-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to prevent third parties from using the same technologies that we use in our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We have issued patents and have filed patent applications, which are currently pending, covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened or infringed by third parties. Any successful actions by third parties to challenge the validity or enforceability of any patents, which may issue to us could deprive us of the ability to prevent others from using the technologies claimed in such issued patents. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While our biosimilar business is based primarily on the timing of our biosimilar product launches to occur after the expiration of relevant patents and on avoiding infringing valid and enforceable rights of third parties, we have filed a number of patent applications seeking patents that cover various proprietary elements of our product candidates when we have believed securing such patents may afford a competitive advantage. Our patent portfolio includes pending patent applications and issued patents, in the United States and globally, covering our biosimilar product candidates and methods of making them. We cannot guarantee that our proprietary technologies will avoid infringement of third-party patents. Moreover, because competitors may be able to develop their own proprietary technologies, it is uncertain whether any of our issued patents or pending patent applications directed to etanercept and adalimumab would cover the etanercept and adalimumab products of any competitors. The product and patent landscape is highly uncertain and we cannot predict whether our patent filings will afford us a competitive advantage against third parties or if our etanercept and adalimumab products will avoid infringement of third-party patents. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We do not consider it necessary for us or our competitors to obtain or maintain a proprietary patent position in order to engage in the business of biosimilar development and commercialization. Hence, while our ability to secure patent coverage on our own proprietary developments may improve our competitive position with respect to the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">product candidates we intend to commercialize, we do not view our own patent filings as a necessary or essential requirement for conducting our business nor do we rely on our own patent filings or the potential for any commercial advantage they may provide us as a basis for our success. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Filing, prosecuting, defending and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may choose not to file patent applications in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but the ability to enforce our patents is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Governments of foreign countries may force us to license our patents to third parties on terms that are not commercially reasonable or acceptable to us. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to maintain effective (non-patent) proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While we have filed patent applications to protect certain aspects of our own proprietary formulation and process developments, we also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. However, confidential information and trade secrets can be difficult to protect. Moreover, the information embodied in our trade secrets and confidential information may be independently and legitimately developed or discovered by third </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">parties without any improper use of or reference to information or trade secrets. We seek to protect the scientific, technical and business information supporting our operations, as well as the confidential information relating specifically to our product candidates by entering into confidentiality agreements with parties to whom we need to disclose our confidential information, for example, our employees, consultants, scientific advisors, board members, contractors, potential collaborators and investors. However, we cannot be certain that such agreements have been entered into with all relevant parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Our confidential information and trade secrets thus may become known by our competitors in ways we cannot prove or remedy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. We cannot guarantee that our employees, former employees or consultants will not file patent applications claiming our inventions. Because of the &#8220;first-to-file&#8221; laws in the United States and the EU, such unauthorized patent application filings may defeat our attempts to obtain patents on our own inventions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:31.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">Although we are not currently aware of any claims challenging the inventorship of our patent applications or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patent applications or patents we may be granted or other intellectual property as an inventor or co-inventor. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act, and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel must devote a substantial amount of time to ensure that we maintain compliance with all of these requirements. Moreover, the reporting requirements, rules and regulations have increased our legal and financial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">compliance costs and make some activities more time consuming and costly. Any changes we have made, and may make in the future to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, may also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. For example, the SEC&#8217;s proposed climate disclosure rule would result in significant costs of compliance if it is approved in December 2022. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches and geopolitical tensions or conflicts, such as the ongoing war in Ukraine, may create a heightened risk of cyberattacks.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Despite the implementation of security measures, our internal computer, server, and other information technology systems as well as those of our third-party collaborators, consultants, contractors, suppliers, and service providers, may be vulnerable to damage from physical or electronic break-ins, computer viruses, &#8220;phishing&#8221; attacks, malware, ransomware, denial of service and other cyber-attacks or disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/ or proprietary data, including health-related information or other personal information, and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. In addition, geopolitical tensions or conflicts, such as Russia&#8217;s invasion of Ukraine, may create a heightened risk of cyberattacks. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. If we or any of our third-party collaborators or service providers were to experience any material failure or security breach, it could result in a material disruption of our development programs, reputation, and business operations. For example, the loss of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory approval or clearance efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize the product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if we or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of personal information, including health-related information, we may have to notify individuals, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party CROs and other third parties to conduct clinical studies, and similar events relating to their computer systems could also have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Further, the COVID-19 pandemic is generally increasing the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#8220;hackers&#8221; hoping to use the recent COVID-19 pandemic to their advantage. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate or unauthorized access to or disclosure or use of confidential, proprietary, or other sensitive, personal information, including health-related information, we could incur liability and suffer reputational harm, and the development and commercialization of our products could be delayed. Our insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face the significant risks associated with our company-wide implementation of an ERP system that may adversely affect our business and results of operations or the effectiveness of our internal controls over financial reporting.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>We recently implemented a company-wide ERP system to upgrade certain existing business, operational, and financial processes. Our ERP implementation is a complex, expensive and time-consuming project and our ERP system initially went live in August 2022. Our results of operations could be adversely affected if we experience time delays or cost overruns during the ERP implementation process, or if the ERP system or associated process changes do not give rise to the benefits that we expect. This project has required and may continue to require investment of capital and human resources, the re-engineering of processes of our business, and the attention of many employees who would otherwise be focused on other aspects of our business. Any deficiencies in the design and implementation of the new ERP system could result in potentially higher costs than we had incurred previously and could adversely affect our ability to develop product candidates, launch products, file reports with the SEC in a timely manner, operate our business or otherwise affect our controls environment. Any of these consequences could have a material and adverse effect on our results of operations and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to governmental regulation and other legal obligations related to privacy, data protection and information security. Compliance with these requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Compliance with these privacy and data security requirements is rigorous and time-intensive and may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm, which could materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In the United States, we and our partners may be subject to numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Even when HIPAA does not apply, according to the Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;) on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;) recently passed in California, which will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Colorado and Utah, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:9pt;"></span>In addition, the regulatory framework for the receipt, collection, processing, use, safeguarding, sharing and transfer of personal and confidential data is rapidly evolving and is likely to remain uncertain for the foreseeable future as new global privacy rules are being enacted and existing ones are being updated and strengthened. For example, on May 25, 2018, the GDPR took effect. The GDPR is applicable in each EEA member state and applies to companies established in the EEA as well as companies that collect and use personal data to offer goods or services to, or monitor the behavior of, individuals in the EEA, including, for example, through the conduct of clinical trials. GDPR introduces more stringent data protection obligations for processors and controllers of personal data. Among other things, the GDPR requires the establishment of a lawful basis for the processing of data, includes requirements relating to the consent of the individuals to whom the personal data relates, including detailed notices for clinical trial subjects and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the EU (&#8220;CJEU&#8221;) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (&#8220;SCCs&#8221;). The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK. The UK&#8217;s Information Commissioner&#8217;s Office has published new data transfer standard contracts for transfers from the UK under the UK GDPR. This new documentation will be mandatory for relevant data transfers from September 21, 2022; existing standard contractual clauses arrangements must be migrated to the new documentation by March 21, 2024. Penalties and fines for failure to comply with GDPR are significant, including fines of up to &#8364;20 million or 4% of total worldwide annual turnover, whichever is higher.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The EU has also proposed a Regulation on Privacy and Electronic Communications (&#8220;ePrivacy Regulation&#8221;) which, if adopted, would impose new obligations on the use of personal data in the context of electronic communications, particularly with respect to online tracking technologies and direct marketing. Additionally, the EU adopted the EU Clinical Trials Regulation, which came into effect on January 31, 2022. This regulation imposes new obligations on the use of data generated from clinical trials and enables European patients to have the opportunity to access information about clinical trials. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Further, since the beginning of 2021, we have also been subject to the UK data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. Other foreign jurisdictions are increasingly implementing or developing their own privacy regimes with complex and onerous compliance obligations and robust regulatory enforcement powers. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The international aspects of our business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We currently have limited international operations of our own and have and may have in the future a number of international collaborations, including our significant collaboration with Junshi Biosciences in China. Doing business internationally involves a number of risks, including but not limited to: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of the FDA to accept clinical trial data obtained by our product candidates in clinical trials in China, which could result in an inability to obtain acceptance or increased costs to pursue clinical trials in the United States;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses, including those that affect our work with a collaboration partner in China; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our collaboration partners to obtain and maintain regulatory approvals for the use of our products in various countries; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:2.25pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations by us or our collaboration partners;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:2.25pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems by our collaboration partners; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our or our collaboration partners&#8217; ability to penetrate international markets; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expose us to sanctions, such as the sanctions levied by United States, E.U. and Russian regulatory bodies in connection with Russia&#8217;s invasion of Ukraine in February 2022; and</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:2.25pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the United States Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be negatively impacted by continued inflation.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We may be adversely impacted by continued increases in inflation. Current and future inflation may be driven by the following factors: supply chain disruptions, increased costs of transportation, increased input costs such as the cost of fuel, shortages, and governmental stimulus or fiscal policies. Continuing increases in inflation could impact the overall demand for our products, our costs for labor and materials and the size of any margins we are able to realize on our revenues. This would have a material and adverse impact on our business, financial position, results of operations and cash flows. Inflation may also result in higher interest rates, which in turn would result in higher interest expense related to our variable rate indebtedness.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_92167c23_1e5a_4c97_a7e3_cbcd61c99de5"></a><a id="ITEM2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We did not repurchase any of our equity securities during the third quarter ended September 30, 2022. A total of 32,319&#160;shares were surrendered to Coherus in the third quarter of 2022, to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_684fc1b3_4f87_482c_8d8d_cb2fb7f41ee9"></a><a id="ITEM3DefaultsUponSeniorSecuritiesg_51029"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160; 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Not applicable</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d70c5724_0f21_43ce_a95b_12fb3cff8e00"></a><a id="ITEM4MineSafetyDisclosures_660567"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160; 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Not applicable</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_358a786b_d081_496e_9251_a9acd104f324"></a><a id="ITEM5OtherInformation_658170"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160; 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Not applicable</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4bb31e00_376b_4216_acc4_8e35d96b32bf"></a><a id="ITEM6Exhibits_857545"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM&#160; 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">See the Exhibit&#160;Index on the page&#160;immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form&#160;10-Q, which Exhibit&#160;Index is incorporated herein by reference.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">INDEX TO EXHIBITS</p><a id="_fa972007_afc9_41d0_ba34_b1088d4ca48b"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="5" style="font-weight:normal;text-align:left;vertical-align:bottom;width:25.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.26%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:53.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date</b><br /><b style="font-weight:bold;">Filed</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Filed</b><br /><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514409798/d820280dex31.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation</span></a>.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/13/2014</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837020013970/chrs-20201112xex3d1.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Bylaws</span></a>.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/18/2020</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reference is made to exhibits 3.1 and 3.2.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex42.htm"><span style="font-style:normal;font-weight:normal;">Form of Common Stock Certificate</span></a>.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10/24/2014</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm"><span style="font-style:normal;font-weight:normal;">Indenture, dated as of April 17, 2020, between Coherus Biosciences, Inc. and U.S. Bank National Association, as Trustee</span></a>.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4/17/2020</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm"><span style="font-style:normal;font-weight:normal;">Form of certificate representing the 1.5% Convertible Senior Subordinated Notes due 2026</span></a>.</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4/17/2020</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837022007420/chrs-20220331xex4d5.htm"><span style="font-style:normal;font-weight:normal;">Notice of Successor Trustee to Indenture dated February 7, 2022.</span></a></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">5/5/2022</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20220930xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Required under Securities Exchange Act Rule&#160;13a-14(a)&#160;and 15d-14(a).</span></a></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20220930xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Financial Officer under Securities Exchange Act Rule&#160;13a-14(a)&#160;and 15d-14(a).</span></a></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20220930xex32d1.htm"><span style="font-style:normal;font-weight:normal;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule&#160;13a-14(b).</span></a></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following materials from Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2022 formatted in iXBRL (Inline eXtensible Business Reporting Language) includes: (i)&#160;Condensed Consolidated Balance Sheets, (ii)&#160;Condensed Consolidated Statements of Operations, (iii)&#160;Condensed Consolidated Statements of Comprehensive Loss, (iv)&#160;Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit), (v)&#160;Condensed Consolidated Statements of Cash Flows, and (vi)&#160;Notes&#160;to the Condensed Consolidated Financial Statements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:53.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_122ac130_a00f_4d24_9395_81cfecf8cc51"></a><a id="SIGNATURES_840188"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COHERUS BIOSCIENCES,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: November 8, 2022</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: November 8, 2022</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ McDavid Stilwell&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McDavid Stilwell</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: November 8, 2022</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Bryan McMichael&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bryan McMichael</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>chrs-20220930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/8/2022 08:54:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">I, Dennis M. Lanfear, certify that:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this quarterly report on Form 10-Q of Coherus BioSciences, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: November 8, 2022</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">President and Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>chrs-20220930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/8/2022 08:54:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">I, McDavid Stilwell, certify that:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this quarterly report on Form 10-Q of Coherus BioSciences, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Calibri','Helvetica','sans-serif';">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: November 8, 2022</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ </font><font style="font-family:'Calibri','Helvetica','sans-serif';">McDavid Stilwell</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">McDavid Stilwell</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>chrs-20220930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/8/2022 08:54:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 18pt 0pt;"><a name="_Hlk74906751"></a><font style="font-family:'Calibri','Helvetica','sans-serif';">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Coherus BioSciences, Inc. (the &#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registrant</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) certify that the Quarterly Report of Coherus BioSciences, Inc. on Form 10-Q for the quarterly period ended September 30, 2022 (the &#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Report</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: November 8, 2022</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">By:</font></p></td><td style="vertical-align:top;width:42.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ </font><font style="font-family:'Calibri','Helvetica','sans-serif';">Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Name:</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Title:</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">President and Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: November 8, 2022</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">By:</font></p></td><td style="vertical-align:top;width:42.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ </font><font style="font-family:'Calibri','Helvetica','sans-serif';">McDavid Stilwell</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Name:</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">McDavid Stilwell</font></p></td></tr><tr><td style="vertical-align:top;width:50.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Title:</font></p></td><td style="vertical-align:bottom;width:42.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>chrs-20220930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2022 8:54:48 PM-->
<!--Modified on: 11/8/2022 8:54:48 PM-->
<xsd:schema targetNamespace="http://www.coherus.com/20220930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:chrs="http://www.coherus.com/20220930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40102 - Disclosure - Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>40401 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" id="DisclosureInventoryBalanceSheetClassificationsDetails">
        <link:definition>40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>40503 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" id="DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails">
        <link:definition>40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2" id="DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2">
        <link:definition>40711 - Disclosure - Convertible Notes and Term Loan - Term Loan Components (Details) Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" id="DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails">
        <link:definition>40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" id="DisclosureDebtObligationsTables">
        <link:definition>30703 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30903 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails" id="DisclosureRevenueAdditionalInformationDetails">
        <link:definition>40201 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" id="DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails">
        <link:definition>40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" id="DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails">
        <link:definition>40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" id="DisclosureInventoryAdditionalInformationDetails">
        <link:definition>40403 - Disclosure - Inventory - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>40502 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" id="DisclosureCollaborationsAndOtherArrangementsDetails">
        <link:definition>40601 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" id="DisclosureDebtObligationsSummaryOfDebtObligationsDetails">
        <link:definition>40701 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" id="DisclosureDebtObligations2027TermLoanNarrativeDetails">
        <link:definition>40702 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" id="DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails">
        <link:definition>40703 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" id="DisclosureDebtObligations2027TermLoanFuturePaymentsDetails">
        <link:definition>40704 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" id="DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails">
        <link:definition>40705 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" id="DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails">
        <link:definition>40706 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" id="DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails">
        <link:definition>40708 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" id="DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails">
        <link:definition>40710 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" id="DisclosureDebtObligations2025TermLoanNarrativeDetails">
        <link:definition>40713 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" id="DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails">
        <link:definition>40715 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>40901 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" id="DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails">
        <link:definition>41001 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41101 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" id="StatementCondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10201 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>10401 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>10501 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" id="DisclosureCollaborationsAndOtherArrangements">
        <link:definition>10601 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations" id="DisclosureDebtObligations">
        <link:definition>10701 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10901 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11101 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30203 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>30403 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>30503 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31003 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails">
        <link:definition>40101 - Disclosure - Organization and Significant Accounting Policies - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20220930_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20220930_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20220930_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20220930_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:element name="ConvertibleNotesPrincipalAmount" id="chrs_ConvertibleNotesPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="TermLoanGross" id="chrs_TermLoanGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PrepaidManufacturingExpenseCurrent" id="chrs_PrepaidManufacturingExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AccruedRebatesFeesAndReserveCurrent" id="chrs_AccruedRebatesFeesAndReserveCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInAccruedRebatesFeesAndReserve" id="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedCompensation" id="chrs_IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsAbstract" id="chrs_CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" id="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" id="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedCashMoneyMarketFundsMember" id="chrs_RestrictedCashMoneyMarketFundsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InventoryCurrentAndNoncurrent" id="chrs_InventoryCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="McKessonMember" id="chrs_McKessonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmeriSourceBergenCorpMember" id="chrs_AmeriSourceBergenCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CardinalMember" id="chrs_CardinalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReserveForDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontAndMilestonePayment" id="chrs_UpfrontAndMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" id="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfGrossProfitsOnSales" id="chrs_PercentageOfGrossProfitsOnSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BioeqIPAGMember" id="chrs_BioeqIPAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialTermOfAgreement" id="chrs_InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfPremiumOnConvertibleNote" id="chrs_PercentageOfPremiumOnConvertibleNote" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HealthcareRoyaltyPartnersIIILPMember" id="chrs_HealthcareRoyaltyPartnersIIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" id="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EquivalentToConversionPricePerCommonShare" id="chrs_EquivalentToConversionPricePerCommonShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" id="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentPrepaymentPercentage" id="chrs_DebtInstrumentPrepaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" id="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeesAndNonemployeesStockOptionMember" id="chrs_EmployeesAndNonemployeesStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesMember" id="chrs_ConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionRelatedToSalesMadeAbstract" id="chrs_ProvisionRelatedToSalesMadeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionRelatedToSalesMadeInPriorPeriod" id="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="BevacizumabLicensedProductMember" id="chrs_BevacizumabLicensedProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InnoventBiologicsSuzhouCoLtdMember" id="chrs_InnoventBiologicsSuzhouCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionExerciseFeeMember" id="chrs_OptionExerciseFeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationCosts" id="chrs_CollaborationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OperatingAndFinanceLeaseLiabilityNoncurrent" id="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" id="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChargebacksAndDiscountsForPromptPaymentMember" id="chrs_ChargebacksAndDiscountsForPromptPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RebatesMember" id="chrs_RebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherFeesCoPayAssistanceAndReturnsMember" id="chrs_OtherFeesCoPayAssistanceAndReturnsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfInventoryTableTextBlock" id="chrs_ScheduleOfInventoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherNoncashAdjustments" id="chrs_OtherNoncashAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorSubordinatedNotesDue20261.5Member" id="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEventsInDefault" id="chrs_NumberOfEventsInDefault" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PaymentForCappedCallTransactions" id="chrs_PaymentForCappedCallTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" id="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentContractualTerm" id="chrs_DebtInstrumentContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapPriceOfCapCallTransactions" id="chrs_CapPriceOfCapCallTransactions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorNotes8.2PercentDue2022Member" id="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaymentsMadeToCmoForManufacturingServices" id="chrs_PrepaymentsMadeToCmoForManufacturingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" id="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="JunshiBiosciencesMember" id="chrs_JunshiBiosciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" id="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementPercentageOfRoyaltyOnNetSales" id="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementThresholdRoyaltyPayments" id="chrs_CollaborationAgreementThresholdRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborationAgreementOptionExerciseFeePerProgram" id="chrs_CollaborationAgreementOptionExerciseFeePerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" id="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" id="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" id="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockPurchaseAgreementSharesAgreedToBeIssued" id="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockPurchaseAgreementSharesAgreedToBeIssuedValue" id="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ExclusiveLicenseAndCommercializationAgreementMember" id="chrs_ExclusiveLicenseAndCommercializationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumAmountPaidCoDevelopmentActivities" id="chrs_MaximumAmountPaidCoDevelopmentActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" id="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ConsultingAgreementWithLanfearAdvisorsMember" id="chrs_ConsultingAgreementWithLanfearAdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueForDiscountForLackOfMarketability" id="chrs_FairValueForDiscountForLackOfMarketability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" id="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseLiabilitiesOperatingAndFinancing" id="chrs_LeaseLiabilitiesOperatingAndFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccruedAndOtherCurrentLiabilitiesMember" id="chrs_AccruedAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" id="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CoDevelopmentRegulatoryAndTechnologyTransferCosts" id="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProductPipelineNumberOfDrugCandidates" id="chrs_ProductPipelineNumberOfDrugCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ToripalimabMember" id="chrs_ToripalimabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AntiTigitAntibodyAndIl2CytokineMember" id="chrs_AntiTigitAntibodyAndIl2CytokineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Chs2020Member" id="chrs_Chs2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermLoansMember" id="chrs_TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheLoanMember" id="chrs_TrancheLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBLoanMember" id="chrs_TrancheBLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCLoanMember" id="chrs_TrancheCLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheDLoanMember" id="chrs_TrancheDLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodOne" id="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodTwo" id="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodThree" id="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MandatoryPrepaymentTerm" id="chrs_MandatoryPrepaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" id="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermLoansPayableNoncurrent" id="chrs_TermLoansPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentNumberOfTranches" id="chrs_DebtInstrumentNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" id="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodFour" id="chrs_LoanAgreementCovenantsNetSalesForPeriodFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodFive" id="chrs_LoanAgreementCovenantsNetSalesForPeriodFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtDiscountsAndIssuanceCosts" id="chrs_DebtDiscountsAndIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TrancheaAndBLoansMember" id="chrs_TrancheaAndBLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BiopharmaCreditInvestmentsVGpLlcMember" id="chrs_BiopharmaCreditInvestmentsVGpLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfCapPriceCappedCallTransactions" id="chrs_PercentageOfCapPriceCappedCallTransactions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="YusimryProductMember" id="chrs_YusimryProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentRemainingTerm" id="chrs_DebtInstrumentRemainingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheaBAndDLoansMember" id="chrs_TrancheaBAndDLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" id="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" id="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedCoDevelopmentCostsPayableToJunshiBiosciences" id="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EstimatedIncreaseDecreaseInNetIncomeLoss" id="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" id="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>chrs-20220930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2022 8:54:48 PM-->
<!--Modified on: 11/8/2022 8:54:48 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryBalanceSheetClassificationsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2" roleURI="http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638035376866979078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638035376866979078" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376866979078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638035376866979078" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376866979078" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638035376866979078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638035376866979078" xlink:to="us-gaap_ReceivablesNetCurrent_638035376866979078" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638035376866979078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638035376866979078" xlink:to="us-gaap_InventoryNet_638035376866979078" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638035376866979078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638035376866979078" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638035376866979078" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638035376866979078" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638035376866989074" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638035376866989074" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_InventoryNoncurrent_638035376866989074" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638035376866989074" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638035376866989074" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638035376866989074" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638035376866989074" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638035376866989074" xlink:to="us-gaap_LiabilitiesCurrent_638035376866989074" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638035376866989074" xlink:to="us-gaap_AccountsPayableCurrent_638035376866999079" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638035376866989074" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_638035376866999079" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638035376866989074" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638035376866999079" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638035376866989074" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638035376866999079" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638035376866989074" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638035376866999079" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638035376866989074" xlink:to="chrs_TermLoansPayableNoncurrent_638035376866999079" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638035376866989074" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638035376866999079" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638035376866999079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638035376866989074" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638035376866999079" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638035376867009078" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638035376867009078" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638035376867009078" xlink:to="us-gaap_CommonStockValue_638035376867009078" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638035376867009078" xlink:to="us-gaap_AdditionalPaidInCapital_638035376867009078" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638035376867009078" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638035376867009078" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638035376867009078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638035376867009078" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638035376867009078" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" xlink:to="us-gaap_OperatingIncomeLoss_638035376867019082" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638035376867019082" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376867019082" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638035376867019082" xlink:to="us-gaap_CostsAndExpenses_638035376867019082" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638035376867019082" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638035376867019082" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638035376867019082" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638035376867019082" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638035376867019082" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638035376867019082" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638035376867019082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" xlink:to="us-gaap_InterestExpense_638035376867019082" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376867029079" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376867019082" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638035376867029079" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss_638035376867029079" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638035376867029079" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_ProfitLoss_638035376867029079" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638035376867029079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_DepreciationAndAmortization_638035376867029079" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_ShareBasedCompensation_638035376867039076" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_GainLossOnContractTermination_638035376867039076" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_InventoryWriteDown_638035376867039076" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376867039076" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638035376867039076" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherNoncashAdjustments" xlink:label="chrs_OtherNoncashAdjustments_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="chrs_OtherNoncashAdjustments_638035376867039076" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638035376867039076" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638035376867039076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInInventories_638035376867039076" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638035376867049078" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376867049078" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638035376867049078" order="13" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638035376867049078" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638035376867049078" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_638035376867049078" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638035376867049078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376867029079" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638035376867049078" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638035376867059073" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638035376867059073" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638035376867059073" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376867059073" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638035376867059073" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638035376867059073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638035376867059073" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638035376867069076" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638035376867069076" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_RepaymentsOfDebt_638035376867069076" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638035376867069076" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638035376867069076" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638035376867069076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638035376867069076" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638035376867079076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376867059073" xlink:to="us-gaap_ProceedsFromStockPlans_638035376867079076" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376867079076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376867079076" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638035376867079076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_638035376867079076" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="InventoryGross" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638035376867079076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryRawMaterials_638035376867079076" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638035376867079076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess_638035376867079076" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638035376867089082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods_638035376867089082" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="InventoryCurrentAndNoncurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638035376867089082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNet_638035376867089082" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638035376867089082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_638035376867089082" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638035376867089082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638035376867089082" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638035376867089082" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638035376867089082" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_638035376867099078" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638035376867099078" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638035376867099078" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_638035376867099078" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376867099078" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376867099078" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376867099078" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376867099078" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376867099078" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376867109076" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_1" xlink:to="chrs_ConvertibleNotesPrincipalAmount_638035376867109076" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_1" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376867109076" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2" xlink:type="extended" xlink:title="40711 - Disclosure - Convertible Notes and Term Loan - Term Loan Components (Details) Calc2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376867109076" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376867109076" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376867109076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376867109076" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638035376867119076" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638035376867119076" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638035376867119076" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_638035376867119076" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_638035376867119076" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_638035376867119076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_638035376867119076" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>chrs-20220930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2022 8:54:48 PM-->
<!--Modified on: 11/8/2022 8:54:48 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsTables" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCollaborationsAndOtherArrangementsDetails" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsSummaryOfDebtObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2025TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: AssetsAbstract to OperatingLeaseRightOfUseAsset" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:AssetsAbstract To us-gaap_OtherAssetsNoncurrent" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent To us-gaap_AccruedLiabilitiesCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:title="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="PublicUtilitiesInventoryAxis" xlink:title="PublicUtilitiesInventoryAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="PublicUtilitiesInventoryTypeDomain" xlink:title="definition: PublicUtilitiesInventoryAxis to PublicUtilitiesInventoryTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:title="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="ReceivableTypeDomain" xlink:title="ReceivableTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="ReceivableTypeDomain" xlink:title="definition: AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis to ReceivableTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="OptionIndexedToIssuersEquityEquityAxis" xlink:title="OptionIndexedToIssuersEquityEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityEquityAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityEquityAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="AdjustmentsForChangeInAccountingPrincipleAxis" xlink:title="AdjustmentsForChangeInAccountingPrincipleAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="ChangeInAccountingPrincipleMember" xlink:title="ChangeInAccountingPrincipleMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="ChangeInAccountingPrincipleMember" xlink:title="definition: AdjustmentsForChangeInAccountingPrincipleAxis to ChangeInAccountingPrincipleMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:title="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="AdjustmentsForErrorCorrectionDomain" xlink:title="AdjustmentsForErrorCorrectionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="AdjustmentsForErrorCorrectionDomain" xlink:title="definition: ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis to AdjustmentsForErrorCorrectionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Debt Obligations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_McKessonMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_AmeriSourceBergenCorpMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_CardinalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_RebatesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RestrictedCashMoneyMarketFundsMember" xlink:label="chrs_RestrictedCashMoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="chrs_RestrictedCashMoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Inventory - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_Chs2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_YusimryProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryValuationReserves" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaidManufacturingExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Collaborations and Other Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_BioeqIPAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InnoventBiologicsSuzhouCoLtdMember" xlink:label="chrs_InnoventBiologicsSuzhouCoLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_InnoventBiologicsSuzhouCoLtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ExclusiveLicenseAndCommercializationAgreementMember" xlink:label="chrs_ExclusiveLicenseAndCommercializationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_ExclusiveLicenseAndCommercializationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_JunshiBiosciencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BevacizumabLicensedProductMember" xlink:label="chrs_BevacizumabLicensedProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LicenseMember" xlink:to="chrs_BevacizumabLicensedProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_ToripalimabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OptionExerciseFeeMember" xlink:label="chrs_OptionExerciseFeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_OptionExerciseFeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_InitialTermOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_UpfrontAndMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdRoyaltyPayments" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementThresholdRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_FairValueForDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PercentageOfGrossProfitsOnSales" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheBLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheCLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheDLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaAndBLoansMember" xlink:label="chrs_TrancheaAndBLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TrancheaAndBLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TrancheaBAndDLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFour" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFive" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_MandatoryPrepaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtDiscountsAndIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentRemainingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_TermLoanGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_EquivalentToConversionPricePerCommonShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_NumberOfEventsInDefault" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_CallOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_PaymentForCappedCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_CapPriceOfCapCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_ConvertibleNotesPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xlink:type="extended" xlink:title="40710 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_EquivalentToConversionPricePerCommonShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_NumberOfEventsInDefault" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40713 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentPrepaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40715 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="chrs_ConvertibleNotesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>chrs-20220930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2022 8:54:48 PM-->
<!--Modified on: 11/8/2022 8:54:48 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address City Or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security12b Title</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaidManufacturingExpenseCurrent" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid manufacturing expense current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Manufacturing Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid manufacturing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment made for manufacturing services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaid and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Including Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedRebatesFeesAndReserveCurrent" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Rebates Fees And Reserve Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoansPayableNoncurrent" xlink:to="chrs_TermLoansPayableNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Subordinated Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 77,770,593 and 76,930,096 at September 30, 2022 and December 31, 2021, respectively)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Of Sold Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of shares used in computing net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of shares used in computing basic net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding - Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of shares used in computing diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on available-for-sale securities, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of RSUs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Paid For Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of RSUs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain (loss), net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of prepaid manufacturing services related to the termination of CHS-2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charge within research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write Down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-downs of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense from amortization of debt discount &amp; issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront license fee payment related to license and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront License Fee Payments Related To License And Collaboration Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and option payments to Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherNoncashAdjustments" xlink:label="chrs_OtherNoncashAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OtherNoncashAdjustments" xlink:to="chrs_OtherNoncashAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OtherNoncashAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents other noncash adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OtherNoncashAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OtherNoncashAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash adjustments, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid manufacturing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaid, current and non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accounts Payable Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in accrued rebates, fees and reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Rebates Fees And Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserves</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IncreaseDecreaseInAccruedCompensation" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current and non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from maturities of investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents upfront and milestone based license fee payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront And Milestone Based License Fee Payments, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and option payments to Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from purchase under the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of 2022 Convertible Notes and premiums</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount payoff</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of 2025 Term Loan, premiums and exit fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount paid off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAndLicenseAgreementsAbstract" xlink:to="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:to="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product sales discounts and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Product Sales Discounts And Allowances Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets and Liabilities Measured on a Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfInventoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfInventoryTableTextBlock" xlink:to="chrs_ScheduleOfInventoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" xlink:to="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of balance sheet classification of Inventory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Balance Sheet Classification Of Inventory Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Balance Sheet Classification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TermLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents term loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027 Term Loans</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1.5% Convertible Senior Subordinated Notes due 2026</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 8.2% Convertible Senior Notes due 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.2% Convertible Notes due 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the Company's Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income And Interest Expense Disclosure Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturities Of Long Term Debt Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Payments on Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Purchase Commitment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Non-cancelable Contractual Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" xlink:to="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee and nonemployee stock option restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Nonemployee Stock Option Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProductPipelineNumberOfDrugCandidates" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProductPipelineNumberOfDrugCandidates" xlink:to="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of drug candidates in the product pipeline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product pipeline, Number of Drug Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product pipeline, number of product candidates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Product Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_McKessonMember" xlink:to="chrs_McKessonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_McKessonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_McKessonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AmeriSourceBergenCorpMember" xlink:to="chrs_AmeriSourceBergenCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AmeriSourceBergenCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AmeriSource-Bergen Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AmeriSourceBergenCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AmeriSource-Bergen Corp</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CardinalMember" xlink:to="chrs_CardinalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CardinalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CardinalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total gross revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accounts Notes Loans And Financing Receivable [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accounts Notes Loans And Financing Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charge backs and discounts for prompt payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chargebacks and Discounts for Prompt Payment</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RebatesMember" xlink:to="chrs_RebatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebates</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other fees, co-pay assistance and returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Fees, Co-pay Assistance and Returns</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Notes And Loans Receivable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Notes And Loans Receivable</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve For Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Activities and reserve balance, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Activities and reserve balance, beginning balance</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision related to sales made in:</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for sales discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve For Sales Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current period</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents provision related to sales made in prior period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision Related to Sales Made in Prior Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior period</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments and customer credits issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents (money market funds)</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RestrictedCashMoneyMarketFundsMember" xlink:label="chrs_RestrictedCashMoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RestrictedCashMoneyMarketFundsMember" xlink:to="chrs_RestrictedCashMoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RestrictedCashMoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash money market funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RestrictedCashMoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash (Money Market Funds)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Raw Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Work In Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Finished Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="chrs_InventoryCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InventoryCurrentAndNoncurrent" xlink:to="chrs_InventoryCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory current and noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current And Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_Chs2020Member" xlink:to="chrs_Chs2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_Chs2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents CHS-2020, a biosimilar of Eylea.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_Chs2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHS-2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_YusimryProductMember" xlink:to="chrs_YusimryProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_YusimryProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Yusimry product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_YusimryProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Yusimry Product [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated increase in the net income (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Increase Decrease In Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate increased the net loss, amount</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated increase (decrease) in the net income (loss) per share (basic and diluted).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Increase Decrease In Net Income (Loss) Per Share (Basic And Diluted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated net loss per share (basic and diluted)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Valuation Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory reserves</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents prepayments made to a CMO for manufacturing services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments Made to CMO For Manufacturing Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments made to a CMO for manufacturing services for UDENYCA</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents prepayments made to a CMO for other research and development program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments made to a CMO For Other Research And Development Pipeline Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment and Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued commercial and research and development manufacturing liabilities current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Commercial and Research and Development Manufacturing Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued commercial and research and development manufacturing</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" xlink:to="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent to pertaining accrued co-development costs payable to Junshi Biosciences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Co-Development Costs Payable to Junshi Biosciences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued co-development costs payable to Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents lease liabilities for both operating and financing leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities, Operating and Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BioeqIPAGMember" xlink:to="chrs_BioeqIPAGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BioeqIPAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioeq IP AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BioeqIPAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioeq IP AG</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InnoventBiologicsSuzhouCoLtdMember" xlink:label="chrs_InnoventBiologicsSuzhouCoLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InnoventBiologicsSuzhouCoLtdMember" xlink:to="chrs_InnoventBiologicsSuzhouCoLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InnoventBiologicsSuzhouCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Innovent Biologics (Suzhou) Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InnoventBiologicsSuzhouCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovent Biologics (Suzhou) Co., Ltd.</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ExclusiveLicenseAndCommercializationAgreementMember" xlink:label="chrs_ExclusiveLicenseAndCommercializationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExclusiveLicenseAndCommercializationAgreementMember" xlink:to="chrs_ExclusiveLicenseAndCommercializationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExclusiveLicenseAndCommercializationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Exclusive License and Commercialization Agreement .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExclusiveLicenseAndCommercializationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_JunshiBiosciencesMember" xlink:to="chrs_JunshiBiosciencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_JunshiBiosciencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Junshi Biosciences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_JunshiBiosciencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed Products</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BevacizumabLicensedProductMember" xlink:label="chrs_BevacizumabLicensedProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BevacizumabLicensedProductMember" xlink:to="chrs_BevacizumabLicensedProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BevacizumabLicensedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the bevacizumab Licensed Product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BevacizumabLicensedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bevacizumab Licensed Product</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ToripalimabMember" xlink:to="chrs_ToripalimabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents toripalimab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Toripalimab</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents anti-TIGIT antibody and the IL-2 cytokine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-TIGIT Antibody and IL-2 cytokine</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OptionExerciseFeeMember" xlink:label="chrs_OptionExerciseFeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OptionExerciseFeeMember" xlink:to="chrs_OptionExerciseFeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OptionExerciseFeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an option exercise fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OptionExerciseFeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rituxan option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements And Noncollaborative Arrangement Transactions</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InitialTermOfAgreement" xlink:to="chrs_InitialTermOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum paid amount for co-development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount Paid, Co-development Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum paid amount for co-development activities (per licensed compound)</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationCosts" xlink:to="chrs_CollaborationCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents costs associated to a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, upfront amount paid</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontAndMilestonePayment" xlink:to="chrs_UpfrontAndMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents upfront and milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront And Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payment</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments upon achievement of certain development and regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone payments</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments upon achievement of with subject to FDA approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Upon Achievement With Subject To FDA Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments related to FDA approval</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents co-development, regulatory and technology transfer costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Co-development, Regulatory And Technology Transfer Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Co-development, regulatory and technology transfer costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" xlink:to="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Number Of Undisclosed Preclinical Immuno Oncology Drug Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undisclosed preclinical</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalty on net sales under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Percentage Of Royalty On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, royalty on net sales, percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdRoyaltyPayments" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementThresholdRoyaltyPayments" xlink:to="chrs_CollaborationAgreementThresholdRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold royalty payments to be made under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Threshold Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, threshold royalty payments</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of option exercise fee per program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Option Exercise Fee Per Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Fee</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalty on net sales for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, royalty on net sales for each exercised option, percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing stock, price per share</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Shares Agreed To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unregistered shares</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Shares Agreed To Be Issued, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate value</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period before the company can sell, transfer or make any short sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Restrictive Requirement on Selling, Transfer and Short Sale of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period before the company can sell, transfer or make any short sale of common stock (in years)</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_FairValueForDiscountForLackOfMarketability" xlink:to="chrs_FairValueForDiscountForLackOfMarketability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the fair value for the discount for lack of marketability (DLOM).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value for the Discount for Lack of Marketability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value for the discount for lack of marketability (DLOM)</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfGrossProfitsOnSales" xlink:to="chrs_PercentageOfGrossProfitsOnSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">percentage of profit shared.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Profits On Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross profits shared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less unamortized debt discount and debt issuance costs, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less unamortized debt discount and debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining unamortized debt discount and debt offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net carrying amount of Term Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheLoanMember" xlink:to="chrs_TrancheLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche A Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Loan, funded January 5, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheBLoanMember" xlink:to="chrs_TrancheBLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche B Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B Loan, funded no later than April 1, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheCLoanMember" xlink:to="chrs_TrancheCLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche C Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C Loan, funded between April 1, 2022 and March 17, 2023</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheDLoanMember" xlink:to="chrs_TrancheDLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche D Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D Loan, funded on September 14, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaAndBLoansMember" xlink:label="chrs_TrancheaAndBLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheaAndBLoansMember" xlink:to="chrs_TrancheaAndBLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheaAndBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to  tranche A&amp;B loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheaAndBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A and B Loans</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheaBAndDLoansMember" xlink:to="chrs_TrancheaBAndDLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheaBAndDLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to  tranche A&amp;B &amp; D loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheaBAndDLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranches A, B and D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional facility amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to BioPharma Credit Investments V GP LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioPharma Credit Investments V GP LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three-month LIBOR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentNumberOfTranches" xlink:to="chrs_DebtInstrumentNumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of committed tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spread on variable rate</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" xlink:to="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equal quarterly payments of principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Number of Quarterly Payments of Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly payments</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve month net sales for current quarter</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFour" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodFour" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants Net Sales For Period Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFive" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodFive" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period five.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants Net Sales For Period Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MandatoryPrepaymentTerm" xlink:to="chrs_MandatoryPrepaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory prepayment, term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory Prepayment, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory prepayment term</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtDiscountsAndIssuanceCosts" xlink:to="chrs_DebtDiscountsAndIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of debt discounts and issuance costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Discounts and Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discounts and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Finance Costs Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, Issuance Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total term of the loan</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentRemainingTerm" xlink:to="chrs_DebtInstrumentRemainingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt instrument remaining term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Remaining Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated coupon interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2022 - interest only</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 - interest only</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 - interest only</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 - interest only</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal After Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 and thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable Current And Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less amount representing interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual future interest payments due in 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoanGross" xlink:to="chrs_TermLoanGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, gross.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from offering</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument convertible number of shares per thousand of principal amount of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial conversion rate, shares of common stock</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of notes converted into shares of common stock at conversion rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of notes converted into shares</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EquivalentToConversionPricePerCommonShare" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equivalent to conversion price per common share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equivalent To Conversion Price Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial conversion price per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument maturity date</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfPremiumOnConvertibleNote" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of premium on convertible note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Premium On Convertible Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, premium percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Covenant Compliance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, covenant compliance</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NumberOfEventsInDefault" xlink:to="chrs_NumberOfEventsInDefault_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of events in default.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Events in Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of events in default</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Noncurrent, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentContractualTerm" xlink:to="chrs_DebtInstrumentContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt instrument contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Converted Instrument Amount1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, converted amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capped Call Transactions in connection with the 2026 Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PaymentForCappedCallTransactions" xlink:to="chrs_PaymentForCappedCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payment made for entering into capped call transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Capped Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for capped call transactions</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CapPriceOfCapCallTransactions" xlink:to="chrs_CapPriceOfCapCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cap price of the cap call transactions (per share).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cap Price of Cap Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial cap price of capped call transactions.</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfCapPriceCappedCallTransactions" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of premium on cap price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Cap Price, Capped Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of cap price</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleNotesPrincipalAmount" xlink:to="chrs_ConvertibleNotesPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 Convertible Notes, principal amount</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Healthcare Royalty Partners III, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentPrepaymentPercentage" xlink:to="chrs_DebtInstrumentPrepaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument prepayment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Prepayment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment premium percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage required to pay an additional exit fee on principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Required To Pay Additional Exit Fee On Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage required to pay an additional exit fee on principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFourthYear" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Fourth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Claims related to certain sales of UDENYCA from October 2020 through December 2021</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" xlink:to="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member represent the information pertaining to options and RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Nonemployee Stock Option And Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense capitalized into inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeesAndNonemployeesStockOptionMember" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and non-employees stock option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, including shares subject to ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleNotesMember" xlink:to="chrs_ConvertibleNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Conversion of Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of EPS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the consulting agreement with Lanfear advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, our President, Chief Executive Officer and Chairman of our Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreement With Lanfear Advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options, granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Long Term Notes Payable</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>chrs-20220930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2022 8:54:48 PM-->
<!--Modified on: 11/8/2022 8:54:48 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenue" roleURI="http://www.coherus.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventory" roleURI="http://www.coherus.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCollaborationsAndOtherArrangements" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations" roleURI="http://www.coherus.com/role/DisclosureDebtObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureNetLossPerShare" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueTables" roleURI="http://www.coherus.com/role/DisclosureRevenueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryTables" roleURI="http://www.coherus.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsTables" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryBalanceSheetClassificationsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureInventoryAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCollaborationsAndOtherArrangementsDetails" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsSummaryOfDebtObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2025TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20220930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638035376868039076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638035376868039076" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638035376868039076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638035376868039076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638035376868039076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638035376868039076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638035376868039076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638035376868039076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638035376868039076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638035376868049075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638035376868049075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638035376868049075" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638035376868049075" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638035376868049075" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638035376868049075" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638035376868049075" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638035376868049075" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638035376868049075" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638035376868049075" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638035376868049075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638035376868049075" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638035376868059076" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638035376868059076" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638035376868059076" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638035376868059076" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638035376868059076" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638035376868059076" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638035376868059076" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638035376868059076" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638035376868059076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638035376868059076" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638035376868069076" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638035376868069076" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638035376868069076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_AssetsCurrentAbstract_638035376868069076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376868069076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="us-gaap_ReceivablesNetCurrent_638035376868069076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="us-gaap_InventoryNet_638035376868069076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638035376868069076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638035376868069076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638035376868079078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638035376868069076" xlink:to="us-gaap_AssetsCurrent_638035376868079078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638035376868079078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_InventoryNoncurrent_638035376868079078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638035376868079078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_OtherAssetsNoncurrent_638035376868079078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638035376868069076" xlink:to="us-gaap_Assets_638035376868079078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" xlink:to="us-gaap_AccountsPayableCurrent_638035376868079078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_638035376868079078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_638035376868079078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638035376868089075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638035376868089075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638035376868079078" xlink:to="us-gaap_LiabilitiesCurrent_638035376868089075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="chrs_TermLoansPayableNoncurrent_638035376868089075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638035376868089075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638035376868089075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638035376868089075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_Liabilities_638035376868089075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638035376868089075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_CommitmentsAndContingencies_638035376868089075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" xlink:to="us-gaap_CommonStockValue_638035376868099078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" xlink:to="us-gaap_AdditionalPaidInCapital_638035376868099078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638035376868099078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638035376868099078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638035376868099078" xlink:to="us-gaap_StockholdersEquity_638035376868099078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638035376868099078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638035376868079078" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638035376868099078" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638035376868109079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638035376868109079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638035376868109079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638035376868109079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638035376868109079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638035376868109079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638035376868169077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638035376868169077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638035376868169077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_638035376868169077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638035376868169077" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376868179076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638035376868179076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638035376868179076" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638035376868179076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638035376868179076" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638035376868179076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638035376868179076" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638035376868179076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638035376868179076" xlink:to="us-gaap_CostsAndExpenses_638035376868179076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638035376868179076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_638035376868179076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868179076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638035376868179076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638035376868179076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638035376868179076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638035376868179076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638035376868189074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638035376868189074" xlink:to="us-gaap_EarningsPerShareBasic_638035376868189074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638035376868189074" xlink:to="us-gaap_EarningsPerShareDiluted_638035376868189074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638035376868189074" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638035376868189074" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638035376868189074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638035376868189074" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638035376868189074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638035376868189074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638035376868189074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638035376868189074" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638035376868189074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638035376868189074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638035376868189074" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638035376868189074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638035376868199074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638035376868199074" xlink:to="us-gaap_StatementEquityComponentsAxis_638035376868199074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638035376868199074" xlink:to="us-gaap_CommonStockMember_638035376868199074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638035376868199074" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638035376868199074" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638035376868199074" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638035376868199074" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638035376868199074" xlink:to="us-gaap_RetainedEarningsMember_638035376868199074" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638035376868199074" xlink:to="us-gaap_EquityComponentDomain_638035376868199074" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638035376868199074" xlink:to="us-gaap_StatementLineItems_638035376868199074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockholdersEquity_638035376868199074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_CommonStockSharesOutstanding_638035376868199074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638035376868199074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_NetIncomeLoss_638035376868199074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638035376868209074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638035376868209074" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638035376868209074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638035376868209074" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638035376868209074" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638035376868209074" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638035376868209074" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638035376868209074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638035376868209074" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638035376868209074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638035376868209074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638035376868209074" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638035376868209074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638035376868209074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638035376868209074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638035376868209074" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638035376868219075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638035376868219075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_StockholdersEquity_638035376868219075" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638035376868199074" xlink:to="us-gaap_CommonStockSharesOutstanding_638035376868219075" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_ProfitLoss_638035376868219075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638035376868219075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_DepreciationAndAmortization_638035376868219075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_ShareBasedCompensation_638035376868229075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_GainLossOnContractTermination_638035376868229075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_InventoryWriteDown_638035376868229075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376868229075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638035376868229075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868229075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherNoncashAdjustments" xlink:label="chrs_OtherNoncashAdjustments_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="chrs_OtherNoncashAdjustments_638035376868229075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638035376868229075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInInventories_638035376868229075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638035376868229075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638035376868229075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638035376868229075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638035376868239076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638035376868239076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_638035376868239076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638035376868229075" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638035376868239076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638035376868219075" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638035376868239076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638035376868239076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638035376868239076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638035376868239076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638035376868239076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638035376868249075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638035376868239076" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638035376868249075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638035376868249075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638035376868249075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638035376868249075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_ProceedsFromStockPlans_638035376868249075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638035376868249075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638035376868249075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638035376868259079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_RepaymentsOfDebt_638035376868259079" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638035376868259079" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638035376868249075" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638035376868259079" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638035376868259079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638035376868259079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638035376868259079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380353768682590791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380353768682590791" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638035376868269075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638035376868269075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10201 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638035376868269075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638035376868269075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638035376868269075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638035376868269075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventory" xlink:type="extended" xlink:title="10401 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638035376868279076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638035376868279076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10501 - Disclosure - Balance Sheet Components" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638035376868279076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638035376868279076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" xlink:type="extended" xlink:title="10601 - Disclosure - Collaborations and Other Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="CollaborationAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638035376868279076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638035376868279076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations" xlink:type="extended" xlink:title="10701 - Disclosure - Debt Obligations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638035376868279076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638035376868279076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638035376868289077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638035376868289077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638035376868289077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638035376868289077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638035376868289077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638035376868289077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11101 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638035376868299077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638035376868299077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638035376868299077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638035376868299077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_638035376868299077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638035376868299077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638035376868299077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638035376868299077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638035376868299077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30203 - Disclosure - Revenue (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638035376868309077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638035376868309077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_638035376868309077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_638035376868309077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638035376868309077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638035376868309077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="30403 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_638035376868309077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_ScheduleOfInventoryTableTextBlock_638035376868309077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_638035376868309077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock_638035376868309077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Balance Sheet Components (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638035376868319075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638035376868319075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Debt Obligations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868319075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868319075" xlink:to="us-gaap_DebtInstrumentAxis_638035376868319075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868319075" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868319075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868319075" xlink:to="chrs_TermLoansMember_638035376868319075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868319075" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868319075" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868319075" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868319075" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868319075" xlink:to="us-gaap_LoansPayableMember_638035376868319075" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868319075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868319075" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868319075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868319075" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_638035376868329079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868319075" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638035376868329079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868319075" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638035376868329079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock_638035376868329079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868329079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868329079" xlink:to="us-gaap_AwardTypeAxis_638035376868329079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638035376868329079" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868329079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_638035376868329079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868329079" xlink:to="chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_638035376868329079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868339078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868329079" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868339078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638035376868339078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868339078" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638035376868339078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638035376868339078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638035376868339078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Significant Accounting Policies - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProductPipelineNumberOfDrugCandidates" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_638035376868339078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_ProductPipelineNumberOfDrugCandidates_638035376868339078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_638035376868339078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecurities_638035376868339078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638035376868349077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash_638035376868349077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638035376868349077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638035376868349077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638035376868349077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638035376868349077" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638035376868349077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638035376868349077" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638035376868349077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638035376868349077" xlink:to="us-gaap_SalesRevenueNetMember_638035376868349077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638035376868349077" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638035376868349077" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638035376868349077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638035376868349077" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638035376868349077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638035376868349077" xlink:to="us-gaap_CustomerConcentrationRiskMember_638035376868359078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638035376868349077" xlink:to="srt_MajorCustomersAxis_638035376868359078" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638035376868359078" xlink:to="srt_NameOfMajorCustomerDomain_638035376868359078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638035376868359078" xlink:to="chrs_McKessonMember_638035376868359078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638035376868359078" xlink:to="chrs_AmeriSourceBergenCorpMember_638035376868359078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638035376868359078" xlink:to="chrs_CardinalMember_638035376868359078" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638035376868349077" xlink:to="us-gaap_ConcentrationRiskLineItems_638035376868359078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638035376868359078" xlink:to="us-gaap_ConcentrationRiskPercentage1_638035376868359078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638035376868359078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638035376868359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638035376868359078" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638035376868359078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638035376868359078" xlink:to="us-gaap_ReceivableTypeDomain_638035376868369077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638035376868369077" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember_638035376868369077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638035376868369077" xlink:to="chrs_RebatesMember_638035376868369077" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638035376868369077" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember_638035376868369077" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638035376868359078" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638035376868369077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638035376868369077" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638035376868369077" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract_638035376868369077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638035376868369077" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638035376868369077" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_638035376868369077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638035376868369077" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_638035376868369077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_6380353768683690771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638035376868369077" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_6380353768683690771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638035376868379077" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638035376868379077" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" xlink:to="us-gaap_FairValueByAssetClassAxis_638035376868379077" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_638035376868379077" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638035376868379077" xlink:to="us-gaap_MoneyMarketFundsMember_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_RestrictedCashMoneyMarketFundsMember" xlink:label="chrs_RestrictedCashMoneyMarketFundsMember_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638035376868379077" xlink:to="chrs_RestrictedCashMoneyMarketFundsMember_638035376868379077" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868379077" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868379077" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868379077" xlink:to="us-gaap_FairValueInputsLevel1Member_638035376868379077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868379077" xlink:to="us-gaap_FairValueInputsLevel2Member_638035376868379077" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638035376868379077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868379077" xlink:to="us-gaap_FairValueInputsLevel3Member_638035376868379077" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868379077" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868389076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868389076" xlink:to="us-gaap_AssetsFairValueDisclosure_638035376868389076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Fair Value Measurements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_638035376868389076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_638035376868389076" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_638035376868389076" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_638035376868389076" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_638035376868389076" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638035376868389076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_638035376868389076" order="6" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials_638035376868399078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess_638035376868399078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods_638035376868399078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryGross_638035376868399078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet_638035376868399078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNoncurrent_638035376868399078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="chrs_InventoryCurrentAndNoncurrent_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_InventoryCurrentAndNoncurrent_638035376868399078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Inventory - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable_638035376868399078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638035376868399078" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_638035376868399078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_638035376868399078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis_638035376868399078" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_638035376868399078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638035376868399078" xlink:to="chrs_Chs2020Member_638035376868409078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638035376868399078" xlink:to="srt_ProductOrServiceAxis_638035376868409078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638035376868409078" xlink:to="srt_ProductsAndServicesDomain_638035376868409078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638035376868409078" xlink:to="chrs_YusimryProductMember_638035376868409078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638035376868399078" xlink:to="us-gaap_InventoryLineItems_638035376868409078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_InventoryWriteDown_638035376868409078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLoss" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLoss_638035376868409078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted" xlink:label="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted_638035376868409078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_InventoryValuationReserves_638035376868409078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638035376868409078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_OtherAssetsNoncurrent_638035376868409078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638035376868409078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_InventoryNet_638035376868409078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_GainLossOnContractTermination_638035376868419077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638035376868419077" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices_638035376868419077" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638035376868409078" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_638035376868419077" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638035376868419077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638035376868419077" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638035376868419077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638035376868419077" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_MachineryAndEquipmentMember_638035376868419077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638035376868419077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_ComputerEquipmentMember_638035376868419077" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_FurnitureAndFixturesMember_638035376868429078" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_LeaseholdImprovementsMember_638035376868429078" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638035376868429078" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638035376868419077" xlink:to="us-gaap_ConstructionInProgressMember_638035376868429078" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638035376868419077" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638035376868429078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638035376868429078" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638035376868429078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638035376868429078" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638035376868429078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638035376868429078" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638035376868429078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Components - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638035376868429078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationAndAmortization_638035376868429078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638035376868439078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences" xlink:label="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences_638035376868439078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_638035376868439078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638035376868439078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638035376868439078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Collaborations and Other Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="CollaborationAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" xlink:to="us-gaap_TypeOfArrangementAxis_638035376868439078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638035376868439078" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" xlink:to="chrs_BioeqIPAGMember_638035376868439078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InnoventBiologicsSuzhouCoLtdMember" xlink:label="chrs_InnoventBiologicsSuzhouCoLtdMember_638035376868439078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" xlink:to="chrs_InnoventBiologicsSuzhouCoLtdMember_638035376868439078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ExclusiveLicenseAndCommercializationAgreementMember" xlink:label="chrs_ExclusiveLicenseAndCommercializationAgreementMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" xlink:to="chrs_ExclusiveLicenseAndCommercializationAgreementMember_638035376868449078" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638035376868439078" xlink:to="chrs_JunshiBiosciencesMember_638035376868449078" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" xlink:to="us-gaap_IncomeStatementLocationAxis_638035376868449078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638035376868449078" xlink:to="us-gaap_IncomeStatementLocationDomain_638035376868449078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638035376868449078" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638035376868449078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" xlink:to="srt_ProductOrServiceAxis_638035376868449078" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638035376868449078" xlink:to="srt_ProductsAndServicesDomain_638035376868449078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638035376868449078" xlink:to="us-gaap_LicenseMember_638035376868449078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BevacizumabLicensedProductMember" xlink:label="chrs_BevacizumabLicensedProductMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LicenseMember_638035376868449078" xlink:to="chrs_BevacizumabLicensedProductMember_638035376868449078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638035376868449078" xlink:to="chrs_ToripalimabMember_638035376868449078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638035376868449078" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember_638035376868449078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_OptionExerciseFeeMember" xlink:label="chrs_OptionExerciseFeeMember_638035376868449078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638035376868449078" xlink:to="chrs_OptionExerciseFeeMember_638035376868449078" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" xlink:to="us-gaap_BalanceSheetLocationAxis_638035376868459077" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638035376868459077" xlink:to="us-gaap_BalanceSheetLocationDomain_638035376868459077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638035376868459077" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember_638035376868459077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638035376868439078" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_InitialTermOfAgreement_638035376868459077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities_638035376868459077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationCosts_638035376868459077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_UpfrontAndMilestonePayment_638035376868459077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_638035376868459077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_638035376868459077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_638035376868469077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638035376868469077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_638035376868469077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="us-gaap_AccountsPayableCurrent_638035376868469077" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638035376868469077" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates" xlink:label="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates_638035376868469077" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_638035376868469077" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdRoyaltyPayments" xlink:label="chrs_CollaborationAgreementThresholdRoyaltyPayments_638035376868469077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementThresholdRoyaltyPayments_638035376868469077" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram_638035376868479077" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_638035376868479077" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_638035376868479077" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_638035376868479077" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638035376868479077" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="us-gaap_SharePrice_638035376868479077" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_638035376868479077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_638035376868479077" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_638035376868489077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_638035376868489077" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_638035376868489077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_638035376868489077" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_638035376868489077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_FairValueForDiscountForLackOfMarketability_638035376868489077" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales_638035376868489077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638035376868459077" xlink:to="chrs_PercentageOfGrossProfitsOnSales_638035376868489077" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868499079" xlink:to="us-gaap_DebtInstrumentAxis_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868499079" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868499079" xlink:to="chrs_TermLoansMember_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868499079" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868499079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868499079" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868499079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868499079" xlink:to="us-gaap_LoansPayableMember_638035376868499079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868499079" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868499079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638035376868499079" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868499079" xlink:to="us-gaap_FairValueInputsLevel2Member_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638035376868499079" xlink:to="us-gaap_FairValueInputsLevel3Member_638035376868499079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638035376868499079" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868499079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868499079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868509076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" xlink:to="us-gaap_LongTermDebt_638035376868509076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638035376868499079" xlink:to="us-gaap_DebtInstrumentFairValue_638035376868509076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868509076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868509076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868509076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868509076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="chrs_TermLoansMember_638035376868509076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638035376868509076" xlink:to="chrs_TrancheLoanMember_638035376868509076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638035376868509076" xlink:to="chrs_TrancheBLoanMember_638035376868509076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember_638035376868509076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638035376868509076" xlink:to="chrs_TrancheCLoanMember_638035376868509076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638035376868509076" xlink:to="chrs_TrancheDLoanMember_638035376868519076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868519076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868519076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="us-gaap_LoansPayableMember_638035376868519076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaAndBLoansMember" xlink:label="chrs_TrancheaAndBLoansMember_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="chrs_TrancheaAndBLoansMember_638035376868519076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868509076" xlink:to="chrs_TrancheaBAndDLoansMember_638035376868519076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="us-gaap_CreditFacilityAxis_638035376868519076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638035376868519076" xlink:to="us-gaap_CreditFacilityDomain_638035376868519076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638035376868519076" xlink:to="us-gaap_LineOfCreditMember_638035376868519076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="srt_CounterpartyNameAxis_638035376868519076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868519076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868519076" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868519076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868519076" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868529076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="us-gaap_VariableRateAxis_638035376868529076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638035376868529076" xlink:to="us-gaap_VariableRateDomain_638035376868529076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638035376868529076" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_638035376868529076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="srt_StatementScenarioAxis_638035376868529076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638035376868529076" xlink:to="srt_ScenarioUnspecifiedDomain_638035376868529076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638035376868529076" xlink:to="us-gaap_ScenarioPlanMember_638035376868529076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="srt_RangeAxis_638035376868529076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638035376868529076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638035376868529076" xlink:to="srt_RangeMember_638035376868529076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638035376868529076" xlink:to="srt_MinimumMember_638035376868539077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868539077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868539077" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868539077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868539077" xlink:to="us-gaap_ConvertibleDebtMember_638035376868539077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868509076" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868539077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868539077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_DebtInstrumentNumberOfTranches_638035376868539077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638035376868539077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_LongTermDebt_638035376868539077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868549077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638035376868549077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal" xlink:label="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal_638035376868549077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_RepaymentsOfDebt_638035376868549077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638035376868549077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_638035376868549077" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_638035376868549077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_638035376868549077" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_638035376868559078" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFour" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFour_638035376868559078" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodFive" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodFive_638035376868559078" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_MandatoryPrepaymentTerm_638035376868559078" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_DebtDiscountsAndIssuanceCosts_638035376868559078" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DeferredFinanceCostsGross_638035376868559078" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868559078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868559078" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638035376868569079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentTerm_638035376868569079" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm_638035376868569079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="chrs_DebtInstrumentRemainingTerm_638035376868569079" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868569079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868539077" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868569079" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_DebtInstrumentTable_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868579077" xlink:to="us-gaap_DebtInstrumentAxis_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868579077" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868579077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868579077" xlink:to="chrs_TermLoansMember_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868579077" xlink:to="srt_CounterpartyNameAxis_638035376868579077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868579077" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868579077" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868579077" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868579077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868579077" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868579077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868579077" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376868579077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638035376868579077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868579077" xlink:to="us-gaap_InterestExpenseDebt_638035376868579077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_DebtInstrumentTable_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868589076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868589076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868589076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868589076" xlink:to="chrs_TermLoansMember_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868589076" xlink:to="srt_CounterpartyNameAxis_638035376868589076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868589076" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868589076" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868589076" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868589076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376868589076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376868589076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376868589076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376868589076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376868589076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376868589076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638035376868599075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868599075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="chrs_TermLoanGross_638035376868599075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868599075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868589076" xlink:to="us-gaap_LongTermDebt_638035376868599075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868599075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868599075" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868599075" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868599075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868599075" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868599075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868599075" xlink:to="us-gaap_ConvertibleDebtMember_638035376868609076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868599075" xlink:to="us-gaap_DebtInstrumentAxis_638035376868609076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868609076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868609076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868609076" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868609076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868599075" xlink:to="srt_StatementScenarioAxis_638035376868609076" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638035376868609076" xlink:to="srt_ScenarioUnspecifiedDomain_638035376868609076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638035376868609076" xlink:to="us-gaap_ScenarioPlanMember_638035376868609076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868599075" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868609076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868609076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868609076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638035376868609076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638035376868609076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638035376868609076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638035376868619075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_638035376868619075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638035376868619075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentMaturityDate_638035376868619075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_638035376868619075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_638035376868619075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_NumberOfEventsInDefault_638035376868619075" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_638035376868619075" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="chrs_DebtInstrumentContractualTerm_638035376868619075" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638035376868619075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638035376868619075" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_SharePrice_638035376868629077" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868629077" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868629077" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868609076" xlink:to="us-gaap_DebtInstrumentTerm_638035376868629077" order="18" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_638035376868629077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable_638035376868629077" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638035376868629077" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638035376868629077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638035376868629077" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638035376868629077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember_638035376868639076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638035376868629077" xlink:to="us-gaap_CallOptionMember_638035376868639076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable_638035376868629077" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions_638035376868639076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" xlink:to="chrs_PaymentForCappedCallTransactions_638035376868639076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions_638035376868689076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" xlink:to="chrs_CapPriceOfCapCallTransactions_638035376868689076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_638035376868689076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions_638035376868689076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638035376868689076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638035376868639076" xlink:to="us-gaap_SharePrice_638035376868689076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868699079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868699079" xlink:to="us-gaap_DebtInstrumentAxis_638035376868699079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868699079" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868699079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868699079" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868699079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868699079" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868699079" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868699079" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868699079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868699079" xlink:to="us-gaap_ConvertibleDebtMember_638035376868699079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868699079" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868699079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868699079" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868699079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868699079" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376868699079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638035376868699079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868699079" xlink:to="us-gaap_InterestExpenseDebt_638035376868699079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868709078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868709078" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868709078" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868709078" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868709078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868709078" xlink:to="us-gaap_ConvertibleDebtMember_638035376868709078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868709078" xlink:to="us-gaap_DebtInstrumentAxis_638035376868709078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868709078" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868709078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868709078" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868709078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868709078" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868709078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_638035376868709078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638035376868709078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638035376868709078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638035376868709078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour" xlink:label="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376868709078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_638035376868709078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638035376868719076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868719076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="chrs_ConvertibleNotesPrincipalAmount_638035376868719076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868719076" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868709078" xlink:to="us-gaap_LongTermDebt_638035376868719076" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xlink:type="extended" xlink:title="40710 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868719076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="srt_StatementScenarioAxis_638035376868719076" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638035376868719076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638035376868719076" xlink:to="srt_ScenarioUnspecifiedDomain_638035376868719076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638035376868719076" xlink:to="us-gaap_ScenarioPlanMember_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868729076" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868729076" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868729076" xlink:to="us-gaap_ConvertibleDebtMember_638035376868729076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868729076" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868729076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868729076" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="srt_CounterpartyNameAxis_638035376868729076" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868729076" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868729076" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="srt_RangeAxis_638035376868729076" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638035376868729076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638035376868729076" xlink:to="srt_RangeMember_638035376868729076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638035376868729076" xlink:to="srt_MinimumMember_638035376868739076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868719076" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868739076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868739076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868739076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638035376868739076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DeferredFinanceCostsGross_638035376868739076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_LongTermDebt_638035376868739076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638035376868739076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_InterestExpenseDebt_638035376868739076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638035376868739076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638035376868739076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentMaturityDate_638035376868749078" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638035376868749078" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_ConvertibleNotesPayable_638035376868749078" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_638035376868749078" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638035376868749078" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638035376868749078" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_638035376868749078" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_638035376868749078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_638035376868749078" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="chrs_NumberOfEventsInDefault_638035376868759076" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638035376868759076" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_SharePrice_638035376868759076" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638035376868759076" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentTerm_638035376868759076" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868759076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868739076" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868759076" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868769076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868769076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868769076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868769076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868769076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868769076" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868769076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868769076" xlink:to="us-gaap_LongtermDebtTypeAxis_638035376868769076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638035376868769076" xlink:to="us-gaap_LongtermDebtTypeDomain_638035376868769076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638035376868769076" xlink:to="us-gaap_ConvertibleDebtMember_638035376868769076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868769076" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868769076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868769076" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868769076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868769076" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376868769076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638035376868769076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868769076" xlink:to="us-gaap_InterestExpenseDebt_638035376868769076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868769076" xlink:to="us-gaap_InterestExpense_638035376868779079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40713 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868779079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="srt_CounterpartyNameAxis_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868779079" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868779079" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="us-gaap_DebtInstrumentAxis_638035376868779079" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868779079" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868779079" xlink:to="us-gaap_LoansPayableMember_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="us-gaap_VariableRateAxis_638035376868779079" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638035376868779079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638035376868779079" xlink:to="us-gaap_VariableRateDomain_638035376868779079" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638035376868779079" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_638035376868789076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="srt_RangeAxis_638035376868789076" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638035376868789076" xlink:to="srt_RangeMember_638035376868789076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638035376868789076" xlink:to="srt_MinimumMember_638035376868789076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="srt_StatementScenarioAxis_638035376868789076" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638035376868789076" xlink:to="srt_ScenarioUnspecifiedDomain_638035376868789076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638035376868789076" xlink:to="us-gaap_ScenarioPlanMember_638035376868789076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868779079" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868789076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentTerm_638035376868789076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868789076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868789076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638035376868789076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_RepaymentsOfDebt_638035376868799077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638035376868799077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638035376868799077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_DebtInstrumentMaturityDate_638035376868799077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="chrs_DebtInstrumentPrepaymentPercentage_638035376868799077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_638035376868799077" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868799077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868789076" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638035376868799077" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40715 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638035376868809076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868809076" xlink:to="srt_CounterpartyNameAxis_638035376868809076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638035376868809076" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868809076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638035376868809076" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638035376868809076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868809076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868809076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868809076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868809076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868809076" xlink:to="us-gaap_LoansPayableMember_638035376868809076" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638035376868809076" xlink:to="us-gaap_DebtInstrumentLineItems_638035376868809076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868809076" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638035376868809076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868809076" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638035376868809076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638035376868809076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638035376868809076" xlink:to="us-gaap_InterestExpenseDebt_638035376868809076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638035376868819080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638035376868819080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_638035376868819080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_638035376868819080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_638035376868819080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligation_638035376868819080" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="ContractualObligationFiscalYearMaturityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_638035376868819080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_638035376868819080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868829080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868829080" xlink:to="us-gaap_AwardTypeAxis_638035376868829080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638035376868829080" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868829080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember" xlink:label="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638035376868829080" xlink:to="chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_638035376868829080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868829080" xlink:to="us-gaap_IncomeStatementLocationAxis_638035376868829080" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638035376868829080" xlink:to="us-gaap_IncomeStatementLocationDomain_638035376868829080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638035376868829080" xlink:to="us-gaap_CostOfSalesMember_638035376868829080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638035376868829080" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638035376868829080" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638035376868829080" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638035376868829080" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638035376868829080" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868829080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868829080" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638035376868829080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_638035376868829080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638035376868829080" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_638035376868829080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638035376868839076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638035376868839076" xlink:to="us-gaap_DebtInstrumentAxis_638035376868839076" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868839076" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868839076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868839076" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868839076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868839076" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638035376868839076" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638035376868839076" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638035376868839076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638035376868839076" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638035376868839076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638035376868839076" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember_638035376868839076" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638035376868839076" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638035376868839076" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638035376868839076" xlink:to="chrs_ConvertibleNotesMember_638035376868839076" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638035376868839076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638035376868839076" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638035376868839076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638035376868839076" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638035376868849075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638035376868849075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638035376868849075" xlink:to="us-gaap_DebtInstrumentAxis_638035376868849075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638035376868849075" xlink:to="us-gaap_DebtInstrumentNameDomain_638035376868849075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638035376868849075" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638035376868849075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638035376868849075" xlink:to="us-gaap_RelatedPartyTransactionAxis_638035376868849075" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638035376868849075" xlink:to="us-gaap_RelatedPartyTransactionDomain_638035376868849075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20220930.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638035376868849075" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember_638035376868849075" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638035376868849075" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638035376868849075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" xlink:to="us-gaap_DebtInstrumentFaceAmount_638035376868849075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638035376868859077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638035376868859077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638035376868859077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638035376868859077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638035376868859077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638035376868859077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638035376868859077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638035376868849075" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638035376868859077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402968192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Coherus BioSciences,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,777,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401836464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,805<span></span>
</td>
<td class="nump">$ 417,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">91,186<span></span>
</td>
<td class="nump">123,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">27,719<span></span>
</td>
<td class="nump">37,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaidManufacturingExpenseCurrent', window );">Prepaid manufacturing</a></td>
<td class="nump">20,633<span></span>
</td>
<td class="nump">13,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaid and other assets</a></td>
<td class="nump">21,932<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">448,275<span></span>
</td>
<td class="nump">602,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,571<span></span>
</td>
<td class="nump">7,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">77,438<span></span>
</td>
<td class="nump">55,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets</a></td>
<td class="nump">5,996<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, non-current</a></td>
<td class="nump">9,627<span></span>
</td>
<td class="nump">10,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">550,907<span></span>
</td>
<td class="nump">679,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,917<span></span>
</td>
<td class="nump">16,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedRebatesFeesAndReserveCurrent', window );">Accrued rebates, fees and reserves</a></td>
<td class="nump">54,021<span></span>
</td>
<td class="nump">79,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">22,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">85,990<span></span>
</td>
<td class="nump">48,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">171,319<span></span>
</td>
<td class="nump">165,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_TermLoansPayableNoncurrent', window );">Term loans</a></td>
<td class="nump">245,246<span></span>
</td>
<td class="nump">75,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">225,250<span></span>
</td>
<td class="nump">332,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Lease liabilities, non-current</a></td>
<td class="nump">6,123<span></span>
</td>
<td class="nump">7,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">648,040<span></span>
</td>
<td class="nump">581,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 77,770,593 and 76,930,096 at September 30, 2022 and December 31, 2021, respectively)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,185,868<span></span>
</td>
<td class="nump">1,147,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,282,738)<span></span>
</td>
<td class="num">(1,049,854)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(97,133)<span></span>
</td>
<td class="nump">97,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 550,907<span></span>
</td>
<td class="nump">$ 679,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedRebatesFeesAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued rebates, fees and reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedRebatesFeesAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_TermLoansPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_TermLoansPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401819616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">77,770,593<span></span>
</td>
<td class="nump">76,930,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">77,770,593<span></span>
</td>
<td class="nump">76,930,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386403011264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 45,424<span></span>
</td>
<td class="nump">$ 82,503<span></span>
</td>
<td class="nump">$ 165,690<span></span>
</td>
<td class="nump">$ 253,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">35,234<span></span>
</td>
<td class="nump">21,280<span></span>
</td>
<td class="nump">55,881<span></span>
</td>
<td class="nump">45,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">45,808<span></span>
</td>
<td class="nump">54,085<span></span>
</td>
<td class="nump">170,336<span></span>
</td>
<td class="nump">312,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">44,831<span></span>
</td>
<td class="nump">39,925<span></span>
</td>
<td class="nump">144,860<span></span>
</td>
<td class="nump">119,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">125,873<span></span>
</td>
<td class="nump">115,290<span></span>
</td>
<td class="nump">371,077<span></span>
</td>
<td class="nump">477,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(80,449)<span></span>
</td>
<td class="num">(32,787)<span></span>
</td>
<td class="num">(205,387)<span></span>
</td>
<td class="num">(224,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,540)<span></span>
</td>
<td class="num">(5,771)<span></span>
</td>
<td class="num">(23,089)<span></span>
</td>
<td class="num">(17,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(86,650)<span></span>
</td>
<td class="num">(38,528)<span></span>
</td>
<td class="num">(232,884)<span></span>
</td>
<td class="num">(241,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,650)<span></span>
</td>
<td class="num">$ (38,528)<span></span>
</td>
<td class="num">$ (232,884)<span></span>
</td>
<td class="num">$ (241,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (3.00)<span></span>
</td>
<td class="num">$ (3.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (3.00)<span></span>
</td>
<td class="num">$ (3.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average number of shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing basic net loss per share</a></td>
<td class="nump">77,746,895<span></span>
</td>
<td class="nump">79,013,240<span></span>
</td>
<td class="nump">77,520,244<span></span>
</td>
<td class="nump">74,984,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing diluted net loss per share</a></td>
<td class="nump">77,746,895<span></span>
</td>
<td class="nump">79,013,240<span></span>
</td>
<td class="nump">77,520,244<span></span>
</td>
<td class="nump">74,984,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401993664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,650)<span></span>
</td>
<td class="num">$ (38,528)<span></span>
</td>
<td class="num">$ (232,884)<span></span>
</td>
<td class="num">$ (241,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (86,650)<span></span>
</td>
<td class="num">$ (38,534)<span></span>
</td>
<td class="num">$ (232,884)<span></span>
</td>
<td class="num">$ (241,378)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398447216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1,043,991<span></span>
</td>
<td class="num">$ (270)<span></span>
</td>
<td class="num">$ (762,754)<span></span>
</td>
<td class="nump">$ 280,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">72,513,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,947)<span></span>
</td>
<td class="num">(172,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">451,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">252,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="num">(95,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Mar. 31, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,063,672<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="num">(935,701)<span></span>
</td>
<td class="nump">127,671<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Mar. 31, 2021</a></td>
<td class="nump">73,122,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,043,991<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(762,754)<span></span>
</td>
<td class="nump">280,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">72,513,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(241,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,135,155<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(1,004,129)<span></span>
</td>
<td class="nump">130,760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2021</a></td>
<td class="nump">76,583,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Mar. 31, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,063,672<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="num">(935,701)<span></span>
</td>
<td class="nump">127,671<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Mar. 31, 2021</a></td>
<td class="nump">73,122,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,900)<span></span>
</td>
<td class="num">(29,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">686,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">9,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences"), net of issuance costs (in shares)</a></td>
<td class="nump">2,491,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the ESPP (in shares)</a></td>
<td class="nump">154,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Jun. 30, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,122,081<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">(965,601)<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Jun. 30, 2021</a></td>
<td class="nump">76,464,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,528)<span></span>
</td>
<td class="num">(38,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">116,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,135,155<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(1,004,129)<span></span>
</td>
<td class="nump">130,760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2021</a></td>
<td class="nump">76,583,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,147,843<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(1,049,854)<span></span>
</td>
<td class="nump">$ 97,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">76,930,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,930,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,084)<span></span>
</td>
<td class="num">$ (96,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">102,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">491,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="num">(185,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Mar. 31, 2022</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,158,766<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="num">(1,145,938)<span></span>
</td>
<td class="nump">12,563<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Mar. 31, 2022</a></td>
<td class="nump">77,338,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,147,843<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(1,049,854)<span></span>
</td>
<td class="nump">$ 97,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">76,930,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,930,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (232,884)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2022</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,185,868<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(1,282,738)<span></span>
</td>
<td class="num">$ (97,133)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2022</a></td>
<td class="nump">77,770,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,770,593<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Mar. 31, 2022</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,158,766<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="num">(1,145,938)<span></span>
</td>
<td class="nump">$ 12,563<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Mar. 31, 2022</a></td>
<td class="nump">77,338,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,150)<span></span>
</td>
<td class="num">(50,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">4,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">173,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the ESPP (in shares)</a></td>
<td class="nump">244,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="num">(58,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Jun. 30, 2022</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">1,173,722<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(1,196,088)<span></span>
</td>
<td class="num">(22,629)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Jun. 30, 2022</a></td>
<td class="nump">77,702,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,650)<span></span>
</td>
<td class="num">(86,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">6,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="nump">93,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="num">(32,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Sep. 30, 2022</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1,185,868<span></span>
</td>
<td class="num">$ (270)<span></span>
</td>
<td class="num">$ (1,282,738)<span></span>
</td>
<td class="num">$ (97,133)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Sep. 30, 2022</a></td>
<td class="nump">77,770,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,770,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401901520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (232,884,000)<span></span>
</td>
<td class="num">$ (241,375,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,649,000<span></span>
</td>
<td class="nump">2,618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">39,011,000<span></span>
</td>
<td class="nump">40,418,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Write-off of prepaid manufacturing services related to the termination of CHS-2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs of inventory</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="nump">5,192,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense from amortization of debt discount &amp; issuance costs</a></td>
<td class="nump">5,631,000<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements', window );">Upfront and option payments to Junshi Biosciences</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">136,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">6,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OtherNoncashAdjustments', window );">Other non-cash adjustments, net</a></td>
<td class="nump">1,844,000<span></span>
</td>
<td class="nump">2,708,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Trade receivables, net</a></td>
<td class="nump">31,849,000<span></span>
</td>
<td class="nump">20,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(37,556,000)<span></span>
</td>
<td class="nump">2,936,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid manufacturing</a></td>
<td class="num">(6,967,000)<span></span>
</td>
<td class="num">(2,884,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other prepaid, current and non-current assets</a></td>
<td class="num">(12,509,000)<span></span>
</td>
<td class="num">(4,590,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(6,149,000)<span></span>
</td>
<td class="nump">30,495,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve', window );">Accrued rebates, fees and reserves</a></td>
<td class="num">(25,006,000)<span></span>
</td>
<td class="nump">3,215,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_IncreaseDecreaseInAccruedCompensation', window );">Accrued compensation</a></td>
<td class="num">(623,000)<span></span>
</td>
<td class="num">(3,451,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current and non-current liabilities</a></td>
<td class="nump">32,317,000<span></span>
</td>
<td class="nump">16,526,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(141,171,000)<span></span>
</td>
<td class="nump">14,890,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,952,000)<span></span>
</td>
<td class="num">(821,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,779,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities', window );">Upfront and option payments to Junshi Biosciences</a></td>
<td class="num">(35,000,000)<span></span>
</td>
<td class="num">(136,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(36,952,000)<span></span>
</td>
<td class="num">(245,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</a></td>
<td class="nump">240,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,903,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">631,000<span></span>
</td>
<td class="nump">9,726,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from purchase under the employee stock purchase plan</a></td>
<td class="nump">1,655,000<span></span>
</td>
<td class="nump">1,985,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="num">(3,621,000)<span></span>
</td>
<td class="num">(1,730,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2022 Convertible Notes and premiums</a></td>
<td class="num">(109,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of 2025 Term Loan, premiums and exit fees</a></td>
<td class="num">(81,750,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(861,000)<span></span>
</td>
<td class="num">(492,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">47,733,000<span></span>
</td>
<td class="nump">50,392,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(130,390,000)<span></span>
</td>
<td class="num">(180,618,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">417,635,000<span></span>
</td>
<td class="nump">541,598,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 287,245,000<span></span>
</td>
<td class="nump">$ 360,980,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued rebates, fees and reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OtherNoncashAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents other noncash adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OtherNoncashAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents upfront and milestone based license fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront license fee payment related to license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402965040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Coherus BioSciences,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Coherus&#8221;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and commercialization of its portfolio of United States Food and Drug Administration (&#8220;FDA&#8221;)-approved biosimilars. The Company&#8217;s strategy is to develop and commercialize innovative cancer treatments funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA <span style="background:#ffffff;">(pegfilgrastim-cbqv)</span>, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. The FDA approved YUSIMRY&#8482; <span style="background:#ffffff;">(adalimumab-aqvh) </span>in December 2021, which the Company plans to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie Inc. (&#8220;AbbVie&#8221;). On August 2, 2022, the FDA approved CIMERLI&#8482; <span style="background:#ffffff;">(ranibizumab-eqrn)</span>, a Lucentis biosimilar, and commercial launch commenced on October 3, 2022 in the United States.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company&#8217;s product pipeline comprises&#160;the following three product candidates: toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly-owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. In May 2022, the Company discontinued development of its bevacizumab (Avastin) biosimilar product candidate from Innovent Biologics (Suzhou) Co., Ltd. (&#8220;Innovent&#8221;). In October 2022, the Company discontinued development of its preclinical immuno-oncology program, CHS-3318, an antibody targeting CCR8, in order to focus on external molecules targeting CCR8.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals, that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with U.S.&#160;GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full&#160;year or any subsequent interim period.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;) filed with the SEC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 286,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,540</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 287,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,980</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Investments in marketable securities primarily consist of corporate debt obligations and commercial paper. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limit its exposure to any single issuer. All investments in debt marketable securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. There were no investments in marketable securities as of September 30, 2022 or December 31, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses on available-for-sale securities are included in other income, net, based on the specific identification method.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2022 and December 31, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><span style="font-weight:normal;">The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401700624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company recorded net revenue of $45.4 million and $165.7 million during the three and nine months ended September 30, 2022, respectively, and $82.5 million and $253.2 million during the three and nine months ended September 30, 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Gross revenues by significant customer as a percentage of total gross revenues are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5203018%;padding-left:0pt;padding-right:0pt;width:101.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">AmeriSource-Bergen Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Sales Discounts and Allowances</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 109,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 321,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426,962</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (181)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,300)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (320,022)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,869)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,829)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (446,720)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,665</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,398</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 356,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520,917</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,859)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,715)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (362,241)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,716)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (516,557)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119,043</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities in the accompanying unaudited condensed consolidated balance sheets.</span> </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386509077408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The fair values of financial instruments are classified into one of the following categories:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Where quoted prices are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds that are included in cash and cash equivalents, and restricted cash.</span> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286,805</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287,245</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,165</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,605</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400724160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,870</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,117</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,265</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,252</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During the third quarter of 2022 and 2021, the Company recorded write-downs of inventory of $26.0 million and $5.2 million, respectively, in cost of goods sold in the condensed consolidated statements of operations. The write-down during the third quarter of 2022 was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration, which increased net loss by $26.0 million and basic and diluted net loss per share by $0.33 and $0.34 per share for the three- and nine-month periods ended September 30, 2022, respectively. The inventory write-down during the third quarter of 2021 was for inventory that did not meet acceptance criteria. Inventory reserves were $26.0 million&#160;and $0.2 million as of September 30, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company began capitalizing YUSIMRY inventory in the second quarter of 2022 and had $24.6 million of such inventory recognized on the condensed consolidated balance sheets at September 30, 2022. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current on the condensed consolidated balance sheets. As of September 30, 2022 and December 31, 2021, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following tables presents the inventory balance sheet classifications:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,642</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,610</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,252</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Prepaid manufacturing of $20.6 million as of September 30, 2022 includes prepayments of $16.6 million to contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing services for our products, which the Company expects to be converted into inventory within the next twelve months; and prepayments of $4.0 million to various CMOs for research </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">and development pipeline programs. Prepaid manufacturing of $13.7 million as of December 31, 2021 included prepayments of $8.3 million to a CMO for manufacturing services for UDENYCA; and prepayments of $5.4 million to various CMOs for research and development pipeline programs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea&#174; as part of a realignment of research and development resources toward other development programs. As a result, during the quarter ended March 31, 2021, the Company recognized $11.5 million within research and development expenses on its condensed consolidated statement of operations, which included an impairment charge of $3.2 million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. No material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386486254736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Balance Sheet Components</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,876</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,033</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,129</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,942</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,294</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 388</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,662</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (19,319)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (16,849)</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,813</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;">Depreciation and amortization expense was $0.9 million and $2.6 million&#160;for the three and nine months ended September 30, 2022, respectively, and $0.9 million and $2.6 million for the three and nine months ended September 30, 2021, respectively.<span style="color:#ff0000;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Current Liabilities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,541</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued co-development costs payable to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,926</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,492</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,168</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,127</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400721728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaborations and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Collaborations and Other Arrangements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Junshi Biosciences </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the &#8220;Collaboration Agreement&#8221;) with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#8217; anti-PD-1 antibody, in the United States and Canada. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the terms of the Collaboration Agreement, the Company paid&#160;$150.0 million&#160;upfront for exclusive rights to toripalimab in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of toripalimab in the United States and Canada. The Company will be obligated to pay Junshi Biosciences a 20% royalty on net sales of toripalimab and up to an aggregate&#160;$380.0 million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. The Company will lead further development of CHS-006 and will be responsible for the associated development costs as set forth in the Collaboration Agreement. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay an additional option exercise fee of&#160;$35.0 million. Additionally, for each exercised option, the Company will be obligated to pay Junshi Biosciences an 18% royalty on net sales, up to $85.0 million&#160;for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of toripalimab and the other licensed compounds, including CHS-006, and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for toripalimab and other licensed compounds and will reimburse Junshi Biosciences for such costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $7.6 million in the third quarter of 2022 and $67.6 million in the nine months ended September 30, 2022, inclusive of the $35.0 million option fee incurred in the first quarter, and $15.4 million and $173.6 million for the three and nine months ended September 30, 2021, respectively. The first quarter of 2021 included $145.0 million for the upfront payment for the exclusive rights to toripalimab and the second quarter of 2021 included a credit of $9.0 million for the discount for lack of marketability (&#8220;DLOM&#8221;), discussed below. Accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022 included $17.5 million related to the co-development, regulatory and technology transfer costs related to these programs. The Company entered into a right of first negotiation agreement with Junshi Biosciences and paid a fee of $5.0 million which was fully expensed as research and development expense in the fourth quarter of 2020. The right of first negotiation fee was fully credited against the total upfront license fee obligation under the Collaboration Agreement. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Junshi Biosciences. The additional milestone payments, option fee for the IL-2 cytokine&#160;and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued 2,491,988 unregistered shares of its common stock to Junshi Biosciences, at a price per share of $20.06, for an aggregate value of $50.0 million cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences is not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the&#160;two-year period </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#8220;Finnerty&#8221; and &#8220;Asian put&#8221; valuation models and determined the fair value for the DLOM was $9.0 million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the condensed consolidated statement of operations for the three months ending June 30, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Innovent&#160;Biologics (Suzhou) Co., Ltd. </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:8.2pt;"/>On January&#160;13, 2020, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) with Innovent for the development and commercialization of a biosimilar version of bevacizumab (Avastin) in any dosage form and presentations (&#8220;bevacizumab Licensed Product&#8221;) in the United States and Canada (the &#8220;Territory&#8221;). Under the License Agreement, Innovent granted to the Company an exclusive, royalty-bearing license to develop and commercialize the bevacizumab Licensed Product in the field of treatment, prevention or amelioration of any human diseases and conditions as included in the label of Avastin. Under the License Agreement, the Company also acquired an option to develop and commercialize Innovent&#8217;s biosimilar version of rituximab (Rituxan&#174;) in any dosage form and presentations (the &#8220;rituximab Licensed Product&#8221; and together with the bevacizumab Licensed Product, the &#8220;Innovent Licensed Products&#8221;) in the Territory.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the License Agreement, the Company committed to pay Innovent a $5.0 million upfront payment and an aggregate of up to $40.0&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the bevacizumab Licensed Product and, if the Company&#8217;s option was exercised, an aggregate of up to $40.0&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the rituximab Licensed Product. The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. During the three and nine months ended September 30, 2022, the Company&#8217;s research and development expense related to bevacizumab Licensed Product development activities directly with Innovent was immaterial. <span style="background:#ffffff;">During the three and nine months ended September 30, 2021, the Company recognized research and development expense of </span><span style="background:#ffffff;">$0.5</span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$1.2</span><span style="background:#ffffff;">&#160;million, respectively, related to bevacizumab Licensed Product development activities directly with Innovent. </span>As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Innovent.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On May 3, 2022, the Company provided notice of termination of the License Agreement to Innovent pursuant to Section 13.6 of the License Agreement. In connection therewith, the Company has discontinued development of the bevacizumab Licensed Product.<span style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Bioeq</b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;">On November&#160;4, 2019, the Company entered into a license agreement with Bioeq AG (&#8220;Bioeq&#8221;) (the &#8220;Bioeq License Agreement&#8221;) for the commercialization of CIMERLI, a biosimilar version of ranibizumab (Lucentis), in certain dosage forms in both a vial and pre-filled syringe presentation (the &#8220;Bioeq Licensed Products&#8221;). Under the Bioeq License Agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. The Bioeq License Agreement&#8217;s initial term continues in effect for ten years&#160;after the first commercial sale of a Bioeq Licensed Product in the United States which occurred on October 3, 2022 and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq License Agreement and a manufacturing and supply agreement between the Company and Bioeq dated as of September 29, 2022 (the &#8220;Bioeq Manufacturing Agreement&#8221;) and will remain in force until the first to occur of the following: (1) the termination of the Bioeq License Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Under the Bioeq License Agreement, the Company must use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company must commit certain post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;">The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#8364;10&#160;million ($11.1&#160;million), which was recorded as research and development expense in the Company&#8217;s consolidated statement of operations in 2019. The terms of the Bioeq License Agreement include an aggregate of up to &#8364;12.5&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#8364;2.5 million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA which occurred on August 2, 2022 and certain other criteria which were satisfied in October 2022. The obligation to pay this milestone was recorded in accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022. The Company will share a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low to mid&#160;fifty&#160;percent range. The remaining milestone payments and royalties are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved or when royalties are incurred.  </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400756576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt Obligations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 9pt 0pt;">A summary of the Company&#8217;s debt obligations, including level within the fair value hierarchy (see Note 3), is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Exit Fee, Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (5,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 3</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025 Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month LIBOR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2027 Term Loans </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company entered into a loan agreement (including as subsequently amended, the &#8220;Loan Agreement&#8221;) with BioPharma Credit, PLC, (as the &#8220;Collateral Agent&#8221;), BPCR Limited Partnership (as a &#8220;Lender&#8221;), and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#8220;Lender&#8221;) that provides for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $100.0 million (the &#8220;Tranche A Loan&#8221;) that was funded on January 5, 2022 (the &#8220;Tranche A Closing Date&#8221;); (ii) a Tranche B Loan in an aggregate principal amount of $100.0 million (the &#8220;Tranche B Loan&#8221;) that was funded on March 31, 2022; (iii) a Tranche C Loan in an aggregate principal amount of $50.0 </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">million (the &#8220;Tranche C Loan&#8221;) to be funded at the Company&#8217;s option between April 1, 2022 and March 17, 2023, subject to certain conditions including the first FDA approval of a BLA for the Company&#8217;s product candidate toripalimab in the United States; and (iv) a Tranche D Loan in an aggregate principal amount of $50.0 million that was funded on September 14, 2022 (the &#8220;Tranche D Loan&#8221; and, together with the Tranche A Loan, the Tranche B Loan, and the Tranche C Loan, the &#8220;2027 Term Loans&#8221;). The Company has the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#8217;s 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans bear interest at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; the interest rate for the third quarter of 2022 was 10.54% for Tranches A and B and 11.73% for Tranche D. In the event of the cessation of LIBOR, the benchmark governing the interest rate will be replaced with a rate based on the secured overnight financing rate published by the Federal Reserve Bank of New York as described in the Loan Agreement. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#8217;s tangible and intangible assets and property, including intellectual property.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were and will be used to fund the Company&#8217;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the Company&#8217;s $75.0 million aggregate principal credit agreement with affiliates of Healthcare Royalty Partners (the &#8220;2025 Term Loan&#8221;), as well as all associated costs and expenses pursuant to which a payoff amount of $81.9&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the Company&#8217;s $100.0 million aggregate principal amount 8.2% Convertible Senior Notes (the&#160;&#8220;2022 Convertible Notes&#8221;), as well as all associated costs and expenses pursuant to which a payoff amount of $111.1 million was outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes affirmative covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that begins at $200.0&#160;million for the quarter ending March 31, 2022, increases to $210.0&#160;million for the quarter ended March 31, 2024, increases to $230.0 million for the quarter ending June 30, 2024, increases to $270.0 million for the quarter ending September 30, 2024, and increases to $300.0&#160;million for the quarter ended December 31, 2024 and thereafter. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, <span style="background:#ffffff;">make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#8217;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#8217;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;</span><span style="-sec-ix-hidden:Hidden_zhRAFkTaEkWJkydvNPJsWQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">&#160;business days.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of Tranche A, the Company incurred $7.8 million&#160;in debt discounts and issuance costs<span style="color:#ff0000;"> </span>of which $6.8 million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $2.3 million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. Until unfunded tranches are drawn, the associated debt discounts and issuance costs are deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $1.0 million and $0.5 million, respectively,&#160;in debt issuance costs. As of September 30, 2022, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $4.8 million will be amortized using the effective interest rate over the remaining term of 4.3 years. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2027 Term Loans:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,577</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,122</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,699</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2027 Term Loans as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,887</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,327</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,402</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,327</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269,151</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358,094</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,094)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,754)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,246</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.5%</b><b style="font-weight:bold;"> Convertible Senior Subordinated Notes due 2026</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company issued and sold $230.0 million aggregate principal amount of its 1.5% Convertible Senior Subordinated notes due 2026 (the &#8220;2026 Convertible Notes&#8221;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were $222.2 million after deducting initial purchasers&#8217; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#8217;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and <span style="background:#ffffff;">structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables</span>. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020, and will mature on April 15, 2026, unless earlier repurchased or converted.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#8217;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. Since inception, </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.815 per share of the Company&#8217;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#8220;make-whole fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#8217;s election before maturity. If a &#8220;fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The 2026 Convertible Notes have customary provisions relating to the occurrence of &#8220;events of default&#8221; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the features embedded in the 2026 Convertible Notes&#160;under the relevant accounting rules and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability on the condensed consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capped Call Transactions</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with the pricing of the 2026 Convertible Notes, the Company paid $18.2 million to enter into privately negotiated capped call transactions with one or a combination of the initial purchasers, their respective affiliates and other financial institutions (the &#8220;option counterparties&#8221;). The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been $25.9263 per share, which represents a premium of approximately 75.0% over the last reported sale price of the Company&#8217;s common stock of $14.815 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and classified as equity instruments; thus, they are recorded as a reduction to additional paid-in capital on the condensed consolidated balance sheets. The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">If the 2026 Convertible Notes were converted on September 30, 2022, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $114.8 million based on the Company&#8217;s closing stock price of $9.61.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:9pt 0pt 0pt 0pt;">The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the effective interest rate method. The remaining unamortized debt discount and debt offering costs related to the Company&#8217;s 2026 Convertible Notes&#160;of <span style="-sec-ix-hidden:Hidden_mJKNNF_1akSrcLTArm_qlw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.7</span></span> million as of September 30, 2022, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;">The following table presents the components of interest expense related to 2026 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,587</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,529</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,800</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,800)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,750)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,250</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.2% Convertible Notes due 2022 </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">On February&#160;29, 2016, the Company issued and sold $100.0 million aggregate principal amount of its 8.2% Convertible Senior Notes. The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company. The 2022 Convertible Notes&#160;bore interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March&#160;31, June&#160;30, September&#160;30 and December&#160;31 of each&#160;year, since March&#160;31, 2016, and matured on March&#160;31, 2022. The 2022 Convertible Notes&#160;also had a premium of 9% of the principal amount which was payable when the 2022 Convertible Notes&#160;matured or were repurchased or redeemed by the Company.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Company fully repaid the 2022 Convertible Notes, and a<span style="background:#ffffff;">s a result had </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> continuing obligations associated with them thereafter</span>. The payoff amount of $111.1 million included the repayment of the entire outstanding principal amount, the 9% premium of the outstanding principal amount and accrued and unpaid interest. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2022 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,150</p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,457</p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,607</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">2025 Term Loan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">On January&#160;7, 2019, the Company entered into a credit agreement with affiliates of Healthcare Royalty Partners. The 2025 Term Loan consisted of a six-year term loan facility for an aggregate principal amount of $75.0 million (the &#8220;Borrowings&#8221;). Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at&#160;6.75%&#160;per annum plus three-month LIBOR. Interest was payable quarterly in arrears.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on the </span>third anniversary of the 2025 Term Loan Closing Date, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $81.9 million included principal repayment in full, accrued interest, a 5.0% prepayment premium fee of the Borrowings principal amount, and an exit fee of 4.0% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the payoff of the 2025 Term Loan totaled $6.2 million and was recorded in loss on debt extinguishment in the condensed consolidated statement of operations for the nine months ended September 30, 2022. As of September 30, 2022, the Company had no continuing obligations associated with the 2025 Term Loan.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2025 Term Loan: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,261</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 751</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,012</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#00ff00;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400692240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Purchase Commitments   </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of September 30, 2022, the Company&#8217;s contractual obligations under the terms of the agreements are as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Years ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Remainder of 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,448</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,740</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 911</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 911</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,218</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are generally cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Guarantees and Indemnifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Legal Proceedings and Other Claims</b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">The Company is a party to various legal proceedings and other claims that arise in the ordinary, routine course of business and that have not been fully resolved. The most significant of these are described below. The outcome of such legal proceedings and other claims is inherently uncertain. Accruals are recognized for such legal proceedings and other claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. The Company did not have any accruals related to such matters on the condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#8220;Zinc&#8221;) asserting Zinc was entitled to approximately $14 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company is unable to reasonably estimate the amount or range of loss that may be incurred, if any, in connection with this matter. At this time, the Company has not made an accrual in connection with this matter.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Other than the matter in connection with the demand letter described in this Note 8, there are no material pending legal proceedings or other claims, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries&#8217; property is subject.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400612720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the classification of stock-based compensation expense in the Company&#8217;s condensed consolidated statements of operations related to options and restricted stock units granted to employees and nonemployees:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,642</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,880</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,418</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:6pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400810352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;Net Loss Per Share</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,535,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,543,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,267,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,847,917</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,305,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,401,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,812,799</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,783,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,875,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,052,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,076,739</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400692240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;Related Party Transactions</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consulting services</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board of Directors. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 (See Note 6). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase 65,000 shares of common stock with an exercise price of $17.60 per share to Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences. During the first quarter of 2021, the Company recognized non-cash </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stock-based compensation expense of $0.8 million and consulting service expense of $0.2 million related to these services. There have been no subsequent material related party expenses. Total liabilities recognized on the condensed consolidated balance sheets with respect to these services were immaterial as of September 30, 2022 and December 31, 2021. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400060656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals, that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with U.S.&#160;GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full&#160;year or any subsequent interim period.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;) filed with the SEC.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 286,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,540</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 287,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,980</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">Investments in marketable securities primarily consist of corporate debt obligations and commercial paper. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limit its exposure to any single issuer. All investments in debt marketable securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. There were no investments in marketable securities as of September 30, 2022 or December 31, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses on available-for-sale securities are included in other income, net, based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Receivables</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2022 and December 31, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><span style="font-weight:normal;">The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400812832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 286,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,540</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 287,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 360,980</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400683008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Gross revenues by significant customer as a percentage of total gross revenues are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5203018%;padding-left:0pt;padding-right:0pt;width:101.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">AmeriSource-Bergen Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock', window );">Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 109,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 321,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426,962</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,064)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (181)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,300)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (320,022)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,869)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,829)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (446,720)</p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,665</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,398</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 356,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520,917</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,859)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,715)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (362,241)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,716)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (516,557)</p></td></tr><tr><td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119,043</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of product sales discounts and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400692240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286,805</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287,245</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,165</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash (money market funds)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,605</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400714768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfInventoryTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,870</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,117</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,265</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,252</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock', window );">Schedule of Balance Sheet Classification</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,642</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,610</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,252</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balance sheet classification of Inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400743344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,876</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,033</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,129</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,942</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,294</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 388</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,662</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (19,319)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (16,849)</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,813</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,541</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued co-development costs payable to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,926</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,492</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,168</p></td></tr><tr><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,127</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401870832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of the Company's Debt Obligations</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 9pt 0pt;">A summary of the Company&#8217;s debt obligations, including level within the fair value hierarchy (see Note 3), is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unamortized Exit Fee, Debt Discount and Debt Issuance Costs</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (5,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 3</p></td></tr><tr><td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025 Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Level 2*</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month LIBOR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2027 Term Loans:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,577</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,122</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,699</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Payments on Debt</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2027 Term Loans as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,887</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,327</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,402</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,327</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269,151</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358,094</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,094)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,754)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,246</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;">The following table presents the components of interest expense related to 2026 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,587</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 942</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,529</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Payments on Debt</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of September 30, 2022 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remainder of 2022 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2023 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,800</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,800)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,750)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,250</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2022 Convertible Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,150</p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,457</p></td></tr><tr><td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,607</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 6pt 0pt;">The following table presents the components of interest expense related to the 2025 Term Loan: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,261</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 751</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,012</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400763872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentTextBlock', window );">Schedule of Non-cancelable Contractual Obligations</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Years ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Remainder of 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,448</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,740</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 911</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 911</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,218</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401856816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember', window );">Employee And Nonemployee Stock Option Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 896</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,642</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,880</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,418</p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:6pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386400710640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,535,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,543,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,267,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,847,917</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,305,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,401,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,812,799</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,442,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td></tr><tr><td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,783,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,875,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,052,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,076,739</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386403237088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Organization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProductPipelineNumberOfDrugCandidates', window );">Product pipeline, number of product candidates | product</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Investments in marketable securities | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProductPipelineNumberOfDrugCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of drug candidates in the product pipeline.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProductPipelineNumberOfDrugCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402874656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 286,805<span></span>
</td>
<td class="nump">$ 417,195<span></span>
</td>
<td class="nump">$ 360,540<span></span>
</td>
<td class="nump">$ 541,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 287,245<span></span>
</td>
<td class="nump">$ 417,635<span></span>
</td>
<td class="nump">$ 360,980<span></span>
</td>
<td class="nump">$ 541,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386393201024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 45,424<span></span>
</td>
<td class="nump">$ 82,503<span></span>
</td>
<td class="nump">$ 165,690<span></span>
</td>
<td class="nump">$ 253,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402982048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) - Net Product Revenue - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">McKesson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">AmeriSource-Bergen Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Cardinal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_McKessonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_McKessonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_AmeriSourceBergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_AmeriSourceBergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_CardinalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_CardinalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386395239808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">$ 109,723<span></span>
</td>
<td class="nump">$ 123,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">426,962<span></span>
</td>
<td class="nump">520,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period</a></td>
<td class="num">(7,300)<span></span>
</td>
<td class="num">(8,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(446,720)<span></span>
</td>
<td class="num">(516,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">82,665<span></span>
</td>
<td class="nump">119,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">29,665<span></span>
</td>
<td class="nump">40,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">321,056<span></span>
</td>
<td class="nump">356,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period</a></td>
<td class="num">(2,055)<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(320,022)<span></span>
</td>
<td class="num">(362,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">28,644<span></span>
</td>
<td class="nump">32,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">54,004<span></span>
</td>
<td class="nump">54,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">50,939<span></span>
</td>
<td class="nump">90,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period</a></td>
<td class="num">(5,064)<span></span>
</td>
<td class="num">(2,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(64,869)<span></span>
</td>
<td class="num">(78,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">35,010<span></span>
</td>
<td class="nump">63,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember', window );">Other Fees, Co-pay Assistance and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">26,054<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">54,967<span></span>
</td>
<td class="nump">73,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(3,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(61,829)<span></span>
</td>
<td class="num">(75,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">$ 19,011<span></span>
</td>
<td class="nump">$ 23,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProvisionRelatedToSalesMadeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProvisionRelatedToSalesMadeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents provision related to sales made in prior period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProvisionRelatedToSalesMadeInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve for discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve for sales discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386395129232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value Measurements Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 287,245<span></span>
</td>
<td class="nump">$ 417,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">287,245<span></span>
</td>
<td class="nump">417,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and cash equivalents (money market funds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">286,805<span></span>
</td>
<td class="nump">417,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and cash equivalents (money market funds) | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">286,805<span></span>
</td>
<td class="nump">417,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and cash equivalents (money market funds) | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and cash equivalents (money market funds) | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Restricted Cash (Money Market Funds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Restricted Cash (Money Market Funds) | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Restricted Cash (Money Market Funds) | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Restricted Cash (Money Market Funds) | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=chrs_RestrictedCashMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=chrs_RestrictedCashMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398282576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401869376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 10,432<span></span>
</td>
<td class="nump">$ 4,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">77,296<span></span>
</td>
<td class="nump">65,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">17,429<span></span>
</td>
<td class="nump">23,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 105,157<span></span>
</td>
<td class="nump">$ 93,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401658048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Balance Sheet Classifications (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 27,719<span></span>
</td>
<td class="nump">$ 37,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">77,438<span></span>
</td>
<td class="nump">55,610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_InventoryCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 105,157<span></span>
</td>
<td class="nump">$ 93,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_InventoryCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_InventoryCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398157728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs of inventory</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,192,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EstimatedIncreaseDecreaseInNetIncomeLoss', window );">Estimate increased the net loss, amount</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted', window );">Estimated net loss per share (basic and diluted)</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaidManufacturingExpenseCurrent', window );">Prepayment made for manufacturing services</a></td>
<td class="nump">20,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,633,000<span></span>
</td>
<td class="nump">13,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, non-current</a></td>
<td class="nump">9,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,627,000<span></span>
</td>
<td class="nump">10,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">27,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,719,000<span></span>
</td>
<td class="nump">37,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Impairment charge within research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">45,808,000<span></span>
</td>
<td class="nump">$ 54,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaymentsMadeToCmoForManufacturingServices', window );">Prepayments made to a CMO for manufacturing services for UDENYCA</a></td>
<td class="nump">16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,600,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram', window );">Prepayments made to a CMO For Other Research And Development Pipeline Program</a></td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=chrs_YusimryProductMember', window );">Yusimry Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member', window );">CHS-2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EstimatedIncreaseDecreaseInNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated increase in the net income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EstimatedIncreaseDecreaseInNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated increase (decrease) in the net income (loss) per share (basic and diluted).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaymentsMadeToCmoForManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents prepayments made to a CMO for manufacturing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaymentsMadeToCmoForManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents prepayments made to a CMO for other research and development program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_YusimryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_YusimryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386393274304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 28,890<span></span>
</td>
<td class="nump">$ 24,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(19,319)<span></span>
</td>
<td class="num">(16,849)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">9,571<span></span>
</td>
<td class="nump">7,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">12,878<span></span>
</td>
<td class="nump">11,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Finance lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">4,721<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386403008640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,649<span></span>
</td>
<td class="nump">$ 2,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401843600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent', window );">Accrued commercial and research and development manufacturing</a></td>
<td class="nump">$ 51,523<span></span>
</td>
<td class="nump">$ 30,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences', window );">Accrued co-development costs payable to Junshi Biosciences</a></td>
<td class="nump">17,544<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LeaseLiabilitiesOperatingAndFinancing', window );">Lease liabilities, current</a></td>
<td class="nump">4,097<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">12,826<span></span>
</td>
<td class="nump">12,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued and other current liabilities</a></td>
<td class="nump">$ 85,990<span></span>
</td>
<td class="nump">$ 48,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent to pertaining accrued co-development costs payable to Junshi Biosciences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued commercial and research and development manufacturing liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LeaseLiabilitiesOperatingAndFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents lease liabilities for both operating and financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LeaseLiabilitiesOperatingAndFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386392142272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,336<span></span>
</td>
<td class="nump">$ 312,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram', window );">License Agreement Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfGrossProfitsOnSales', window );">Percentage of gross profits shared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG | Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Maximum aggregate milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval', window );">Additional milestone payments related to FDA approval | &#8364;</a></td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePayment', window );">Upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember', window );">Innovent Biologics (Suzhou) Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember', window );">Innovent Biologics (Suzhou) Co., Ltd. | Bevacizumab Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember', window );">Innovent Biologics (Suzhou) Co., Ltd. | Rituxan option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram', window );">License Agreement Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember', window );">Collaboration Agreement | Anti-TIGIT Antibody and IL-2 cytokine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram', window );">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember', window );">Collaboration Agreement | Research and Development Expense | Anti-TIGIT Antibody and IL-2 cytokine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MaximumAmountPaidCoDevelopmentActivities', window );">Maximum paid amount for co-development activities (per licensed compound)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,600<span></span>
</td>
<td class="nump">$ 173,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates', window );">Undisclosed preclinical | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram', window );">Collaboration agreement, royalty on net sales for each exercised option, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram', window );">Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssued', window );">Unregistered shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,491,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock', window );">Period before the company can sell, transfer or make any short sale of common stock (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_FairValueForDiscountForLackOfMarketability', window );">Fair value for the discount for lack of marketability (DLOM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts', window );">Co-development, regulatory and technology transfer costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Toripalimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales', window );">Collaboration agreement, royalty on net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementThresholdRoyaltyPayments', window );">Collaboration agreement, threshold royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Research and Development Expense | Toripalimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments upon achievement of certain development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments upon achievement of with subject to FDA approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents co-development, regulatory and technology transfer costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of option exercise fee per program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementOptionExerciseFeePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty on net sales under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty on net sales for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementThresholdRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold royalty payments to be made under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementThresholdRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents costs associated to a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_FairValueForDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value for the discount for lack of marketability (DLOM).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_FairValueForDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MaximumAmountPaidCoDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum paid amount for co-development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MaximumAmountPaidCoDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfGrossProfitsOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>percentage of profit shared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfGrossProfitsOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period before the company can sell, transfer or make any short sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockPurchaseAgreementSharesAgreedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_BevacizumabLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_BevacizumabLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_OptionExerciseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_OptionExerciseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_ToripalimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_ToripalimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398247280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - Summary of Debt Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">(4,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">245,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">245,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">(4,750)<span></span>
</td>
<td class="num">(5,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">225,250<span></span>
</td>
<td class="nump">224,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">175,950<span></span>
</td>
<td class="nump">271,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386391739568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loan - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th">
<div>Jan. 05, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal', window );">Quarterly payments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodOne', window );">Loan agreement covenants, minimum trailing twelve month net sales for current quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodTwo', window );">Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodThree', window );">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodFour', window );">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodFive', window );">Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MandatoryPrepaymentTerm', window );">Mandatory prepayment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC | Three-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Additional facility amount | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember', window );">Tranche A Loan, funded January 5, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember', window );">Tranche B Loan, funded no later than April 1, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Convertible notes, Issuance Cost</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember', window );">Tranche C Loan, funded between April 1, 2022 and March 17, 2023 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember', window );">Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Convertible notes, Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember', window );">Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC | Three-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | BioPharma Credit Investments V GP LLC | Scenario, Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="nump">111,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaAndBLoansMember', window );">Tranche A and B Loans | BioPharma Credit Investments V GP LLC | Three-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember', window );">Tranches A, B and D | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentRemainingTerm', window );">Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtDiscountsAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt discounts and issuance costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtDiscountsAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equal quarterly payments of principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of committed tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to debt instrument remaining term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MandatoryPrepaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mandatory prepayment, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MandatoryPrepaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaAndBLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheaAndBLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386496669088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loans Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="nump">$ 5,665<span></span>
</td>
<td class="nump">12,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="nump">$ 6,287<span></span>
</td>
<td class="nump">$ 16,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386395038736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loan Future Payments (Details) - 2027 Term Loans - BioPharma Credit Investments V GP LLC<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022 - interest only</a></td>
<td class="nump">$ 6,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023 - interest only</a></td>
<td class="nump">27,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024 - interest only</a></td>
<td class="nump">27,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025 - interest only</a></td>
<td class="nump">27,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">269,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">358,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less amount representing interest</a></td>
<td class="num">(108,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_TermLoanGross', window );">Term Loan, gross</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less unamortized debt discount and debt issuance costs, net</a></td>
<td class="num">(4,754)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount of Term Loans</a></td>
<td class="nump">$ 245,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_TermLoanGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_TermLoanGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386392020720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="nump">$ 14.815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NumberOfEventsInDefault', window );">Number of events in default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentContractualTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from offering</a></td>
<td class="nump">$ 222,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes', window );">Initial conversion rate, shares of common stock</a></td>
<td class="nump">51.9224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate', window );">Principal amount of notes converted into shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EquivalentToConversionPricePerCommonShare', window );">Initial conversion price per common share</a></td>
<td class="nump">$ 19.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Apr. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfPremiumOnConvertibleNote', window );">Convertible notes, premium percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Convertible notes, covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 1.5% Convertible Senior Subordinated Notes due 2026 | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes, converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to debt instrument contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible number of shares per thousand of principal amount of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EquivalentToConversionPricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equivalent to conversion price per common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EquivalentToConversionPricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NumberOfEventsInDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of events in default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NumberOfEventsInDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfPremiumOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium on convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfPremiumOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount of notes converted into shares of common stock at conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398234208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Capped Call Transactions - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="nump">$ 14.815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember', window );">Capped Call Transactions in connection with the 2026 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentForCappedCallTransactions', window );">Payment for capped call transactions</a></td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CapPriceOfCapCallTransactions', window );">Initial cap price of capped call transactions.</a></td>
<td class="nump">$ 25.9263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfCapPriceCappedCallTransactions', window );">Percentage of cap price</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CapPriceOfCapCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cap price of the cap call transactions (per share).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CapPriceOfCapCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment made for entering into capped call transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfCapPriceCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of premium on cap price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfCapPriceCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386496673696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="nump">$ 1,185<span></span>
</td>
<td class="nump">$ 1,178<span></span>
</td>
<td class="nump">$ 3,550<span></span>
</td>
<td class="nump">$ 3,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398341712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - 2026 Convertible Notes Future Payments (Details) - Convertible Notes - 1.5% Convertible Senior Subordinated Notes due 2026<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022 - interest only</a></td>
<td class="nump">$ 1,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023 - interest only</a></td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024 - interest only</a></td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025 - interest only</a></td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">231,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">243,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less amount representing interest</a></td>
<td class="num">(13,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ConvertibleNotesPrincipalAmount', window );">2026 Convertible Notes, principal amount</a></td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less unamortized debt discount and debt issuance costs</a></td>
<td class="num">(4,750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount of Term Loans</a></td>
<td class="nump">$ 225,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ConvertibleNotesPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes, principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ConvertibleNotesPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398359824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Convertible Notes due 2022 Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 8.2% Convertible Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="nump">$ 2,571<span></span>
</td>
<td class="nump">$ 7,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2022 Convertible Notes&#160;bore interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March&#160;31, June&#160;30, September&#160;30 and December&#160;31 of each&#160;year, since March&#160;31, 2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfPremiumOnConvertibleNote', window );">Convertible notes, premium percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfPremiumOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium on convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfPremiumOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386398266256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 7,540<span></span>
</td>
<td class="nump">$ 5,771<span></span>
</td>
<td class="nump">23,089<span></span>
</td>
<td class="nump">17,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="nump">$ 2,571<span></span>
</td>
<td class="nump">$ 7,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401938848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2025 Term Loan - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2019</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,222)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember', window );">Lender | 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Total term of the loan</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentPrepaymentPercentage', window );">Prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount', window );">Percentage required to pay an additional exit fee on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage required to pay an additional exit fee on principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402799728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2025 Term Loan Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember', window );">Lender | 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="nump">$ 1,773<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">5,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 6,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386404575696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 9,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">28,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2024</a></td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2025</a></td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2026</a></td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total obligations</a></td>
<td class="nump">$ 40,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386403966592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Contractual Obligation Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate', window );">Claims related to certain sales of UDENYCA from October 2020 through December 2021</a></td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Best estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.Y.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14453-108349<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14394-108349<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14472-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386402852496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Employee And Nonemployee Stock Option And Restricted Stock Units [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,282<span></span>
</td>
<td class="nump">$ 11,939<span></span>
</td>
<td class="nump">$ 39,011<span></span>
</td>
<td class="nump">$ 40,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense capitalized into inventory</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember', window );">Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,173<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
<td class="nump">14,707<span></span>
</td>
<td class="nump">14,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,925<span></span>
</td>
<td class="nump">$ 7,419<span></span>
</td>
<td class="nump">$ 23,749<span></span>
</td>
<td class="nump">$ 24,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386401947120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">36,783,266<span></span>
</td>
<td class="nump">37,875,696<span></span>
</td>
<td class="nump">38,052,771<span></span>
</td>
<td class="nump">38,076,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember', window );">Stock options, including shares subject to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">22,535,371<span></span>
</td>
<td class="nump">19,543,671<span></span>
</td>
<td class="nump">22,267,304<span></span>
</td>
<td class="nump">19,847,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">2,305,743<span></span>
</td>
<td class="nump">1,916,002<span></span>
</td>
<td class="nump">2,401,188<span></span>
</td>
<td class="nump">1,812,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Shares Issuable Upon Conversion of Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,473,871<span></span>
</td>
<td class="nump">1,442,127<span></span>
</td>
<td class="nump">4,473,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Shares Issuable Upon Conversion of Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">11,942,152<span></span>
</td>
<td class="nump">11,942,152<span></span>
</td>
<td class="nump">11,942,152<span></span>
</td>
<td class="nump">11,942,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140386404529712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Consulting Agreement With Lanfear Advisors - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 17.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chrs_ConsultingAgreementWithLanfearAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chrs_ConsultingAgreementWithLanfearAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>chrs-20220930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:chrs="http://www.coherus.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="chrs-20220930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eonw1mXuJUKOgVxQh1GSyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aJyitt-I006ugkqGquTXGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8V4HsE260kqaeuFD1bYwvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fkK5vNIN3kSwIqGaWNmteQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dHQDPExykagF_cy6siyDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_STiZudwhNUCxi022GQWjaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_IY-plOYV2EqQEJeaoZX88A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0hoMqPJyYUGnNJU59za1pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cb_X4L3p7EqqJH9nNd244g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h-ZTFPDr4EGbKfgG5ILwvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_eO8v2cr00kC45dIQYpWoLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w0nhYumrGkKrSb62bMeN2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iLCwIUmxe0y6CzAmEfiM4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zLA-RFtqoEew3-CZd0KOuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oFlUazjEnEWuN2MvAjRdcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gel7KLMwm06jHs-JrN3l4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ee2kjvAP4E6pnApIyvWmzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WH4pGIMYQk6BmQKSFzo65Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AHRLomthMUyUHM-nJtaJpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hLEdkaDzskaOra-KRKMpeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_xF3ZNwxQJkiLgijGJT1LhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q5iIlf1RGUq5nwYySyZq7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0AZ9AYU4JUiN7rdHxiI_4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28c3LpHdD0WZKehT5O6ONQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_f_HHaVH0CkK6RCmYXbR8_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KKNGL6SA9UeDBmazTlWOFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LYkuifxZg0OV34ZetlagUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_2wwQK9AUSwRjasJS_ULw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_14_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_iUGghFecu06NDEYjC7SfZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="As_Of_4_14_2020_ThcS1SrdqkuYZeougINqKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_1qOFFGpSOkmstIVIX3zj7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_7jfBPaL450eXa1Y2g46z5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_84R_iMTr3kerbyr6upUqew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_FAORKnYJyESjSDSKaLODGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_lSeY1zTOCE6BV42943qNiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_Yibptfnp5UWmdGj-9kWtqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_ihiIu3McBkWodWSPBrrhmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:Chs2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_ETG3zuq6rEOjceZCC4QiRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lgVJdipFVkupB9l6dHBIsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_inJcJWO_YkiWXRyFQlnw4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3qhcXT0gtkypEYBUMeOpTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LqG5RoqoJEeZzKbXCggF-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_d9EHcCoTPk-AEH8jjwR_JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_yRUVgXSoDEydOBMMHjKAow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ghgoc7GaRUiVIJi-rnTZKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_2dIU4Wv5tE6Evkjk6He0eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_clg6kOzlW0-1bv2N8PSJDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_k4tZxvbaTESkkzwTRJUQcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B2ODLCj890aKQI7OAcmbTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1UFzj38Bbk-gQfCQaA9EHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_8yRk0_sXYUyHmkgGMlwvkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yBXFf2ogREGygqnskg8KNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R54yYimj30CJzK88nXK4mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xsaiQkMDeEurcwXQo7nNiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CR00ztb51Uqx2BIB8vBdNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ehG8basW0S3Sder5I7-Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiPDGwH4rUu0h2LujsdWDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mncLQiS1qE-Uskr7RtFgoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oIOC0Uy60EWaDKyAYFI7Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gKYdCCv6LE-IykKhJk4XGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_02uw6OI6VEef4Old7iSxSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6qmOksBoz0uXpji7uweM_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_eGmvrJ29CUKSMH_a7DSGFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_ProductOrServiceAxis_chrs_YusimryProductMember_JbvK-d-MGECmbZL_2UDv9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:YusimryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SjhD1IrJykmX9woy0w48cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_UyhokirZm0i2-644r14vMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_12_31_2021_y7OZ_vllI0mGatYYUEzb9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_ZdRhP2tlY0uSkxF4mWUkLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_gVgB94UeLkKTlxsG-jRXZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-07</startDate>
            <endDate>2019-01-07</endDate>
        </period>
    </context>
    <context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_m-RRMH3z8UK2FguJb0RdSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaAndBLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Vahrp9O7ZE6CBtpYv1agDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaAndBLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nxmJVGXvoESV6WgNqF9pPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_FPqARq6mV0masUy1BsR29w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Iy6ly7BuYkCb3Hlrkpohpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_EPh9mQbc5E-s3ez_S3RVbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember_kdQLio7HLEqitGwRYsXFkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_qqqXHtfBs0OufPeCKnuFoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-07</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_1LbWHBCaeUiM3ttGuW95EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Ia8aHRxcikWcNmk3c7HDQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IviSwz1WNEmFo8vw--sRpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EiNpUK2b7k2PkIzqMYiCHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3156mbgj9UORepDGQ616-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4f86z1_gaUCyD4LR0zbwzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PEUy1iet8kGcmgswzbVqLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_MXAI7K0dnUqRQpnDD2bDzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__IeX3c6reEm-Apq48lU1Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aak9ct_niUi7Lq7sxeyMwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P30QcEujV0-5fFkIRIwjtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W4ZbE0h9nEqugpQqg-733w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vhI6ja0bQUKTRyCoU2x99g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_493Ej-l6IkadHd0s8Ev8iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rP5uVqxc9EqbTFWsU--suQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wzMkWYw-jkG5Z-S_a34Cdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fLEz9P6UwkuwqfzYcZElYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vv--ebqCnkqV5_hs0bFUXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7Ka18T27VkWuuzFhDZZuGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CnSVpPJZzU-M8zr97h3FzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JB1ySyU9gkuJVo799k_sDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Rq5_ejfD4E-zhmch0hzaXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OZ7xG5FttEWv9GoORmuT0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gcq3kr0aY0K5_CRVytES5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-GKhnbmx6EqrslRQyD5gVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zkV-yxWOFkCnW-ddikAq5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kn89hn5N_US1XfKr0SQ33Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VlaCc70eukKJoN2_W3ugDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h5ZptWvOE0uCY9Ybl5SojA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:RestrictedCashMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnYHy2xhCkCb9J7p4hkgRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Bc_irE1EYEa0-ZkdPtAZuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_twLiW2yaC0qy7WXGVse05g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_dEoY-sHSzUK02mdFlAWJzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lz0mTF4wV0GFylKh3m490w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_dED-Hyl570q2Gq2GdE_Mmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FSdT6Jp3yEaigOhy6sE_5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_Xt8hsRyWYUinCw6qBafEHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Aww4QNVaLk64YAzs3J9iFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yEOGTOZIeEWn5yVBWgq8Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_g1id0jQAJ0KFh6228c8jNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_kXWTWhXhFk2byCH1j93xkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_8AMDQ5u-0kqsUupldYB_uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_U4ZdZnH3fkC5viSWX3m83Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gkYrhJtFPkWcVDhkufdQuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_9008h6QJQk6ZQdJ45f6bfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wwwSCpIHT0qG7pxdRVzYHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_J1o7boGRZkedZZJHTOblEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XmTlwxSGn0m_uPHHGMPW9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_XYdisJOhq0qqXhF-fMCTHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5hmkNI6CL0Kpwf9YcrulMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1z-ozshyUUCySLmdDcUEPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ZH1LNjXzG0q7CAxQn1L9Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WaMcf-CWnEOlS3SaJTgvdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9qbE_7hJb0OAo7eMUGImJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cGIwu14pwEeco2TOLfoZWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_50U8Eql0mBG5Pu9OJs8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hXNe2mN_6kq827XHdcENIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chrs:EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_Qgwbc6x-6UChshllodc3Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_S_Q2ffeVKEC2FuV_r-0CyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_canvBDnSX0CAUr-ueKniXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_g3-gLMpZw0yYViaorsg8fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_r2ythOcrUUuTOM2mUeKjUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_5m_vF3mcb0iKQxtzWjcHZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_NTm60yerS06PfnGj4p8sbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_bfx-u6Wr1EqVZ6v_MBIiiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_FCwSTIPa0ECHMWQCuTIDsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_S3yaMtzKYEafjmMKoXco-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_KqBdumQ4qkSE2fcmpfAufA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_gnbxKpVogk6rFKwK3_goRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_vqkwbtvNdk6jZk0lQqoE8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iM8hqKoK6kGGORI4m24fvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-29</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bmA1J7_-g02NoTnD-cDbEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-04</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_iHwIvN5laESr5Qc_H4fekA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SJkhVBwrA0SLA7eqmarAbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_76kJxJgZgEGENktd8re-Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_RXxIsuRCkkGGaNhY42HHGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_FgRJm8jDqkSf5ige14aHFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDCtyjQAwkKPEG_SutcvdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_287011mlzEmiZ0X0m6eNuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_AMgKdK-BQEurLZKKdbATnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_k-3RgBaCqUq-ucT3E9EGSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDVgIzSJCEyihHczolrtHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_-oXBZarHtkK0JSkSA05zDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_dj746ZuzZEuFlhD-iyPunw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_cD5KRETU-UOVx1YHhrwR2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:ExclusiveLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_MTxWxPxnDkiqyDu_XrhHiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2022_To_8_2_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rAiEo9Y69EihH3kDtMl5ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_OptionExerciseFeeMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_uiPlNyA8AkK6KThMVOfv-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:OptionExerciseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-13</startDate>
            <endDate>2020-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:BevacizumabLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:InnoventBiologicsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-13</startDate>
            <endDate>2020-01-13</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_Lph8a238DkeDMCSZPU71Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-04</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w">
        <measure>chrs:item</measure>
    </unit>
    <unit id="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_tranche_irYBJZf4GU-2pDQ3aghfCg">
        <measure>chrs:tranche</measure>
    </unit>
    <unit id="Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA">
        <measure>chrs:product</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      id="Hidden_Kb4GUTQev0Orv7RycLYxXg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      id="Hidden_aENO8CqzWEi7pm9MYkUZ4w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="0"
      id="Hidden_ECF8NXIzLkyGuqG0mf7IJQ"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77746895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="0"
      id="Hidden_1u4EHCP8NUmFYqPbh5RmvA"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">79013240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="0"
      id="Hidden_3rEZiFw3HE6ZvR_Z9ABgjg"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77520244</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="0"
      id="Hidden_euSITpJkbEmKgkSOWTbSZw"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">74984811</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_xSTIKUQQe0aHLym0CfmFow_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_gRicjeOIwUipHwNSjuOWYA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_rBO_tdPs30m9FhWOlBtteA_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_N8DwcJ49R0azT83uwa6z9g_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_km_lNbZrvUerhxQadn0obg_6_1">false</dei:AmendmentFlag>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Hidden_KJvqdFFSVUamaeho3x17Sg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Hidden_akGEym0pHU26fsiUnvvG6Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Hidden__X7SCryzrEKB5UwqHX_2ew"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Hidden_o_UwxwCk6E-gu6vXZrueRQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Hidden_kpofWQWnEEeu3thsIH_a9g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Hidden_Z29eaBaajUGP3SId5ppCIw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-5"
      id="Hidden_eQGquZC9vkOnHDFWp1UtUQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ"
      decimals="-5"
      id="Hidden_-kJSaP2CeUiuU4iA32rAdg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-5"
      id="Hidden_8Bz8Lkp8yEKjA2W9Sk2Upw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021_YiSf2WkRC0qxMEznGBXxzQ"
      decimals="-5"
      id="Hidden_Wa3cqRH1dUis1oQ1emvtGQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="INF"
      id="Hidden_bdIxfh13o0KisJnEyHBoSg"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">76930096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="INF"
      id="Hidden_hoR0QtiyGUGfLjpvEN1Erw"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77770593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="2"
      id="Hidden_Po6M_OUNuU6JSGR57SKfnQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="2"
      id="Hidden_PTLiJ86BQ02BxxEIxmF4lA"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="2"
      id="Hidden_Km26HVskkUuB_voLJ-jedQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-3.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="2"
      id="Hidden_co5ZJw0eiU-gfN_NI5P91g"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-3.22</us-gaap:EarningsPerShareBasic>
    <chrs:MandatoryPrepaymentTerm
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      id="Hidden_zhRAFkTaEkWJkydvNPJsWQ">P10D</chrs:MandatoryPrepaymentTerm>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Hidden_mJKNNF_1akSrcLTArm_qlw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4750000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_4qC0r_i3Dkm29tw4qt-yYQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_p90OjY0Kr0KReGGTJFpLdQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_NB9yCNtFlUyQw0T-nLDx9g">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_5bUx9PHkBkuf80FODBSFzg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_6C2NywBVFkqtadJAnY4lLg">001-36721</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_GLnhdmA8N02eFhdcYMvKBw">Coherus BioSciences,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_djhFJsDsWEKdbMNucZ34bQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_pj2bHdSYBEOJMZtXnLug9Q_0_2">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_ggOM0WHztECvfz3Eyxe33A">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_Dnx1gexPS0mafVlExJGh7Q">Suite&#160;600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_3YCO3fx6EU2pevb5gGMf6Q">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_nTA0AimnI0Gb3ZpgqsKfPg">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_7AXoNn_910iVvOyyR61XwQ">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_X4yEye7xSEWMEPpp3sBAuA">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_U-jgUhSl8UmA0XYh1DMFvw">649-3530</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_SdgYy_FsTEeA06DvDXwLpw_1_0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_HrseCBlGGUC1MzJZLbceJw_1_1">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_0xHG47keWUqClXso-NFmzA_1_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_vLhMhCnh_E6DAb_mReq_AA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_2vmW7Mp_C0eSgZINaq2_hA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_9eBuxjqFsEWNjftxqvVB-A_1_0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc__Rr8K6eIEkm4P3zd99xS1g_3_4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tc_FJh5bbAaG0uDyvtpWk7BLQ_5_4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Narr_l6yidhqzZkuqO-QcBCp3JA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_10_31_2022_Qgwbc6x-6UChshllodc3Yw"
      decimals="INF"
      id="Narr_pH4_pNrA-Ey_CxuDDTPOTg"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77777938</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_ISmhtGY6bEGsceNgd3nO-Q_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">286805000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_K2iuZX1vP06oCB-hqetdJg_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_DD7DQG9g8kC4ohh5BPwdqA_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">91186000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_eGYCkNcvtEaDl17tAAnvAQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">123022000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_W3qzCjwelESS4C3rQNEBwQ_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">27719000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_XOAAuA4FiEa35Dcx3u5lwA_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">37642000</us-gaap:InventoryNet>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_DbevHgHZL0Cafzo5AA8DOQ_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">20633000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_ZMU2Xk9N_UylMPfQaZ8c-w_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13666000</chrs:PrepaidManufacturingExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_vXbJQmdd7UeU8cswdT7Esg_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">21932000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_NGyEZ1N3vEmaOeIVcd_z-Q_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">10798000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_ElJx4tv1OUaUQUcrUOBacQ_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">448275000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_kRXjFU4CBUq7frNud0uA8w_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">602323000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_kJQCMjPDdkGFSroYI4qcrg_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9571000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_5HLJNrFHGUiVkld5s1mi-g_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7813000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_taDrc5SbjkK3onHse-EwxA_12_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">77438000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_o0alKKdR3k6Qu7YqzGpaYA_12_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">55610000</us-gaap:InventoryNoncurrent>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_SfYn-YbFAEKOXZL8bCkZCQ_13_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5996000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_IeaM3FtgDkK2BDohrj_CsQ_13_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3563000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_JvdkYGwlUU-CcDrDTE4QVA_14_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9627000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_zYyZL4lHzkOO3JsrnUHsiQ_14_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">10025000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_2qa1HVzlkEWcs-LyLQwqgg_15_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">550907000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_m3T3-rHyaECEDxUNrY_VtQ_15_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">679334000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_13ThgZnA6Euy2FXFAde4XA_18_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9917000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_iGV8LRPLFEGUIvZVN8uDMA_18_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16159000</us-gaap:AccountsPayableCurrent>
    <chrs:AccruedRebatesFeesAndReserveCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_xp6Fl8_Uw06lznHzQS78Xw_19_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">54021000</chrs:AccruedRebatesFeesAndReserveCurrent>
    <chrs:AccruedRebatesFeesAndReserveCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_FGhDgT1-H02qcqAXfj-51g_19_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">79027000</chrs:AccruedRebatesFeesAndReserveCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_xEiRZRvs1Eqh5Rr0w0Wciw_20_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">21391000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_Bw2Xta4pc0aDhzz5lAG3xQ_20_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">22014000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_bhTb0jJZcUu3f86dScwmew_21_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">85990000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_HoHp4Fcx2kOekU4RkWE9UQ_21_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">48127000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_PZP3cKo3oEOMMn8r-dvqbg_22_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">171319000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_oDWkgCRH3k-f_IobcjwpMQ_22_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">165327000</us-gaap:LiabilitiesCurrent>
    <chrs:TermLoansPayableNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_khumen12-0CDYRtwQqJ54A_23_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">245246000</chrs:TermLoansPayableNoncurrent>
    <chrs:TermLoansPayableNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_zCE1iSFFY0-NEvxyX6N5EQ_23_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75513000</chrs:TermLoansPayableNoncurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_XOBPCiFO5Eex2X8Ra-NVAg_24_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">225250000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_odJKtEPAOkqikNGV1v_wCQ_24_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">332767000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <chrs:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_jwnYmF8vkk2tN4-FJDeBhw_25_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6123000</chrs:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <chrs:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_2S29cTTNpEWsz-wQHKrG2A_25_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7251000</chrs:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_PcG5V3dd5UaohknZcKUqDA_26_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">102000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_rVlajgRVOkmtDmxWJ5FBeQ_26_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">750000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_K7rk1Hr1yUeNcb6AjgfleQ_27_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">648040000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_Wea4Wgws9kSfGCiJnd6SSw_27_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">581608000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="INF"
      id="Narr_BVv8wKKFhkW9LDbCaCFQDg"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="INF"
      id="Narr_6-65xeiPSUCuuDlKYtO5cg"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="INF"
      id="Narr_tkathzOtsk2WuYaQvMBFcw"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="INF"
      id="Narr_SwUGnugSpk--s_cZeu6QqQ"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="INF"
      id="Narr_uuepMVJBzE2m_wVFUy8zGA"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77770593</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="INF"
      id="Narr_e4nu94e0NkmuDGDSB--aRA"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">76930096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_J6SPwTZW8kWODk4G8dQ1NA_30_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_lmb6VUX40kuxHiKxT11QWA_30_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_7g-RV3CiR0eV8-6K9Pp0IA_31_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1185868000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_Ud4bcPa630KWU1CZItj5lg_31_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1147843000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_T4qgnlXZCkm3xCraxVrJog_32_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_hKpcfYrzuk-fT0MCVYiuzA_32_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_muQTHM5Iw0O4DndR4i66Og_33_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1282738000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_d3nZ9hV_vkmTqxzw3emWcg_33_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1049854000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_QqFhNyRlX0eqM_5F6LfybQ_34_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-97133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_nK9rDDK3hEe0TJuJiUJLTw_34_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">97726000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_t5Ej7w0N40SB7Dvgp2ulQA_35_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">550907000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_ZgkxwSEuBEmrISJBrNS5_A_35_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">679334000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_RPzsap8mNUeNAMR6c-NvWg_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">45424000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_qLx8qoayBE6XbM4fxJGDYQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">82503000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_fHgdrfHA-0-mxR1LNpdXgA_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">165690000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_0bMwfRDW9U-WCMULSwXxWg_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">253180000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_IRbY2FOOKk2RSli42-8pUQ_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35234000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_I_LxRcHfj0iVRc7odAp1dQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">21280000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_6tnLkRTW8U-85tMePlDCpw_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">55881000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_PUxiuW1RkEWcC4rKVEztqQ_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">45487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_Ak8_cEvbDEmQEJI0kIvWHg_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">45808000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_eXwcryfXtkyll2ETlKL6jg_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">54085000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_NiI3WphT602IpB-x5WUPRg_7_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">170336000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_8CSoxn6j1kqxYNPfBaUVkA_7_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">312343000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_5JwApScTsEecbEFa4GhGVg_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">44831000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_bRJBPM7At0SN4CJwA9xRdg_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">39925000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_w2HiO_m470CnUfZJdnJUoQ_8_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">144860000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_Oabbs6j2J0mq7UPoYdOK6g_8_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">119661000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_rPhvo_BuHkiNvKW4anv-NA_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">125873000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_1YSF1Gt5X0uj_Srd_Pfyxg_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">115290000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_BaY5XV4Ock-nWbGwMepHOQ_9_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">371077000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_TJXWCV9XaU-mUmZ_os2G9g_9_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">477491000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_3WH0LqEZd0KjeHfYURNP5Q_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-80449000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_j57WjCxjYUG9AwaA5_Vy7w_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-32787000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_AKamivPzbkmYX2FCyGJuAg_10_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-205387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_CF0tleJKVEe5Tpi6GtgRGQ_10_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-224311000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_lK8zhs5yGEeR45gW-5okxQ_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7540000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_6qAv6wG_QkaohCSoyKdYRg_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5771000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_SZdUsPdSrE2tfoZx8TuxiA_11_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">23089000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_LP0fE0TGKECkaJ-WdDMcOw_11_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">17166000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_4_n8xgn840-zgtNvUCU9jA_12_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_Fbj-C3aR6UeUhXlKiaFPrA_13_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1339000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_dQdWj_Tth0GRnKImLvg8Tw_13_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">30000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_Yjmag-C8gUuaRyMP9bjzDw_13_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1814000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_K6Ff7W1C9Eq6-IO0BYzSNA_13_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">102000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_5n1U_TgVnEy6Ot0z4ldQqg_14_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_Jb3OurDyA0StYnr6jlALmg_14_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_oyQJLs6Ut0ibY6rkKVHtcA_14_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-232884000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_bQpKs2mryUSL4CfmjEt4cA_14_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-241375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_JFkEHU8Lu0S2p9jj_x7fgQ_16_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_Jk7eyaK8sEutUn2XRLz1VA_16_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_eZHoRuVoCUGsOnyBbfJ-wg_16_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-232884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_81BYH_lkrUiEzYA4UBrp4w_16_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-241375000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="2"
      id="Tc_Wg0FJgdSeUCSCotKpnMr9g_18_3"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="2"
      id="Tc_Q99uO8jv80WtJqNwaeE-KA_18_6"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="2"
      id="Tc_z0NYSC8fyki0KQIyzKo-sQ_18_9"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-3.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="2"
      id="Tc_yGPqEnPe5E22URb9uaZlvg_18_12"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">-3.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="0"
      id="Tc_Io2SXoWU6E-zUe5jcjNf1Q_20_3"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77746895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="0"
      id="Tc_NzP3a1VPQkyzVTVjMpFY3g_20_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">79013240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="0"
      id="Tc_53E6gmapIk627HKxv1QvZw_20_9"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77520244</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="0"
      id="Tc_yrHZT_i62UKvtia9e0EBYQ_20_12"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">74984811</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_g--9p0DkHkmf4V__6iIuSg_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_1iVQgm3l4UOEIdAeURYzBQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_58g9WO_cpUqcRvD51fMCzw_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-232884000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_HP4WZURAz0mPeikFXH8InQ_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-241375000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_eA4aGgDAIUup8nXd_7ugYQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_JRfgNRix5UOCF0AUIZ4G5A_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_9xyTmgrHzkmBVOktpvvP8g_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_dR_595kxiEOxCawDsGJCTQ_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_vPpSWzlAdk-dBQiM487TSw_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38534000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_0tr19ZINSUaJZFbs1yC_Cg_7_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-232884000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_hsWI20lXp0KsfTTYJHHBeQ_7_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-241378000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ"
      decimals="INF"
      id="Tc_gki8eLvm-k6zTJvQ9tL6Ow_5_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">76930096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QxRVledCxUKXlvS_nCEtRQ"
      decimals="-3"
      id="Tc_Za3Y-xEmTUmj7ezF8_nI8w_5_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iLCwIUmxe0y6CzAmEfiM4A"
      decimals="-3"
      id="Tc_hfhjZwIRg0q7zR7L9J_5Ng_5_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1147843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zLA-RFtqoEew3-CZd0KOuA"
      decimals="-3"
      id="Tc_7YMLENn-_EC9uvhlYliCRQ_5_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w0nhYumrGkKrSb62bMeN2g"
      decimals="-3"
      id="Tc_3beJcr6r_0Cy_ux2yVnnCA_5_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1049854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_YAqmF8RFB0GwJaHe8ugcWQ_5_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">97726000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oIOC0Uy60EWaDKyAYFI7Ng"
      decimals="-3"
      id="Tc_7Z2E18Vvj0Wul39GFgLNWw_6_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-96084000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"
      decimals="-3"
      id="Tc_qJY-jwE2rUGldSV4f--HzA_6_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-96084000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw"
      decimals="INF"
      id="Tc_z2hjpq-rSU2Fe-K_XWmung_7_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">102632</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA"
      decimals="-3"
      id="Tc_co0Zlkw3aUGLdORKw2fGFw_7_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">544000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"
      decimals="-3"
      id="Tc_iIRz4QIWA06r2sjUyLtcqw_7_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">544000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw"
      decimals="INF"
      id="Tc_r0dDwkbNXEmkoE7jYK8nNw_8_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">491087</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A_Io7Nv-nkKuVeO7-Pq7jw"
      decimals="INF"
      id="Tc_l6nsKd_0ZEWco9bquTJKig_9_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">185644</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA"
      decimals="-3"
      id="Tc_cuX1PRI91U2cFyvY28kYLQ_9_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2658000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"
      decimals="-3"
      id="Tc_ix-qlxp-eE-k21diAlrfSQ_9_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2658000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eq-umm9nOEKMma3i7enKjA"
      decimals="-3"
      id="Tc_RGNBEzgD5EiBHwLLzWnrvg_10_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"
      decimals="-3"
      id="Tc_W5J0rE56oUWY6XrZwbqX8w_10_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R54yYimj30CJzK88nXK4mQ"
      decimals="-3"
      id="Tc_SKk4soc_Wkug-JwJKRmtwQ_11_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_3sp5qopxKUaozyQIs5QIIA"
      decimals="-3"
      id="Tc_EnFfMZEKL0WD8tzlfqoS-Q_11_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw"
      decimals="INF"
      id="Tc_gi_r8NCRwkqWJbBPqCoeyQ_12_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77338171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_946F5kLXWkOXLi6OSuIdvw"
      decimals="-3"
      id="Tc_krxmslx1wUqwg2drsXtbrg_12_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cb_X4L3p7EqqJH9nNd244g"
      decimals="-3"
      id="Tc_j7J_MWWzYEKNhktCUJlsvg_12_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1158766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h-ZTFPDr4EGbKfgG5ILwvg"
      decimals="-3"
      id="Tc_6PsTjZ8QXUWFPztyYnsMcQ_12_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0hoMqPJyYUGnNJU59za1pQ"
      decimals="-3"
      id="Tc_WAJTBQ7Br0afT6c44b0F1Q_12_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1145938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_eO8v2cr00kC45dIQYpWoLg"
      decimals="-3"
      id="Tc_4V0u0SLUNkaHSuGhy6SI1g_12_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12563000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mncLQiS1qE-Uskr7RtFgoA"
      decimals="-3"
      id="Tc_0Jdr62_7R02Z4Cafo8J6bg_13_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-50150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_3V3sFOdlk0eege4yo6XL5g_13_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-50150000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA"
      decimals="INF"
      id="Tc_wpXm7_-DZ0Gk_KB4NdmJcA_14_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">4499</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw"
      decimals="-3"
      id="Tc_zPAptWaZYECqJofQ3HdOsA_14_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_G-_udKvzFkSOnW_jQmUeHA_14_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA"
      decimals="INF"
      id="Tc_7fDoLS0NHkWEtXavbwFrug_15_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">173867</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA"
      decimals="INF"
      id="Tc_0Pw6VGHrQUOG5SgXgmMdIg_16_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">58771</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw"
      decimals="-3"
      id="Tc_bljk38zhKE--RpSEQ0Z0Jw_16_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">642000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_y3yq4rkQWUG70l_BWaojDg_16_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">642000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cSdZm2nn50Kzxry3hwutxA"
      decimals="INF"
      id="Tc_GO92AYTL3Ei5CgDe7fP8oA_17_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">244983</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw"
      decimals="-3"
      id="Tc_jBD00nNPykiFuN2hNGdEUg_17_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1655000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_KROKNMcIS0CZPWs5pwZbug_17_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1655000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sKLx2KwArU-U6OqywQ9TGw"
      decimals="-3"
      id="Tc_MYHDXZBMIUyXj_FPWAqIoQ_18_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_jP3s9hLWqEmXhwropp5zhQ_18_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yBXFf2ogREGygqnskg8KNA"
      decimals="-3"
      id="Tc_ncSjUwu0L0GBbU3f2ymu_Q_19_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2022_To_6_30_2022_wFG5wR173kOWTKqZyFdQNA"
      decimals="-3"
      id="Tc_v-s_LMp3p0Cnnm5Oecxzkg_19_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w"
      decimals="INF"
      id="Tc_qbREtfz_zUqMhUd-O8D6aQ_20_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77702749</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qXILL2Yh6UypUgH-G96h0w"
      decimals="-3"
      id="Tc_CmaeRpPS2027G1QxjDc9Fg_20_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5dHQDPExykagF_cy6siyDA"
      decimals="-3"
      id="Tc_wsSXn9t4eUigAmcZcI1-1A_20_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1173722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_STiZudwhNUCxi022GQWjaQ"
      decimals="-3"
      id="Tc_kPTf9DO37EWXUt33Cye9XA_20_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fkK5vNIN3kSwIqGaWNmteQ"
      decimals="-3"
      id="Tc_QShgNGvJiUacZxSj1aBYMQ_20_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1196088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_IY-plOYV2EqQEJeaoZX88A"
      decimals="-3"
      id="Tc_mc8GC6HkJkyz0-pclatDHg_20_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-22629000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiPDGwH4rUu0h2LujsdWDQ"
      decimals="-3"
      id="Tc_9c9ptv1U9UqX5qjaGZdqaQ_21_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_x5rQUnjFWE2LIEoXQZ7xBg_21_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-86650000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg"
      decimals="INF"
      id="Tc_aV6DyqFXH0msen4BWqRohA_22_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">6557</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA"
      decimals="-3"
      id="Tc_McheWmF9RESSdBZgN1Ev0g_22_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_198BV1ZBH0yk-PKwmA3pnA_22_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg"
      decimals="INF"
      id="Tc_eT1k3XsqTUuBcGjcKUbXEw_23_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">93606</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KP3GCpwLPUyhJUB84pHzeg"
      decimals="INF"
      id="Tc_azd-qj1710ezinukwH-JFA_24_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">32319</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA"
      decimals="-3"
      id="Tc_OdA33CNnWEKdrqUismV8rg_24_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">321000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_wiOGw9TNgEClyX1LC4pihw_24_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">321000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpZFPP4Hf0ChVyGVaAEkaA"
      decimals="-3"
      id="Tc_Tmd9OiV9-0apKl0ub-Bbfg_25_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-3"
      id="Tc_uFAVjSax_UGEBGOZ04BQVw_25_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ"
      decimals="INF"
      id="Tc_TrM3Jw9bzEira5UsM4OP0Q_26_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">77770593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1r80a-fc10iDeWzfhtCwQQ"
      decimals="-3"
      id="Tc_I6LlS69tuUG5lFv2UGepqw_26_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aJyitt-I006ugkqGquTXGQ"
      decimals="-3"
      id="Tc_VGwr06qiiUmNV0rK3sIK8w_26_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1185868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8V4HsE260kqaeuFD1bYwvw"
      decimals="-3"
      id="Tc_kYidWCK28UyMhz2ec8qbqg_26_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eonw1mXuJUKOgVxQh1GSyQ"
      decimals="-3"
      id="Tc_Ol03f2OjCEC-GdtlP9qOdA_26_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1282738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_X7-Pm2qYfE6BlPlACcg2vg_26_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-97133000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA"
      decimals="INF"
      id="Tc_Qpl3CztXhkO7wshlKYtGvA_5_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">72513348</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA"
      decimals="-3"
      id="Tc_UMMgS8kkQEO4h1MsXiV-BQ_5_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LYkuifxZg0OV34ZetlagUQ"
      decimals="-3"
      id="Tc_sbS0P16fQEG4NMHkEaaOkg_5_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1043991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_2wwQK9AUSwRjasJS_ULw"
      decimals="-3"
      id="Tc_zuUjQkR84kih-UNUIUETgg_5_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KKNGL6SA9UeDBmazTlWOFQ"
      decimals="-3"
      id="Tc_Xywcgx5QuEugdw0ZkIpGrw_5_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-762754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc_h2Q5qfLtokiVDz_7Idw_Tg_5_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">280974000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6qmOksBoz0uXpji7uweM_Q"
      decimals="-3"
      id="Tc_Ho2R6HY2REWFmDZ0PHR9Gg_6_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-172947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-3"
      id="Tc_H9YbyhbJ2kSgE6TbBwNlCg_6_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-172947000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig"
      decimals="INF"
      id="Tc_0YCnWxLB7UqpwUFwyy8zyA_7_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">451883</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw"
      decimals="-3"
      id="Tc__rCBcfBgWk-WucgDbjbEng_7_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4429000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-3"
      id="Tc_cjLLbLa_nkyifC1gWqq33Q_7_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4429000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig"
      decimals="INF"
      id="Tc_O7dSl4siW0yceAWwr0l4jA_8_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">252846</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w1YcFZaBaEmuBjKiO473ig"
      decimals="INF"
      id="Tc_hzLuEx4IF0OyIN19DaB-zw_9_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">95169</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw"
      decimals="-3"
      id="Tc_CGE0GvbpxUKByuaGSfwi4g_9_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1730000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-3"
      id="Tc_T35KmaQVxEGpi_1KDBWKKA_9_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1730000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WnlUzi11ZUiS9ZSibenCQw"
      decimals="-3"
      id="Tc_bu363KDpAk2lsDLh-ce_VA_10_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16982000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-3"
      id="Tc_08wDOxuivkyAJ8106ZnwMQ_10_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16982000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ehG8basW0S3Sder5I7-Tw"
      decimals="-3"
      id="Tc_cll1W1AusEOHcxitwdARVA_11_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-37000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-3"
      id="Tc_aO9wuyTZckqoXrwkjJN6yw_11_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-37000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ"
      decimals="INF"
      id="Tc_U2-keWw-pk-O76gytVMFlg_12_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">73122908</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rYJFVMZUcEav5YhBK3e4PQ"
      decimals="-3"
      id="Tc_9V_w883p40eyh5kXTJCGbQ_12_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0AZ9AYU4JUiN7rdHxiI_4w"
      decimals="-3"
      id="Tc_I822HlASw0uLdxwYnXxDXA_12_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1063672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28c3LpHdD0WZKehT5O6ONQ"
      decimals="-3"
      id="Tc_iLOFSfTapkCVXRrEvOtkzg_12_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q5iIlf1RGUq5nwYySyZq7Q"
      decimals="-3"
      id="Tc_NXRZNRllL0WOuY0Yt_F8Hw_12_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-935701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_f_HHaVH0CkK6RCmYXbR8_g"
      decimals="-3"
      id="Tc_g3XpJg3JTECfzTvZN5GFKg_12_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">127671000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_02uw6OI6VEef4Old7iSxSQ"
      decimals="-3"
      id="Tc_TnA-d2940Ei-QcjqeTrw9Q_13_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-29900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_1fslAWVbREuJH4FlFUTBJg_13_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-29900000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw"
      decimals="INF"
      id="Tc_kPM-BLROLE2D3eOcNW5JHg_14_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">686145</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA"
      decimals="-3"
      id="Tc_RTO42nrqb0irsloQn3ss6A_14_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4009000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_BqscKpROR02EvVcvT74GNw_14_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4009000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw"
      decimals="INF"
      id="Tc_84buSQhS1Uai6-YF1TSL_g_15_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">9334</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw"
      decimals="INF"
      id="Tc_elX9JvgGO0qQhbEBZU28OQ_16_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">2491988</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA"
      decimals="-3"
      id="Tc_TnQUZrKo3kmS5ZOGbteE-Q_16_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40903000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_KPNkTAEzl0WyaACtlnm68w_16_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40903000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WMY76aKyQEaldGKQC-jChw"
      decimals="INF"
      id="Tc_y2jtsB6vikG4e7VqljkbCw_17_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">154325</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA"
      decimals="-3"
      id="Tc_Rzqgko16tk-YcL76iRiqlQ_17_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1985000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_ZDGlOzdIe0ud3TMSwjbpaA_17_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1985000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Ay7EvksT0S0GEto00fxmA"
      decimals="-3"
      id="Tc_3LEwXhR9gECry70vgmUu6A_18_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_-hdef4LXw0mW38PR5daGpg_18_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CR00ztb51Uqx2BIB8vBdNA"
      decimals="-3"
      id="Tc_4frVS5bqtkSuyP1pwS-U8w_19_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2021_To_6_30_2021_mi0IdvjwjEyn3n5Pa85oGQ"
      decimals="-3"
      id="Tc_lOs34OLqq0SZJ0kGMohCmQ_19_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg"
      decimals="INF"
      id="Tc_MgXyTJb0ZEujCWOyI0TGow_20_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">76464700</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__qGs7g3xakGQsPdwEiQkdg"
      decimals="-3"
      id="Tc_RxOw4arQAUGzjMh3AR0X2g_20_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AHRLomthMUyUHM-nJtaJpw"
      decimals="-3"
      id="Tc_3ThiwduNAUWnndy9P8SHiw_20_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1122081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hLEdkaDzskaOra-KRKMpeQ"
      decimals="-3"
      id="Tc_ye5AkA6du0uxUagwdV4vVQ_20_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WH4pGIMYQk6BmQKSFzo65Q"
      decimals="-3"
      id="Tc_ILnBEiWLa0OQvGygxlG1gA_20_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-965601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_xF3ZNwxQJkiLgijGJT1LhQ"
      decimals="-3"
      id="Tc_q58yWaOJeUqDJ5z-Pe0bQA_20_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">156220000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gKYdCCv6LE-IykKhJk4XGg"
      decimals="-3"
      id="Tc_kgsM-1TQ70yoQ3vIBpxY6A_21_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_xzEfze1-NEqKXBL7Kd91RQ_21_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-38528000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g"
      decimals="INF"
      id="Tc_vrd_TNzv5U2UPJv63soSNQ_22_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">116246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ"
      decimals="-3"
      id="Tc_pMj_-tqSqk-B37kA2nDwBQ_22_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1288000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_t1HVmx5ho02BJPugl1ch9w_22_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1288000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1_InLKF-T0mGqo4e2bRx9g"
      decimals="INF"
      id="Tc_3oi7zIWAOU6H8GoDleLU3w_23_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">2333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_77qqvBSy7kSpZ07-9n0LvQ"
      decimals="-3"
      id="Tc_gyvFGqPBB0a6Lt1nMaK5vg_24_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_ONqDj-7EZUS75hvuJFpxTg_24_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xsaiQkMDeEurcwXQo7nNiQ"
      decimals="-3"
      id="Tc_zSApSON68kuZKDVhL1OYkw_25_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-3"
      id="Tc_AjpXf8hFokudoGBWmmZuEQ_25_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA"
      decimals="INF"
      id="Tc_eEkU2TjQTUa4LYFFtZnf5Q_26_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">76583279</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UxxNyCUIRUCVc7pp_N8MdA"
      decimals="-3"
      id="Tc_bGbIJyihNkS3qp9Q_esq5Q_26_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gel7KLMwm06jHs-JrN3l4Q"
      decimals="-3"
      id="Tc_NWwCEblOlU-fR7I3blvEjg_26_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1135155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ee2kjvAP4E6pnApIyvWmzw"
      decimals="-3"
      id="Tc_FDDPzqJzcUy7gDqSJ69HXQ_26_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oFlUazjEnEWuN2MvAjRdcA"
      decimals="-3"
      id="Tc_IKQymB3adUGpxXMmBAN5hw_26_14"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-1004129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_exwicoPfS0yt3Yaml1Yw3Q_26_17"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">130760000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_frnSGG8VSEqCU3r1lrsLvg_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-232884000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_nfwATkj9-USdM3-BP6Cvsw_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-241375000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_e72Gt4VU2EmhagKbyMBlSw_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2649000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_QpOSS6Kn-UeXHkt7603vAw_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2618000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_eusNcPBFP0SayBT1E4Bpqg_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">39011000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_sBxEfaOkkUugIgVwSErisg_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40418000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_0n7jon13u0ui8i8y9OYt8A_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-3210000</us-gaap:GainLossOnContractTermination>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_FMImtTMFWkGA4kpdMrZ5Qw_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_Pmr39xVUMk69luqA8oUk8Q_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5192000</us-gaap:InventoryWriteDown>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_fCfS8fD2m02nv7dv5RFcbg_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5631000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_JF89PfqQT06yWz9hzDWR0A_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3150000</us-gaap:AmortizationOfDebtDiscountPremium>
    <chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_g1I7YJ0PiEGFxNbfGmVQcg_12_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35000000</chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements>
    <chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_7HsEoGhDtEii6bwFxjVNlw_12_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">136000000</chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_7fmuO2NW-0OSsIqOemSpOQ_13_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <chrs:OtherNoncashAdjustments
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_8zHHmFEFpE-cKHY6NVbinw_14_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1844000</chrs:OtherNoncashAdjustments>
    <chrs:OtherNoncashAdjustments
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_5UZ9-aOmukOFYeP7i1lM7w_14_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2708000</chrs:OtherNoncashAdjustments>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_8AtuLeDqVUeX0eeSH3F2-g_16_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-31849000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc__OWfC4s-hEaj7CwxZXb0sw_16_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-20722000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_-s1PuZjwuEaGP4f1BJOC7w_17_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">37556000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_EecjZ4w6kUqzjdGCtoSr0A_17_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2936000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_zU8FbVun7E2I2VL0uOOzkA_18_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6967000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_NKS4v9xECkuCkWm2PVh_Vg_18_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2884000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_wSVrPYrWTk-N8x8cBFDumA_19_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12509000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_8olT3PeN9kG5rHMw9hAC8w_19_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4590000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_i9ZVzThQOUaEbwKjmgIPMw_20_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6149000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_B_JT2lLG30WdOnENkjUw9Q_20_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">30495000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_0ZXxTLltGUCdC_8g5_160g_21_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-25006000</chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve>
    <chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_MuzGc-Du6kmvjrvcVooj4Q_21_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3215000</chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve>
    <chrs:IncreaseDecreaseInAccruedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_XQ0r6FHOcUSnsLne0cSiOA_22_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-623000</chrs:IncreaseDecreaseInAccruedCompensation>
    <chrs:IncreaseDecreaseInAccruedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_4P0FSw4EYEqFIRvo5O9LkA_22_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-3451000</chrs:IncreaseDecreaseInAccruedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_eoubDXVmAUSnb-NCBUhYgw_23_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">32317000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_ZQ5ij2yUNEqYIOqHp8u_EQ_23_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16526000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_DhXxrpOqyEaB_jiywLKP5w_24_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-141171000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_1s0EZ7oa8kehc95lxzYiPw_24_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">14890000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_vk4yf0k4Y0igF3PVWP8r8Q_27_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1952000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_Z1_81HqC8EWJXJoLr0bNwA_27_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">821000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_NpkpS3_CJUuoGWCCDngB6A_28_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">171779000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_krgqpG4OWk-LmG8fQvYsdw_29_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">62700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_7B6Ly50nQk2v-mmhlGz80g_30_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35000000</chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities>
    <chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_R96mAMxrFkG14X6TQcVT1Q_30_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">136000000</chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_Bms8J25DwkitjqOYCbZYTA_31_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-36952000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_4hVUn0LAFku-ihvew06rDA_31_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-245900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_10LiTMRykU2AghGodHLBOw_34_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">240679000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_IcJgQhCVG0y0o3sODkejdQ_35_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40903000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_Kr2OOon6UUWzTJWVQygsJA_36_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">631000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_sEie6ce9e0KHuFqVRl59rQ_36_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9726000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_2MlsHc8m70mFSLm2CJY2AA_37_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1655000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_8TC9be3CkESq2Uq6l8vQ3w_37_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1985000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_SDqchBNLsESzJZ3jhPnAuQ_38_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3621000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_K4eNvgtf0kSbjyf1H5lN_A_38_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1730000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_iT1Pufsmbk-tp1p1RToxJA_39_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">109000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_Q2bZlvhL40eMoC7RxdA1qQ_40_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">81750000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_ESt3hOX_S0mHYeaq6zUwDw_41_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-861000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_kgEcBBgYWUiq0adJssM6dg_41_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-492000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_rEGwGkCZDUaqcBw-Lw4U5w_42_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">47733000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_PZqyeiq7uEyjmH4wdc_ddw_42_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50392000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc__s7OZwQoeUW_T5PxOU1b4w_44_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-130390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_hebJPenCEUerXXJvhvNdag_44_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-180618000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_XL11D0RZx02UpB-LWxEVtA_45_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc_38yl_hRPeEy4WkYzRr4OpQ_45_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">541598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_7V5s4j3-i0avo_5OQfeW3g_46_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">287245000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_ftGgTmrs2kSPSkW92F0ZBA_46_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">360980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_d8twu95RB0emhLBqLsvV0w">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Organization&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;Coherus BioSciences,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Coherus&#x201d;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and commercialization of its portfolio of United States Food and Drug Administration (&#x201c;FDA&#x201d;)-approved biosimilars. The Company&#x2019;s strategy is to develop and commercialize innovative cancer treatments funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. The Company&#x2019;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA &lt;span style="background:#ffffff;"&gt;(pegfilgrastim-cbqv)&lt;/span&gt;, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. The FDA approved YUSIMRY&#x2122; &lt;span style="background:#ffffff;"&gt;(adalimumab-aqvh) &lt;/span&gt;in December 2021, which the Company plans to launch in the United States on or after July 1, 2023, per the terms of an agreement with Humira manufacturer, AbbVie Inc. (&#x201c;AbbVie&#x201d;). On August 2, 2022, the FDA approved CIMERLI&#x2122; &lt;span style="background:#ffffff;"&gt;(ranibizumab-eqrn)&lt;/span&gt;, a Lucentis biosimilar, and commercial launch commenced on October 3, 2022 in the United States.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The Company&#x2019;s product pipeline comprises&#160;the following three product candidates: toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly-owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. In May 2022, the Company discontinued development of its bevacizumab (Avastin) biosimilar product candidate from Innovent Biologics (Suzhou) Co., Ltd. (&#x201c;Innovent&#x201d;). In October 2022, the Company discontinued development of its preclinical immuno-oncology program, CHS-3318, an antibody targeting CCR8, in order to focus on external molecules targeting CCR8.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals, that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with U.S.&#160;GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full&#160;year or any subsequent interim period.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#x201c;2021 Form 10-K&#x201d;) filed with the SEC.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Investments in Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;Investments in marketable securities primarily consist of corporate debt obligations and commercial paper. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#x2019;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#x2019;s investment policy requires that it only invests in highly rated securities and limit its exposure to any single issuer. All investments in debt marketable securities are held as &#x201c;available-for-sale&#x201d; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. There were no investments in marketable securities as of September 30, 2022 or December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses on available-for-sale securities are included in other income, net, based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Trade Receivables&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;a customer&#x2019;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2022 and December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-weight:normal;"&gt;The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <chrs:ProductPipelineNumberOfDrugCandidates
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="0"
      id="Narr_4jRqGRJVn0yDCLCuszwpiw"
      unitRef="Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA">3</chrs:ProductPipelineNumberOfDrugCandidates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_DDLF6bl8Bk-6H4kaS19uEA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Coherus and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements reflect all adjustments, including normal recurring accruals, that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with U.S.&#160;GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full&#160;year or any subsequent interim period.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#x201c;2021 Form 10-K&#x201d;) filed with the SEC.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_Ykaqw1pkLUWOtmBSN6swLw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_fGSTpzoh2ke-mMMKjC68mA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current on the condensed consolidated balance sheets.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_ZOVCHZkDR0-9KlLFu09zEA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"&gt; 360,980&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_aPh5m0Xx-USJyptPODCH5w_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc_bvN_PitZ_ESMeIOAL5MpVQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">541158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_G3Our49_kEm2UStVOMGStw_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc_S4e85_gXDUuQIc8TDZM_TQ_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_ajzfLNI4u0qHJLJemYybng_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc__Km-RlYVOUii7Hlf-BNSHg_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">541598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_pPRW7Jg2YUOHCVxfMoPpqA_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">286805000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_GF_wm_oPIUm147y0M7C45g_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">360540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_9SduIG_R0kKbG10ykBty4Q_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_8sKL31I-Vkq4iMgpWUsQKg_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_D0EfH0TV206OyBhges3Kfw_12_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">287245000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_5c61DeDYSkSbSbWVHfbPlQ_12_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">360980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_txqJZcaquUe-ipvYfLLMkA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Investments in Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;Investments in marketable securities primarily consist of corporate debt obligations and commercial paper. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#x2019;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#x2019;s investment policy requires that it only invests in highly rated securities and limit its exposure to any single issuer. All investments in debt marketable securities are held as &#x201c;available-for-sale&#x201d; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. There were no investments in marketable securities as of September 30, 2022 or December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. Realized gains and losses on available-for-sale securities are included in other income, net, based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Narr_nr39YOs2dUmn69V8XhecVQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Narr_jUgoafykYUKqyD9Tdn5VLA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:MarketableSecurities>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_oZSO_nIsmUCbWpwQHCxl6Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Trade Receivables&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;a customer&#x2019;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of September 30, 2022 and December 31, 2021.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_B8DkrRwvYUmsuzqhLQgjUw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-weight:normal;"&gt;The Company has reviewed recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_Z4pGZAvaaUuFF0JY81qYSQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded net revenue of $45.4 million and $165.7 million during the three and nine months ended September 30, 2022, respectively, and $82.5 million and $253.2 million during the three and nine months ended September 30, 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Gross revenues by significant customer as a percentage of total gross revenues are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5203018%;padding-left:0pt;padding-right:0pt;width:101.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;AmeriSource-Bergen Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Product Sales Discounts and Allowances&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 109,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 321,056&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (181)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,300)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (320,022)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,869)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (446,720)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 356,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 520,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,859)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,035)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,715)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (362,241)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (78,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,716)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (516,557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities in the accompanying unaudited condensed consolidated balance sheets.&lt;/span&gt; &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-5"
      id="Narr_bcLvvX1mQkCwHOprntRvTw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">45400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-5"
      id="Narr_f-1qg3HoykS8lLBP6EvySg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">165700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-5"
      id="Narr_a4MDO_gIQE6oT4ennfW0rw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">82500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-5"
      id="Narr_MtpiQt0g-Umb10vKvbjljA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">253200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_2U1tMbmx_kKHWcJLXyzPSQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Gross revenues by significant customer as a percentage of total gross revenues are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5203018%;padding-left:0pt;padding-right:0pt;width:101.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;AmeriSource-Bergen Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA"
      decimals="2"
      id="Tc_EMjAmcNvJU-kOgmkkZZeiA_3_2"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_MXAI7K0dnUqRQpnDD2bDzA"
      decimals="2"
      id="Tc_AwX9x64lmEyOSW6RnAxQzw_3_5"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3156mbgj9UORepDGQ616-Q"
      decimals="2"
      id="Tc_qaGdmyboL0eqwhpr1DhVDg_3_8"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P30QcEujV0-5fFkIRIwjtA"
      decimals="2"
      id="Tc_J8X4nfKkqUuZVZ91ebm51A_3_11"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EiNpUK2b7k2PkIzqMYiCHw"
      decimals="2"
      id="Tc_ccwSbVBd_Eu2L_bQStXe3A_4_2"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aak9ct_niUi7Lq7sxeyMwQ"
      decimals="2"
      id="Tc_KWS_4BfEP0WCmvbFeBapNw_4_5"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PEUy1iet8kGcmgswzbVqLg"
      decimals="2"
      id="Tc_umA9ArISd0qgjypuZ8vaAg_4_8"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vhI6ja0bQUKTRyCoU2x99g"
      decimals="2"
      id="Tc_mSCQvhngSkWMQDhGJcihuw_4_11"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IviSwz1WNEmFo8vw--sRpQ"
      decimals="2"
      id="Tc_gN2wzr2rY0ufCZqXTPTP-g_5_2"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__IeX3c6reEm-Apq48lU1Ew"
      decimals="2"
      id="Tc_jA6h1pZRcUeY5JanahuaLQ_5_5"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4f86z1_gaUCyD4LR0zbwzw"
      decimals="2"
      id="Tc_R2VVJ0bvaUChdc6dHGpcUQ_5_8"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W4ZbE0h9nEqugpQqg-733w"
      decimals="2"
      id="Tc_rIgUTBCvZkajA2pmcE48Uw_5_11"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.20</us-gaap:ConcentrationRiskPercentage1>
    <chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_RY1_V707M06DHmPJHUVkbw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 109,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 321,056&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,064)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (181)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,300)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (320,022)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,869)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,829)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (446,720)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 356,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 520,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,859)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,035)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,715)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (362,241)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (78,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,716)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (516,557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_NTm60yerS06PfnGj4p8sbg"
      decimals="-3"
      id="Tc_9eGXMpEYLkqRanNM6RhLyA_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">29665000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_r2ythOcrUUuTOM2mUeKjUQ"
      decimals="-3"
      id="Tc_6mGS0KUgIU-uHMhMWdwkxQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">54004000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_5m_vF3mcb0iKQxtzWjcHZQ"
      decimals="-3"
      id="Tc_dFeRu-c9fEaY-4dzJ5JJVA_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26054000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_CXL4KlLti0GN2Yimf0QuAw_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">109723000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA"
      decimals="-3"
      id="Tc_HU43DKMTikOOw25Avd4ZPQ_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">321056000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ"
      decimals="-3"
      id="Tc_plLuvqAV_EiANFytHQkypw_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50939000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw"
      decimals="-3"
      id="Tc_ElaV8kpJ8EmrqFAsPU40mw_8_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">54967000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_8ES3zh4DqEGE0w9uP0pLPg_8_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">426962000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA"
      decimals="-3"
      id="Tc_elNZ7l4QyEOQTlnTmhZ9vA_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2055000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ"
      decimals="-3"
      id="Tc_vkCJyKsjfkOBch3nV0VV0A_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-5064000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw"
      decimals="-3"
      id="Tc_EJdMOZQWqEiK-gURDY0SPQ_9_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-181000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_TXU-e5sGgEWTY-49RVoJvw_9_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-7300000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_c8LJsg-FRk-9BG4z2EpyUA"
      decimals="-3"
      id="Tc_J_v-Gvr6iE2BcXgzJKW7Bw_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">320022000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_qqt0nP-qIkGAGMKH1O9MxQ"
      decimals="-3"
      id="Tc_jjpJGnO8bESpk_Q4RMvu9g_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">64869000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_B3TjGxfcx0-ESVQbJbormw"
      decimals="-3"
      id="Tc_3cOerRNfHUKareFEFPeLmA_10_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">61829000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-3"
      id="Tc_g0Fnby9jcUCOiM8zvmNt9g_10_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">446720000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_g3-gLMpZw0yYViaorsg8fw"
      decimals="-3"
      id="Tc_COEwT1P0nUWM4MrXUewFJA_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">28644000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_S_Q2ffeVKEC2FuV_r-0CyQ"
      decimals="-3"
      id="Tc_y15NTGNESEeslOkjdIwWTw_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35010000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_canvBDnSX0CAUr-ueKniXA"
      decimals="-3"
      id="Tc_lYGvtDN310SEvjQpYNppLA_11_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">19011000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_ZncGRNOE9EuYWg07gthi9g_11_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">82665000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_vqkwbtvNdk6jZk0lQqoE8w"
      decimals="-3"
      id="Tc_lVZgkq-YZk62hKCWC1xYEg_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40580000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_KqBdumQ4qkSE2fcmpfAufA"
      decimals="-3"
      id="Tc_qKwaPDpCSEGvZXtBN7-75w_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">54058000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_gnbxKpVogk6rFKwK3_goRQ"
      decimals="-3"
      id="Tc_OkykCr--w0qDZM42DE6nRw_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">28760000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_vsA6Kmd2xE6N6GZy2fY0XQ"
      decimals="-3"
      id="Tc_bahNhCGKN0y7qGnQJIl_KA_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">123398000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg"
      decimals="-3"
      id="Tc_wqsX_mPcLkacDuX70sKHtw_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">356663000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg"
      decimals="-3"
      id="Tc_1RFGKBmndUunjrs0_lYQgg_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">90965000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg"
      decimals="-3"
      id="Tc_GibhBik-XkuLElMuAXgMtA_8_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">73289000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_YqDFKHJUuk2liEM_I2OFGQ_8_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">520917000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg"
      decimals="-3"
      id="Tc_J6SvidAO30uM3MEB5pEIlQ_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2859000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg"
      decimals="-3"
      id="Tc_2M-wEpRDVUSs9F8aG6AtxA_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-2821000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg"
      decimals="-3"
      id="Tc_t9UQOaUm80ClfQaR7U9Ymw_9_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-3035000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_4LIZiaggCUi8Dr31l8iLZw_9_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-8715000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_RhisddNr30idTzUpPs_gIg"
      decimals="-3"
      id="Tc_8Rqp4jOZPUmpx4EzjdQjmg_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">362241000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JjkuWEE-FkyfyOgFhIVgGg"
      decimals="-3"
      id="Tc_4M-TIqIXtEm3Gwuxp56lWw_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">78600000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fhmhIKoT9UaaR5jiMR_Bwg"
      decimals="-3"
      id="Tc_XR1jR2Y4a0eF0p69LCccww_10_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75716000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-3"
      id="Tc_xjZ3wk2wlEW_Md_pC2XySw_10_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">516557000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_S3yaMtzKYEafjmMKoXco-w"
      decimals="-3"
      id="Tc_muPQCFP-E0e0mq2dwGepdg_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">32143000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_bfx-u6Wr1EqVZ6v_MBIiiA"
      decimals="-3"
      id="Tc_qDwb34SqfEOMcYgjzE-Ayg_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">63602000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_FCwSTIPa0ECHMWQCuTIDsg"
      decimals="-3"
      id="Tc_W90HVEwNYEaLxRXFPezR4A_11_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">23298000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A"
      decimals="-3"
      id="Tc_t7c3LAGvZkWQquEQCckumw_11_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">119043000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_CcSJRDmRj0aR_aRlVAlnDw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair values of financial instruments are classified into one of the following categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Where quoted prices are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds that are included in cash and cash equivalents, and restricted cash.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Narr_r6x-hbvLjE22nNbp5KWtdQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Narr_aEP-oHd0v0iybK67WoJV_Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_NiA4AHpbeU6rNC7pruKdGw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 286,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wzMkWYw-jkG5Z-S_a34Cdw"
      decimals="-3"
      id="Tc_lu_jNl7xM0qh7jTs_YmaXQ_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">286805000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rP5uVqxc9EqbTFWsU--suQ"
      decimals="-3"
      id="Tc_4bJk6BdvnkSqqbB6WOCd-g_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_493Ej-l6IkadHd0s8Ev8iQ"
      decimals="-3"
      id="Tc_qR8510MA7EuzIiN57XxWfw_5_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CnSVpPJZzU-M8zr97h3FzA"
      decimals="-3"
      id="Tc_ERd4STGECkiv-6AxPE9E7g_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">286805000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7Ka18T27VkWuuzFhDZZuGg"
      decimals="-3"
      id="Tc_Nn-bmKFNskWo2mNyb6gBLw_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vv--ebqCnkqV5_hs0bFUXA"
      decimals="-3"
      id="Tc_04qw2_M0oUOU-Kw_4u5GGA_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fLEz9P6UwkuwqfzYcZElYA"
      decimals="-3"
      id="Tc_bv654wWC_EqTKiTHJhtX2w_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gcq3kr0aY0K5_CRVytES5A"
      decimals="-3"
      id="Tc_tHHN5tg1Zk63tzK5MOUq4w_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OZ7xG5FttEWv9GoORmuT0g"
      decimals="-3"
      id="Tc_KHAAZw4Nn0W9mMdXg7SaPQ_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">287245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Rq5_ejfD4E-zhmch0hzaXQ"
      decimals="-3"
      id="Tc_v8OZw2mGh0CBqRQ6s9fcCg_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_JB1ySyU9gkuJVo799k_sDQ"
      decimals="-3"
      id="Tc_l4pfqXb2t0erT4a0fWRvsQ_7_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q"
      decimals="-3"
      id="Tc_urBwu9TfakKWHu4-f9eB6w_7_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">287245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-GKhnbmx6EqrslRQyD5gVA"
      decimals="-3"
      id="Tc_ipkwzPMU8kOKI_8XMTPVoA_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417165000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kn89hn5N_US1XfKr0SQ33Q"
      decimals="-3"
      id="Tc_nIRejwbFaUic0ISy0RQi0Q_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417165000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zkV-yxWOFkCnW-ddikAq5Q"
      decimals="-3"
      id="Tc_na0N20oQDESj4llOJjJ4iA_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_chrs_RestrictedCashMoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_h5ZptWvOE0uCY9Ybl5SojA"
      decimals="-3"
      id="Tc_m_MmvTiDD0CjO7_W89PLnw_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">440000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VlaCc70eukKJoN2_W3ugDA"
      decimals="-3"
      id="Tc_YlmWeOn_UUqm4mNpqh8w9w_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnYHy2xhCkCb9J7p4hkgRQ"
      decimals="-3"
      id="Tc_hoCtmyU2wkGk2d3GPaMbVw_7_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">417605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_ade33Wli902o9NYCu4gXEQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During the third quarter of 2022 and 2021, the Company recorded write-downs of inventory of $26.0 million and $5.2 million, respectively, in cost of goods sold in the condensed consolidated statements of operations. The write-down during the third quarter of 2022 was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration, which increased net loss by $26.0 million and basic and diluted net loss per share by $0.33 and $0.34 per share for the three- and nine-month periods ended September 30, 2022, respectively. The inventory write-down during the third quarter of 2021 was for inventory that did not meet acceptance criteria. Inventory reserves were $26.0 million&#160;and $0.2 million as of September 30, 2022 and December 31, 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company began capitalizing YUSIMRY inventory in the second quarter of 2022 and had $24.6 million of such inventory recognized on the condensed consolidated balance sheets at September 30, 2022. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current on the condensed consolidated balance sheets. As of September 30, 2022 and December 31, 2021, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following tables presents the inventory balance sheet classifications:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;Prepaid manufacturing of $20.6 million as of September 30, 2022 includes prepayments of $16.6 million to contract manufacturing organizations (&#x201c;CMOs&#x201d;) for manufacturing services for our products, which the Company expects to be converted into inventory within the next twelve months; and prepayments of $4.0 million to various CMOs for research &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;and development pipeline programs. Prepaid manufacturing of $13.7 million as of December 31, 2021 included prepayments of $8.3 million to a CMO for manufacturing services for UDENYCA; and prepayments of $5.4 million to various CMOs for research and development pipeline programs.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea&#xae; as part of a realignment of research and development resources toward other development programs. As a result, during the quarter ended March 31, 2021, the Company recognized $11.5 million within research and development expenses on its condensed consolidated statement of operations, which included an impairment charge of $3.2 million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. No material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <chrs:ScheduleOfInventoryTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_I-WXVlNjtkyd3_Z2ZT6QXg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfInventoryTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_SHmDGbVStEeG8SXbkQuSuA_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">10432000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_4xcKvIQ1mUSwdDmO9Lr7Cw_3_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4870000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_PSVs5q7NF0m_XMqHAA-5EA_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">77296000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc__Ook4Gln60a5FYJWGLKG-A_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">65117000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_nQ784kTN3kGJ0Xc9Ket2qA_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">17429000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_uUYdULZDNkKxnVOLtaxQ8g_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">23265000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_qZbUJ3HrPEWESRj8XGUhig_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">105157000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_nxh1hGdkH0q10TWMtkBHnA_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">93252000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-5"
      id="Narr_XLNap-_BM0S25dihIZKcEw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26000000.0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-5"
      id="Narr_I9O_bUd9s0WxOIJToWt8_w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5200000</us-gaap:InventoryWriteDown>
    <chrs:EstimatedIncreaseDecreaseInNetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-5"
      id="Narr_4SrdoH92fU6rEFnzuXl0kA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26000000.0</chrs:EstimatedIncreaseDecreaseInNetIncomeLoss>
    <chrs:EstimatedIncreaseDecreaseInNetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-5"
      id="Narr_XdBHyDSXC0aVEJkCkIzY7g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26000000.0</chrs:EstimatedIncreaseDecreaseInNetIncomeLoss>
    <chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="2"
      id="Narr_PM1J_BKJ30-J8Li5wOobLQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">0.33</chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted>
    <chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="2"
      id="Narr__iA7ewMImEuscDRr7-wknA"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">0.34</chrs:EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Narr_KfeXNCYoL0m6QKBrc-tp_A"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">26000000.0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Narr_QKeUZ7ZRUEe-mVFTrmIy0w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2022_srt_ProductOrServiceAxis_chrs_YusimryProductMember_JbvK-d-MGECmbZL_2UDv9w"
      decimals="-5"
      id="Narr_UctsxIulpUuR3QqzKlg7UA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">24600000</us-gaap:InventoryNet>
    <chrs:ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Group_oehF2OA_jE6nCZ1pDDJiBQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_Qu-zh5vtB0enpMZtbRWL1Q_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">27719000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_V8h95cVH1E-76-xEj22KjA_3_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">37642000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_30wgIp6A2UWUoY6yWf0JAw_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">77438000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_KO8k68u31kq_m0xaMuJ2tQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">55610000</us-gaap:InventoryNoncurrent>
    <chrs:InventoryCurrentAndNoncurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_SWM1VWWvxUSJziu-GQvyow_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">105157000</chrs:InventoryCurrentAndNoncurrent>
    <chrs:InventoryCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_vATGsAznn0eT4SY1CwrAZA_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">93252000</chrs:InventoryCurrentAndNoncurrent>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Narr_CxM4BkQ1FkiRQLpQ_RuAsA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">20600000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaymentsMadeToCmoForManufacturingServices
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Narr_g4yXP8_hUEysCTPdec4K2g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16600000</chrs:PrepaymentsMadeToCmoForManufacturingServices>
    <chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-5"
      id="Narr_0ndJstbNgUm0eRr1QuAW6Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4000000.0</chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Narr_b1NJx2-OnUmZ28crsGDW8w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13700000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaymentsMadeToCmoForManufacturingServices
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Narr_cFxeMI4KykKQUUHZtegHVA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">8300000</chrs:PrepaymentsMadeToCmoForManufacturingServices>
    <chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-5"
      id="Narr_Ooskb1SFWk2UqGRFj_byFw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5400000</chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_ihiIu3McBkWodWSPBrrhmg"
      decimals="-5"
      id="Narr_WTvWTBrkSkuSiJcWpyvEPw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_3_31_2021_13sEXRESQkGMwzJ6Bk2cwQ"
      decimals="-5"
      id="Narr_pi2Ft4WyXUqmj4sb9B4IqQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-3200000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_4_1_2021_To_12_31_2021_y7OZ_vllI0mGatYYUEzb9A"
      decimals="0"
      id="Narr_gg41X0oMXUGM00mJklPkWw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="0"
      id="Narr_hlFdlwk8X0uHzrG3daakmg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_6sEg06ZG4U2vHkj6hDXIrg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Balance Sheet Components&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,319)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,849)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;"&gt;Depreciation and amortization expense was $0.9 million and $2.6 million&#160;for the three and nine months ended September 30, 2022, respectively, and $0.9 million and $2.6 million for the three and nine months ended September 30, 2021, respectively.&lt;span style="color:#ff0000;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:1.5pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and other current liabilities are summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued commercial and research and development manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued co-development costs payable to Junshi Biosciences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,492&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,168&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_cAICcqMvkUeaMiIa_jpIfQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,319)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,849)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_inJcJWO_YkiWXRyFQlnw4w"
      decimals="-3"
      id="Tc_EvoZ3bBXbEO6fqdWmoD8XQ_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12878000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_2dIU4Wv5tE6Evkjk6He0eQ"
      decimals="-3"
      id="Tc_wDXFBc9vsk6Fbiax4aBH_w_3_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11876000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ghgoc7GaRUiVIJi-rnTZKQ"
      decimals="-3"
      id="Tc__GCtQjzq30qPliUDzDZtDA_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3055000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_8yRk0_sXYUyHmkgGMlwvkA"
      decimals="-3"
      id="Tc_nUN3hNUALUSz9ayJpv5xSg_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3033000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_d9EHcCoTPk-AEH8jjwR_JQ"
      decimals="-3"
      id="Tc_-ED5RPpOQkOLTuxKiOQTHQ_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1246000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B2ODLCj890aKQI7OAcmbTA"
      decimals="-3"
      id="Tc_GRy8_BOnoUaZMveKrrG01g_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1129000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_LqG5RoqoJEeZzKbXCggF-g"
      decimals="-3"
      id="Tc_ZxUtUYEekUyENBcJmVfJ4w_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6145000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_k4tZxvbaTESkkzwTRJUQcg"
      decimals="-3"
      id="Tc_d-HUckoJkkWCMtp_yysuWQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5942000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3qhcXT0gtkypEYBUMeOpTg"
      decimals="-3"
      id="Tc_iMVeN0dGg0ur8uydq8CSSg_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4721000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_clg6kOzlW0-1bv2N8PSJDg"
      decimals="-3"
      id="Tc_lmzPxEJHEUCfzNlCrxwt8g_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2294000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_yRUVgXSoDEydOBMMHjKAow"
      decimals="-3"
      id="Tc_4Deuujn-Y0GMwz6b-2e8EQ_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">845000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1UFzj38Bbk-gQfCQaA9EHA"
      decimals="-3"
      id="Tc_aNhDw5yEY0uia9SLl3Y4GA_8_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">388000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_XJBxqIjEJkKndqWGTf-mKw_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">28890000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_bRXtTbXaf0SxzwElydEwTQ_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">24662000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_58cfxSk-NEmCvBo4QaQ0Fg_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">19319000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_ACGg_hyJ_UOGIUYKeCmRIw_10_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16849000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_LLspQ0NhX0GHii6HAmJ1Gw_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9571000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_twxoXKHYIUmdJFXZJ-_BiA_11_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7813000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="-5"
      id="Narr_yNnVu9UsIEuOneNJYNmInA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="-5"
      id="Narr_8tPNjCXT90WPTqsaCHwqGQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="-5"
      id="Narr_xkQoyTotW0-y_cuB8YuIKQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="-5"
      id="Narr_sjsws-xi0k6pbvoK3Q9JWA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_8OzdxdY4QkewRzGpk-fwUQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and other current liabilities are summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued commercial and research and development manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued co-development costs payable to Junshi Biosciences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,492&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,168&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_ji7S4eZEbEuTswo2UziMKw_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">51523000</chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent>
    <chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_dDdnB3y9KUaNe8PD-ad6ng_3_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">30541000</chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent>
    <chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_C_vGGH6qs0ibxMaonqpnbw_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">17544000</chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences>
    <chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_R6vWjTudJECDPAezl0BwJQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1926000</chrs:AccruedCoDevelopmentCostsPayableToJunshiBiosciences>
    <chrs:LeaseLiabilitiesOperatingAndFinancing
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_mqKS_uCqT0-OiWKLwRsflg_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4097000</chrs:LeaseLiabilitiesOperatingAndFinancing>
    <chrs:LeaseLiabilitiesOperatingAndFinancing
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_H8FFU9TWL0e7fch281cesw_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3492000</chrs:LeaseLiabilitiesOperatingAndFinancing>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_yrhCNHKM4kCUVVLvxzdAjg_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12826000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_5psQTG7AgkSJ0Xz16wruxg_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12168000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_ppGAAnHjYUuEPfYa33bOrw_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">85990000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA"
      decimals="-3"
      id="Tc_WOlaZOJMsECAU65oBSQqtw_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">48127000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_yMqhl7DFg0ilFCQEhiG2cw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Collaborations and Other Arrangements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Junshi Biosciences &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;On February 1, 2021, the Company entered into an Exclusive License and Commercialization Agreement (the &#x201c;Collaboration Agreement&#x201d;) with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#x2019; anti-PD-1 antibody, in the United States and Canada. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;Under the terms of the Collaboration Agreement, the Company paid&#160;$150.0 million&#160;upfront for exclusive rights to toripalimab in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#x2019; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of toripalimab in the United States and Canada. The Company will be obligated to pay Junshi Biosciences a 20% royalty on net sales of toripalimab and up to an aggregate&#160;$380.0 million&#160;in one-time payments for the achievement of various regulatory and sales milestones. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. The Company will lead further development of CHS-006 and will be responsible for the associated development costs as set forth in the Collaboration Agreement. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay an additional option exercise fee of&#160;$35.0 million. Additionally, for each exercised option, the Company will be obligated to pay Junshi Biosciences an 18% royalty on net sales, up to $85.0 million&#160;for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of toripalimab and the other licensed compounds, including CHS-006, and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for toripalimab and other licensed compounds and will reimburse Junshi Biosciences for such costs. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $7.6 million in the third quarter of 2022 and $67.6 million in the nine months ended September 30, 2022, inclusive of the $35.0 million option fee incurred in the first quarter, and $15.4 million and $173.6 million for the three and nine months ended September 30, 2021, respectively. The first quarter of 2021 included $145.0 million for the upfront payment for the exclusive rights to toripalimab and the second quarter of 2021 included a credit of $9.0 million for the discount for lack of marketability (&#x201c;DLOM&#x201d;), discussed below. Accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022 included $17.5 million related to the co-development, regulatory and technology transfer costs related to these programs. The Company entered into a right of first negotiation agreement with Junshi Biosciences and paid a fee of $5.0 million which was fully expensed as research and development expense in the fourth quarter of 2020. The right of first negotiation fee was fully credited against the total upfront license fee obligation under the Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Junshi Biosciences. The additional milestone payments, option fee for the IL-2 cytokine&#160;and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued 2,491,988 unregistered shares of its common stock to Junshi Biosciences, at a price per share of $20.06, for an aggregate value of $50.0 million cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences is not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the&#160;two-year period &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#x201c;Finnerty&#x201d; and &#x201c;Asian put&#x201d; valuation models and determined the fair value for the DLOM was $9.0 million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the condensed consolidated statement of operations for the three months ending June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Innovent&#160;Biologics (Suzhou) Co., Ltd. &lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:8.2pt;"/&gt;On January&#160;13, 2020, the Company entered into a license agreement (the &#x201c;License Agreement&#x201d;) with Innovent for the development and commercialization of a biosimilar version of bevacizumab (Avastin) in any dosage form and presentations (&#x201c;bevacizumab Licensed Product&#x201d;) in the United States and Canada (the &#x201c;Territory&#x201d;). Under the License Agreement, Innovent granted to the Company an exclusive, royalty-bearing license to develop and commercialize the bevacizumab Licensed Product in the field of treatment, prevention or amelioration of any human diseases and conditions as included in the label of Avastin. Under the License Agreement, the Company also acquired an option to develop and commercialize Innovent&#x2019;s biosimilar version of rituximab (Rituxan&#xae;) in any dosage form and presentations (the &#x201c;rituximab Licensed Product&#x201d; and together with the bevacizumab Licensed Product, the &#x201c;Innovent Licensed Products&#x201d;) in the Territory.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;Under the License Agreement, the Company committed to pay Innovent a $5.0 million upfront payment and an aggregate of up to $40.0&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the bevacizumab Licensed Product and, if the Company&#x2019;s option was exercised, an aggregate of up to $40.0&#160;million in milestone payments in connection with the achievement of certain development, regulatory and sales milestones with respect to the rituximab Licensed Product. The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. During the three and nine months ended September 30, 2022, the Company&#x2019;s research and development expense related to bevacizumab Licensed Product development activities directly with Innovent was immaterial. &lt;span style="background:#ffffff;"&gt;During the three and nine months ended September 30, 2021, the Company recognized research and development expense of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million, respectively, related to bevacizumab Licensed Product development activities directly with Innovent. &lt;/span&gt;As of September 30, 2022, the Company did not have any outstanding milestone or royalty payment obligations to Innovent.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;On May 3, 2022, the Company provided notice of termination of the License Agreement to Innovent pursuant to Section 13.6 of the License Agreement. In connection therewith, the Company has discontinued development of the bevacizumab Licensed Product.&lt;span style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Bioeq&lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;"&gt;On November&#160;4, 2019, the Company entered into a license agreement with Bioeq AG (&#x201c;Bioeq&#x201d;) (the &#x201c;Bioeq License Agreement&#x201d;) for the commercialization of CIMERLI, a biosimilar version of ranibizumab (Lucentis), in certain dosage forms in both a vial and pre-filled syringe presentation (the &#x201c;Bioeq Licensed Products&#x201d;). Under the Bioeq License Agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. The Bioeq License Agreement&#x2019;s initial term continues in effect for ten years&#160;after the first commercial sale of a Bioeq Licensed Product in the United States which occurred on October 3, 2022 and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq License Agreement and a manufacturing and supply agreement between the Company and Bioeq dated as of September 29, 2022 (the &#x201c;Bioeq Manufacturing Agreement&#x201d;) and will remain in force until the first to occur of the following: (1) the termination of the Bioeq License Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt;"&gt;Under the Bioeq License Agreement, the Company must use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company must commit certain post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#x20ac;10&#160;million ($11.1&#160;million), which was recorded as research and development expense in the Company&#x2019;s consolidated statement of operations in 2019. The terms of the Bioeq License Agreement include an aggregate of up to &#x20ac;12.5&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#x20ac;2.5 million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA which occurred on August 2, 2022 and certain other criteria which were satisfied in October 2022. The obligation to pay this milestone was recorded in accrued and other current liabilities on the condensed consolidated balance sheet as of September 30, 2022. The Company will share a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low to mid&#160;fifty&#160;percent range. The remaining milestone payments and royalties are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved or when royalties are incurred.  &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <chrs:CollaborationCosts
      contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ"
      decimals="-5"
      id="Narr_VG-QQcb_7U6UnncjAiCkug"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">150000000.0</chrs:CollaborationCosts>
    <chrs:CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA"
      decimals="INF"
      id="Narr_LTyZesAsb02umQGc9BR4CQ"
      unitRef="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w">2</chrs:CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates>
    <chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales
      contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uxe_uZpFEkSEch43sMOUUQ"
      decimals="2"
      id="Narr_a4xBZxc8qUe1ZJ_vw29Wqg"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.20</chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales>
    <chrs:CollaborationAgreementThresholdRoyaltyPayments
      contextRef="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_k-3RgBaCqUq-ucT3E9EGSg"
      decimals="-5"
      id="Narr_k4G20Ol4mU2V-Cek-UNwgw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">380000000.0</chrs:CollaborationAgreementThresholdRoyaltyPayments>
    <chrs:CollaborationAgreementOptionExerciseFeePerProgram
      contextRef="Duration_3_1_2022_To_3_31_2022_-oXBZarHtkK0JSkSA05zDg"
      decimals="-5"
      id="Narr_JUMkpcpdPE6_vLLzxRXfKg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35000000.0</chrs:CollaborationAgreementOptionExerciseFeePerProgram>
    <chrs:CollaborationAgreementOptionExerciseFeePerProgram
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_dj746ZuzZEuFlhD-iyPunw"
      decimals="-5"
      id="Narr_kB8WpjOX3k2XwSeMV-6c4w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35000000.0</chrs:CollaborationAgreementOptionExerciseFeePerProgram>
    <chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA"
      decimals="2"
      id="Narr_5GzFO-o74EW_KwG8zW5I1A"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.18</chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram>
    <chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
      contextRef="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDVgIzSJCEyihHczolrtHA"
      decimals="-5"
      id="Narr_-9xshifxjUuts_kMQxYdeA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">85000000.0</chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram>
    <chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
      contextRef="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_cD5KRETU-UOVx1YHhrwR2A"
      decimals="-5"
      id="Narr_HQGtQPDLO0aR-e-ruA9sSA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">170000000.0</chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram>
    <chrs:MaximumAmountPaidCoDevelopmentActivities
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_SeCY9YBAE02JMhfk82yVRA"
      decimals="-5"
      id="Narr_ofLpt1G7dEGs3FH-IL08eQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">25000000.0</chrs:MaximumAmountPaidCoDevelopmentActivities>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_1qOFFGpSOkmstIVIX3zj7Q"
      decimals="-5"
      id="Narr_-72Hn-bcSkGbw1gDtg7xSQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_7jfBPaL450eXa1Y2g46z5Q"
      decimals="-5"
      id="Narr_1YSpYo7DDECKViPfIlHwnA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">67600000</us-gaap:ResearchAndDevelopmentExpense>
    <chrs:CollaborationCosts
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_ExclusiveLicenseAndCommercializationAgreementMember_FgRJm8jDqkSf5ige14aHFw"
      decimals="-5"
      id="Narr_kkF0Ox__-0mhbWzFe_rYkA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">35000000.0</chrs:CollaborationCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_84R_iMTr3kerbyr6upUqew"
      decimals="-5"
      id="Narr_SJxkY6i_WkWKbu4-j5eJmA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">15400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_lSeY1zTOCE6BV42943qNiA"
      decimals="-5"
      id="Narr_u2NZJAGjD0KI2mXhlvCnkQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">173600000</us-gaap:ResearchAndDevelopmentExpense>
    <chrs:CollaborationCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_287011mlzEmiZ0X0m6eNuQ"
      decimals="-5"
      id="Narr_NMIUgg3A70KtFetn7aPg2g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">145000000.0</chrs:CollaborationCosts>
    <chrs:CollaborationCosts
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_IDCtyjQAwkKPEG_SutcvdQ"
      decimals="-5"
      id="Narr_ahMeTOPRNEajZxEXiboKjw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9000000.0</chrs:CollaborationCosts>
    <chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts
      contextRef="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_MTxWxPxnDkiqyDu_XrhHiw"
      decimals="-5"
      id="Narr_6nNsTnAGQ0m93tDB9sAb6Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">17500000</chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts>
    <chrs:CollaborationCosts
      contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_AMgKdK-BQEurLZKKdbATnw"
      decimals="-5"
      id="Narr_SGxiPeuB9U-6wAKfW3ie-g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5000000.0</chrs:CollaborationCosts>
    <chrs:StockPurchaseAgreementSharesAgreedToBeIssued
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA"
      decimals="0"
      id="Narr_O9_j65Xm8kGmiKsUD3H4jQ"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">2491988</chrs:StockPurchaseAgreementSharesAgreedToBeIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA"
      decimals="2"
      id="Narr_wUXO1sTam0mcWhwFoAdM_g"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">20.06</us-gaap:SharePrice>
    <chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA"
      decimals="-5"
      id="Narr__4nhjuELPEya_uorMphXHw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50000000.0</chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue>
    <chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
      contextRef="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iM8hqKoK6kGGORI4m24fvw"
      id="Narr_lSQ4oxtyX0WYrTgWbRQIhw">P2Y</chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock>
    <chrs:FairValueForDiscountForLackOfMarketability
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_8BNCWvz2-EC4pRZnpWl1IA"
      decimals="-5"
      id="Narr_lru5z3CQGE-DwGbEsHM_2Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9000000.0</chrs:FairValueForDiscountForLackOfMarketability>
    <chrs:CollaborationCosts
      contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg"
      decimals="-5"
      id="Narr_7BAAp7AzFUi5t7RIgh1cKQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5000000.0</chrs:CollaborationCosts>
    <chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_BevacizumabLicensedProductMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_HW03BBLmHU-8JqNvuk_Smg"
      decimals="-5"
      id="Narr_EqHrQEZRTU6-_VjBNAa-xA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40000000.0</chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="Duration_1_13_2020_To_1_13_2020_srt_ProductOrServiceAxis_chrs_OptionExerciseFeeMember_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_uiPlNyA8AkK6KThMVOfv-Q"
      decimals="-5"
      id="Narr_7KIezKnTxkOYct-d8TB1vg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40000000.0</chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_FAORKnYJyESjSDSKaLODGw"
      decimals="-5"
      id="Narr_hIaUBpZhjEu2jYaUbaHmnA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_chrs_InnoventBiologicsSuzhouCoLtdMember_Yibptfnp5UWmdGj-9kWtqw"
      decimals="-5"
      id="Narr_O9pYChuNWES7_rSClbGNjA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <chrs:InitialTermOfAgreement
      contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ"
      id="Narr_Vhp0q5C8c0yiYEmbzULXcw">P10Y</chrs:InitialTermOfAgreement>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA"
      decimals="-6"
      id="Narr_dQtmLy_WwkehJmpF-vltTQ"
      unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA">10000000</chrs:UpfrontAndMilestonePayment>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_AlVmLJTA2Uy_iG88zsJcrA"
      decimals="-5"
      id="Narr_CEmQUTSYtUenCz8KZNAs4A"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11100000</chrs:UpfrontAndMilestonePayment>
    <chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_Lph8a238DkeDMCSZPU71Og"
      decimals="-5"
      id="Narr_qem1UGDAbEC_CskC-YnpEw"
      unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA">12500000</chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
      contextRef="Duration_8_2_2022_To_8_2_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rAiEo9Y69EihH3kDtMl5ug"
      decimals="-5"
      id="Narr_gr5naIStnES7qhNcE2zV4w"
      unitRef="Unit_Standard_EUR_0P9Q5sJULU-eA9-TDrvcyA">2500000</chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval>
    <chrs:PercentageOfGrossProfitsOnSales
      contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_C1uT_LtTsEeBsea_4T7CnQ"
      decimals="2"
      id="Narr_lOI8Mpq1_E-g_7rFt5KuPw"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.50</chrs:PercentageOfGrossProfitsOnSales>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_ranbE7plx0Gi7ib0js3lSA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt Obligations&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 9pt 0pt;"&gt;A summary of the Company&#x2019;s debt obligations, including level within the fair value hierarchy (see Note 3), is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Exit Fee, Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,712)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025 Term Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The principal amounts outstanding are subject to variable interest rates, which are based on three-month LIBOR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximates fair value.&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2027 Term Loans &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The Company entered into a loan agreement (including as subsequently amended, the &#x201c;Loan Agreement&#x201d;) with BioPharma Credit, PLC, (as the &#x201c;Collateral Agent&#x201d;), BPCR Limited Partnership (as a &#x201c;Lender&#x201d;), and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#x201c;Lender&#x201d;) that provides for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $100.0 million (the &#x201c;Tranche A Loan&#x201d;) that was funded on January 5, 2022 (the &#x201c;Tranche A Closing Date&#x201d;); (ii) a Tranche B Loan in an aggregate principal amount of $100.0 million (the &#x201c;Tranche B Loan&#x201d;) that was funded on March 31, 2022; (iii) a Tranche C Loan in an aggregate principal amount of $50.0 &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;million (the &#x201c;Tranche C Loan&#x201d;) to be funded at the Company&#x2019;s option between April 1, 2022 and March 17, 2023, subject to certain conditions including the first FDA approval of a BLA for the Company&#x2019;s product candidate toripalimab in the United States; and (iv) a Tranche D Loan in an aggregate principal amount of $50.0 million that was funded on September 14, 2022 (the &#x201c;Tranche D Loan&#x201d; and, together with the Tranche A Loan, the Tranche B Loan, and the Tranche C Loan, the &#x201c;2027 Term Loans&#x201d;). The Company has the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#x2019;s 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans bear interest at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; the interest rate for the third quarter of 2022 was 10.54% for Tranches A and B and 11.73% for Tranche D. In the event of the cessation of LIBOR, the benchmark governing the interest rate will be replaced with a rate based on the secured overnight financing rate published by the Federal Reserve Bank of New York as described in the Loan Agreement. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#x2019;s tangible and intangible assets and property, including intellectual property.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were and will be used to fund the Company&#x2019;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the Company&#x2019;s $75.0 million aggregate principal credit agreement with affiliates of Healthcare Royalty Partners (the &#x201c;2025 Term Loan&#x201d;), as well as all associated costs and expenses pursuant to which a payoff amount of $81.9&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the Company&#x2019;s $100.0 million aggregate principal amount 8.2% Convertible Senior Notes (the&#160;&#x201c;2022 Convertible Notes&#x201d;), as well as all associated costs and expenses pursuant to which a payoff amount of $111.1 million was outstanding.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes affirmative covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that begins at $200.0&#160;million for the quarter ending March 31, 2022, increases to $210.0&#160;million for the quarter ended March 31, 2024, increases to $230.0 million for the quarter ending June 30, 2024, increases to $270.0 million for the quarter ending September 30, 2024, and increases to $300.0&#160;million for the quarter ended December 31, 2024 and thereafter. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#x2019;s ability to incur liens, incur additional indebtedness, &lt;span style="background:#ffffff;"&gt;make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#x2019;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#x2019;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_zhRAFkTaEkWJkydvNPJsWQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;business days.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the closing of Tranche A, the Company incurred $7.8 million&#160;in debt discounts and issuance costs&lt;span style="color:#ff0000;"&gt; &lt;/span&gt;of which $6.8 million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $2.3 million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. Until unfunded tranches are drawn, the associated debt discounts and issuance costs are deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $1.0 million and $0.5 million, respectively,&#160;in debt issuance costs. As of September 30, 2022, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $4.8 million will be amortized using the effective interest rate over the remaining term of 4.3 years. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of interest expense related to the 2027 Term Loans:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2027 Term Loans as of September 30, 2022 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Remainder of 2022 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2023 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,402&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 269,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 358,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,094)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 Term Loans, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,754)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1.5%&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; Convertible Senior Subordinated Notes due 2026&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, the Company issued and sold $230.0 million aggregate principal amount of its 1.5% Convertible Senior Subordinated notes due 2026 (the &#x201c;2026 Convertible Notes&#x201d;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were $222.2 million after deducting initial purchasers&#x2019; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#x2019;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and &lt;span style="background:#ffffff;"&gt;structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables&lt;/span&gt;. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020, and will mature on April 15, 2026, unless earlier repurchased or converted.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#x2019;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. Since inception, &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.815 per share of the Company&#x2019;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#x201c;make-whole fundamental change&#x201d; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#x2019;s election before maturity. If a &#x201c;fundamental change&#x201d; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;The 2026 Convertible Notes have customary provisions relating to the occurrence of &#x201c;events of default&#x201d; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the features embedded in the 2026 Convertible Notes&#160;under the relevant accounting rules and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Capped Call Transactions&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the pricing of the 2026 Convertible Notes, the Company paid $18.2 million to enter into privately negotiated capped call transactions with one or a combination of the initial purchasers, their respective affiliates and other financial institutions (the &#x201c;option counterparties&#x201d;). The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been $25.9263 per share, which represents a premium of approximately 75.0% over the last reported sale price of the Company&#x2019;s common stock of $14.815 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and classified as equity instruments; thus, they are recorded as a reduction to additional paid-in capital on the condensed consolidated balance sheets. The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;If the 2026 Convertible Notes were converted on September 30, 2022, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $114.8 million based on the Company&#x2019;s closing stock price of $9.61.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:9pt 0pt 0pt 0pt;"&gt;The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes on the condensed consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the effective interest rate method. The remaining unamortized debt discount and debt offering costs related to the Company&#x2019;s 2026 Convertible Notes&#160;of &lt;span style="-sec-ix-hidden:Hidden_mJKNNF_1akSrcLTArm_qlw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$4.7&lt;/span&gt;&lt;/span&gt; million as of September 30, 2022, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;"&gt;The following table presents the components of interest expense related to 2026 Convertible Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2026 Convertible Notes&#160;as of September 30, 2022 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0070c0;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Remainder of 2022 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2023 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,800)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026 Convertible Notes, principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.2% Convertible Notes due 2022 &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;29, 2016, the Company issued and sold $100.0 million aggregate principal amount of its 8.2% Convertible Senior Notes. The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company. The 2022 Convertible Notes&#160;bore interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March&#160;31, June&#160;30, September&#160;30 and December&#160;31 of each&#160;year, since March&#160;31, 2016, and matured on March&#160;31, 2022. The 2022 Convertible Notes&#160;also had a premium of 9% of the principal amount which was payable when the 2022 Convertible Notes&#160;matured or were repurchased or redeemed by the Company.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, the Company fully repaid the 2022 Convertible Notes, and a&lt;span style="background:#ffffff;"&gt;s a result had &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; continuing obligations associated with them thereafter&lt;/span&gt;. The payoff amount of $111.1 million included the repayment of the entire outstanding principal amount, the 9% premium of the outstanding principal amount and accrued and unpaid interest. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following table presents the components of interest expense related to the 2022 Convertible Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;2025 Term Loan&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"&gt;On January&#160;7, 2019, the Company entered into a credit agreement with affiliates of Healthcare Royalty Partners. The 2025 Term Loan consisted of a six-year term loan facility for an aggregate principal amount of $75.0 million (the &#x201c;Borrowings&#x201d;). Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at&#160;6.75%&#160;per annum plus three-month LIBOR. Interest was payable quarterly in arrears.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on the &lt;/span&gt;third anniversary of the 2025 Term Loan Closing Date, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $81.9 million included principal repayment in full, accrued interest, a 5.0% prepayment premium fee of the Borrowings principal amount, and an exit fee of 4.0% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the payoff of the 2025 Term Loan totaled $6.2 million and was recorded in loss on debt extinguishment in the condensed consolidated statement of operations for the nine months ended September 30, 2022. As of September 30, 2022, the Company had no continuing obligations associated with the 2025 Term Loan.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table presents the components of interest expense related to the 2025 Term Loan: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,261&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,012&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#00ff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_JyUER1LECU-3R_q3GsKSIQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 9pt 0pt;"&gt;A summary of the Company&#x2019;s debt obligations, including level within the fair value hierarchy (see Note 3), is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Exit Fee, Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,712)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025 Term Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Level 2*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The principal amounts outstanding are subject to variable interest rates, which are based on three-month LIBOR plus fixed percentages. Therefore, the Company believes the carrying amount of these obligations approximates fair value.&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA"
      decimals="-3"
      id="Tc_Otgz4GSGFkCAG6blm1e_VA_4_2"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA"
      decimals="-3"
      id="Tc_iLwpkTzjg0eAcCgmZwyaYg_4_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-4754000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA"
      decimals="-3"
      id="Tc_SucPvTMg6E-DOh-JYXnkXQ_4_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">245246000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA"
      decimals="-3"
      id="Tc_k1F5sWr00Eq1AYxINJenIA_4_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">245246000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q"
      decimals="-3"
      id="Tc_L3_F7WIGBkmTE42O2WEN2g_5_2"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">230000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q"
      decimals="-3"
      id="Tc_AGWniHgp_06IgwVVctBJ8A_5_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-4750000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q"
      decimals="-3"
      id="Tc_-83CaLAteUCCOvRbgaawDw_5_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">225250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_dDaxqF683kyArySadSaO3Q"
      decimals="-3"
      id="Tc_Xk8wFd_7HEyLQY5-Gc0abQ_5_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">175950000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg"
      decimals="-3"
      id="Tc_eOOKtGddQ0yv5EOiJStQIA_10_2"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">230000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg"
      decimals="-3"
      id="Tc_Vqrz49xHOku5sIPlusw0zQ_10_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-5712000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg"
      decimals="-3"
      id="Tc_fuxyRdIfdECGGJQz-dckVA_10_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">224288000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_bGd7vOe6jEGQij-yo0nRtg"
      decimals="-3"
      id="Tc_lvukmfD_uUupzrKIZbwqJA_10_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">271860000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w"
      decimals="-3"
      id="Tc_SqXdT_GETEKrdVqK-4weLQ_11_2"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">109000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w"
      decimals="-3"
      id="Tc_WrCVtdF6O06ganl7ieQomA_11_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-521000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w"
      decimals="-3"
      id="Tc_9h6NQuDiPUW4PU1K-PS-gA_11_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">108479000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Ae0s3BY-T0GSD2TttkZ08w"
      decimals="-3"
      id="Tc_XKdzR-sAd066bAnlPlhB2g_11_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">108361000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw"
      decimals="-3"
      id="Tc_njLxf4lTJ0m8PmyFnjVtlg_12_2"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw"
      decimals="-3"
      id="Tc_K7ho3ac4bUCZ3ii9M7wnCA_12_5"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">513000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw"
      decimals="-3"
      id="Tc_RM63L4TviUO2zhAyd-2xzw_12_8"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75513000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_8VMOW1qLgkWJ24ciGPLXuw"
      decimals="-3"
      id="Tc_jQVn0qkneU6_Xuh5eWOXVg_12_11"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75513000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w"
      decimals="-5"
      id="Narr_4Dem1FxmC06LtE-OUORmJQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">300000000.0</us-gaap:DebtInstrumentFaceAmount>
    <chrs:DebtInstrumentNumberOfTranches
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w"
      decimals="INF"
      id="Narr_U0q2mu_PGk2-x2fm0XiVgw"
      unitRef="Unit_Standard_tranche_irYBJZf4GU-2pDQ3aghfCg">4</chrs:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_qqqXHtfBs0OufPeCKnuFoQ"
      decimals="-5"
      id="Narr_AWA4KvZRdUK8q3mRrxf8rw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ"
      decimals="-5"
      id="Narr_y3NUpqMtykOfPkCBXVXGwg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember_kdQLio7HLEqitGwRYsXFkA"
      decimals="-5"
      id="Narr_etf0v29ry0yPQ5Fou4nXOQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg"
      decimals="-5"
      id="Narr_AUukf7jhKUan3koVylcb5w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_FPqARq6mV0masUy1BsR29w"
      decimals="-5"
      id="Narr_JH1BCdeiUEKsNg5oFVi4Ow"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nxmJVGXvoESV6WgNqF9pPg"
      decimals="-5"
      id="Narr_h6EHC9-hBk-yQ0n5nsKrbw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg"
      decimals="4"
      id="Narr_FPjdu0G0fkuq2cELi3vxqQ"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_1LbWHBCaeUiM3ttGuW95EQ"
      decimals="3"
      id="Narr_qvmmgT7SE0uDc6N4BGsXgg"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_7_1_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaAndBLoansMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Vahrp9O7ZE6CBtpYv1agDA"
      decimals="4"
      id="Narr_ayEHhhz-OUiBXlJ7SxkDJA"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.1054</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_m-RRMH3z8UK2FguJb0RdSg"
      decimals="4"
      id="Narr_9KYDwuHbNkm0RZrNxjvFiA"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.1173</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <chrs:DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_dJtvDGh43k28lxYKOCunEg"
      decimals="INF"
      id="Narr_9KqKhyN1U022M8XXx0RbZA"
      unitRef="Unit_Standard_item_bmiXUHIn0Emf2AxEUqcy0w">5</chrs:DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Iy6ly7BuYkCb3Hlrkpohpw"
      decimals="-5"
      id="Narr_jdlGixV1fUWMnLNVMLKpng"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_ETG3zuq6rEOjceZCC4QiRg"
      decimals="-5"
      id="Narr_XvBuFQaz_kyJxvClBkwnxg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">81900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_EPh9mQbc5E-s3ez_S3RVbQ"
      decimals="-5"
      id="Narr_rWg9wGORTk6lDhDIdEo3Sg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ"
      decimals="3"
      id="Narr_43U5YRzDxkmwNw6aXFGqPw"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lgVJdipFVkupB9l6dHBIsQ"
      decimals="-5"
      id="Narr_5h02lbUnQ0mvcKoMIqDyBg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">111100000</us-gaap:RepaymentsOfConvertibleDebt>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodOne
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_daqLY4br_Uu1fyoZNNWJWw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">200000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodOne>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodTwo
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_SPYuYeOWfkihAF9Ur1NELw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">210000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodTwo>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodThree
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_8v9BXzxk7Uq6beSnEiyh7g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">230000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodThree>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodFour
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_ng7GZA6gvU-JHhn_LOj6CA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">270000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodFour>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodFive
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_us6GpnuKeEOkM40KUQzCEg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">300000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodFive>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_RXxIsuRCkkGGaNhY42HHGg"
      decimals="-5"
      id="Narr_2yva7gvzIEODPPzcQOiuSQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7800000</chrs:DebtDiscountsAndIssuanceCosts>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_gDtSu5nw3EapC7kTWAt91w"
      decimals="-5"
      id="Narr_2RaxJRT63k2XFAEZM5Yvog"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6800000</chrs:DebtDiscountsAndIssuanceCosts>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_76kJxJgZgEGENktd8re-Jg"
      decimals="-5"
      id="Narr_JGEZVTp3o0WyHwbngsnkAg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2300000</chrs:DebtDiscountsAndIssuanceCosts>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_4y5GyUTfQ0uUn63aLUuPWQ"
      decimals="-5"
      id="Narr_FqUKSzDWTEKYQwtv9cQS_w"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1000000.0</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_tGOHKSUC6UqNJty8oxptlg"
      decimals="-5"
      id="Narr_9jJAb2nN8UmquR7D6scuyg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_ZdRhP2tlY0uSkxF4mWUkLw"
      decimals="-5"
      id="Narr_emlz_GgFC0y2gLYMQXJlFQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <chrs:DebtInstrumentRemainingTerm
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_iHwIvN5laESr5Qc_H4fekA"
      id="Narr_ymHhzqmBu0-594aeHEwDPw">P4Y3M18D</chrs:DebtInstrumentRemainingTerm>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w"
      id="Tb_AJFX04q7aUWIUWpurdzLyQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of interest expense related to the 2027 Term Loans:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw"
      decimals="-3"
      id="Tc_N-8IhEaz2EigU2lMeehoBg_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5665000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g"
      decimals="-3"
      id="Tc_Ju3uikaP4k61RRfujIadBQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12577000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw"
      decimals="-3"
      id="Tc_7jqVKXgr2Ei4vYSRWEEvTA_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">622000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g"
      decimals="-3"
      id="Tc_xHF7jkmy40WPvKiPm-2wFw_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4122000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw"
      decimals="-3"
      id="Tc_akiiEE5byk-bFyzSpLflxw_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6287000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_P1FJOIkKc0aaeudgDtdw6g"
      decimals="-3"
      id="Tc_FKsFnmYgYEe2_fiD9NhvuA_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16699000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_ao9wvplpFEqW6L6FcXZ_6w"
      id="Tb_qoaklaNpUUu1f9gA9R-WFQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2027 Term Loans as of September 30, 2022 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Remainder of 2022 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2023 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,402&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 269,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 358,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,094)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 Term Loans, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,754)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_gjYqjpVdP0KJXndrEfR13Q_2_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6887000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_iLXt1yfS9EaHuI-ujtx-RQ_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">27327000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_D59vqe5YlEilwzdr3FTQog_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">27402000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_DfOV11BamEC3tMPsFzGWCA_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">27327000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_JNqwO9tkZkmPbXqFCn4IFQ_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">269151000</chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_bPv-nt1PUkGTRPUUfVc5Lg_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">358094000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_gzpR56HRoEq-yFu5MjSUQw_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">108094000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <chrs:TermLoanGross
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_r-wKsVY5qUmT6FLakT7FYQ_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">250000000</chrs:TermLoanGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_CswlqvZsR02Rz70YCXOE_g_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4754000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag"
      decimals="-3"
      id="Tc_CpUjExLrQUWWpP4_yWBbnA_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">245246000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="3"
      id="Narr_zXE2eF-YdUe7uHR5cDAcqQ"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="-5"
      id="Narr_qq-UG2Ry506tWzrqVo_Obw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">230000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="3"
      id="Narr_Phv-XsBT4EWLy3tsBOvyug"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"
      decimals="-5"
      id="Narr_C70tNvrFYkOoqqemb2TEyw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">222200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"
      id="Narr_yllf-PmAUkyE8uGCLm8Crw">The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="3"
      id="Narr_ldheLSp01kODQ__2ikiRjA"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"
      id="Narr__-evxVnINU6A-SojGfaNKw">2026-04-15</us-gaap:DebtInstrumentMaturityDate>
    <chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="4"
      id="Narr_h3ueFOxIrk-cdk230WWV4g"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">51.9224</chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes>
    <chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_nffCu3onMESWatrufmgoEQ"
      decimals="0"
      id="Narr_NvIqma5-HEKAC2QYcDWDBQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1000</chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate>
    <chrs:EquivalentToConversionPricePerCommonShare
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"
      decimals="2"
      id="Narr_hfEJTyxAT0epFNiiXYPkbQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">19.26</chrs:EquivalentToConversionPricePerCommonShare>
    <chrs:PercentageOfPremiumOnConvertibleNote
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lfB88UoOA0qcEaz0tSYX0Q"
      decimals="3"
      id="Narr_h3gRwxxvekqCYXI8-taDLQ"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.300</chrs:PercentageOfPremiumOnConvertibleNote>
    <us-gaap:SharePrice
      contextRef="As_Of_4_14_2020_ThcS1SrdqkuYZeougINqKA"
      decimals="3"
      id="Narr_o4wLlTcuW0iWoYcIXmMTPA"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">14.815</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg"
      id="Narr_qAMGiRivYkmE7MCcjp-UdA">As of September 30, 2022, the Company was in full compliance with these covenants and there were no events of default under the 2026 Convertible Notes.</us-gaap:DebtInstrumentCovenantCompliance>
    <chrs:NumberOfEventsInDefault
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bmA1J7_-g02NoTnD-cDbEw"
      decimals="0"
      id="Narr_r4B9nsZyP0qlatM_VpSd2g"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</chrs:NumberOfEventsInDefault>
    <chrs:PaymentForCappedCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g"
      decimals="-5"
      id="Narr_NU1OwdCtRUiYqkpPayLhRg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">18200000</chrs:PaymentForCappedCallTransactions>
    <chrs:CapPriceOfCapCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g"
      decimals="4"
      id="Narr_pK28cN1h_EGAEZzA7hkP8Q"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">25.9263</chrs:CapPriceOfCapCallTransactions>
    <chrs:PercentageOfCapPriceCappedCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g"
      decimals="2"
      id="Narr_22bA5LKKD0mT8l9-3bBpRA"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.750</chrs:PercentageOfCapPriceCappedCallTransactions>
    <us-gaap:SharePrice
      contextRef="As_Of_4_14_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_iUGghFecu06NDEYjC7SfZg"
      decimals="3"
      id="Narr_4i3LrH4nWEqN_krSQFQzsQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">14.815</us-gaap:SharePrice>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Ia8aHRxcikWcNmk3c7HDQg"
      decimals="-5"
      id="Narr_Eu7CwJXEKkCrCQybuT6wKg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">114800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="2"
      id="Narr_8eMBIezfSE6z-vkdnq838g"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">9.61</us-gaap:SharePrice>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-5"
      id="Narr_qS832gScc0GQHsdYbtcJ6A"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">900000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <chrs:DebtInstrumentContractualTerm
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA"
      id="Narr_KnVyUue0BEaumIrTqxpWGQ">P6Y</chrs:DebtInstrumentContractualTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="4"
      id="Narr_iSApamJ8mEaioWfyeVs7bg"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA"
      id="Tb_xEhN3LB-rES1JCabPV8MNA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;"&gt;The following table presents the components of interest expense related to 2026 Convertible Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg"
      decimals="-3"
      id="Tc_TU-TdkpOp0WLV7PFJ0abZg_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">863000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw"
      decimals="-3"
      id="Tc_U7VTnqdhaUimGCozYgEpHA_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">862000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg"
      decimals="-3"
      id="Tc_-F8iBpPCyUyePy3uPCv24g_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2588000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q"
      decimals="-3"
      id="Tc__Jtj5-u8B0SQeOtkQw_c7w_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2587000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg"
      decimals="-3"
      id="Tc_ryYH_ALHrEW8RDvjYa60yg_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">322000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw"
      decimals="-3"
      id="Tc_GgXIJX3xSka1X45AhoSLwQ_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">316000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg"
      decimals="-3"
      id="Tc_jIWpczcyc0uOqalmd2mkDQ_5_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">962000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q"
      decimals="-3"
      id="Tc_NoFx5mj0EkmwrA4YmzZXjw_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">942000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg"
      decimals="-3"
      id="Tc_AG5r8jzO5kGXje3VGVHvzA_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1185000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WLJXU1CORUOs_k-NQ8TgNw"
      decimals="-3"
      id="Tc_2r-Cu16F2UOPzBMekPR1MQ_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1178000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_oNfEZa4rikC7ImwD2CcZqg"
      decimals="-3"
      id="Tc_0skM80LbHEGvqVZgfIq_jA_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3550000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_UZ3vpxnHRkOOj8Gxq2Wq3Q"
      decimals="-3"
      id="Tc_TMDxpFMgN0acyyOnub-fMA_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3529000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_32YxOGELOkCsIM-OXlWxTA"
      id="Tb_BACf8bTLRkK7wi23XcgMdQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2026 Convertible Notes&#160;as of September 30, 2022 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0070c0;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Remainder of 2022 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2023 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,800)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026 Convertible Notes, principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_QiTZYPCXwUqvNoHkj0366A_2_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1725000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_Z8sF4x6nDUmvX4RAESJ0pg_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_soDidgudd0ix67mzN6fzEQ_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_v4Xqeut47k-9d7iftT8rYw_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">3450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_SrO552YK-U2bRRHPj3tXdQ_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">231725000</chrs:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_CXYBYXAgX0WwHRn5lG1Zfg_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">243800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_fm6iQSggK0GDW1IAYJL0ig_8_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">13800000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <chrs:ConvertibleNotesPrincipalAmount
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_8oAmEKnSPkmpDZ0QntE8Dg_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">230000000</chrs:ConvertibleNotesPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_VpqMBfTuXE2Q5r3G9sGnuQ_10_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4750000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg"
      decimals="-3"
      id="Tc_IB2Low8lIUezDkWefHWF5w_11_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">225250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw"
      decimals="3"
      id="Narr_oLdM9LhJ2Uq0LzFOoakWdQ"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw"
      decimals="-5"
      id="Narr_VepU_nxJW0WWmeoeZIc9rg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw"
      decimals="INF"
      id="Narr_eg4PnPPvLkeb7dmAEnzT3Q"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q"
      id="Narr_7tOEmqAzX0-Q9pAkdSCcjg">The 2022 Convertible Notes&#160;bore interest at a fixed coupon rate of 8.2% per annum payable quarterly in arrears on March&#160;31, June&#160;30, September&#160;30 and December&#160;31 of each&#160;year, since March&#160;31, 2016</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_wwDCjcDzPkuuXPFvIMVlzw"
      decimals="INF"
      id="Narr_OqF7FuEngUCUgYLAEJVe1Q"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ"
      id="Narr_oFd6qVgazE2Vmo9ZiHdc-g">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
    <chrs:PercentageOfPremiumOnConvertibleNote
      contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_raVrwONxfUyznOgwXVpVlQ"
      decimals="2"
      id="Narr_bMNfgCNEukyX7iQF-tw9Rw"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.09</chrs:PercentageOfPremiumOnConvertibleNote>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mOf6zlT2-0aupd-oM5ftjQ"
      decimals="-5"
      id="Narr_ADdKYukTtUuAb4fI8GaYmQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg"
      decimals="-5"
      id="Narr_m4gNrG_ymkC11FeBIglj2Q"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">111100000</us-gaap:RepaymentsOfConvertibleDebt>
    <chrs:PercentageOfPremiumOnConvertibleNote
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_KGFlZhBGXkylZRXCE8OzYg"
      decimals="2"
      id="Narr__TaD-SH-Y0qqN1pF_a6axg"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.09</chrs:PercentageOfPremiumOnConvertibleNote>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_UyhokirZm0i2-644r14vMg"
      id="Tb_FnF-_Z32JEGrTVBSyzyr9Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following table presents the components of interest expense related to the 2022 Convertible Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w"
      decimals="-3"
      id="Tc_-bdGByOTkk-hSsRHDdksSQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2050000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q"
      decimals="-3"
      id="Tc_zssuObOazEu2IN01R6EF7Q_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2050000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg"
      decimals="-3"
      id="Tc_ynECuyiiF02A2HsHEpp9wg_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6150000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w"
      decimals="-3"
      id="Tc_3UZU89F1UUK35T_q_TF07Q_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">497000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q"
      decimals="-3"
      id="Tc__7nS_5iTqk-Crc34ChvAaQ_5_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">521000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg"
      decimals="-3"
      id="Tc_H2o8GpD5_UaU06RFnEAs0g_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1457000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w"
      decimals="-3"
      id="Tc_vClOfaQBxUecY1okHJGYJA_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2547000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q"
      decimals="-3"
      id="Tc_Wrt8g7o5AkuOsnCEdDZTvw_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2571000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_H704fBTgEk-02LFFkbAXGg"
      decimals="-3"
      id="Tc_BGOwHePIpUiYIYZolvipKQ_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7607000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_gVgB94UeLkKTlxsG-jRXZg"
      id="Narr_vOKujek3L0y0TiunAfXmXg">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w"
      decimals="-5"
      id="Narr_013WYEaIFEeLduU4RVB9pQ"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_bBSNDUjUnEaZ-RMx_cW1_w"
      decimals="INF"
      id="Narr_3o8tH3TKVEWimP0KP3lYHQ"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g"
      decimals="-5"
      id="Narr_BzSPj7QMBUiTvLZBvtYxeA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">81900000</us-gaap:RepaymentsOfDebt>
    <chrs:DebtInstrumentPrepaymentPercentage
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SJkhVBwrA0SLA7eqmarAbg"
      decimals="3"
      id="Narr_W-vlV-u-20mIg6K0rqYEag"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.050</chrs:DebtInstrumentPrepaymentPercentage>
    <chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g"
      decimals="3"
      id="Narr_tqIc8-augkKNZBW6Rwe7Lw"
      unitRef="Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ">0.040</chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ShTzqJSdTUms93Qc_FgS2g"
      decimals="-5"
      id="Narr_P2DaE6YyYUyLCiVW9r9TZA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">-6200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_eGmvrJ29CUKSMH_a7DSGFw"
      decimals="-5"
      id="Narr_1sGWaNWqGkq4OdudW_Fvvw"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">0</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_SjhD1IrJykmX9woy0w48cg"
      id="Tb_g21J7syCmU24b-ejR-FfXw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table presents the components of interest expense related to the 2025 Term Loan: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,261&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,012&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ"
      decimals="-3"
      id="Tc_d3tI6jY_rEOy1apb0cRKWQ_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">1773000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw"
      decimals="-3"
      id="Tc_pItZIN1yD0KTOqRQOIbvhw_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">154000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw"
      decimals="-3"
      id="Tc_Fzbw4RyQ9UWjVefn3f5KRg_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5261000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ"
      decimals="-3"
      id="Tc_ayCpfnXnOkGIM-wlCQJOCw_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">273000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw"
      decimals="-3"
      id="Tc_RjNqz4J3iUajOp9hHAuYhw_5_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">16000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw"
      decimals="-3"
      id="Tc_6V3KmNdFDUSdV014GJ77UQ_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">751000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ"
      decimals="-3"
      id="Tc_BmDTzGujjEWTLZ9zOlL_Sw_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">2046000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-4iB4qMIHUKs6XM6Dv77jw"
      decimals="-3"
      id="Tc_j417iohuqkuLRO5VJcElQg_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">170000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_a_4Ie-UTP0KgAa9totUoRw"
      decimals="-3"
      id="Tc_hJ1jmaEkoEKec0lYimC4-w_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6012000</us-gaap:InterestExpenseDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_rN7epk7AUES2V1KpnHRb7w">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Purchase Commitments   &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of September 30, 2022, the Company&#x2019;s contractual obligations under the terms of the agreements are as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Years ending December&#160;31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Remainder of 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are generally cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Guarantees and Indemnifications&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Legal Proceedings and Other Claims&lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"&gt;The Company is a party to various legal proceedings and other claims that arise in the ordinary, routine course of business and that have not been fully resolved. The most significant of these are described below. The outcome of such legal proceedings and other claims is inherently uncertain. Accruals are recognized for such legal proceedings and other claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. The Company did not have any accruals related to such matters on the condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#x201c;Zinc&#x201d;) asserting Zinc was entitled to approximately $14 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company is unable to reasonably estimate the amount or range of loss that may be incurred, if any, in connection with this matter. At this time, the Company has not made an accrual in connection with this matter.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Other than the matter in connection with the demand letter described in this Note 8, there are no material pending legal proceedings or other claims, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries&#x2019; property is subject.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_366qgrYoJk-bhCqC1GreXw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Years ending December&#160;31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Remainder of 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermPurchaseCommitmentTextBlock>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_NVSVjJZa2EeqbBfEOqqexA_2_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">9448000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_9Gh4Ag0J-kGLLkHb7ZAFHg_3_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">28740000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_a8cQcvgl3EWFs2yKxTFO8g_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">911000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_HmHY30HdaEOmzXho08pgOQ_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">911000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc_DCE1VF5fdkiV63QRGP0eWg_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">208000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligation
      contextRef="As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w"
      decimals="-3"
      id="Tc__yq0NRrnvk6RiT9IbQJe_g_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40218000</us-gaap:PurchaseObligation>
    <us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
      contextRef="Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ"
      decimals="-6"
      id="Narr_Si_vyQObSE-CVzmrn_H5ng"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">14000000</us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_9TqgzzbBVkSZJcQSbcFOtA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the classification of stock-based compensation expense in the Company&#x2019;s condensed consolidated statements of operations related to options and restricted stock units granted to employees and nonemployees:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of goods sold &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense capitalized into inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w"
      id="Tb_Xv6JBvhkMUi5FA2MPnAvXQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of goods sold &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 896&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation expense capitalized into inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"/&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_XmTlwxSGn0m_uPHHGMPW9Q"
      decimals="-3"
      id="Tc_VVlDJtVo_UaGzbnn5b3Zhw_4_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9qbE_7hJb0OAo7eMUGImJA"
      decimals="-3"
      id="Tc_oH8sXoEUjUW0ysPb8OPRbw_4_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1z-ozshyUUCySLmdDcUEPA"
      decimals="-3"
      id="Tc_1O8DexTOFkWMrQ7CpLmJVQ_4_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">555000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hXNe2mN_6kq827XHdcENIA"
      decimals="-3"
      id="Tc_r7kbByQalUOekRFZczpgsQ_4_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_J1o7boGRZkedZZJHTOblEw"
      decimals="-3"
      id="Tc_Kr5Mthne8EK0q6wCXK63ug_5_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">5173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WaMcf-CWnEOlS3SaJTgvdg"
      decimals="-3"
      id="Tc_TNIBH83hUkiS2G4qBettNA_5_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">4126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5hmkNI6CL0Kpwf9YcrulMA"
      decimals="-3"
      id="Tc_IEUEPAF8y0SYImGH7GYi6w_5_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">14707000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2_50U8Eql0mBG5Pu9OJs8Q"
      decimals="-3"
      id="Tc_-CdSK2VKiEy3LxEXV04twA_5_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">14642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wwwSCpIHT0qG7pxdRVzYHQ"
      decimals="-3"
      id="Tc_Fzt5X_LsDUa0SZ7yjAebIA_6_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">6925000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ZH1LNjXzG0q7CAxQn1L9Tg"
      decimals="-3"
      id="Tc_NzZ7abnJZk6mtwWyLSfBqw_6_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">7419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_XYdisJOhq0qqXhF-fMCTHg"
      decimals="-3"
      id="Tc_QsTGFh-7pE6Ta8Gw3uVqdw_6_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">23749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cGIwu14pwEeco2TOLfoZWw"
      decimals="-3"
      id="Tc_Jue68wOlm0Sunc_j5EZ2_A_6_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">24880000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg"
      decimals="-3"
      id="Tc_LwtzcMzHCUeeGS5Vcg6Xlg_7_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">12282000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ"
      decimals="-3"
      id="Tc_0DXFLQ93EE6o_A8xyyL4eg_7_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">11939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q"
      decimals="-3"
      id="Tc_stGAM_UjN0WPjnxBXR9hiA_7_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">39011000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw"
      decimals="-3"
      id="Tc_agwtojqk5E2Ju7YnIyv-oQ_7_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">40418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg"
      decimals="-3"
      id="Tc_6Ym_9DTQEkOcTRJ2zFOzfA_9_3"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">290000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_ME7-4ZIjfkStZcXYTmN7OQ"
      decimals="-3"
      id="Tc_NrT6t99Nd0WNiZAkyfD3Lw_9_6"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">241000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_cxj7fqOjgUS6Tr6ZKNVv3Q"
      decimals="-3"
      id="Tc_ZeT9L2pUr0mtOcVOu2XMoA_9_9"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">904000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_8r6IFPy-Wke57widYCveBw"
      decimals="-3"
      id="Tc_MiNpDVcKoEC1B1zRfkzKUw_9_12"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">758000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_Ju5uKuFPHU69gb-6o8tVug">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;&#160;&#160;&#160;&#160;&#160;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock options, including shares subject to ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,535,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,543,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,267,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,847,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,305,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,916,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,401,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,812,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,783,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,875,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,052,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,076,739&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_cYASZ11jR0G4ilbNCXSleg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.37090683%;padding-left:0pt;padding-right:0pt;width:100.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock options, including shares subject to ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,535,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,543,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,267,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,847,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,305,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,916,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,401,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,812,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,442,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,783,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,875,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,052,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,076,739&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_dEoY-sHSzUK02mdFlAWJzw"
      decimals="INF"
      id="Tc__93dHk2GdkC8le36gbY0EA_4_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">22535371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_kXWTWhXhFk2byCH1j93xkg"
      decimals="INF"
      id="Tc_wOtcxas_q0icbieMDtykVQ_4_4"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">19543671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_Xt8hsRyWYUinCw6qBafEHQ"
      decimals="INF"
      id="Tc_2SAhnbhb8ECfABm3If0FLQ_4_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">22267304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_9008h6QJQk6ZQdJ45f6bfw"
      decimals="INF"
      id="Tc_2g93G0HbwEON7-YMZMv4cw_4_8"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">19847917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_twLiW2yaC0qy7WXGVse05g"
      decimals="INF"
      id="Tc_WT6s5SH400aQxnerUFmdng_5_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">2305743</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_g1id0jQAJ0KFh6228c8jNg"
      decimals="INF"
      id="Tc_ge0wdEb2REGJZGZaeSXAng_5_4"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">1916002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FSdT6Jp3yEaigOhy6sE_5w"
      decimals="INF"
      id="Tc_5Xf4AwTSM0em4YNdAo5HhQ_5_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">2401188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gkYrhJtFPkWcVDhkufdQuA"
      decimals="INF"
      id="Tc_gqTyRUWLpUWFyYZ0ipF2CA_5_8"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">1812799</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yEOGTOZIeEWn5yVBWgq8Iw"
      decimals="INF"
      id="Tc_vufCa4_ZZUG0xyFZUsLTHA_6_4"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">4473871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_dED-Hyl570q2Gq2GdE_Mmw"
      decimals="INF"
      id="Tc_LUwyvCGSUUSm9I-4X_rbQA_6_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">1442127</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_U4ZdZnH3fkC5viSWX3m83Q"
      decimals="INF"
      id="Tc_nBAL0_yEQkaPENG7hb0y7Q_6_8"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">4473871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Bc_irE1EYEa0-ZkdPtAZuQ"
      decimals="INF"
      id="Tc_qnw3R5i7U0WQoOIQYpYMFA_7_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_Aww4QNVaLk64YAzs3J9iFA"
      decimals="INF"
      id="Tc_HgNG4MWdyE-1IMnipaJCdg_7_4"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lz0mTF4wV0GFylKh3m490w"
      decimals="INF"
      id="Tc_KZbikrYHtUOfEiukYcGipw_7_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_8AMDQ5u-0kqsUupldYB_uA"
      decimals="INF"
      id="Tc_GRL4H3kk40aY8iR495J5Og_7_8"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ"
      decimals="INF"
      id="Tc_efHu2d2cw0KXBgdxt1rypw_8_2"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">36783266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ"
      decimals="INF"
      id="Tc_JbFlLxILkkeqdH_kwimFUg_8_4"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">37875696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      decimals="INF"
      id="Tc_wzmJqwdXS0imkgt-NqmrDA_8_6"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">38052771</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_l3G3OyUppEuMDW0DOfUU7g"
      decimals="INF"
      id="Tc_TUb-_3tnZUeIIqUx9wMYJA_8_8"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">38076739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA"
      id="Tb_UwOcmbDVakmDKTZA3L9oMA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;&#160;&#160;&#160;Related Party Transactions&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Consulting services&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#x2019;s President, Chief Executive Officer and Chairman of the Board of Directors. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 (See Note 6). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase 65,000 shares of common stock with an exercise price of $17.60 per share to Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences. During the first quarter of 2021, the Company recognized non-cash &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;stock-based compensation expense of $0.8 million and consulting service expense of $0.2 million related to these services. There have been no subsequent material related party expenses. Total liabilities recognized on the condensed consolidated balance sheets with respect to these services were immaterial as of September 30, 2022 and December 31, 2021. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug"
      decimals="INF"
      id="Narr_sEJjuKrdO0WbrQfw1Pgzsg"
      unitRef="Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug"
      decimals="2"
      id="Narr_Xo49SJP-KkixiwfQaxkFeQ"
      unitRef="Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q">17.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw"
      decimals="-5"
      id="Narr_pgPhPnaDwUKDXEozULlleA"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_1bo3e7kB90GaNZUXhPY0yw"
      decimals="-5"
      id="Narr_nt3nEVs0zkeDmpdaTCfrlg"
      unitRef="Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4>86F>Y$ID=&'=#>Z.>N,TURKP&V>C)Q4CMQPIB,E-I&<4(F=!(\$ =_7=Z
M.%F?]_WJ1 FV!<0!2T8R'69A&!$\(70/C<0K]!<I\Z>B++LN+6K-Z\<"5B//
M#.@='BA)T_%RY+!B8335KP/*B)<>?4YMQ1WO6FI/@(C&8Z6V%<&83BSO9" 1
M\:-HFU&>?F2.$<4IMO39=E&<,A9,"!P 1(*OJ@O*@C\49:$+X2X.B!=DWUH=
M?"]OAT$//"-^H+W),ME"/8#6_-E@UQFPC:PT)=:XV%8D(F$Z,2P#V8@?;:"P
M::$\;<0#E*DPRY="J"X]^_YPSR8;86'0U8^'HFVS.,5[.7$H>D =\;/N170F
M*]A\*6ZV+TZ9+L2QU)+I,*.83$WY 7+$3[D7F0.,,SL)G+IMH"6PZN&Q;@<>
M$S+9O0/WB!]\AW0^IM5&&M2KS"K,7'91R*;4T@%^U ^_#Z*I4"EY[91';9+1
M(*3!F" .NS@,I]!,!^)1/_%@#[B!(J*C7"VUNP^IC2]*0QJ.!]QAQZ 'HZD^
MW-NS^4'WFX!]^_Y('Z4=M3D6$3JN=!U6,0W)A-P!=M0/NRV7OTFNC36"QZ6N
MPR@.)VH>.H"/'MEZ==ET)(NHO:&*@@0'U@RP[<($<#51C].!5-1/JAM9584V
M!>YV]<]DK6&3(^H,%*.3/V#JHN34*=WKV(U8Y-S)_W]'A\$/$*21MS:YUS+[
MM))E+AKU4U?J0]5_DHMED17ZU'V&X<7J-Q]B?"=OA_$//*5^GIK!ES52IAO0
MR2M\@3$F4+,T:,/+5KQ&:L4;4Q:T>B6;XA^17R*&\1G>_MN]+Y3:\:[5"LK[
M'.;0)8KCLSC&9V'*NG=Q=)8R:)E&B&MT+]9:5 ^0T"^'6)W1K<CZI_W9U)FI
M2-:B.Z0LG]U3T0;YN([RFAQVW\!Y>H3S>5Z8$@32W&R^SXL:97Q=0-H[1=K4
M)B0)DVB\"7,:!G$23$%I #SU QX*D[9JR^Y<LB],H))JQ,H<)F\ !%*Y5RF;
MX><TMM:H(U:'1VT#YYF?\_NB^]1T'K/9(#\G-*&QM<EU6N(@3<*)RH\-U&=^
MZF_7?.5=5ISB;<"?IU!-C;GJL$OCF$X<(;&A#F#^.L!B59>*_R$.:IUB.G>;
M#COG;G.^=QQO?@OYG3>/1:U0*9;0$%_$T!/-]N>%[8V6Z^Z$_D%J+:ON<B4X
M!& ,X/U2 M#Z&W/HO_N19_$O4$L#!!0    ( %N :%4M&A#V=P(  #4'   8
M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK571;M,P%/T5*R $TFC<I,UH
M:2.Q3@@>D*I5P+.;W#96'3O83COX>JZ=+&I'-EI!'A)?^Y[C<ZYC>W90>F<*
M $ON2R'-/"BLK:9A:+("2F8&J@*)(QNE2V8QU-O05!I8[D&E""-*D[!D7 ;I
MS/<M=3I3M15<PE(34Y<ETS]O0*C#/!@&#QUW?%M8UQ&FLXIM807V:[74&(4=
M2\Y+D(8K231LYL&'X721N'R?\(W#P1RUB7.R5FKG@L_Y/*!.$ C(K&-@^-G#
M H1P1"CC1\L9=%,ZX''[@?VC]XY>ULS 0HGO/+?%/'@7D!PVK!;V3AT^0>MG
M[/@R)8Q_DT.3FV!R5ANKRA:,"DHNFR^[;^MP!!B.G@!$+2 Z%Q"W@-@;;91Y
M6[?,LG2FU8%HEXULKN%KX]'HADNWBBNK<90CSJ8+)7-<$\@)MHP2/&<6@QLF
MF,R K!RQ(:^73(.T!5B>,6'>D+?D)0F)*;#;S$*+0AQ=F+63WC231D],NH)J
M0&)Z12(:13WPQ?/P6\@0/O3PX2D\1/M=#:*N!I'GB_^E!GTN&]I1/ZW;?U-3
ML0SF 6XP WH/0?KJQ3"A[_L\_R>RDPK$707BY]BQ F6)>PK_MFQW12JFR9Z)
M&OH\-T37GL@=$?N4#BBEN [[8S=_33O1.>ITCB[0V?Q^A-6V4)K_@KQ/;T,X
M/A(2T_9Y)/F<S!/5XT[U^'+5W)BZ7_'X#QW7^-#Q)'XDN"<QF:#F2=*O-^GT
M)I?KQ1O 6"9S+K=]HI-S1?<D]HL.CPXU=Z%\87K+I2$"-@BE@VODT,TAW016
M5?Z<6RN+IZ9O%GBO@78).+Y1RCX$[NCL;LKT-U!+ P04    " !;@&A5Y)*_
M2JX%   4&P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U977.;.!3]
M*QIO9Z>=:6,D\2&RCF<:X\YV9KO-).WV&1O99@K(BV0G^^]7 AL;<<TF65YB
M(.<>Z5Q=K@XP>13E3[GA7*&G/"ODS6BCU/9Z/);+#<]C>26VO-#_68DRCY4^
M+==CN2UYG%1!>38FCN./\S@M1M-)=>VNG$[$3F5IP>]*)'=Y'I?_W/),/-Z,
M\.AXX3Y=;Y2Y,)Y.MO&:/W#U?7M7ZK-QPY*D.2]D*@I4\M7-Z".^GI,JH$+\
ME?)'>7:,C)2%$#_-R>?D9N28&?&,+Y6AB/7/GL]XEADF/8^_#Z2C9DP3>'Y\
M9/]4B==B%K'D,Y']2!.UN1FQ$4KX*MYEZEX\_LX/@CS#MQ29K/ZBQQH;A".T
MW$DE\D.PGD&>%O5O_'1(Q%F YH$#R"& V 'NA0!Z"*#/'<$]!+C/'<$[!%32
MQ[7V*G%1K.+II!2/J#1HS68.JNQ7T3I?:6$*Y4&5^K^ICE/3F2@2O>P\0?I(
MBBQ-8J5/'I3^T?6@)!(K]'7+R]BLJT0?T/>'"+U]\PZ]06F!OFW$3L9%(B=C
MI6=C.,?+P\BW]<CDPL@4?1&%VD@TUS-(@/BH/S[LB1_K+#2I(,=4W))>P@>^
MO4+4>8^(0P@PG]GSPS$DY_^-/G_UZ*UDT*8N:,5'+_#=\STO=OP:6M<ZTH4C
M36>[EMMXR6]&NG5)7N[Y:/KK+]AW?H.2.B19-"39?""R5OK=)OUN'_OT3[U%
ME/420"M0!_M5L-D*]E/7<XD[&>_/4]M%,>(YM(V*NBCL>W[HM&'S+HQX%+,3
MK*73:W1ZO64V$U*W&-U $'_:FCXDP8KSAJRX(<FB(<GF Y&U5L)O5L+OK3BS
M$J;7KX5()-([ =22;VL.[ZP*J$>H77A=%,&$6145=5&>QQBVZJZ+TJ7. KCL
M@D9LT"OV7J<O+I>;JO(2?9]E8FMV.TAR $R .<R2W$5YKL,\2W(7A0.'4M_2
MW(51K+-,8=&L$<UZ13]H-Y86Z_=HS0N]GV>5^#C1IB*5RNSO>[#7L*Y^EU%K
MF69=% U#8NOOHK F\^U> \!PZ/L8UA\V^L->_=^$TJ*7G8X#B0Z[,R >"ZS>
M.0-@V"-V[XRZ,!I@)P@LV5V8&P1N>$$V=DX6S^D5_H>0$JU*D2/1&#G0KSF=
M"7Q@CNN&EFH(1TG +#T1A"..1VW@' 02E^)+TL_<+>Z5_KE07/=*=5QL4#;N
MCA[HN]=6#<"\(,"V: !&J,-"6S. PP'V_0N2R4DR^>_5UH]@"5\8V4K?\KM4
M;BZUMWZVE^ZM@[)%![96CGQB['$[E0,-VD[XR2GC7B<X_:HVO-0/0TN1<_3V
M4&COWJ."PPFGW:9!:><>ZZ*HW58@)H9=.SL RB$7JNSD3W&_0:VJ;,%7HN1'
MZ2I^@IOI@:K=5WS?Z]QA (XRCS!;-X CE##6D0X!74P#[X+\DVW%O5ZL\N>9
M3@$HU^M895@N@ /E CA8+@3LDWORAMCOM>E'N4CO'TANXA)^,,2]%O/%O61(
MMFA0MOE0;.WU.-E7W.]?;V.9+DV#L58%7)2:BK4VFBML&S@(YES9>W]T@+6+
MUJY#@(I>D4L]Y^1?<;^!C=)L9UY./5,W>YYN  ;I9L_0#5#UZ#[Y5ASVWGT_
MJK>=//D0[[5]6W-4[/*%EJZ?UBKU$NW,"[RTT.8VW^[,C@_D"+YC>RWSB^_8
M(=FB0=GF0[&U7RV>/#CI]^"O6</%"^YRTK70@7YX\%EH/8/-(&3H8$ILQQN!
MG!YQB&OO/!#2#9G++CEX<G+PI-_!OR9QR8L:!>DZ\4NI Y 74@=QPJD#D'#J
MQF=O^7->KJO/*U++WA6J?K';7&T^X7RL/EQ8UV_Q]0P#UR-\/:\_T)SHZ^]%
M7^)RG18297REAW*N CW=LOX$4Y\HL:V^,2R$4B*O#C<\3GAI /K_*R'4\<0,
MT'P(F_X+4$L#!!0    ( %N :%5ABN5L(@,  *<+   8    >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULK59=;]HP%/TK5E9-FU2:D!!@#"*MP+1)ZU:5=7LV
MR858=>+,-M#MU^\Z"1E0%[&-%["=>\[].D[N<"/D@TH!-'G,>*Y&3JIU,7!=
M%:>0474E"LCQR4+(C&K<RJ6K"@DT*4$9=WW/Z[H99;D3#<NS6QD-Q4ISEL.M
M)&J5953^O 8N-B.G[6P/[M@RU>; C88%7<(,]'UQ*W'G-BP)RR!73.1$PF+D
MO&L/ICUC7QI\8[!1.VMB,ID+\6 V'Y.1XYF @$.L#0/%OS6,@7-#A&'\J#F=
MQJ4![JZW[._+W#&7.54P%OP[2W0Z<OH.26!!5US?B<T'J/,)#5\LN"I_R::V
M]1P2KY0660W&"#*65__TL:[##@!Y[ "_!OB'@,XS@* &!*=ZZ-2 SJD>PAI0
MINY6N9>%FU!-HZ$4&R*--;*915G]$HWU8KG1R4Q+?,H0IZ.QR!/L.B0$5TIP
MEE"-FYG&/Y2#5D0L\%&&(DR-.M9 /@FE2(O<SR;DU<5K<D%83KZF8J5HGJBA
MJS$JP^W&=037503^,Q$$Y$;D.E5DBI$D%OSD./[-$;R+U6A*XF]+<NT?)9Q!
M<44"[Y+XGN];XAF?#F_;TOD_[]-_]KY7C*#11U#R!>?5ATT&E:..W9%Y'PY4
M06,8.<BE0*[!B5Z^:'>]M[8>G)-L<DZRZ9G(]KK5:;K5.<8>?<8/"W^F_!6R
M6R+-UV,=M?K=;N@-W?5N82UF03_T^_MF$XN9'_C]?F??;FJSZ[2#7MC8[24:
M-HF&1V7Y1:<@2;RG.Y/XP)9Y>$[AG9-L<DZRZ9G(]OK1;?K1/2J\^QR'%,Y^
MX:O!M(&8$6!-&:=S#BV<9EJ*<B *XI5DFH&Z)#E*%5\=FC[:6G;4V]^VK"(+
M=S78/9#S4Y.#>S&UD 1V#?>:FO6.UFS\1+VV2O1.N[86,[RVP<%UG%C,K-?6
M9F>N;?\@97=G\LA +LN13^'%7.6Z^L@TI\U4^:X<I@[.K]N#<=MR/L$IM!H:
M_]!7(^P-E4N6*\)A@:Z\JQ[V1E9C8;71HBCGGKG0.$65RQ0G:9#& )\OA-#;
MC7'0S.;1;U!+ P04    " !;@&A5Y[3H3J\-  !MA@  &    'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;,5=;7/;-A+^*QQ=YRZ9J2,"($&R9WNFL8BYW+1W
MF;J]^\Q*M,6))+HB':?__D!9$01@M33L=:X?&LE:/ O@(5[VX1(\?VBWG[IE
M7??1E_5JTUU,EGU_]\-TVLV7];KJWK5W]4;_<M-NUU6OOVYOI]W=MJX6NT+K
MU93'L9RNJV8SN3S?_>WC]O*\O>]7S:;^N(VZ^_6ZVO[YOEZU#Q<3-OGZAU^:
MVV4__&%Z>7Y7W=;7=?_;W<>M_C8]H"R:=;WIFG83;>N;B\F/[ >5QT.!G<5_
MFOJA._H<#4WYO6T_#5\^+"XF\5"C>E7/^P&BTO]\KJ_JU6I TO7X8P\Z.?@<
M"AY__HJN=HW7C?F]ZNJK=O7?9M$O+R;Y)%K4-]7]JO^E??A'O6]0.N#-VU6W
M^W_TL+>-)]'\ONO;];ZPKL&ZV3S^6WW9=\11 29.%.#[ MPIP+,3!<2^@' *
MB%,%DGV!Q/5PJ@WIOD#ZU#;(?0&YZ_O'SMKU]*SJJ\OS;?L0;0=KC39\V-&U
M*ZT[N-D,5]9UO]6_-KI<?WG5;A;Z.JD7D?[4M:MF4?7ZRW6O_]$74-]%[8W^
MULX_+=O5HMYV?XO*/^Z;_L_HS:R^:>9-_S8ZBWZ[GD5OOGL;?1<UF^C797O?
M59M%=S[M=0T'/]/YOC;O'VO#3]9FO=:7V\X?4/H*+_WC8M$,EVNUBCY6S>+L
MPR:ZJNZ:OEH!6+,1K/G\?GV_VG7&O_MEO=7]L]9C=SD,JL]U]%/;0>TKGXZZ
M[SX 1.$@O[9>BZ::]0/U_$ ]W^$D)W#>U[?-9M-L;J/WU:K:S.LNJGI=K?F[
M2+#O(Q[S&&+P$53N0(=YZ_-E=C[]?,R2;\'B1!0%L^UFOMT9SV+;J 2,,LFS
M-+'ME&_'\[C(C)G51^+01R*TC][H2[Q;5MNZ>_ND_GITD![W%T^9$$GN=!M:
MDV&%^:&[J^;UQ41?AEV]_5Q/+O_Z%R;COT-7-R5820FFB, L.I,#G0E*Y[_T
M4KV"1^Y[M&1@(Z\HP6:48&7B78YG+.-%X@QB-6YG,9 >&$A1!CYTW?TPCH9E
M9?XXVW?#;!_=W^F/]9=Z.V^ZW:^/?V[OAAD=) QU%$I8ZC4W27CA3%B4'DM*
M,#52?8LJ>:!*O@95QQ,D1)OTJYJR/!?.;(C6+70$48*5E&"*",PB.#L0G+V
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MXYOVQJJZ^7[E5EFKRN9R*U*@<F< OV\4,$9WXP;H/X%:_P]02P,$%     @
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M\5B*9B6B6?EZ[G6N)<6.D9@5P,A GB8W(%@:+[F<C 3FLJ!@B"@D$1CG2@$
M>!GX(;[JRIH>IS@U^E[2=?=!H16B''L4$78Y<13=:3N-Q*!,PF*?JNB)[)(Q
M(@INJ4AAC>E]&EV/Q$^SV<<VF2(@1D1TV>-+F]@<-)E_#R>D!6V0;>J$'FR&
MJFHQ&0__R8>N8"OT;3PA+5VI95U$BM?#?],*4;B&13D=*+#/,C;IR?/C8U@I
MM %<* ?U:X3M[9T#S9@Y"%ULV'G@-588&UJ; 4C-E;NR81O(.75;:P)]OA$M
M2HP.:;90Y.I[U,;J]^I_U#G:%>IEF#N9_X'>@-<'B6U2HB%>"^R$X(X6H =7
MR\*3G#)L18HY+!7Q(>9(HV#%GLHU<F:I':R$KXXIIF6G0G!KL4CU$?H?W\"U
MF[L0ZV-\3]4/%0<+I"N_94K8I&WN]YIP@R[%/=X]C+O;FYE]**\108-UC8";
MQ6H%C/5X[/%#RMIF1Z*0 ;8;%'STE/,[ @)T30%TF]GOYLD><;^ (1&4,N5%
M\T=MLBXK[@.VN6HOS<Y0J7Y24&FR;*:_C]S,&)@)W(Y*,8KCC7/^G9&A(PQ+
M=+*W@+JD_',\X=9KLN5VO-">[V*'+IH:D7WYW<5(?/*LH'=4+G&,(E!C1&N+
MXP>B.\%$KHE*;L=2&N_TZ),-BGU.?\"@E)^5^*/.XPI<0K77$F#2^[JL4G0B
M9Y&+!;E;M'+"A0)FV282[%=$I=!RK@L.,U0I(E?7B@FJ+Q49@1_P-Z<*-@)*
MT(7UM:,,\Z%CD$8+GC-2QQ8 6*'21_%&Z9KH.:Z*4DTDUK!V2WF7U+Q' *<:
M+\\)@&ACWAHY+R@(<>Z&=)EV65T"74IE38SJN""4>=^<$S;9 Z DBR<PD\7-
M;1VARJ1S[ YK6=2JAU0LSCNPD'D5&R,N2WL;5R9/(#=&&X E@,-U4Y32V]HQ
MFYW1T#&ZPY/'*9FMDH_RC745G0_R-P&4@F/TZ#:VC_I]Z;9==!;#%VE#+F4"
MV*NI#PI2M]$0%UCB)0LU1^$8=C)V\%S#G%R4)&PC/$*SX5<#_E^\@^T"CM:/
MK[ -^B<1^/G-=LG/JJ1F2>?$+X5^U'. N/6?C&ESJ%,[M%U'FY^W9DX.E2+%
M [$L53Z")T^D2TT],D&Q7#JUQ!YR!IYKF&@8T76Z.QZGW_/U)$,O4-,Y0YU0
M&<=),2I=4TT3PU*:"+&0%(Y>M$7G]_I[R.S#^7"%[_JW7R3B*+(HXN(,/JV6
MZ)M)3Y AVN2+R!C'2-9GFQ;[RFG(_4V<3)X-)L]/>RNG)Y/!Y/2L;QA\?I?#
MDY/QWK4;&VC<\?56L<W,T^-=9DZ?GWTW6+=U" @51;H.O&8?@]C[\G5@3L^>
M#L[&??Z/GXX'IP#E(3#[('XC>-.S9X/IR>[ES\^Z"W:9((= ^&</R!677M'^
M46#RN(,\ U6H#O>KNY7T35C@V.>I)%2<7^R\T,M4!,4DT(2Q0G$2XAK>;]4,
M;8;AE&>L&39!U/Z%,-'U?I<&E6=H<_D'Z3ZK&,MZ1?O.IK+;Y+M-Z%O*6/0E
MN!@5ZRH:+"C@-@];$F^/MD0E85I;B3A']8ZRPJ3Q"H^B< D1RPH@P(/,;M[W
M%2PFU2#:<[53(8%!/9Q/FRZQJU3:DHSJ3;##M0U%5)=SU^1KY+?NVF1TBC(H
MIRQ^CER@ER9U+6PGG!:WM"%(0_MG:CWR%<UH-UU)Q8:F2>U<9M,^EGREERNL
MQ*%?7W9.^JC28FGSI>+2AP3A\IJ:,%@E*A?20FRXMQ!E_3T *^BL5$&56U-Z
MRK74!>T;PDV&-&]L!L1<X;E8GM#(,>FDR<$Y-SVQ#B%ZK1'D?2W=UI:V1G;(
M\JCUMXX_490O;:Z*Z*+-#*CCEZ$&!W>*JYRO-!U6WI[,ABON5>&=>_5'E(W1
M*O_55Z(G<6%("+1%VB:.')RB%WTD*TV97*IT@&!SFGHLH]H>JD!1UM8\>^WO
MDT&U1R/F7"Q!.EF,I7*.8LM]C>Z:0%>;ITD_-)4&7FC/ZK*.=3</3=6*7B>N
MJ8K#=R4.Z:(G@ZXK45]H,I*<N^Y82PS=JZ:+IK9,<3CN0R&T(/L>Q+HHL9G9
MI6%B@![P$(J^J8)2P<H3!ZA-NSBS _\TN;_LEF*=VY6CI:1Y14BSBEPCX)-&
M$D8;*&"MBNC]$2B>]:06]O>DW+[Q$VRF'P&0"5B+\'S#3IQ9!-ETY7V-HMMI
MO2<&(.T3EQR_8%"<2W9$U;Z/INSC21;!B%(0\7'<R9)$+>T08BI<&F\I)5Y
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MW'0T"R/+^G9A(0VBIWY< Z9,60;<7TII=@MKH+MNFOT%4$L#!!0    ( %N
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M#I-&0V.OH?%/JZ'I^'0PGKVT#ZW7_ZLAQV+V8OWO>S6_A_[[#'M7@P+UVE^
MW*>BDK:^)72[W1WKLKY:/)G7%[0;IM?TJ:7)F9'K:'AZ$H"N+SWUPJK27S1B
M9>G:XA]SNB>B=@;T/E/T%6P6+D!W\US]!5!+ P04    " !;@&A5'28,VB\'
M   S$P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RU6%ESVS@2_BLH
MC6MJIHK605UV?%0E3E*3A\RFXLE.Y1$B6Q(V),  H&7/K]^O 9*B8MG9S.Z^
MV"30=W]]B)<[8[^X+9$7]V6AW=5@ZWWU8C1RV99*Z8:F(HV;M;&E]'BUFY&K
M+,D\,)7%*!V/%Z-2*CVXO@QG'^SUI:E]H31]L,+592GMPRLJS.YJ,!FT!Q_5
M9NOY8'1]6<D-W9+_5'VP>!MU4G)5DG;*:&%I?35X.7GQ:L;T@>"?BG:N]RS8
MDY4Q7_CE77XU&+-!5%#F68+$OSNZH:)@03#C:R-ST*EDQOYS*_UM\!V^K*2C
M&U/\J7*_O1J<#41.:UD7_J/9_4:-/W.6EYG"A;]B%VDGTX'(:N=-V3##@E+I
M^%_>-W'H,9R-GV!(&X8TV!T5!2M?2R^O+ZW9"<O4D,8/P=7 #>.4YJ3<>HM;
M!3Y__4[?D?;&/ER./,3QX2AK6%]%UO0)UG/QWFB_=>*-SBD_Y!_!C,Z6M+7E
M5?JLP%NJAF(Z3D0Z3M-GY$T[WZ9!WO3O^!999\=9N11>N$IF=#4 UAW9.QI<
M__S39#&^>,:P66?8[#GISQOV/.ML*#KNWE-F4";.4R[,6O@MB;4I4&]*;UZ(
MGW\Z2\?3B[_]'VGQ5*[(AMRTIZ\I:PXGB?A%:6@UM9,Z=[]V-)S'_LM$?)0[
MH->35;)PW=6)F(R3V33M'<R2L^58_(F*%I!=69.1VS,LETEZONA>%_-D,EF*
MMTHK5$(N-L;D>^+),IFEYWL[IDFZF(L_C)?%@040,E_V3LY!.-_;M ^V<L)Y
MR<&6/@0;D48@$/G,."^,%>2\*@.%1E]%LRS47W)5D+B314TH<;^-M#DA%BAK
M4-:H(AMSIZSSIW [/J"5BI(0WGPH_L!URR-#6X-6N@_!@5ZS<J; -6+6&FOI
M:ZT 8?&O.M^@FWK<946= QH1-=#:22JE?A!K=$IC78)&G6V%=)TWCDG6M:\M
M<4;R.F,'P),G:%76LG"\M"1H\E_@/93DBA5 8LM%]Y5JM"H=)PN>D\!=&0]!
MP$='';UR&>F,0%,:F&X0*.N&XG5MV1,.F]\JFXNOM;0^9B/ CT4R])) <V/*
MBGVTE!F+KB5V5GDZS<U.!^_V<</+2;H8CM%TBR+,#P@ZF0_3]B"!$%=1F"K%
M0\(PC>E?-_B#T;D(A4$A")AD4,@Q-X7* SH"C#@I03DF;0R*BXG>VR;R[[FY
M0YYR0,N;1E]9D5=LFR!]IZS199N>B-:8./0)*SZ]?O/[YYN7[ ]F&>MA7\AZ
MS/1>1%:(6<FW0+U5[DN$7IO(1.RV"G@!NH!WUT"_, #FZN%(*#%*51:><E74
MOD^/, BWE8 0<XZ'TVD,/IYFO4LV/0;$$IT&$HU*.BUY*C&=XBP0#Z=O>AA'
M[#!],>![7__ST$]"Z-F6/;??(D2Y@CV&2Q=^R2R#!1( %AF+1O_K-_)FQ#B!
MS- QW(WWN..*A.K''@7*@[8<<?_8S[8*5K21R+2LE.<.Q6Y^_G3[[OW'SSUG
M&@0[8@P?+:^MA(7I;+CH3,1M:![]-I29C59_\81ZMB16L@AA"BN-8ZP]]K0?
M.B 0SH$1R%]1++K26$X6?/,[*E "95Q4UM:40?>!$L&*N:EGA71.K14W=K>W
M/4$:]6G;X'[$^J%X^8.Y8M%];96Q;6]6QX>][4_4).S _8G)>F1?S/I@2$8\
M=,N"\#RE4($,2.Y*_J J#L/6ABN+/>N_7S3^'PO''BC[P9XND^7DO'<P72:+
M6;JG/<QX;^F83<^ZU_D\64S&/[Y'?+!42?0&M-^:1VUL+V'<C'LE]&25Q_$=
MDU3)AVYZG$P6/794 V#B+11\J\FBZ+&.A*2)7]BL='QQ\_X?+CQ.+GX-W>R0
MB=N3 J#"E:EM.YM=V_;[PS66I&LJ$F;<8980ST*<]'HLMJ"FN6BZ]X>U>A%W
M@6]<G/7Z(F3=2?3XV@DV/EC&L)66MQ:>*X2.9ZHP]RI5$:_2;/?&RA+ ?SH/
MD^EP^4T>'I5JFX;'-IX-IWT;)5OWO8@V$_BXT_/A['_F]#LMWM+*HHD_'-F*
MI-:F1H'GX317CB&D=-WMA^&XIP%'-[_=GD(2T"G%2AFG8*H,\^'-0T$2OYF6
MLPN.8H7!P<<R[L,;W4IXTGY< &H<(V]V$I,W+'V'+G:>H=/*9H-)^C.['5AQ
M#W@?%!WVV_Y.V(RHD\ED..^"W@#U23L9[Q@%CF>#0M*^M^P=[GJ]Q2D""F-+
MP2)E VV&76=# 0C3WA+0+C]Q43'K-5-41R'=(4T;[%=Z$T((0\+(W$J47+.P
MKTC36O'8^MUT,Z7U#NX7,BR'S8IY!!XM%L)*U NG7',&#F,_//8[>M3[D%$2
M_.;/-1S06OOX3:,[[;X(O8P?0O;D\7,2M&T4&EQ!:[".A\OY %MK^$037[RI
MPF>1E?'>E.%Q2Q*_AI@ ]VN#'R+-"ROHOI-=_QM02P,$%     @ 6X!H5;X
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M6:X()Z*BZ,9EP(5L6BFH,'H>&4"W,E%U0%KU2/@%I!)=26%JC3Z*#=T\U(_
MJM$T/)BVPB<!;V@[06D<(AQC? (O'5U-'5[Z USMD;+GD6RAG.N65'010"5H
MJFYIL'S]*LGC=R?LS$8[LU/H_\K.TTC3"7H)#%TK*&QE[A$1&_3Q6\=:*#43
MHE]![,$>/>X)V*LD%*0& +E%IJ9H*SD4-A.[<_3Z58'C]-U__D/ #6W65+FH
M#]P/M#HPDQ"]80).E9T&R_3;4<9FB$\DZ(I4-=R&>N3#*'2&$AP6L\)G),#(
MW1UU!LX[*ED(+;=F3Q0=%=(PGDY]*DW19:<$,QU(694MN[-K/0HE(<YRCTIP
MB3Y3Z"FUY!O$FE;)6]JX\ Q">9ADQU.F89EA=,F$BRFWJDC9OF.CT0%!M*:>
M]O#/PAG<R6,N#G&9@;]"&]7U31*N%XS8@=%'D,(S("T*]+LTA%NQ9W+DB%V$
M11D?R2S,<XS>5U77=)P8NH'6";53,=(W9P AC52&?>\9@^*;I S3I'SK,?*P
MR(!Q*DF/02W#Z2SQZ%E8)*F76Z=LH'?P],&E[HE&9_&DA/[+^2!YAB?YR(#'
MT16#J17M8R\@^5#3-T1J&^*C[+89&\*KIEOJWB5^'_:P/_Z<Y.$YD]%[B(;J
M0,/B_ :P"EUT2MDH?F9DS3@S#)+7EY).JCI(<4_*5D;_L+/O5E@?&H/^?[6%
MP9E*-@U5$'GN_+)-G*BJ=L2&PC7)/IT;(KHM3 Z=@@[GI=$T":<X]1A@VC3S
M\7_R82II.V9+[LF:0_0D^J43NF9HQ:2N&(5B?EJSR0P0LZ?LL,1YWS7\ (1C
M5)[6?ES.GG#3,"OQ:&X?U_$(Z(PX]\DD'\K^GV7#\5X*:%E>'SA#60%M;[3G
MN><R\J89"-+.S6P:[K 3IA]L1NXX%K[OIZ&C>#]37A&U8T)#I]R":CR9P12F
M^CFM)XQLW6RTE@8F+;>L8;2ER@K _E9*,Q#V@'%87OX-4$L#!!0    ( %N
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M(GP#;"M%#42:#5%^%)8,8I)&D]8M6#%/S<:@@2);/X3_RQ=M%V8"^N@FS'#
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M#>M#BR!INV=:.DM$*%(CZ3C9K]^1DA4%33P,*/HB\HYW'[\[WI%:'96^,PV
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MIP$='BOZ(D++!O2^--2D_8(##-]8\W\ 4$L#!!0    ( %N :%7V;A-W)0L
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M?J_^HL]17ZCXL'8R_XQDSN/#I#8YT9"N!6;BX(X&X =7R\+3.67@$]TF,,^
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M\0L[6H %)=I"S;%T/#H[&0@7OUK'AV K_E(\LP'!P3^7"AG(T02\GUN0L_1
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MFOY$4#L#VB^5LH>)"S#\VZS_!E!+ P04    " !;@&A5BSF.8],$  !S$0
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ME*.0*U59KZ 3G[H.-DZ/NRAPQE'<-^$Y8]HW$001[BJF8"/G2),B,,9.%-C
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M7U9G$EK#6LN<9RQ77.1(LL71X!B_.L$C,\!*_,K9M7)^(S.5J1!_FL;[^='
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MX'5O1QT)ZXZ7Z +RY:H&!;6@4 AJ)J5AN\U&4LD@.T__@-H%:0%Y57)#RY"
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M\*62K;8T.@V-K<[E"&E?R5U727RDDB4V(TBB2XBC.(;'Y1S.SRZ@43)OJ3E
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M^/(P<'?GE#'?$#^P6!$F$86E)GKG%UI'5.=R-5&\M ?/ U?Z&+/#7'_*@#
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MYU]4C>2V0]B)9+4I@0],JH)JAH5JJL U0.TO&9/;B0[0M>GD+U!+ P04
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MY/<32L7KB7H3J7KS;/0_4$L#!!0    ( %N :%5N!8LZ_ (  "8*   9
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MR94N$VPSUH4<"!.@YU><JUW'+%"6AL%O4$L#!!0    ( %N :%6H[K6E<@(
M *H&   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U574_;,!3]*U:&
M)I VDCA?P-I(HQ4:#Y,0A?%LDMO&PK$SVVW@W\]VTJBTH=O#7A)?^Y[C<V+?
MFTDKY(NJ #1ZK1E74Z_2NKGR?5544!-U+AK@9F4I9$VT">7*5XT$4CI0S7P<
M!*E?$\J]?.+F[F0^$6O-*(<[B=2ZKHE\NP8FVJD7>MN)>[JJM)WP\TE#5K
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M^Y[C<VZX-\F.BU=9 "CT5E(FQTZA5#5R79D54&)YRRM@^F3%18F5#L7:E94
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M($R"/E]QKO:!&1OM5R+]"U!+ P04    " !;@&A52%B <^0%  "%*   &0
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MPE2!_'Q'J7@]43/&?J8<_PM02P,$%     @ 6X!H5<DY&Z&. @  W@<  !D
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M/4F3Y21I/3#O1H[-:E2344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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M[ KQQF<K7[B,=S=U=&"3FHQJ"JJIJ*:AFK[5=J/B;/PT*@QT3+-E3&DTW+M
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M=D&WVOGNO$KO76_<S%@9'51!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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M0D7=/=<#Q4O33ZZXPN[4/*;XP0%"&^#[->?J8: 7:#]A@F]02P,$%     @
M6X!H5:=J10U' P  ,0D  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
ME5;O;]LV$/U7#EI1M$ 2_; DVZDMH$G0+H"W&4G:?1CZ@9;.%E&)U$C*;O;7
M[R@IBCO+3N8/-BGQWGOW:-YQMI/JN\X1#?PH"Z'G3FY,=>FZ.LVQ9/I"5BCH
MS5JJDAF:JHVK*X4L:X+*P@T\+W9+QH63S)IG2Y7,9&T*+G"I0-=ER=3C%19R
M-W=\Y^G!'=_DQCYPDUG%-GB/YDNU5#1S>Y2,ER@TEP(4KN?.1__RR@]L0+/B
M*\>=WAN#364EY7<[N<WFCF<588&IL1",?K9XC45AD4C'WQVHTW/:P/WQ$_JG
M)GE*9L4T7LOB3YZ9?.Y,',APS>K"W,G=K]@E%%F\5!:Z^89=M]9S(*VUD647
M3 I*+MI?]J,S8B\@"(X$!%U 8X3;$C4J;YAAR4S)'2B[FM#LH$FUB29Q7-A=
MN3>*WG**,\D-K@S\L2KXAEF7-)Q#X 5C>$!5PD(R 9]J4RN$)7NDS3 :WMV@
M8;S0[P^6VN K+I<Y([O@6F'&#=R*+6K3AGZ%STM8+*[A#7 !#[FL-1.9GKF&
M,K%ZW+13?=6J#HZHOL?J D;>F140P)?[&WCWYOW/,"X9T;L1]&X$#>[HE!NW
M0AM56\7PUX(6P*W!4G\;4MFBA<-H]D!=ZHJE.'?HQ&A46W22M[_XL??AA-91
MKW5T"CVY0WOH,E0@UZT/Y^2J06(R($7Q."2XA8P;2'M@MTD\F8QG[G9 2-@+
M"4\*(>[1:[A;E&B/.QB/@B/D44\>O40>OH8\&B /O6"8/.[)XY?(H]>0Q_\G
M\W%//GZ)/ 8Z/F!R8F=KTC#$/3[DCJ=^Y ^33WKRR4GR!VE88>L1+^L2JJXV
M#/%/#OA'T<2;AL/\TYY_>I)_@5H#*V5-AU1A<[J$X6+3[\60E.F!E'/?.Z[%
M]YYKJ'?:C:<*> 8;)?5P0?,.-R+RZ'.$?*^ ^R];40LR0QG^#V;4DZB(95RG
MC3OV'](\X5K73*0(J=1&GX' 09,ZMI]<"L?1,8^>*ZM_LA@FO],-(V5*/=I=
MZG:."M=S\Q@4$QS4JR",@C#^CQIWKP':R\1O3&TX]:,"UQ3H78PI'=7VYW9B
M9-7TQ)4TU&&;84YW&E1V ;U?2VF>)K;-]K>DY%]02P,$%     @ 6X!H5>6_
M>,Y*!@  %B,  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULM5IK;]LV
M%/TKA/= "Z2V)#\2=XZ!U.JP?&@:U.OVF99HFZ@D:B1E-\-^_"XI68^$9B*4
M,8)8KWM('I)7Y]!<'!G_)O:$2/0]33)Q/=A+F;\?C42T)RD60Y:3#.YL&4^Q
MA%.^&XF<$QSKH#09!9XW&Z689H/E0E^[Y\L%*V1",W+/D2C2%/.'#R1AQ^N!
M/SA=^$)W>ZDNC):+'._(FLBO^3V'LU&-$M.49(*R#'&RO1[<^._#8*8"]!-_
M47(4K6.DFK)A[)LZN8VO!YZJ$4E()!4$AJ\#69$D44A0CW\JT$%=I@IL'Y_0
M?]>-A\9LL" KEOQ-8[F_'EP-4$RVN$CD%W;\@U0-FBJ\B"5"_T?'ZEEO@*)"
M2)96P5"#E&;E-_Y>$?&2@* *"%X:,*X"QH\"_,F9@$D5,-',E$W1/(18XN6"
MLR/BZFE 4P>:3!T-S:>9ZO>UY'"70IQ<AF0CT>=-0G=8]8- []"*90?")=TD
M!*U)1AE'ZV+#>$PS+$F,[I@D L4%08$7S"#@#G..5?>A-R&1F";B+5S]N@[1
MFY_?+D82JJD*&T55E3Z450K.5,E'GU@F]P)]S&(2&^)7]OBY)7X$]-0<!2>.
M/@16P)N<#]'8NU#M]4SUL8>O25Z'!X;P\ 6E^Q-3Z9W6C.L>'VN\L:W';S,A
M>0'S5YKZIP28F %4)GHO<AR1ZP&D&D'X@0R6O_[DS[S?3.2X! L=@76(F]3$
M36SHRU7"!,UV".9D].T"Y9Q&!.4$DN@><V+BT8K7E\<2[$J#J6Q^6,Z',V_>
M_BQ&AS99983OM4+\R?#*G];/=7B8UCQ,K3SXP^DO/9.$B1QK(7W)<0D6.@+K
MD#NKR9W]Z.R<N23.)5CH"*Q#W&5-W*5U5-X5Z0;F(MLB<@#B!*+9Z?UO(M$*
MUI?$$FS:FF?>HZGHJ+@.,U<U,U?VO 5O0P[ZJL )DH2G)CJL"'WIL%=GAAX(
MYL(T?AS5HL/2O&9I_AQ+=4(KD]=_R%&FLQ;<EUR78*$CL [AOM=(3^]'<UV%
MX(@[IVBA*[0N>RWA[EL'[#VG641SF-0X9<49^DJ(62LS!6.O_'0SU,I>6F]N
M'*%UN0D:;@(K-VNIIR;-(-\1(1'8$Z- JV#\<3MU#[V60JK(L1;7FQQ':%UR
M&OWO6U7R\HY($*\L(B06:,M9"B_-+8'1M#-2-'XZA.!C'$).I;XKM"Y+C=CW
M[6K_-J.2PN2*=/HOESE@%%V4:E\HH1&Q-(7+V@\8J:L$^*3%W=0?SH-@\I@Y
METXA=(769:ZQ![[='SQ.3(JJ3+\D2RZKF<DJ)HW,39\,.M\PWIRJ?E=H7=8:
MW>];U;%IO#4.\S32SAG-"KMM#OWY4*F1+F%.U;XKM"YAC=[W[8+_MIW<0>J+
MB--<K6$9";)C_;FO%K.>JD <11RT7?TJP?!7%@G#6@M$U4$XRXKT N7X :M0
M05+Z3EW#2?*@G CF7(E>!)UX ]V:('\*,3'Z'$FF; N<*N>"H[U6QY!E8 Z1
MUNWSBT_VIO7NU-=P*GYC57R[.="2D-:2$*58%IS*!Q2?>X/;\<K%,V#OG#A?
MV0%ZT_<:%L9O/(S_<A.C4ZY:IH*Q6*1JE$; *-Z9:2QQYQT=-'Z</IQZ#U=H
MW27=QGP$5GENHBIB!Y)A&'60;O.$8IB!)J[LP'T]R3/5O-%*8TUR2?3ZQFD=
M^0))R%DKJ"C.'M 1Z_6.;9$DK<JC(Y5[]9P@==N$3CMPC<-M]2]CIP43**=:
M,$%%%D-9\FQ6'!J7L5_##P6-'PKL?JA,'4(4NND1$](H+>PHO7OOJ<&:&Z1Q
MZ*K4+C>-'PKL?N@+43\!JL7K(@-1!EWY+XBP6#$64Q%IE:;&A;YR<@,6#EW:
MH56%UN9P<CDUD?@:OBEH?%-@]TT?@1?]*^7SOM*.U)N@L=&E!OYC?E[#,06-
M8PJ>^7W$S0H:1*WA384Y91?H/L%&/6>O2F^"G=HO5VC=;FCL5S#]T56UP.EO
M+T[10E=H7?8:&Q;8;9A1%IQ<Z_F%-CMJ;T9G3^VO/[DROEB<FK!1:R-!2OA.
M;\A0OAV:7>XIJ*_6FSYN]%:'4?-XN6/D$^8[$/(H(5L(]8:7T*^\W(11GDB6
MZVT)&R8E2_7AGF#0'>H!N+]E0']UH@JHM\(L_P=02P,$%     @ 6X!H5?BF
M/CN8 P  6PX  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULM9=K;]LV
M%(;_"J$56PNDUL67V)DM(+$ZS,#2!DVS?1CV@9:/+2(4J9*TG?S['4J*(@6R
M5@.:/U@DQ?<ESR->YT>I'G4"8,A3RH5>.(DQV97KZCB!E.J!S$#@FZU4*368
M53M79PKH)A>EW T\;^*FE DGG.=E=RJ<R[WA3,"=(GJ?IE0]WP"7QX7C.R\%
M7]DN,;; #><9W<$]F(?L3F'.K5PV+ 6AF11$P7;A7/M7D>]905[C3P9'74L3
M&\I:RD>;66T6CF=[!!QB8RTH/@ZP!,ZM$_;C>VGJ5&U:83W]XOY;'CP&LZ8:
MEI+_Q38F63A3AVQ@2_?<?)7'WZ$,:&S]8LEU_D^.95W/(?%>&YF68NQ!RD3Q
MI$\EB)H ?=H%02D(W@I&)P3#4C#\4<&H%(QR,D4H.8>(&AK.E3P296NCFTWD
M,',UAL^$_>[W1N%;ACH31K VY,N:LQVUWT&3CV1)LPPV^."<?%-4:!J_O/I,
ME:+V0Y'W$1C*N/Z I0_W$7G_[@-Y1URB$ZI $R;(@V!&7V AIF\9Y]9B[AKL
MLVW9C<O^W13]"T[TSR>W4IA$DT]B YNFWL58JX"#EX!O@D[#ZTP-R-"[(($7
M>"W]67;+[R&KY$&+//J!UOU16^N-:(;5YQOF?L,3?E^R?/:L$,X3?C,CR4KK
M/:A?$-CW/3//Y.\_4$)6!E+]3QO^PG_4[F]7G2N=T1@6#BXK&M0!G/#GG_R)
M]VL;NS[-HI[,&EQ'%==1EWNXY%(SL2,X_^+'"Y(I%@/)0!7CNXUCI]^Y' NS
M:6YF5^Y#.!M,O%G]-W</=5B% M??5XD_&DS]<56OP6%<<1AW<SBU%N"DCJ40
MY>I]9"8A)@$[K"=D*<4!E&%K#N2S-- Z[3O;/9=7GV913V8-WI.*]^1_GL^3
M/KGV:1;U9-;@>EEQO>P<QW?T&0\KAN!!B<3%F([MF#:U,=U&LW"UN_WKM)H.
M@N;D6W:V?2ZFGLP:F*85IFDGIA7NV8QRBZA<\^3V)*]!&[#"_[+&*Q@/9L%D
M^ 999S_.1=:360/9K$(VZQY9H&(<67A&+ED5X-K8%$:S&AMO<#E^ Z:SM7/!
M]&36 .-[KT=+K^=-M-OPW-6K5[>H=/OO+=:MG<934+O\5J-QN]P+4QS,J]+J
MYG2=WQ?<U^K%M>N6JAW#W9;#%J5VM#A$%3>9(F-DEI_MU]+@32%/)GC[ V4K
MX/NMQ/VWS-@&JOMD^"]02P,$%     @ 6X!H50M'%?J2 P  =PX  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#DN>&ULO5?;CMLV$/T50DV+!&A7-TNVM[:
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M3%5:>-/F- /)*G./WS*IN@+S>%"=(7 -4.]W3'UOVH%VT/6:R;]02P,$%
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MY8O2@.ZH<;=:HWUF_&1JP;'-)3!'0Z_=1W=4V;G+B9%9T2UGTF#O+89+?.V
ML@=P?RXQJ=7$-N#Z_13^!U!+ P04    " !;@&A5OU49N)H%  #.)0  &0
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M$1P1KC.HSS=,>;>ZT0741[@6_P-02P,$%     @ 6X!H57/KW6.G P  U0\
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULO5=MDYLV$/XK&IIFDIGV
M> ?[8C-S9YS)?4A[$R?M9]FL;28@44G8ETY_?"7!$1LXQFZ8?K&1V.=9[;/2
MBIT=*?O*]P "/>49X7-C+T1Q:YI\LX<<\QM: )%OMI3E6,@AVYF\8( 3#<HS
MT[&LP,QQ2HQHIN<>632CI<A2 H\,\3+/,?MV#QD]S@W;>)[XE.[V0DV8T:S
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MW,N^&Y@RD.^W5-YX]4 Y:#KYZ%]02P,$%     @ 6X!H59,>EI?Y P  O!(
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M,.TPM@;I.@S 2I,;I["LW/N%Q@>X_;76M#-\@?Y%S/X"4$L#!!0    ( %N
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MSRT1)PX"9]S!;!W,H8/]AH/5.ECG1K!;!_O<"$[K4 ]=;\9>$Q<BCA8S2@Z
M2FN!)@]J]FMOP5=:R(FRYE3<384?7WP5<_$7PAA880K6>T0Q^ 1^K3CCJ$C2
M8@?"-*MD+<&*<%SP%&6-&0/1<YQ5"4[ EI(<+%$65QFJJT^VC9NX)_$_9"+
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M([B8_ 0JRZ42+%0)%BD"ZY4+&L<FR?BF!*A-IZ<7EN%XMC40H!%#&(AA&^9
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MQRC!5!J(^ULBM+ ]D0&Z[;;%/U!+ P04    " !;@&A59H@\]=P"  "<"
M&0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RMEFM/VS 4AO_*488FD*"Y
ME%[$VDAM 3%I3!4=X[.;G"86B9W9[H5_/]M)LX"R:*!]:6W'[^OS'$?G9++G
MXEFFB H.><;DU$F5*JY<5T8IYD3V>(%,/]EPD1.EIR)Q92&0Q%:49V[@>4,W
M)Y0YX<2N+44XX5N5489+ 7*;YT2\S#'C^ZGC.\>%!YJDRBRXX:0@":Y0/19+
MH6=N[1+3')FDG(' S=29^5>+D=EO-_RDN)>-,1B2->?/9O(UGCJ>"0@SC)1Q
M(/IOAPO,,F.DP_A5>3KUD4;8'!_=;RV[9ED3B0N>/=%8I5-G[$",&[+-U /?
MWV'%,S!^$<^D_85]M==S(-I*Q?-*K"/(*2O_R:'*0T.@?=H%024(_E70KP1]
M"UI&9K&NB2+A1/ ]"+-;NYF!S8U5:QK*S"VNE-!/J=:I\ $SHC"&)1'J!7X(
MPB2Q"99P>HV*T$R>P04L]().#&4)S!*!J.]1P1-5*7PC;(-$P"S>4<F%U)L?
M5]=P>G(&)^""3(E "93!(Z-*GNM%/;ZG66;.F+A*,YA(W*B*=U[&&_PE7A_N
M.5.IA!L68]RB7W3K^QUZ5^>N3F!P3. \Z#2\Q74/@O$Y!%[@M\73+;\GH@=]
MOTW^*IQ^?9]]Z]=_[WVVI;JTNFRW,O7C2A8DPJFC"X1$L4,G_/S)'WI?VCC_
MD]DKZLN:^K++/?R^S=<H@&^ %_;E/8=$HZO6-V1>>@VLEZERNW X\#QOXNZ:
M/)TG?I!G4/,,.GEN#B@B*A$*02-L8RCUXP:#/^H-WR!T'O)!A&&-,.Q$6"D>
M/5^8"AM#Q'/==22QA1L/9MP*U>GXWO>Q-/.;U^SUQG6&7D&-:JA1)U2C#'9@
M='J\%V/4AA&\P7 ;#2!'D=B^*'7>MTR5O:!>K5OOS'8<]\_VLF_K@I107?TS
MW&BIUQOIDT79"\N)XH5M)VNN='.RPU1_/J P&_3S#>?J.#$'U!\DX6]02P,$
M%     @ 6X!H540J:?5W P  ,1<   T   !X;"]S='EL97,N>&ULW5C1;MHP
M%/V5*%VG3IH:(&L@*R!M2)4F;=.D]F%OE2$.6'*<S#$=[''?LZ_:E\S73@A0
M7T;[L#8+*K'O\3WW^/HZ,1V6:LWI]8)2Y:TR+LJ1OU"J>!L$Y6Q!,U*>YP45
M&DESF1&ENW(>E(6D)"G!*>-!K].)@HPPX8^'8IE=9:KT9OE2J)'?[6QLGKU]
M2+0U>N-[EF^2)W3DWYZ]_+;,U>4+S]Y/7I^<=&Y?7>[;SPSPR@^<I!='D)YW
M](4R&Q2CCXZC/T2.4?=WJ<WP4TUD'4\QM\&1$SXX7XP\=I/__OEKEWZ+O,%J
M>H2\WSF*_  U1MQU9%+/LDDF=##GGMO9)/#O!=(/CUJ. XMAB(-J"XV':2Z:
MG13ZUJ CDXQZ=X2/_ GA;"H9>*4D8WQMS3TPS'*>2T_I+:RE=,%2_K!PU_9@
M=U<\&1.Y-+%M!/L]K8;O 74/!#+.-P)[OC6,AP51BDIQI3MFL#'>@[RJ?;,N
MM,*Y).MN[\)O',Q-!YGF,J&R>:+XM6D\Y#0%.9+-%W!7>1$ J%2>Z4;"R#P7
MQ&BH/:J&IIU1SJ_AT?<UW>%>I5MK:LI4;)I:4-6T-+8#_-MLEGN;-GH4KU>P
MNUR]7^KI"-.'6J%?)$W9RO17Z48 QM[%V4E1\/4[SN8BHW;R1P<<#TGMYRUR
MR7[H:% J,VV@TO?NJ%1LMFWY+DEQ0U>J+J=5BFONM5#SO\WSG HJ"=\6K6O_
M.6?YT8K#_E-)-D^5?<%.C=5QYKF+O&B#R*@-(EM1DX,VB(Q;(++_9$_-AXCL
MMD%DKPTBPV<I,J@.E5LGUYUSZ\;JP>^#D?\9?HGP)J@W73*NF*AZ"Y8D5-P[
MOFIZ1::<[O+K\0E-R9*KFPTX\IOV)YJP919O1GV!1%2CFO9'F)X^"]<_3G0L
M)A*ZHLFDZLKYU#0]W=!1JPL<]I$K<[D1S,=B;@0P+ ZF /.Q7EB<_VD^ W0^
M%L.T#9S( /49H#[6RX5,S >+X_:)]>6>:1R'811A&9U,G HF6-ZB"/[<;)@V
M\,#B0*2'Y1I?;;Q"#M<!MJ:'*@2;*5Z)V$SQ7 /BSAMXQ+%[M;$XX(&M E8[
M$-\=!VK*[1.&L*J8-FP'XT@<8PC4HKM&HPC)3@0?]_I@NR0,X]B- .96$(88
M KL11S %H %#PM"\!_?>1T']G@J:?Y*/_P!02P,$%     @ 6X!H59>*NQS
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M]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0    ( %N :%47R,P;VP$
M -$B   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:74^#,!0&X+^R<&M&UZ_Y
M$>>->JM>^ <JG TRH$W;S?GO+4Q--$I<9N)[ X&VYSVTR7/%Y>.+HS#9M4T7
M%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1KLR(F9K,Y*VP7J8O3V-?(KBYO
M:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI"Q/3.-MVY9>4Z5M"GE8.<T)5
MNW"2)F3LVX1^Y.> MW7W6_*^+FGR8'R\,VV:Q78-"_&EH9"/E_BF1[M<U@65
MMMBT:4D>G"=3AHHHMDV^+WHRGAS3#M/^RH_.'\J,!::9#]ZZD$[,T^%Q[T?2
MKYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]_GS&'_4/[$.
M]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'096CJ,I16.4H
MKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625
M*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D
M52BR:A19-8JL&D56C2*K1I%5H\BJ4635*+)J%%GU?\KZ9.WZKW^RZ.]Y:^KN
M/9\-?[)<O0)02P$"% ,4    " !;@&A5!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %N :%6N]V.*
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( %N :%697)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6X!H5?[MZB[W!0  Z!\
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M965T-2YX;6Q02P$"% ,4    " !;@&A5Y[3H3J\-  !MA@  &
M    @(&Y(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M6X!H5:?]E[DG"   #B4  !@              ("!GBX  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %N :%5J3C.V)0T  -(C   8
M          " @?LV  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " !;@&A5C1,U\VD%  !Z$@  &               @(%61   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 6X!H57ILG#FM!   A0X
M !D              ("!]4D  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " !;@&A5'28,VB\'   S$P  &0              @('93@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %N :%6^ (XB
M,@0  #@+   9              " @3]6  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ 6X!H5>RTFXF7#0  3"P  !D
M ("!J%H  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !;
M@&A5L(Z,Z9 5  !W30  &0              @(%V:   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %N :%4,,_N<F @  /45   9
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M970Q.2YX;6Q02P$"% ,4    " !;@&A5\8FN2%D#  #G"   &0
M    @(%HG@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M %N :%6+.8YCTP0  ',1   9              " @?BA  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ 6X!H5=,THX\/ P  YPD  !D
M             ("! J<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " !;@&A5#4F4;]8"  "<!P  &0              @(%(J@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %N :%6A^I5<!P0
M 'H*   9              " @56M  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ 6X!H57[4DI!3!P  <2(  !D              ("!
MD[$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !;@&A5
M)1;&W7X"  # !0  &0              @($=N0  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( %N :%6?0]PJ;@,  %D)   9
M      " @=*[  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ 6X!H53VUS)UB P  ( @  !D              ("!=[\  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !;@&A59E[KS'D"  !.!@
M&0              @($0PP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( %N :%7:4XF0U0(  "@)   9              " @<#%  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 6X!H5>I8(P:#
M @  L@<  !D              ("!S,@  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " !;@&A56++3!6L#  "X$0  &0
M@(&&RP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %N
M:%731.=ML 4  &0=   9              " @2C/  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ 6X!H56]WK@'N!   A28  !D
M         ("!#]4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " !;@&A5;@6+.OP"   F"@  &0              @($TV@  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %N :%6H[K6E<@(  *H&
M   9              " @6?=  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ 6X!H51:&W:-> @  ,08  !D              ("!$.
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !;@&A52%B
M<^0%  "%*   &0              @(&EX@  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( %N :%5+(&\:.P0  %\6   9
M  " @<#H  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M6X!H5<DY&Z&. @  W@<  !D              ("!,NT  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " !;@&A5  +@$N\"   6"   &0
M            @('W[P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( %N :%6&*26.O14  /AO 0 9              " @1WS  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 6X!H5;]8_ _5!
M!AP  !D              ("!$0D! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " !;@&A5SK)O2>(/   KY0  &0              @($=
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %N :%5$
MX!#%9@,  ,X,   9              " @38> 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ 6X!H5:=J10U' P  ,0D  !D
M     ("!TR$! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %N :%6_51FXF@4  ,XE   9              "
M@=@V 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 6X!H
M57/KW6.G P  U0\  !D              ("!J3P! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " !;@&A5DQZ6E_D#  "\$@  &0
M        @(&'0 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( %N :%4<>.%M10,  !0,   9              " @;=$ 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ 6X!H52\.-\YZ @  ?P8
M !D              ("!,T@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " !;@&A52/R.=7L"   =!0  &0              @('D2@$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( %N :%6'@3M8
M4 0  '@6   9              " @99- 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ 6X!H57"Y'[&R!   >AL  !D
M ("!'5(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !;
M@&A59H@\]=P"  "<"   &0              @($&5P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( %N :%5$*FGU=P,  #$7   -
M          "  1E: 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 6X!H59>*
MNQS     $P(   L              ( !NUT! %]R96QS+RYR96QS4$L! A0#
M%     @ 6X!H5<)!5["D!   :2<   \              ( !I%X! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( %N :%59=@'X]0$  #@C   :
M      "  75C 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( %N :%47R,P;VP$  -$B   3              "  :)E 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(  *YG 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>256</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureRevenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureInventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Debt Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsTables</Role>
      <ShortName>Debt Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureDebtObligations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Significant Accounting Policies - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails</Role>
      <ShortName>Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureInventoryTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails</Role>
      <ShortName>Inventory - Balance Sheet Classifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails</Role>
      <ShortName>Debt Obligations - Summary of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loan Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails</Role>
      <ShortName>Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails</Role>
      <ShortName>Debt Obligations - Capped Call Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40708 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails</Role>
      <ShortName>Debt Obligations - 2026 Convertible Notes Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40710 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails</Role>
      <ShortName>Debt Obligations - Convertible Notes due 2022 Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40713 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails</Role>
      <ShortName>Debt Obligations - 2025 Term Loan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40715 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails</Role>
      <ShortName>Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="chrs-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept FairValueAssetsLevel2ToLevel1TransfersAmount in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. chrs-20220930x10q.htm 9</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept FairValueLiabilitiesLevel1ToLevel2TransfersAmount in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. chrs-20220930x10q.htm 9</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept FairValueLiabilitiesLevel2ToLevel1TransfersAmount in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. chrs-20220930x10q.htm 9</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept FairValueAssetsLevel1ToLevel2TransfersAmount in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. chrs-20220930x10q.htm 22</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 22 fact(s) appearing in ix:hidden were eligible for transformation: chrs:MandatoryPrepaymentTerm, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet, us-gaap:EarningsPerShareBasic, us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount, us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount, us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount, us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet, us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  chrs-20220930x10q.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  chrs-20220930x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="chrs-20220930x10q.htm">chrs-20220930x10q.htm</File>
    <File>chrs-20220930.xsd</File>
    <File>chrs-20220930_cal.xml</File>
    <File>chrs-20220930_def.xml</File>
    <File>chrs-20220930_lab.xml</File>
    <File>chrs-20220930_pre.xml</File>
    <File>chrs-20220930xex31d1.htm</File>
    <File>chrs-20220930xex31d2.htm</File>
    <File>chrs-20220930xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="619">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "chrs-20220930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 256,
   "dts": {
    "calculationLink": {
     "local": [
      "chrs-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "chrs-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20220930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "chrs-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 440,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 23,
    "http://www.coherus.com/20220930": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 29
   },
   "keyCustom": 68,
   "keyStandard": 199,
   "memberCustom": 34,
   "memberStandard": 29,
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Inventory",
     "role": "http://www.coherus.com/role/DisclosureInventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Balance Sheet Components",
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Debt Obligations",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stock-Based Compensation",
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net Loss Per Share",
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Related Party Transactions",
     "role": "http://www.coherus.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Revenue (Tables)",
     "role": "http://www.coherus.com/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "chrs:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Inventory (Tables)",
     "role": "http://www.coherus.com/role/DisclosureInventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "chrs:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Debt Obligations (Tables)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsTables",
     "shortName": "Debt Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember_bh6OtBOdKke7TnmsxZJn7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "chrs:ProductPipelineNumberOfDrugCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Significant Accounting Policies - Organization (Details)",
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails",
     "shortName": "Organization and Significant Accounting Policies - Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "chrs:ProductPipelineNumberOfDrugCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_product_kRa4O7QRw0C_bclgR0oiDA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Organization and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2021_BlZWa-i1xk6soWhBNThU6A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Revenue - Additional Information (Details)",
     "role": "http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)",
     "role": "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails",
     "shortName": "Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yeLYnpuhDEexi1wQ7rV7aA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_NL2CFuF1WkSSROUHNK8GmQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)",
     "role": "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails",
     "shortName": "Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_12_31_2021_druC2YaYp0KRaXdBfhmOlA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_X5p0QePvYUSPIdUOuIE79Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Inventory (Details)",
     "role": "http://www.coherus.com/role/DisclosureInventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)",
     "role": "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
     "shortName": "Inventory - Balance Sheet Classifications (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "lang": null,
      "name": "chrs:InventoryCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Inventory - Additional Information (Details)",
     "role": "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
     "shortName": "Inventory - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)",
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_3_1_2022_To_3_31_2022_-oXBZarHtkK0JSkSA05zDg",
      "decimals": "-5",
      "lang": null,
      "name": "chrs:CollaborationAgreementOptionExerciseFeePerProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
     "shortName": "Debt Obligations - Summary of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_lFOxcKLpPk67TJq2Qp-DLA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
     "shortName": "Debt Obligations - 2027 Term Loan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JwyHhzbobkizq1UiX-a22w",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
     "shortName": "Debt Obligations - 2027 Term Loans Interest Expense Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wQu3-gqvhU6TJkoVnh8zmw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
     "shortName": "Debt Obligations - 2027 Term Loan Future Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_pv347xvZP0O6maGZMxoaag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
     "shortName": "Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentCovenantCompliance",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bmA1J7_-g02NoTnD-cDbEw",
      "decimals": "0",
      "lang": null,
      "name": "chrs:NumberOfEventsInDefault",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_v5WZnyOer0qHohglmCkn4Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails",
     "shortName": "Debt Obligations - Capped Call Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_nZTt4PhF20WkmB_IPByA9g",
      "decimals": "-5",
      "lang": null,
      "name": "chrs:PaymentForCappedCallTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40708 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
     "shortName": "Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WN8twISgpUWQsH_Ktu1xjg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_wmOfIMLSIEGbEzA3Hc7tSQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40709 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
     "shortName": "Debt Obligations - 2026 Convertible Notes Future Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_8DU6KCb1BUele1zKz8gkYg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40710 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
     "shortName": "Debt Obligations - Convertible Notes due 2022 Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_r_1usf0fdkqJ28_BPspM_Q",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40712 - Disclosure - Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
     "shortName": "Debt Obligations - 2022 Convertible Notes Interest Expense Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_GUiILlYGD0OThkKEDXof6w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40713 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
     "shortName": "Debt Obligations - 2025 Term Loan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_gVgB94UeLkKTlxsG-jRXZg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40715 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)",
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
     "shortName": "Debt Obligations - 2025 Term Loan Interest Expense Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_fnZU4NpA_km7FjYbCEF-AQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)",
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_5jnWiPFyPEmr0eK_tetk0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_4_1_2022_To_4_30_2022_FGWwlhmZwkyvhrfG4M2pIQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember_Vba-RZn_vUahpV1rGB7pTg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)",
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails",
     "shortName": "Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_0NkbbaX7ZUK_0AfdfnANHQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_8vH9qbbnSUCDS3cwRmIXug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_LhcsPLKUGkSxtec9iGQCMQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NuBq-345SE2DdIL_jjCYtA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6qmOksBoz0uXpji7uweM_Q",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_FJe7PkIsa0qCpjvB8PLSpg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Revenue",
     "role": "http://www.coherus.com/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "chrs-20220930x10q.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_vC5-vOxLbkCJSiJyJbLbVA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "chrs_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued and other current liabilities.",
        "label": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_AccruedCoDevelopmentCostsPayableToJunshiBiosciences": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent to pertaining accrued co-development costs payable to Junshi Biosciences",
        "label": "Accrued Co-Development Costs Payable to Junshi Biosciences",
        "terseLabel": "Accrued co-development costs payable to Junshi Biosciences"
       }
      }
     },
     "localname": "AccruedCoDevelopmentCostsPayableToJunshiBiosciences",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued commercial and research and development manufacturing liabilities current.",
        "label": "Accrued Commercial and Research and Development Manufacturing Liabilities Current",
        "terseLabel": "Accrued commercial and research and development manufacturing"
       }
      }
     },
     "localname": "AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_AccruedRebatesFeesAndReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued rebates, fees and reserve.",
        "label": "Accrued Rebates Fees And Reserve Current",
        "terseLabel": "Accrued rebates, fees and reserves"
       }
      }
     },
     "localname": "AccruedRebatesFeesAndReserveCurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments upon achievement of certain development and regulatory milestones.",
        "label": "Additional Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones",
        "verboseLabel": "Maximum aggregate milestone payments"
       }
      }
     },
     "localname": "AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments upon achievement of with subject to FDA approval",
        "label": "Additional Milestone Payments Upon Achievement With Subject To FDA Approval",
        "terseLabel": "Additional milestone payments related to FDA approval"
       }
      }
     },
     "localname": "AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_AmeriSourceBergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmeriSource-Bergen Corp.",
        "label": "AmeriSource-Bergen Corp"
       }
      }
     },
     "localname": "AmeriSourceBergenCorpMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_AntiTigitAntibodyAndIl2CytokineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents anti-TIGIT antibody and the IL-2 cytokine.",
        "label": "Anti-TIGIT Antibody and IL-2 cytokine"
       }
      }
     },
     "localname": "AntiTigitAntibodyAndIl2CytokineMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_BevacizumabLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the bevacizumab Licensed Product.",
        "label": "Bevacizumab Licensed Product"
       }
      }
     },
     "localname": "BevacizumabLicensedProductMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_BioeqIPAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioeq IP AG.",
        "label": "Bioeq IP AG"
       }
      }
     },
     "localname": "BioeqIPAGMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_BiopharmaCreditInvestmentsVGpLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to BioPharma Credit Investments V GP LLC.",
        "label": "BioPharma Credit Investments V GP LLC"
       }
      }
     },
     "localname": "BiopharmaCreditInvestmentsVGpLlcMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_CapPriceOfCapCallTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cap price of the cap call transactions (per share).",
        "label": "Cap Price of Cap Call Transactions",
        "terseLabel": "Initial cap price of capped call transactions."
       }
      }
     },
     "localname": "CapPriceOfCapCallTransactions",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "chrs_CardinalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal.",
        "label": "Cardinal"
       }
      }
     },
     "localname": "CardinalMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge backs and discounts for prompt payment.",
        "label": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_Chs2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents CHS-2020, a biosimilar of Eylea.",
        "label": "CHS-2020"
       }
      }
     },
     "localname": "Chs2020Member",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents co-development, regulatory and technology transfer costs.",
        "label": "Co-development, Regulatory And Technology Transfer Costs",
        "terseLabel": "Co-development, regulatory and technology transfer costs"
       }
      }
     },
     "localname": "CoDevelopmentRegulatoryAndTechnologyTransferCosts",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program"
       }
      }
     },
     "localname": "CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.",
        "label": "Collaboration Agreement, Number Of Undisclosed Preclinical Immuno Oncology Drug Candidates",
        "terseLabel": "Undisclosed preclinical"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "chrs_CollaborationAgreementOptionExerciseFeePerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of option exercise fee per program under the collaboration agreement.",
        "label": "Collaboration Agreement, Option Exercise Fee Per Program",
        "terseLabel": "License Agreement Fee"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePerProgram",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty on net sales under the collaboration agreement.",
        "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales",
        "terseLabel": "Collaboration agreement, royalty on net sales, percentage"
       }
      }
     },
     "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSales",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty on net sales for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program",
        "terseLabel": "Collaboration agreement, royalty on net sales for each exercised option, percentage"
       }
      }
     },
     "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program",
        "terseLabel": "Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program"
       }
      }
     },
     "localname": "CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_CollaborationAgreementThresholdRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold royalty payments to be made under the collaboration agreement.",
        "label": "Collaboration Agreement , Threshold Royalty Payments",
        "terseLabel": "Collaboration agreement, threshold royalty payments"
       }
      }
     },
     "localname": "CollaborationAgreementThresholdRoyaltyPayments",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.coherus.com/20220930",
     "xbrltype": "stringItemType"
    },
    "chrs_CollaborationCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents costs associated to a collaboration agreement.",
        "label": "Collaboration Costs",
        "terseLabel": "Collaboration Agreement, upfront amount paid"
       }
      }
     },
     "localname": "CollaborationCosts",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_ConsultingAgreementWithLanfearAdvisorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consulting agreement with Lanfear advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, our President, Chief Executive Officer and Chairman of our Board of Directors.",
        "label": "Consulting Agreement With Lanfear Advisors"
       }
      }
     },
     "localname": "ConsultingAgreementWithLanfearAdvisorsMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes.",
        "label": "Shares Issuable Upon Conversion of Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ConvertibleNotesPrincipalAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes, principal amount.",
        "label": "Convertible Notes Principal Amount",
        "terseLabel": "2026 Convertible Notes, principal amount"
       }
      }
     },
     "localname": "ConvertibleNotesPrincipalAmount",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_ConvertibleSeniorNotes8.2PercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 8.2% Convertible Senior Notes due 2022.",
        "label": "8.2% Convertible Notes due 2022"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes8.2PercentDue2022Member",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026.",
        "label": "1.5% Convertible Senior Subordinated Notes due 2026"
       }
      }
     },
     "localname": "ConvertibleSeniorSubordinatedNotesDue20261.5Member",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_DebtDiscountsAndIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt discounts and issuance costs incurred.",
        "label": "Debt Discounts and Issuance Costs",
        "terseLabel": "Debt discounts and issuance costs"
       }
      }
     },
     "localname": "DebtDiscountsAndIssuanceCosts",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_DebtInstrumentContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debt instrument contractual term.",
        "label": "Debt Instrument Contractual Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "DebtInstrumentContractualTerm",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument convertible number of shares per thousand of principal amount of notes.",
        "label": "Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes",
        "terseLabel": "Initial conversion rate, shares of common stock"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "chrs_DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equal quarterly payments of principal.",
        "label": "Debt Instrument, Number of Quarterly Payments of Principal",
        "terseLabel": "Quarterly payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfQuarterlyPaymentsOfPrincipal",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "chrs_DebtInstrumentNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of committed tranches.",
        "label": "Debt Instrument, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTranches",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "chrs_DebtInstrumentPrepaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment percentage.",
        "label": "Debt Instrument Prepayment Percentage",
        "terseLabel": "Prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPercentage",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_DebtInstrumentRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debt instrument remaining term.",
        "label": "Debt Instrument Remaining Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "localname": "DebtInstrumentRemainingTerm",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "chrs_EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent the information pertaining to options and RSU",
        "label": "Employee And Nonemployee Stock Option And Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeStockOptionAndRestrictedStockUnitsMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee and nonemployee stock option restricted stock units.",
        "label": "Employee And Nonemployee Stock Option Restricted Stock Units"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeStockOptionRestrictedStockUnitsMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_EmployeesAndNonemployeesStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and non-employees stock option.",
        "label": "Stock options, including shares subject to ESPP"
       }
      }
     },
     "localname": "EmployeesAndNonemployeesStockOptionMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_EquivalentToConversionPricePerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equivalent to conversion price per common share.",
        "label": "Equivalent To Conversion Price Per Common Share",
        "terseLabel": "Initial conversion price per common share"
       }
      }
     },
     "localname": "EquivalentToConversionPricePerCommonShare",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "chrs_EstimatedIncreaseDecreaseInNetIncomeLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated increase in the net income (loss).",
        "label": "Estimated Increase Decrease In Net Income (Loss)",
        "terseLabel": "Estimate increased the net loss, amount"
       }
      }
     },
     "localname": "EstimatedIncreaseDecreaseInNetIncomeLoss",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated increase (decrease) in the net income (loss) per share (basic and diluted).",
        "label": "Estimated Increase Decrease In Net Income (Loss) Per Share (Basic And Diluted)",
        "terseLabel": "Estimated net loss per share (basic and diluted)"
       }
      }
     },
     "localname": "EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "chrs_ExclusiveLicenseAndCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Exclusive License and Commercialization Agreement .",
        "label": "Collaboration Agreement"
       }
      }
     },
     "localname": "ExclusiveLicenseAndCommercializationAgreementMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_FairValueForDiscountForLackOfMarketability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value for the discount for lack of marketability (DLOM).",
        "label": "Fair Value for the Discount for Lack of Marketability",
        "terseLabel": "Fair value for the discount for lack of marketability (DLOM)"
       }
      }
     },
     "localname": "FairValueForDiscountForLackOfMarketability",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_HealthcareRoyaltyPartnersIIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Royalty Partners III, L.P.",
        "label": "Lender"
       }
      }
     },
     "localname": "HealthcareRoyaltyPartnersIIILPMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_IncreaseDecreaseInAccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued compensation.",
        "label": "Increase Decrease In Accrued Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCompensation",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued rebates, fees and reserve.",
        "label": "Increase Decrease In Accrued Rebates Fees And Reserve",
        "terseLabel": "Accrued rebates, fees and reserves"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRebatesFeesAndReserve",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_InitialTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of agreement.",
        "label": "Initial Term Of Agreement",
        "terseLabel": "Initial term of agreement"
       }
      }
     },
     "localname": "InitialTermOfAgreement",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "chrs_InnoventBiologicsSuzhouCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Innovent Biologics (Suzhou) Co., Ltd.",
        "label": "Innovent Biologics (Suzhou) Co., Ltd."
       }
      }
     },
     "localname": "InnoventBiologicsSuzhouCoLtdMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_InventoryCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory current and noncurrent.",
        "label": "Inventory Current And Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryCurrentAndNoncurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_JunshiBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Junshi Biosciences.",
        "label": "Junshi Biosciences"
       }
      }
     },
     "localname": "JunshiBiosciencesMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_LeaseLiabilitiesOperatingAndFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents lease liabilities for both operating and financing leases.",
        "label": "Lease Liabilities, Operating and Financing",
        "terseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "LeaseLiabilitiesOperatingAndFinancing",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period five.",
        "label": "Loan Agreement Covenants Net Sales For Period Five",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter"
       }
      }
     },
     "localname": "LoanAgreementCovenantsNetSalesForPeriodFive",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period four.",
        "label": "Loan Agreement Covenants Net Sales For Period Four",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024"
       }
      }
     },
     "localname": "LoanAgreementCovenantsNetSalesForPeriodFour",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period one.",
        "label": "Loan Agreement Covenants, Net Sales For Period One",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve month net sales for current quarter"
       }
      }
     },
     "localname": "LoanAgreementCovenantsNetSalesForPeriodOne",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period three.",
        "label": "Loan Agreement Covenants, Net Sales For Period Three",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024"
       }
      }
     },
     "localname": "LoanAgreementCovenantsNetSalesForPeriodThree",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period two.",
        "label": "Loan Agreement Covenants, Net Sales For Period Two",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024"
       }
      }
     },
     "localname": "LoanAgreementCovenantsNetSalesForPeriodTwo",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_MandatoryPrepaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mandatory prepayment, term.",
        "label": "Mandatory Prepayment, Term",
        "terseLabel": "Mandatory prepayment term"
       }
      }
     },
     "localname": "MandatoryPrepaymentTerm",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "chrs_MaximumAmountPaidCoDevelopmentActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum paid amount for co-development activities.",
        "label": "Maximum Amount Paid, Co-development Activities",
        "terseLabel": "Maximum paid amount for co-development activities (per licensed compound)"
       }
      }
     },
     "localname": "MaximumAmountPaidCoDevelopmentActivities",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_McKessonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson.",
        "label": "McKesson"
       }
      }
     },
     "localname": "McKessonMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_NumberOfEventsInDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of events in default.",
        "label": "Number Of Events in Default",
        "terseLabel": "Number of events in default"
       }
      }
     },
     "localname": "NumberOfEventsInDefault",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "chrs_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.",
        "label": "Operating and Finance Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_OptionExerciseFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents an option exercise fee.",
        "label": "Rituxan option"
       }
      }
     },
     "localname": "OptionExerciseFeeMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_OtherFeesCoPayAssistanceAndReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other fees, co-pay assistance and returns.",
        "label": "Other Fees, Co-pay Assistance and Returns"
       }
      }
     },
     "localname": "OtherFeesCoPayAssistanceAndReturnsMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_OtherNoncashAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other noncash adjustments.",
        "label": "Other Noncash Adjustments",
        "terseLabel": "Other non-cash adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashAdjustments",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PaymentForCappedCallTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment made for entering into capped call transactions.",
        "label": "Payment for Capped Call Transactions",
        "terseLabel": "Payment for capped call transactions"
       }
      }
     },
     "localname": "PaymentForCappedCallTransactions",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.",
        "label": "Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration",
        "negatedLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PercentageOfCapPriceCappedCallTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of premium on cap price.",
        "label": "Percentage of Cap Price, Capped Call Transactions",
        "terseLabel": "Percentage of cap price"
       }
      }
     },
     "localname": "PercentageOfCapPriceCappedCallTransactions",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_PercentageOfGrossProfitsOnSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "percentage of profit shared.",
        "label": "Percentage Of Gross Profits On Sales",
        "terseLabel": "Percentage of gross profits shared"
       }
      }
     },
     "localname": "PercentageOfGrossProfitsOnSales",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_PercentageOfPremiumOnConvertibleNote": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium on convertible note.",
        "label": "Percentage Of Premium On Convertible Note",
        "terseLabel": "Convertible notes, premium percentage"
       }
      }
     },
     "localname": "PercentageOfPremiumOnConvertibleNote",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage required to pay an additional exit fee on principal amount.",
        "label": "Percentage Required To Pay Additional Exit Fee On Principal Amount",
        "terseLabel": "Percentage required to pay an additional exit fee on principal amount"
       }
      }
     },
     "localname": "PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "chrs_PrepaidManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid manufacturing expense current.",
        "label": "Prepaid Manufacturing Expense Current",
        "netLabel": "Prepaid manufacturing",
        "verboseLabel": "Prepayment made for manufacturing services"
       }
      }
     },
     "localname": "PrepaidManufacturingExpenseCurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PrepaymentsMadeToCmoForManufacturingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prepayments made to a CMO for manufacturing services.",
        "label": "Prepayments Made to CMO For Manufacturing Services",
        "terseLabel": "Prepayments made to a CMO for manufacturing services for UDENYCA"
       }
      }
     },
     "localname": "PrepaymentsMadeToCmoForManufacturingServices",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prepayments made to a CMO for other research and development program.",
        "label": "Prepayments made to a CMO For Other Research And Development Pipeline Program"
       }
      }
     },
     "localname": "PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount of notes converted into shares of common stock at conversion rate.",
        "label": "Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate",
        "terseLabel": "Principal amount of notes converted into shares"
       }
      }
     },
     "localname": "PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_ProductPipelineNumberOfDrugCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of drug candidates in the product pipeline.",
        "label": "Product pipeline, Number of Drug Candidates",
        "terseLabel": "Product pipeline, number of product candidates"
       }
      }
     },
     "localname": "ProductPipelineNumberOfDrugCandidates",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "chrs_ProvisionRelatedToSalesMadeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ProvisionRelatedToSalesMadeAbstract",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "chrs_ProvisionRelatedToSalesMadeInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents provision related to sales made in prior period.",
        "label": "Provision Related to Sales Made in Prior Period",
        "terseLabel": "Prior period"
       }
      }
     },
     "localname": "ProvisionRelatedToSalesMadeInPriorPeriod",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period before the company can sell, transfer or make any short sale of common stock.",
        "label": "Purchase Agreement, Restrictive Requirement on Selling, Transfer and Short Sale of Common Stock",
        "terseLabel": "Period before the company can sell, transfer or make any short sale of common stock (in years)"
       }
      }
     },
     "localname": "PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "chrs_RebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates"
       }
      }
     },
     "localname": "RebatesMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for discounts and allowances constitute variable consideration.",
        "label": "Reserve For Discounts And Allowances Constitute Variable Consideration",
        "periodEndLabel": "Activities and reserve balance, ending balance",
        "periodStartLabel": "Activities and reserve balance, beginning balance"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for sales discounts and allowances constitute variable consideration.",
        "label": "Reserve For Sales Discounts And Allowances Constitute Variable Consideration",
        "verboseLabel": "Current period"
       }
      }
     },
     "localname": "ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_RestrictedCashMoneyMarketFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash money market funds.",
        "label": "Restricted Cash (Money Market Funds)"
       }
      }
     },
     "localname": "RestrictedCashMoneyMarketFundsMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of balance sheet classification of Inventory.",
        "label": "Schedule Of Balance Sheet Classification Of Inventory Table [Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetClassificationOfInventoryTableTextBlock",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "chrs_ScheduleOfInventoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories.",
        "label": "Schedule of Inventory [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryTableTextBlock",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of product sales discounts and allowances.",
        "label": "Schedule Of Product Sales Discounts And Allowances Table [Text Block]",
        "terseLabel": "Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances"
       }
      }
     },
     "localname": "ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "chrs_StockPurchaseAgreementSharesAgreedToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.",
        "label": "Stock Purchase Agreement, Shares Agreed To Be Issued",
        "terseLabel": "Unregistered shares"
       }
      }
     },
     "localname": "StockPurchaseAgreementSharesAgreedToBeIssued",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.",
        "label": "Stock Purchase Agreement, Shares Agreed To Be Issued, Value",
        "terseLabel": "Aggregate value"
       }
      }
     },
     "localname": "StockPurchaseAgreementSharesAgreedToBeIssuedValue",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_TermLoanGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, gross.",
        "label": "Term Loan Gross",
        "terseLabel": "Term Loan, gross"
       }
      }
     },
     "localname": "TermLoanGross",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans.",
        "label": "2027 Term Loans"
       }
      }
     },
     "localname": "TermLoansMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TermLoansPayableNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Term Loans Payable, Noncurrent",
        "terseLabel": "Term loans"
       }
      }
     },
     "localname": "TermLoansPayableNoncurrent",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_ToripalimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents toripalimab.",
        "label": "Toripalimab"
       }
      }
     },
     "localname": "ToripalimabMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche B Loan.",
        "label": "Tranche B Loan, funded no later than April 1, 2022"
       }
      }
     },
     "localname": "TrancheBLoanMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche C Loan.",
        "label": "Tranche C Loan, funded between April 1, 2022 and March 17, 2023"
       }
      }
     },
     "localname": "TrancheCLoanMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheDLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche D Loan.",
        "label": "Tranche D Loan, funded on September 14, 2022"
       }
      }
     },
     "localname": "TrancheDLoanMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche A Loan.",
        "label": "Tranche A Loan, funded January 5, 2022"
       }
      }
     },
     "localname": "TrancheLoanMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheaAndBLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to  tranche A&amp;B loans.",
        "label": "Tranche A and B Loans"
       }
      }
     },
     "localname": "TrancheaAndBLoansMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_TrancheaBAndDLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to  tranche A&amp;B &amp; D loans.",
        "label": "Tranches A, B and D"
       }
      }
     },
     "localname": "TrancheaBAndDLoansMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront and milestone based license fee payments.",
        "label": "Upfront And Milestone Based License Fee Payments, Investing Activities",
        "negatedLabel": "Upfront and option payments to Junshi Biosciences"
       }
      }
     },
     "localname": "UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_UpfrontAndMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront and milestone payments.",
        "label": "Upfront And Milestone Payment",
        "terseLabel": "Upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePayment",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront license fee payment related to license and collaboration agreement.",
        "label": "Upfront License Fee Payments Related To License And Collaboration Arrangements",
        "terseLabel": "Upfront and option payments to Junshi Biosciences"
       }
      }
     },
     "localname": "UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "chrs_YusimryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Yusimry product.",
        "label": "Yusimry Product [Member]"
       }
      }
     },
     "localname": "YusimryProductMember",
     "nsuri": "http://www.coherus.com/20220930",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "verboseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "verboseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r101",
      "r102",
      "r209",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r161",
      "r263",
      "r266",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r246",
      "r278",
      "r280",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r419",
      "r422",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r161",
      "r263",
      "r266",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r159",
      "r263",
      "r265",
      "r380",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r159",
      "r263",
      "r265",
      "r380",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r246",
      "r268",
      "r278",
      "r280",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r419",
      "r422",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r246",
      "r268",
      "r278",
      "r280",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r419",
      "r422",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r101",
      "r102",
      "r209",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r113",
      "r118",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r113",
      "r118",
      "r183",
      "r279",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Notes And Loans Receivable [Line Items]",
        "terseLabel": "Accounts Notes And Loans Receivable"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r55",
      "r56",
      "r57",
      "r406",
      "r427",
      "r428"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r63",
      "r64",
      "r65",
      "r105",
      "r106",
      "r107",
      "r313",
      "r423",
      "r424",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r295",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r292",
      "r293",
      "r294",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Adjustments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of RSUs"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r281",
      "r283",
      "r297",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r283",
      "r288",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r76",
      "r90",
      "r228",
      "r349"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Non-cash interest expense from amortization of debt discount &amp; issuance costs",
        "verboseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "verboseLabel": "Antidilutive securities excluded from the calculation of diluted net (loss) income per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities excluded from computation of EPS"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r148",
      "r151",
      "r157",
      "r168",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r308",
      "r314",
      "r339",
      "r365",
      "r367",
      "r383",
      "r402"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r47",
      "r100",
      "r168",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r308",
      "r314",
      "r339",
      "r365",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r284",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Capped Call Transactions in connection with the 2026 Convertible Notes"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r28",
      "r92"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r93",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r92",
      "r96"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r340"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r182",
      "r388",
      "r411"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r190",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 77,770,593 and 76,930,096 at September 30, 2022 and December 31, 2021, respectively)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r62",
      "r71",
      "r307",
      "r317",
      "r393",
      "r415"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r161",
      "r336",
      "r337",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r161",
      "r336",
      "r337",
      "r429",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r161",
      "r336",
      "r337",
      "r429",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r139",
      "r140",
      "r161",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Percentage of total gross revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r141",
      "r336",
      "r338",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r161",
      "r336",
      "r337",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r208",
      "r218",
      "r219",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r238",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Long Term Notes Payable"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r14",
      "r385",
      "r403",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "totalLabel": "Total Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Convertible Subordinated Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r380"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Sold Goods",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Goods Sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r138",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion Converted Instrument Amount1",
        "terseLabel": "Convertible notes, converted amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Obligations"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r229",
      "r230",
      "r232",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r99",
      "r103",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r238",
      "r239",
      "r240",
      "r241",
      "r352",
      "r384",
      "r385",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r233",
      "r385",
      "r401"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r14",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument Covenant Compliance",
        "terseLabel": "Convertible notes, covenant compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r205",
      "r238",
      "r239",
      "r350",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r220",
      "r238",
      "r239",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument Fair Value",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r35",
      "r236",
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt Instrument Interest Rate Terms",
        "terseLabel": "Interest rate description"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r36",
      "r208",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r99",
      "r103",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r238",
      "r239",
      "r240",
      "r241",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r99",
      "r103",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r238",
      "r239",
      "r240",
      "r241",
      "r249",
      "r250",
      "r251",
      "r252",
      "r349",
      "r350",
      "r352",
      "r353",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term",
        "terseLabel": "Total term of the loan"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r218",
      "r234",
      "r238",
      "r239",
      "r351"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureConvertibleNotesAndTermLoanTermLoanComponentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": -1.0
      },
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Less unamortized debt discount and debt issuance costs, net",
        "negatedTerseLabel": "Less unamortized debt discount and debt issuance costs",
        "terseLabel": "Remaining unamortized debt discount and debt offering costs",
        "verboseLabel": "Unamortized debt discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred Finance Costs Gross",
        "terseLabel": "Convertible notes, Issuance Cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r30",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r90",
      "r173"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r119",
      "r121",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r324",
      "r325",
      "r394",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "Basic net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r121",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r324",
      "r325",
      "r394",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount",
        "terseLabel": "Stock-based compensation expense capitalized into inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r132",
      "r169",
      "r248",
      "r253",
      "r292",
      "r293",
      "r294",
      "r301",
      "r302",
      "r323",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r423",
      "r424",
      "r425",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r326",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r220",
      "r238",
      "r239",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r327",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r329",
      "r330",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r220",
      "r269",
      "r270",
      "r275",
      "r277",
      "r327",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r220",
      "r238",
      "r239",
      "r269",
      "r270",
      "r275",
      "r277",
      "r327",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r220",
      "r238",
      "r239",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r327",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r220",
      "r238",
      "r239",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "negatedLabel": "Write-off of prepaid manufacturing services related to the termination of CHS-2020",
        "negatedTerseLabel": "Impairment charge within research and development expenses"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r90",
      "r242",
      "r243"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r148",
      "r150",
      "r153",
      "r156",
      "r158",
      "r381",
      "r390",
      "r396",
      "r417"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase Decrease In Accounts Payable Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued and other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Other prepaid, current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase Decrease In Prepaid Expense",
        "negatedLabel": "Prepaid manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Receivables",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r147",
      "r348",
      "r351",
      "r395"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r76",
      "r226",
      "r237",
      "r240",
      "r241"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "positiveLabel": "Interest expense",
        "totalLabel": "Total Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r78",
      "r227",
      "r240",
      "r241"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense Debt Excluding Amortization",
        "terseLabel": "Stated coupon interest"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income And Interest Expense Disclosure Table [Text Block]",
        "terseLabel": "Components of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r387",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable Current And Noncurrent",
        "negatedLabel": "Less amount representing interest",
        "terseLabel": "Contractual future interest payments due in 2022"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Current [Table]",
        "terseLabel": "Inventory Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory Finished Goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r45",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "order": 1.0,
       "parentTag": "chrs_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "order": 2.0,
       "parentTag": "chrs_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory Noncurrent",
        "terseLabel": "Inventory, non-current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Raw Materials",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r45",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory Work In Process",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write Down",
        "terseLabel": "Write-downs of inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Finance lease right of use assets"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r100",
      "r152",
      "r168",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r309",
      "r314",
      "r315",
      "r339",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r100",
      "r168",
      "r339",
      "r367",
      "r386",
      "r408"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r100",
      "r168",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r309",
      "r314",
      "r315",
      "r339",
      "r365",
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "Licensed Products"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Additional facility amount"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "2025 Term Loan"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "Three-month LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r219",
      "r235",
      "r238",
      "r239",
      "r385",
      "r404"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "terseLabel": "Net carrying value",
        "totalLabel": "Net carrying amount of Term Loans"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r103",
      "r191",
      "r224"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2023 - interest only"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r103",
      "r191",
      "r224"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2025 - interest only"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r103",
      "r191",
      "r224"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2024 - interest only"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year",
        "terseLabel": "Remainder of 2022 - interest only"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long Term Purchase Commitment [Text Block]",
        "terseLabel": "Schedule of Non-cancelable Contractual Obligations"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2022ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash and cash equivalents (money market funds)"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r61",
      "r65",
      "r69",
      "r91",
      "r100",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r122",
      "r148",
      "r150",
      "r153",
      "r156",
      "r158",
      "r168",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r325",
      "r339",
      "r391",
      "r413"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r150",
      "r153",
      "r156",
      "r158"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r245",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "auth_ref": [
      "r245",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options.",
        "label": "Option Indexed to Issuer's Equity, Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Option Indexed to Issuer's Equity [Line Items]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r33"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets, non-current",
        "verboseLabel": "Other assets, non-current"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r64",
      "r66",
      "r70",
      "r248",
      "r341",
      "r346",
      "r347",
      "r392",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities, non-current"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of RSUs"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments in marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Other prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuance of Convertible Notes",
        "verboseLabel": "Net proceeds from offering"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from maturities of investments in marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r291"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from purchase under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Best estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded.",
        "label": "Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate",
        "terseLabel": "Claims related to certain sales of UDENYCA from October 2020 through December 2021"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r58",
      "r61",
      "r65",
      "r86",
      "r100",
      "r108",
      "r116",
      "r117",
      "r148",
      "r150",
      "r153",
      "r156",
      "r158",
      "r168",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r307",
      "r311",
      "r312",
      "r316",
      "r317",
      "r325",
      "r339",
      "r396"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r175",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r48",
      "r176",
      "r356"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property Plant And Equipment Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r10",
      "r174",
      "r354"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r176",
      "r367",
      "r398",
      "r410"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Total obligations"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Fourth Year",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Second Year",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Third Year",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.",
        "label": "Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r24",
      "r367",
      "r409",
      "r431"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables Net Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivables Policy [Text Block]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r276",
      "r359",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "verboseLabel": "Consulting expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r358",
      "r360",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of 2022 Convertible Notes and premiums",
        "terseLabel": "Outstanding amount payoff"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of 2025 Term Loan, premiums and exit fees",
        "terseLabel": "Outstanding amount paid off"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r300",
      "r379",
      "r442"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r96",
      "r382",
      "r405"
     ],
     "calculation": {
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r253",
      "r295",
      "r367",
      "r407",
      "r426",
      "r428"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r169",
      "r292",
      "r293",
      "r294",
      "r301",
      "r302",
      "r323",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r149",
      "r154",
      "r155",
      "r159",
      "r160",
      "r161",
      "r262",
      "r263",
      "r380"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue From Contract With Customer Including Assessed Tax",
        "terseLabel": "Net revenue",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r139",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Net Product Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]",
        "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net (loss) Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of the Company's Debt Obligations"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r283",
      "r287",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r283",
      "r287",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Schedule of Future Payments on Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r96",
      "r382",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r141",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "netLabel": "Number of options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r282",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "netLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing stock, price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid For Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of RSUs (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r63",
      "r64",
      "r65",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r132",
      "r169",
      "r248",
      "r253",
      "r292",
      "r293",
      "r294",
      "r301",
      "r302",
      "r323",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r423",
      "r424",
      "r425",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r132",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock to Shanghai Junshi Biosciences Ltd. (\"Junshi Biosciences\"), net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r248",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Issuance of common stock upon vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock to Shanghai Junshi Biosciences Ltd. (\"Junshi Biosciences\"), net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r15",
      "r16",
      "r248",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r248",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r100",
      "r163",
      "r168",
      "r339",
      "r367"
     ],
     "calculation": {
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted-average common shares outstanding - Diluted",
        "terseLabel": "Weighted-average number of shares used in computing diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted-average number of shares used in computing basic net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.coherus.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB TOPIC 5.Y.Q2)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r446": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r447": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r448": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001558370-22-016850-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-016850-xbrl.zip
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M[67?/D_MNF3&HTKA>!/[4@CB+VC9?F=]P'))O\O++9NHC3UN$WLOW>;9P:?
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M#$OV-5,L%;[5!^EL NN.^PM,JF#&Y9[@RA4)?DP6;V:QWEQ1\7=8N=WRP-2
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MJ\O20_3%TA61S-8?<+N!2I4$[HTI)VIXN8^D<OU2>,]2>-/)+_\'4$L#!!0
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M;41Q-I3GE35&]K-7H&NW)PC-A?^AU\&68X??"(;UVMU>L+;_*?CZ^YEM1U0
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M%)M7UN4V7WBEI&TF(Z4^UJ_+R"D>'T4U-6/9\8!?,'5QJ$QQY/(WXDP'KNT
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MCS_@PK'FT22KP,)9D=R;F)EG+\F0AS_T&W4;QX;XG>O*A(AGB^ODHP:'&+?
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M8>)683*A9$Q,L9WD1U5Y=^U81+POE^(,6G'_7(@W4"RUFV,^=GO=OM$VEM+
M_T0%,A =&1&1C*5,1BB4N&T&ZOW9OTXF(IJ7>2F<__O? _G^T=KA*V<DS7/-
M,NNY!]P7*\DZ:+^<OP,-,I^94\FK7^^T$=/'[@TOK0>-/6=1_-)5<C31'AA:
M ;!*U$C%(\[B4'JQH0(&B^10L2BI,=WZ0N*O?/4^HN2/]5ZH\(!>;V$!S0FR
M9 -*:EI]VEFZLE/O1\@%T(Q[D9;W/3#^0QRH@&FI]-JK],2--%\^@F9$RRT
M78E+_J=XY#WVD6>_6.(X^J,:[\8O8+]\!"7=]]4/8N?($AL0CU,,BTH+V;:W
M5/'6_T7'MY6ET')\:QM!/897D9&HJ?KQ3WJ>(9!PX#\Q#S.6Y7OSLN$M/6V]
M#>X.RY\R7";1L'%E*3ZUK<E@-&R$D](L(^5.F"\;C1Y7#2][L5CWR&9S1L7B
MY=&$SMZU\' <!C!'8Y>!H<6ZSD^K2X-$=[FH6=Q3'%0NKB .J_=\10L!?C9
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M[M"3_"/R'$P>0ZKFZ%F+W=B^X( >F4)$A_K4]1)J,3$(NIF[';T-F:[[1/<
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MKO*DB"Y#3Q3'<PKD-YGMHMLYX.U8:I-WM]B#LV3<4!DGR(_#]RA6R1=7K\P
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MTP3<FEY8%KLY^%0[L9N\.-EP56,0B1_[7L8RY"&RE!D),U;!2J[*VH-('#D
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M<XVCB;^;Q*[(V59H \> U2O3<UHZ3P$(2EB"(B$L+IV'7YSO#VWN(X<6Q^.
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M'+1&O)'CXM?CB FQ<?_?_P=02P,$%     @ 6X!H54_C:^##;   8MX& !4
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MNI$HA:YX *AC5Z0NUL< X'U=^B%TS%[B]XXQ1 S^0W@1C_V51('O\2?PSIT
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M$[XPO:+XP)146.*H"7*?JU-(=C7Y>\0>5BMFWU%7$ .WLN-.X^C3QW'<39R
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M&6WYD[/.0L@Y<P+<48'7R(92![E"C\8DW3!3/=S=X0,? >I*P_1:[C12FR<
MZ9I)>T&D)C4_$-+6:+PE4Q,.85Q%C6@L32A"LB:2PE_WE*<X/D:/SNM/?KK9
MB,(2UU'Q@D$U_M4>4.M!$3D\&3"7(O3=E1QBF#*AE8F =<8< M=0ID#B3Y@
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MTK%@BST+,42YWJ> L\5[KE'(C6,U6B@4OV.&WC!YR]?8V[!$KR=R^.B@?C7
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MG#0?NSEQBV/W%C(A-E'@W6QW<?0BWCYO'+S-/9"/7@UUY>';T!SQ^-61NN\
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M,^L*CG"7[YP2P=3"5G92FWP*V=;33YA$3'&.FB83(;JH\C<GV!^O-GH3^5(
MM&*47BC**7Q)4%I5J.^XYU1@OY3\'V U8]$^Z+H@G#=RD#5CGV41Y7NITWD
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M'HP+:G)5.HS ]M+DZ6>;^]U<",S85$&"#%D%<6!=>.L*;[YHET)YJRP8L!7
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MO$6+-FEMM0EYB+)4P0QQ$14?*+:EN5ORFP*%%JH#X72X82V+736TI9N<8YR
M6X7 *H7"'AT<'AQI#(6U_E+\]*_ [<=XHV+Q!CC&/7$I/K1/*['G@%T%C%50
MBVI5%JDW [!C^+_'>%MR%2?>@KPYP@"\6FBD$$L(84I>[_QJA^CJQ_:%-TI[
MUICOT.1(":-=9%/R^C7E^^62AUUAI-10%*B'S$8#[2_6K\3*K138%48*O*)
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M#V[6*R$VW"V:J4K^T4C\=:E%XNJ +D]BS2G*!IU1=!^ 51$=UBOR6?['!PP
M%?\VS)[<XRR].37 03W8 EQ528 O?S%$X=[MY=8!QQ)5L*3AYL@+>-_%3=K$
MW6M)U!P+^!SHZO"WE7MW)-CM(R@ 8-VYY5?2S.[N?@[U,LJ %%!"HA% 2>$
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MH/2]U>LPPJLO+\03:..#\?*U#>&"#JES7IR:P(O'GV$'7N#:>\@+EM2%^^O
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M[V'U<C@(@!V2"+8]'!018/2'@^ @%""A[W!0+[3]KFTX%IQ3 QS2?9IR53T
M/B1AB,(UV-PZX(B@"I8TW&ULN/Y'UK!5BE.?)(U:OSWVFY?,;^U@ANSHS'WQ
MXC#BNT^EZX\%6R6;WDUZ":0/80UMD3-55 T<"0:P]'QE&.GCK*Z<KFV'[[9D
M%0?'GE8(BY;X GF-] ,(<Z&P4J%D1\KQ5UPPB6^"[,+)URB,61:JAR]583H9
M_DUX3;3<E:JZ7OHYS1@=H 1,8N3VN7T:=?<;\I[G&-$SO(>TG]'5*]XT>C&:
M1I[#=+7NK@=[R_^>5=AU*0!P7.S\1K(Y;.P@?:\O%0Q%)89:B_P4Y%RVO(PG
M.[-R%;4-C&RKII*O#[5H>A&!=?I]PCW]_NLO&?KY^?"__W]02P,$%     @
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M!L[8BR @EL(2&?*- \XK<T4" 4-LACQ/](:&WP0V-BN9\D33:=6@X) =96)
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MC-&0"(JZ]2C5E11:*&;[9(4FQX?=0BMO4TQQ5!U/BHER;3&_^9F_OD*[# I
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M?=I.NI1A2B)M=EMJ/,N4TM/IHL-70FN0O&G2GQ_U=YASM*P.#3=QG7X"WYS
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M5Z'+ 'J3/W FRAVS)FG3@P5L"YTBVA#T/6LRIYB6+-BZ0-M 4EQT1H?C!EG
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M1L<-7:PM6HZ[=7"?Y!^= =?DILHLP!PR-XAWL2*;)[JNJPZQ]$W)Y6OX3>>
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ML-(#@Z!P%'RP43)F<%R"9R"6VZXB*M#/<%S;#TXXNL*I"1?.COF,LUY2R>A
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MS/6Z/:^+FT$PGZC"84N3-<<"T^B%5DC5U4K/'WK;:E,5C\Q2C=9G3=I8RK0
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MQ.72H(E 'WN<[KX4[RZX%U^$PC<;+F2]N?3HKX,-/R.:^ C[E07/H@H>M5%
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M[H^W=UN-K:\MQ'E- ;54M<7K1&W50W<KF&__L%R2I=^ZNWM7$+^ 70P#_KX
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M^-PS?&[?;1?;QEYE+=R9#9]WWH)KHSG-:Z:#;(EUI_VTW:8\*!C.!/88_MN
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M/*W2MV$V2]:SFCTE+Y"VFNYI[BP;6U)0X.;[M+XO%KOI&,!+!%.0 /.%[6X
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MTBFV^=U>E^<E2=ESCK8O_N'5PI^ACN_T1F;630)1F^=6RD2IT@DZAU '%ZE
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M-_%3\!6N,VIZ?Z5F!6V035#RNFY0WC21G\[F$I/"[=>8.'NF#PD!Q$_+6R6
M^,&\UGL"1*)W?';>*Q&S#^;%$C$C8O;[>;.WYIY0YM7>FB@15N6OYP#_+/7;
M*^4&RYZ\D\0RGR\+$RJ9[PQ\I'XC+_E']>_H9S7G90,51W!BLAOK@;6+S:M
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M![O.@B[W]A?67=Z$%<&@V!DC+ M\(5%67:.=W0AJ#L-*$FDQ3(:)I]E3+8:
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M2J,HWLK#*3K8L"H\MZN"EC+'B$T6+,H9:.\.J1[;@[N3JJ83_=^/V+SU-M3
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M!#B#2 ?)H;WC'-K3T_GYG=N..+'K%JNO>JF)4)ZZ@$_@TQGES5+Q+,62HYD
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MK@H#Z8K#6^5%T>4UC9OZI=URT#)\! ,<:A/Y,X=L),JTO:\,H3!>#/("=K?
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M/W@VL@W)94%]/A#TXE'@X>^&A[:!WRD+V9R#KNP"?C8#BON> U5RTL+$[UA
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MYE<V!>J2"UR=\D.#E>E!RDDNV81&R5M+2@F=&1BRT"3$=5J93#K.)*^H)Q'
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M^;TRK:">N:)#YJX#DYRP$E0=EDL#Y$V[@GX@5P\9OIR0GDJ%1%ZA3 Y<"7+
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MO3CZ<)25JJP5.5CEH6_R/'7VV=3M@[>'74"P@X:ND:(&FP%(\2K8-M"7 /R
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MTPRU0_F9P.6W!:+>17;B>O=A,-3%!H,J(JY ZW-9HN1RR9:X/?U-X@TE,)3
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M;=2>3B1Q-.XYI:ZL;A+O[T?QY+;@SR511:[_!AK.UD-0; M#$^1,$UAY -\
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M^K_"X8GA\,2/2MXZL%A5[7@,Y@E)IS=\F(_[6I%Q^':^V:PLZSGMJV6_)XK
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M&W[?$J.=8I3"/\TTWHD0N, 1$$C-1!V1+-8"+M456)7EV1AQ3^@;PN>\MD[
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M&":2-C.W:_""M9#S?K]C?P4O) :7A[O%7V>/C-T]H/R-^M9O[)YHHZHB *K
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M7^ __[;X5\!](5H@"A?@4.@9P<L_9XQ.A9BX!TQD8R058N(>,$''J$2(B7O
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MKBD6PKRJSYR-^6\+$?"G]GE$#IQ70AEOSE_!ZS3#:;+,ZB;XY?_P]T=L>=_
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MJ+I>!; &!XV2 Z;I>H[@!_CPKA$X _!;4&N6B+D&-235]W4<RY<-U#"0\\4
MN@PU%]Z_?O ? VDO8!\S=Q=#QJ+@#HJ"Z^*G=7LFB^8"/C)S\#=*@,<Q_1Z
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MFN)U"2O!Y#U[#]5CN>;F('H2%=[.J,3*=57#MVH*\DO@OR(O&Z]QF$GPDI&
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MF4A[,P]>5Y#E?//.I=P-A PRLU =657=IUY$+AF2KO6$3#JHC"$D(<N8T]9
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MFO]>X\?1>^SDXH' VK)U%-.Y -M+(!6@IHZB>%B-EP".MP7BU($LP'V0<[,
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M>7O2L=2S7J\0,3="#-3@GHV"A(BY%6*H&/5L+"[$S.]AYHV.M)>NEH].T;T
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M^KB*>.;6*?1M54:R%+Y8%B&:#.!?6E"V&@CRZ%B C]W22(.W10Z%[QS"$A4
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M@INR)R6'/SLWD<D!?B5NRL&9?C5N>B]LNCPW?9X3C*._&I>0[Z'1':;<DR0
MCE/N?;P]&A0O0\F;K* X$H[(>2]E+FZK_9.$AN\1[A&W??CO=XOBN,;*#L0:
M1VH=+I5^NM3WSG>ZCS1D/T'6VDF;<_W:8&F-)CVG.F^X'GF_/GX._CO9<9X&
M+\*!^"A;=CZ(^L5[LX\'I7]$L>G#47HHJU;'(B;-,=LMUPE!G(5/#;@S6:?>
MS5*(&X/& I-0Y,W7Q"044!,WDG\X)I&'F$3&#9.:]>F(+';ZHXXS5]/M'C=<
MMOUK8-*('0^-C;P21HI>*9H/=TO>JJ(G50S"I--<G>]F(<2-06.!2=<"ZP_
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M@0%L0;M).4$7GN$<:"@I4X3@@5,;X Q(AT*/I-V'*TPM(3P(<+&PN;A+27!
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M+7>[OS[ZN1=)M!$IDKBEL_]*'?R,-N1D-U%RX(,].\H#''[M.!5P]*'I*(A
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M#'O+O?CP/"',E0A#W9()E,61,.1M)H&R.!*&N:42PL21,(G$Q)8PB;H<2\)
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ML4*<N"@Y[^PS^1/$8<9T0V_+Y=)H((\),E.IL^RH%U8"9[/O[RJ)CRORXG7
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MA L(%X-ND,&#CTP,%9B::-I _B>UBH <PH=A/GXYI-;^"R)P77SX"09&6[P
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M /N[SN1WN1[.J&:D.I)KHO*9D/6(&USS$,$HJH*)LP1&!:X%7"HSG+VPM %
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M(_TO@JG]:(5F/D*KL$L;(+W@$#>P:,-O6(A!!!'Y6?>_H --!$@^PP,7!83
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M2Y 3S=?DK'8 /+S!U9L.A5VJ)HV1I(,[8-#(Z@*+JF88O5^"_LK58N8(!!\
M,44C8@N+!BL"+!-[B6(2^#"/E-)RZ*@QG\FK)<<@?(X&S+8$Z<=KGPZO01[
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M"0_^Z@N__T02IEXN5< \F<#L8T^Q3"C!?!5E,@K#G*N!7 &A M<7+HM<E/;
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MA/N(F0FT*F+)/*!8'&1^Z&9%_PE/>*&,"H\!)4-D?,RR/(R8\((T4QG(0SI
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MHA0D<85J>XGI9A1=X6N:T\!N76RIR<D++XPZ73;*5I^LMNMZ"[O;:I+7*&G
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MNT5SY,YI!>RLJ^52+4SSX"6VR>VT<ZW XK\D9F/ YYINU=79FE_4XV\K?&/
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M'4^R."JB@$6N1,3 /&#<<Q4+A!NKS(^#.!Q@P15!%&>)"%@>XA,R4RQS5<+
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M9WZCKG^[=/Z3+[=\?=7FD?=JS793J6OC)F $I)1*IT"#0E^6\ .E<RN36[_
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MXK#'$:5CUMJ(K3-M']1^R P.D@5XB\VVA4VU!1VAO;S.+L89DSN]LG[E>;5
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MLM)8';V8J7$?3>"K=L2BHL)+L[WL+GB1S6-O_O"WG+<)%NY%E(2)FRK3:W7
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MV;NI06E_DIR\.Y\^.7\'KWWVY-A,S8/$W'+7GX0D%-HD;5/J+SBNH=]\YL;
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MP!P:/O9@<Q^O/>V^\^GV,7F$SJ;+P]<?1S^9:A6]*&$-8N++WJ<4@+_ZZB3
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MV(O7,HZ^,T4!]NGE)'J1%'.3"#EH-E<^:,H^H+12B95.'N,(5D1&;I_-8WS
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M^=G#X[. ==_^Y?3\T2U/K?@P2X:2A]31C;&ZEXR;K9IV-QXG2WA91=:TAI%
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MHI1( +,2UUO"X5%V1]G=4W:+EM(,I#\M_1@L_ZP613N(/@5QX_SX*&FCI-U
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MZG]Y+"._$PY'ZNP^81P8V*" D<#/)\"M!X"#A]<97C8RN$(8%DUWC$Q2(9D
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M5@0%MY[K^/!T_OM;UDA.GL)]F2T-T^D@MT(68'@H)2;)"U!*#6XYS[@.A)6
M!YG3\GK56J>:V>]PS[3M4W8[CKW1LA'T((G4I>AA;>)_\#D<_@=%9%U1%_[*
M)$6W9DFC%5F^M4,6)<4[T"@5*&S["K:*<T=R/0/F!,XJ75U27XJWG!*17'9X
M\2DS)@XXPASGHI"AH/0;IW8RZAV'T(PT%M5'0#+"=D^M;%Z[]%IREOL'.]'=
M")" %,M"J=O@2?22ZK+;U1>:"JXO2(!O7]Y_X,Y.DECI1?6X:?'&TX.>LN#$
M'YZ;/+FJ->&FU_"U<.W)B*?L[ *342#/NB!A+I'+M:T2GLTG\8FH<.J4V5.-
MD^CT_)ZM5D7>H&=8.N_LOUG7%;O)TZ686?0$F[8 'Y,FW5]U*KZA^G 5'W7@
M?-=LRMB1?*,H/QS 7-3MBB=ZHX#;@I>[0[_JM -*[W5NR'A39+8(CMJ<#6XG
MVI!7V;:>!UL0T)QB8CNU75)TF=6TMZ@GB@C.5[7@BJ#==5-<9E4I<Z%UEF]3
M"F?QL.]\0&6W7[CFEN"$XS5Z^\G,M#( 7CC$F*;IXQ=G/C!%&>=EYVA%%TM;
M/!4JE51GV%GL:-S!EK(EX_+%PG@?5()H+1S..Q4Y#I*\\G- "D/7[O,P"(5!
MD6_<F&G;]J3#CG_^[MF/OSX%(R]#K3DPYSG5(AOB3?$%=IZDCL,G40&M$2A2
M-QE5+T;[H!.K(80#7413!0ZJSMLIO]F"$SHAL%?S-K<SM+FZV!FN+,0+72!)
M+/XK#M-$>?5KWO[>*MXA[O7/VYG?J0!1O YZ@3>5CMN>C'XPIHL_8REFPHA]
M"Z^^(Z'I#@V-ARK,JK77V1H!%<93WW$X=7MDFAB1J3='IH*V6,.U5\ET'),\
M"LSU O/TA[='Q\>/1F$9A>5Z8?$BFS7" @J+")VKVT39EU&81F':2_/ ZAY/
M_CS41@]/1DS"B$GX,V(2_BP<P</I$[]2)*GA043E0(!+>8B RS'FY'E6VS!W
M:9)+9)F4<%="5HSUB7<P043%R#HX&MB#8!T4/\XE*@)'S\N%C2'#*(0W%L)
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MU"XZ.*FP&;1[=HFY0E\9])#JP(=(A*&?)W/P) =//_KQ& =?,M3#H_S7\S7
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M)Y-D[=9U+.;<)8)UL/?J/+'3V_%XNT,]*5.-*GRS2T<$>P)OJ V^M#NNNND
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MFDY1&JLR!9/H@2M8P*:&0$&,[T&,1UFYL*X#]5%R4[3Q3&)8<)L#LNGGN:H
M7AMOCH2V!W@ZX"[0W(^O-5*ZA5PY[H@18;HL9%0CY: _!)D1T!X'<S,\")$P
M??M1C">2TS;%">5$RB&BJ"P]Q)S&!/(^F3R!H9@50FQ-K*@Q9VQ#L?1(G4D>
MK>CQ6Q%+IY#0;I0*!@X(Z ACI ^=9590!U9I.<$3E;_C0>"F! JN2H3V$S?E
M3-&]TIHC2]U03)+8J[%EFN?('48@!S)YF+07@DZO*:?#K^&MM"ZO'4XRI!CH
MS?"3>#FX-H(NB O.(Q1#?@1AF*U]X!@M8(G'4OI*9V3W+(-!5A""F$@S\C9C
M$]L68D/0J$^B&^@U^\QD/= HD5="72OHCSO"!&UI&J+!L4I"$SE^AF?H"\R]
MQCO%;L+7OO:8;KP;#ZSP#5R&B;PZ63IL7\ F]TM6O1"=("0-P2ZPUB0%\4##
M@/< V N-'41E*HQC];)MHA1!-Z1^!9W6Q7?0(WM,178[8K@B0:KF;967[6*)
M!57:^LZ..?IT;G4HU_:3GBP=E)?SUJ,Z\0,Y$?*GK_[]_+NCDR>@+N""JVQ&
MGWI)I^7T^/38ZB-"?\%7<6P/=J!U;)J:.CIA0@:WU=!-HK>(FT- 4R//]3]M
MONG<$)7 RKCM+(LCHMWHW/G:NX6 4*0./F)NCS5($.Z>0&"Y%9U9DO#^H-K8
M9A(_@_<];B]@1DSZCD!EL[KILEA=(8<$N=_,\04..L@>8@_K)L NZJ,8;_F\
M%_4[U7'%"*!?97ET\C#&93MQRS8%NUWHA?$9+LL<O,*$XFS"G6(+&_5K7"+V
M#$)6ERC0M2:0\=8%#=AWK'+%S:E#E)3W'42+9M6L7=4T@*?VD&KXU+IHJK<%
M8$;/ZYY15(U.;((5(!)K96K1KB9F-Z26Q2K!SE /\$Y&1:7MI"]M^'@I=@BZ
MU<=(TH8P@<@%(IU9[B#N:G 6K_9F7GE0=>96EWR\CZ7-"'OJW=ZS4T0:2:AL
M#\6*A.?PG5 ],6.9@.@0\UFC_(E2-&1ID2@1@UV+X#7(MXV[W=,+D^C-8*R_
MG9! VE$A-+9,C&%RN+)8.O* 5B:Q':#7JBF*X"E_EX.X&9^5CJP!&8-R-FLK
M&W43?MKVH+!]D'H'FP0*JO336^,&CWE#''3=:/M"PUD1H4=W!Y/##OYPY9_V
M6&RR%Q$$U[32X#NB\$(<%7Z9' N/1U3&B,KX\W L;"?DMJ,)= 3-ECDUW=$T
MQ-_/H7F8'I?HO.G%OWLI)52PG [P@F,[ J(-ON<:A^LP5W"S>2R3*(@#),/U
M],T+7!5I:$O#@2F]M= _N'8UMKQ+&WER@&!)R]"^^VW/^+N@<;,[-,RZ&KR^
MPAW&_D2O:PAKF62[R.14@3[V(EJ]\8 Y8W8(ZVP+>R[QI!)75(X4N!FN,#5M
MH\EJLA6/C,#GDY@)YS?1AS@K;AM' M)F'J<QITH8\O4X(VY+%]<V2MZ@V/B$
M0I0]<H$[LHK3SU$\E(0DCFFJP=VQI+NZ7?_]]717PNM3+,E'YEX_>*&8',%E
M_ ?2_/%PCI^+;U5YU:AVZ'"](X.(,O&IBJBWG@PO8W695=07Q7^XBQ0DS<';
M2B?QB^GV'])X,)^^F4NDUJO$.D%(GBQNIWO[NBYG&7T=[81D,@=5"/_MHJ=M
M^/?Z>?X)SCMY1[&=D>,X6=PTX6[#MG"VI%YBRZO,,3_-<+HX5K9'+A2++8X'
M.WO!K>[BX#P_-R9R-RS8*,UQ4_[]K]Y^8^<SWB4ZY.3\2\&&Z#B0E F1NGV?
MW_SU $:C 'W,''L=;D*>_(^FQ81V$KTJ0*! W3Y^\$V4*OV*4;\4=3.F]J^4
M9589D$O<^A2T:(%6!),1S%;L<Y?I[P+N13<K CD(>+YW5+2K*=;XO$D?_OPW
MS*#8(7$$?>#"M%%23:[G-]$2)TP(F9::DGC8+A,-T:4IV%BX&C77SL;#-1ZN
M&QTNBXRAF'&M1'3><)TAOG<6U5XVFJNW0P3-L3_*P)X5/&1<!Y!^:(;Z=*;D
MZ,%PD#FNRN,A(P!.4->G\8"<L-[A\>*\3C).C4E6CJ( 20A,GO>>@&^H+E&J
MT^4Q+:\/X9ZN>R:=!]H/;\?S.I[7W>=U;JY,%8PE(>:KA@?*,P0%22%XJ"OF
MT9&*,6FD#[^L9+(TLAY(XJ03%L26MSY5AGJ&B_N5"B3(S.='64W 5[[S[\SP
M+Q-ERB@OKZ3F3!-$B7*N?R6>J82_\3"!/)"+)Z>$(=8@W7LC#1B>N;1:93Q2
MXY&ZW@2&DYX&Z?'04""4 VN1M2=\/$N+P*%=>*DELKV'/S!#N4>1=I\[A#;^
M]+^.M1TD8M7IXGIN [ZIZ\A9P5D&\^8#]P(&-X3"8#F/&YA@A]>$[2.D@9>)
M8-ZK#*1BHZSRXT$;#]IUF0!B2F-9DIE2BE:P.2@&G?# AI#]M/N=RLRJ-NLP
M+_'7M4^CK#KX"?H['0%BI+XR2'Q8*X<;L?6$-S%%5;(':-U4;R8>TWWB)XSG
MQV9<@>G8U?%\C.?CFJ8^+-N+BD5%CHC34(@"-(+&$9V/D(C3A'B!OE >5[1_
MEXR20Q#N)DRY6XNL#TT_GVX4:19;UF&R"FC2' 0$*9L9"^//IJN9Q2U\H^ZC
M2O+^,JNS1F%^R&'F4>+>8W\541O4G13\T>)IIUB#,UCI*,KBR$Y]O:^54^'*
MTM(M/M>BDN*M/@6M6:@MZ&%@,=9E-KJ2XPF^X0FN/&Y0JH 'N+8;$)9V(,">
M, =]?1VX/1XS!!M@3>BOV%8^RNZ-9+=C&F@JFD <738K#L&.P=0*I0Z-I3F.
MZI0N$S?M)>,\ OW@0DI(K5UO'@&^X:$EJ+6SV7OZ-/(UFJ0*?S?WX)FE]ASI
M\-9O\"7&\S">AYWGP79:BZHEB)0'?*7U!NFT:2]M5!#X;>^CVJEIL[V3NVZ
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M@!V9!,G?]W0H#3-&GP+V&W%=.!_5"$O<MR\NO)XUB<>DV0<WT+]/VRQ+;,0
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MZ#J'3A'(VAY<O];1"B\RX+W)D7"9*'YT'<>)"A'_+2D5BFCV.NW@3NJ5;#"
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M:7DT:[IMA;:Y. /.HS ^\HAA54#N_/EMG2[:N#+)>_8OM%$/D4L)2&U+*/U
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M4V;E@JS,B@J'_IKKVKRQ1'R0I2P.>+B"I5OFK!O-1FA=4!=<V'RJ=C6&Z4/
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MZXSRC?56XW);]SVAGA0 %A(W<ZR<<[6";\CBMFU'*#9LU UP"(NYLIJO44&
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MB:#4N.A81C:RXD.'&6D]/[0_URL\%\O3\>F<I!^CH5&R3@4'9^O!0,#J.FA
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M)=#2$=.H4Z[134CI7-@,U\PL<M\_(ZQI8A=+1/ ,>H=133''EI"'2L%D1^%
MZ/"@'7LC#+\02F'D 9L!X"/:<?#VZ8I9RTMXJ6#!UYUM[%5"],[MQH%I5V/P
M6 (O5E42/$\0[H1'5)9FH$0OD$*A"SM5H&4'5N^'GS_I#8,[5<_0"GT$X]=(
MV'X8!,]7B3KH^B@Z0J:$@!?:MHT;X%+^;;J*#$-6=XB 8:SH?2A/:O+2L8#O
M'%L;TC=08WG%?:F'"<?6!YLDC\OM3E!R%FUSB*-OY8#D*'MD9P\G4P"L$=A
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M:;_5[0#35;DC^ZTG/60)&:"VL8S2NU(:@'PP8:@:<L6\[$FOJ)N@()!:2=E
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M@'&L=:_W1Y@4VP#NT/XM BO&FJ5.1 1\:D5O1^#+<H1W1O NO/'8PT%8M%,
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M_((+4\AL>"W*N'#,\%%R/\R>?CF)GI[\_8. L-YJXESJGK"53)("JFXE[)5
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M>"/BRH(N+43J,9?6R8F>;/,NMDE=^GSHSJL3PJD&]NN@W*TROI!DDCX*% ]
MUPOI+$M*.K3>IDX&>3+(N])/ 9=/%@ ]#TY?.K"\2]C(13,".QPD372ROI/U
MW<4=WMWBZ$_D[TBWDT2HA/3X6ILBK-A-H*4:>U2U$?^IWE>.4/#WV]O[3&]5
MN?0/U^9UA9@:^L0#>%H*'WZ\2J0Z%8<*FN@EZ7!>^X>H2NFI)/5,_X]/2%*3
M!38_02($$>?$W+X"^WJRO'\!O4+$CSE'(I(!,!L9GMSZF/295JVPWI$XC%^"
M+2J^'CV38"0/YH>T&W>L)0Q:6DIB,>'=(=J=9@62.=2>MZG?NTU]!<D<T5>V
MO9W>:VD&G(<QV(5@[<  7--Y[X#_BX!H]%C22"M0Z8DZ.Q %1E,2L,@!@^PB
MKNL8\A\1 ,:T?]9;(C>@OSR5@8!WJ.Y2RA6%F[)B<R+"1FK76V[Q,QRPP.KJ
MUXSPRTM /=L!'[3AG:NL>_\H&Y2^>'!J4#HU*/U%&Y2,"S$=SOX6U271+6W;
MBFCR\LQ;TKL$"1^2HH]82>" LAFP!?( M30)$'[[]NSA9X\>4 \^,G2Q]Q!A
M/P%#6_V[6\AX0S,2=:PR#UU@Y,T^$=+K0:\'?:_*9ZQ4-KVSE/+H/O%&YMX@
M,?C+Z.4+XL$FQ;B52[BU<)MJN[N0X 4:7/,R$K;GR&@SI+<?$QG$.^P;-K+L
MAF@\H1 W7!TY!A"2$KLNNQJ46B\W[3)6(_1G[ROPX)!H!TNH_S4Z)/T_2IJ&
M'V]5#(;.02)?0S(PI_3)D< :C<-FKZ12B9 9R)8NEX )P\0O#U+$7#@WX,!.
MY#!:KONK$.I]_?KIBPL(P\H5]Z&]++O5%35I$\_EPP=(Z0"O(C'O:\8OO.[:
M@<%A\/X7ZS74_F !/H4%? &+ 2!@D.\+]_S6>?=U15]!N4W_A/3^;QR<@GUH
M1?_TOU_<8]4\I-XB,#(#W"Z>JA8]D1?@NT0OB<*FN1$C\TN$\.3EOGU[<;YX
M&SK^V<O@&!&";FW'+J%1U91GU:[&+>/<+LNN$OZ%V(5%TR7D:=AG2GY2(LV$
M[=O0>\(/ DS0,HT9@KGSQ4OO$H$KK%#3(V0XEQ=R-I.EK2*6+MAWSQ??B]1R
M3Y^5';>G"@][1RW[PI8G9K8I;_J(I\A1*H,8=N0%%:\+AH-W6# Q )_S#*D.
M==#FNE-GB/K\C)V#K<-(\.EA=NE0!RZ0,<("2;:_5LM]A7^\?>\/IB40^NW*
M/6J=X^QLW#5L+A.)$SPI142$<G<_]LKHEJ-HR%#V33CECHL,Y4>G#+9^Y(B)
M 9NG_RTD::NVV[4=@?/X'&3F(\I+^9-ACZ?P=6UT;/$LR^LPS',A9K./K4I%
M"L0LU<PN8:$TH8Q!0(,(DF *'8E;S<TV.2@Z3X)H4R)Y'230RDTK(#$.*9:&
MSU\,5=K%#U+<%=I_3+8+-T.!]%2H&<'%>UJ49*YS@ZFO-L^@=#SV]G5F*2._
M)+3YSW6O!!=RQI3$&]HV2 ZN&];>:%H:)_YKW:S!V5''#8BT7+(6=\C>8E!I
M1 :DA3JA3=V4WK->1<+IUF_KG@,?7M7+>NAU\R$%,/3HE#6+9IB8MFV'?Z@0
MMUDV2K! 8&H&*R-6(B7L2;ZJR![RL(Q'4Q<;)4.B-X#C!^PQC;=\3(,+<27W
M*#U\1%&(WM[]3 ER6 RJM8TO0<]6=^$9"L&4TR0@!Y*,%7?P!RWX_0<,UD?@
M:'_ X$:TP9^?_W!NEW21,X[<X28E+L5. QZ[I9/";="3Q!N-WK<#;^2N[HQS
M6>"1Y QFD@Z<=BIW?A#:2JG*PN#>"XOQ?CA<;5T)$UQE3>" >0HET8RX<<*&
MT<(EA$:S$%XB8Q$\"DJ3FWWQA7<0]-;ZDJPD;IJ.9Q]I]IV8)3V].-4RT9=5
MPESR\"$OWWKF6AD=>YHRD\2 82EWR,9D1-4*<1*8!:^[?J!IYAN&5ZV'6T>_
M"-JBU ABC^2:MA6]-TC48^Q3]TAO[YV%^[GN.1T!SWITF]$+X8,M9/O-+S)2
MIY<Q\K%VX#;V]K#S ]$VR:;\_.4%DPI#7;#/?.$ITY*MT;0#NW-$(\BQV36S
MH,),=,AJ?+[XMKUQN -%X5/NT8W8 D3A2(.F3X41;PV;<.46G#1JI)=I R%1
M*AA0+BQ/&,,\A61G!U*W=!5O2RTH(*PF3Y@>$9('5/]MQ@?I8"EMSZF?'.EB
MFPY3R,^WNJCBQP'$JJ%P(7OPT]J(8T9^VY1J-*XV\-G-E CXF 9I$DNE?63V
M_PHC:!+FC>1 B%6X6/RCA-P3V/';UGN&Q?_Z(2H+"M;P#$D;//#\;8"!C\LF
M_KL;:O0L,^DCG:9\=H3(NP.7=PHHIAN[FJ+_JD55#YTV/>C?>^OO7^Y:3F>\
M+"&#6)?4=M<YXPGU)_$"_;'M?%#(:9%7W679R YP[^FX+/&J7W?EO^O-_?/%
MCU>U=^T?9]'GX:GH<RKZ_$6+/DI.#EOHIMQ)6#P+CUQU;=\'ETB_5QXZ]$HE
M%-R10KIMSOBZZ1YYHY1DS*ZJQ'/!CTF)'K:GF[J_,CN)?THZ(O&NNG?,J0I1
MNTEL@"/U_W:5?:%U5V[=3=N]YW,M I,P[D0'%TL_=L'],:@#72J0V[><-W0=
M'P4AF[EK:V(SET8/'JIHLZXQHO#SWE/$"R\ZW< #(P8>&F 7OB)O&T0Z,!N%
M1^B-(P4&2++XX_36FT UR3X9S1LGVB7 ("OR&2WQ'<>OA+D&.B-SR0,24VV3
M!/SIO?R4>Y,HY*1&8C=H+G,5NF0N#6 &Z(>]3> F) :*CV;S4)/83@\>1**>
M2G-V0/T6,DN&E[IL[-PM[KGSR_,BDU7F?1K.D/?C AKE3C ,BK2G*'E,)[>:
MUT+.&GH6'."EH#)%>ORW[PEG">C5B,DAY:190]_'3A ;3$LNH&:M@V:2<DM;
MI67$/HU^+4.#^)?D6>WEP=W][B'=;RQ+15-O0W#@E7:7ZWISV97^EMO%O>^=
M'T_O9RA:JD X;$2QC6_'K3]*>V, EU@Y8*"I&UII(LXB%9)-*+]E]7WRS,E!
M$R!;-R!FPB*JUDI-%QF(C[$0^2Y4PV7='<S8<G:2!W<19-?GM!M@?7']+9D"
MKL71<3R34BQ$?.C@2F$U>3TWN5QBR"8I8;52+L4_#215C1]E'[^"N>2$HU_B
M5P!^</VJJY<J&3AY5DZ7V#P9\U;VUIM:[;U KEU&>  \Q8<WG<LA!O&F6B6(
MP%FO!@5L^*\).?[6\'<R=HTK@QEEH09SG)<U[(M<K$*<Q>$Y*"MO$T T"QX+
MMVC:B[&= [+&?*G"CI0?$R2+C>G\>4"@?A]I1W%A"_&=>#.(-"S=/^)<&@6(
M]G[&B>-JZ88;YYJY5P@I6]:-R0LN(9&KQ?[K4_I[C[WDZ>8MC]0*Y2%I4Z"'
M1-4TQ*V47*.29:9;_;3*6QQ:IMH]8P&*S;H&^X/O6UMD9<4;COL@B,"H3!6"
M*'LK)!BS.HA!CQ$-P!]3*K>#]0UU.R)G]R\ 3;PNI/+\*M\:S0. TE!J-4_K
M'\1V9A96!&\@!EK8N!5@&LN.'%?>X\?9Z-P(9W_ IH7AR]:YK$-/3AC1N*$R
M(^@\(25/+D8!.EXX>< 7FLD&FS@3FVI*4N<V/4.%5*7.CB$-'-\A!1RD0B(E
MN)8Z;QD:$*<)%S>0,/'GOB.;;-A]45)J@W:_SNZ4^.ZR68*:!X+>P7$N'<*P
MBWFY,(4 AI1[5""_)4CBK9E:G$?XB7HV##]#'%3H?*]9*A70QLIAA6CY?N'\
M4-4,MX/K4AG"?\YG2UOE8?0>@NN\>4&0$CM$CCUZ@ !5W!DH")Q\'))]/5(#
MFP1T\^]!A1O,Y3+LLEU_M;CW\#Y5'^&LB$66(!!& V_JMB$_+#T!^(V9)?1D
M<>\17_SA%]ZO-L-5KVQ??;LQV?5<A1F(C93,#@M/$-5\]FCQP_G;\Z?G"[CR
MYT\6CQX_NK>Y?^_Q?7_X+>'KR2[-\!.IX:7!CHK3'7J32'F1-CF_IKLAI/P#
M\@GDLD6_!]]*X46A9$Z!0 _ IE*_;3[&"6[#*<V[U)_\/K)R?D@_Y2'U Q$-
MJ3W2WN&%ZH]@V,'V2;6F;;#SY D,RKW/9HSJ@T8@"7Q_JR<6[._2H;B"&3]Z
M9AI$^G\:248@RG!"TF>$VG76:S22N <IF;V6?&_W%='93_ '_BE1=<ODC\P0
M$LBS(Y%T-.W#0I,!_X&VKPWWF?>(JCIE-^/ \R6L.&FR+5$R%;4@<PIW><%A
MB#GP40M%J(!((G#SW][U\C'AF+\)U#6')<Y1/\O?R"6)SRA4N8DP/6-/^2*S
M*=AIQ9/3!BZI/"$VJ43X*SSHD:'I)M,B6?G8$-+J^%(//U+R.KSV#\^>?__/
MIQ?9:$940A2!I8=@'OP$.,D>&7_DAF%#/CFD=0/N@L#] 6YM"J9I.NH6H"NE
ME(8>,]K3A"6=G* >R3N2ZFID$> H#X,%,D3,H!F$IL;6YJAIFQN[C[3(]^A4
MY#L5^?ZB13Y&D;O%JZ[]66.?V[I>I(\+08S^J.>_Z_RDW'O>>,/>W%_<@PO1
M]GT#>8U>(-)1V>E^L?!G_%&TJ.%_RP;RX].D.64/YA+M )]BE>VGI?<_2\?(
MB^\@T;:X\.\"H5\H1*#ORKK4PZ'/K%M%W47GW@LG:^/L5@>A"@"7;=U@S@\?
M5P+@!6P&%54!9Y$Z5.7*%<$"U#Q"\A2WBZY2TI5CF=ZA&)?+!36]M&GM-GO:
M:!KIX8 /1.ALIFA-,'8 G-7]@B+@7A, N!+\MSI8!M3;N/*13.=,!O_2QCDV
MJB;%E2VDR*#2 C>J>W,)H^P&X,#F<N-F89.",T-R ?R%MR9$IZI%%[:?QG_C
MQ<K[DJ8J%M_5;G4%8/#!U?24W[>=WW#HS1%&K(SR(7H,9/'+KBW)OCFOQ;7#
MP'YD?X<-ERK']NXJW[@H%Y=&2F[&1Q$M<ZS&[K@)+UA@PK<WLYK,F!FDYSEP
M]WXJV!8KE<F5 _A[4;6.CGU<\R[-=V82W5-6QR*V%> Z;0XV>.Y_U7WEPJ$*
MVW81H/W'6Z22([4[1N&"E.@<SCIX1 L<;!Q,=1E]CW2!=:=Q$]\"IQ5:%$$.
M.!@;E^[U<C>3DV(SHX<NY<\"DSP-'D="'HT"]<QY\J,J5__H%EG].RF1..AM
MI/-;#9N!OW\ANS,W'YN9,36:Z;YXC(7CBPVDU"XA/6R5V<LM+ -)>] 84 UB
MW:[&7C ?(5X)5!W"]A(R'I'SR<9,>!-!<N<ZFK#X&;KUHMH\%B^HU:FG1J<D
M9S&=M_1!;IVX-WX)07^L$B/9ZR*!728,DL*='=C!;S,L1Q?6%#P.;820"!Y]
ME$BA%^HWTW@;2^1U1]];8#^;C+0^75YO&K<C8&:!Q;^1>AK5#,;&:C^^&N.^
M.[FW593>UVY3'1ZXP,8/3C!+PY*W"2HL!! XX.$2 #'4K6()2<I'"NCV)"AY
M(K'Z8!*KFP.[@2QW]%%VR667V:[L:=ER;W._ZIS#>&SE0P_8>D\4@R>3_&"3
ME,@2ZNLK0 WBAD+U"X"5CEVU(3(9ZV2I3#O!R)CKKLJ=I&IV2E1HLM"&: T+
M+U9?CN@W.SX2G,SZ9-:_V*R]TW1;M)$ "0JQ#GQA13$558RI;>U@"'(RQY,Y
MWH5S/4\=*2:*D0"U/%MR01O4\L'G9&\G>[NKO1T*(NU)"^'%QB/&Q$$0#018
MP+;=N-6X<2?JWI,QWIG%NMWN_-603)I@*YPF$8#SM5/:)H3OS'C+=MFW2, *
MZ!%,S0P#"OT0UW5H0!?@8#8B93Y!HCK0QH29T)5-1)'&)NK]&'AYUX91.&A\
MH "(]I4O,7NRHA2'D':W,PD:'5C( W$:2%-"^9CKUZ8U!8%$>67J(=3T<I O
MX;1RDR3O C>.>$-@\BT1H4FI;^0>-MGE/R^YO(QN&N>1WV 5Y@V4IFFF((7V
M%.IM=1#%N@A,4M^5-_U_?[+\G]\7/_5KP%+4EXY---AUN14*EB@-!XOZQ9N+
M8DH5;:00:9;[@2FW37%BAF)AFJ"U-8]"BA34;8,Z8FS;O1NH</0+['"VF'%L
M2?L\220U$N-[(]R2QC!PKL&2-RE5A>M?"R$-^WEDF,;)N0H6@!1F"1]MS:21
MS!4)CW3Q%/@PD#72G^0J<0TF [[91T2P0-9@V[7JGO/BQ)+P<2*A/CTAH4Y(
MJ+\H$@J>Q_ D<O7*.^%KXF^$#8+I+P'\#=SYV,EHO1%5S_"3#!J&21N1=@K1
MN)5_CHZ1&.A@RBV0):K@:7/IO9]2:R-0W3^>7S6V^;JCC4)ETB]>OE:9],JM
MT0/Z38'@Z7"-EX!)*>MJ\0SXS]ZX);S?:PZLY"HOG[T)EX&-"\C2.%8F(/=5
MN0$_6#?KL:?_00@__N\6^O.8<:!N?G(Z4-B?B$AK\)<*%\6WZ[!<2[": 0Z(
MX$X;MWD"8-@2^78[>MA=N:>&,/-2_GFI(9!@)'Z,M>:VW"/)UW5=C0 3((4&
MRGGH6/@!+<%UHZ]N#6,-'#<KN'=)';<]=\9&$8%>AA]PC2CSQ@D/(Y"LPO@]
MB1@H_-N-$!8X1DH-Y<]4][2SB[NVH-N6'8T#M_NBUH5>609)6)PPIQUU-&%B
M<8P'[O7H'V<E7#UO77<-QO3I9P^^)GX\,"XN7H.!T.$[IB26]^^ 1[D;%L^(
M=0OL]++<Z5WE$D6@Z(A?%"%?B!K&. K11LB9<=:NSWIO;N8%_*<@-]0.3(-,
ML1+T&(5(%$=+#+<-0T&L:S[^(O(MHE4DZH+HP:G]BPB?#3QDK2>^\/#:H>&/
M^P*"UQM#%0*NJTTBR7#]WH'_AT1@;VLDTACZP X]#<"P1ZF&4K_[V:U&C+1@
MJ/T.X&</29RIC]8O,]$ $1,N>^@ 5_9-[_;.%Z^:Q3]&OUH>?@[TW(\>YJ"$
M;\<=8/;\/; ?BYJJ1#  (G  &C6#/ENXO130_:V\28"3&9 8%QC@L'.7^U"Y
M =H_'O+T@8/J1FI\5%"(<I^5PF"K+W%DL,W 44K;B8V*19HES*@2)!!DBHC!
MLFC7OFZX9Q_&$TG8B6P8M[$^7%P\,7Y5$+AOO-_R0?MK:-\&,G0_@#3AY \<
M8!X:KC4[G)H1L64KOQQY%M37HGLBAUL(.>@&#TI0L(-X@GH.X7NZ/OWN6/A7
M]N.&)>M_^#4,F+2':'B?_7DK,3.)+\&J([4%8/%<7(R7X"<?/L9'?E3XK=OU
MF.I8? W_P9_PPO#G5VK-V)0WC$"E,:5\51]6CZ6G+%>R;<J"ID,^X&.YNP7/
MI_EPABT$C<A05UQ0XPR<J*BWT$<JF6A'GIHA1OW\7AC\>G-9DDP'!4*R+1"K
M$#RX^MM[8>;Q61X]OD^DG[*!8'S#7!5F>S%]/278XA-L<NX1"K5$<\TY]J^)
M/2_9&U%=O*&S/SVPA!*]-,T-D'6%R(JQQ?>H%[$:'3_VI_>?\,'>!UHK7BUW
MV7NE8QJ 7?*9V=VG _2W^S);[WAFB*62;OG6K2!6Z]03/@.DMFH*<% !3_HM
MHL XO.@US/SVV[<:95+HS)U0VRA]J)%7KW&B4&_A]@RM9#UEIP(DN]"=6KA:
MD<>5SOK<9EDIJXS L!!H';P)*P,LB >%1D!8R"GC,H*%4&KF!ID,\8YT!N!1
M@1_E\C*'5A&3+ #C%>1)40<L],/+@Z)JV9Z##+.&D0<RM,5+&["R-P'"HK=F
M+8]I%H^)=[EU+81:L @*&D1,3D6:,)A=IS#4;YDMR*UU3'? <2BE8UD-+\J'
M$?%EJ ,=E4=^=Q4D6:,0/)[$>9V),%T^EF$(L\X"4L*2U 2&K[ ^1PRFF"#.
M[-<2O,015]V@7J93LHVPIZM0A>&RJ)QL%6W^Z,G9T7 H5C_1N7J['+N>%ZOS
ML5.%6!U1!C!R>D ,(^O:LL+U+EJ >"N;KR-=#O+VJA_C;05,!%=R8=/W-KXQ
MG/\8/'!$0NEXI"XC3K_HM,_)NH"#Q:T@(WG$:SM9N-2J+6.?@?7FT+<_"B,2
MW>UJ-C$=EMK2I?$9=VG&HJK(;M/5ERUVPNB>(!"]@J"]=(Z.YX]#0!W8JKUI
M;LJ.#IW8?<"!&#D"86(4G+_04@C5>& D!HU#[ 06[N#8B+"O1#=+Y?N:&E^?
MO&JI$B/1U35)@!>6/([_:]NQC4ZM<L4DAV!R/#(\_OH\DSGJF<$G;I8FZG*I
M1*7-Y044$$N,6-HU (E9$",M3\W9#>W(Q^0:7VB"10Y461_(XCE]>[MW0@45
MF2'3PH51@'%="Y:U2!>DC!LG,&QIARRW#?WJL26NB.BK1@4<33D4@<4:.Q]#
MSZ&V>N-Z+TSI!^T)KK!I>U$48Q?;^;D L9MFM3?E)VS9JBV%<Q%LT+XT:I/B
MDF:Z'4I-(!EHW&Z$-UV.F_<@U.5=88_*KHGGB03^A&5L[2K<9 ZX)0F%LBZI
MD!JP)7(@\@7,96XIE8,/(/?"AOB)9 W>9L?TU^9Q(G*IGH/+F#@B^ EB(8 .
MU"UK LZ6^Q/HG63 R/_U@4-,._=2 ZK($69:\\\_SLK/9Z?*SZGR\]>I_,SO
M;0^$^^,4F)T"LP\-S(XK(C.M^;H+M< ^AEUZ>C9/3DL&?,7R8J%OUO0>R@"1
M//FM0T,9"#:]2$1+0KBZ&>TNB_U_E)13D$W. (KHY!<]/).T8J,\ $@=(D0H
MNB#:Q=A>HQQH6&<1!268&T ^5AN[]K48B PZ!+'A\(]-NO*G8;]>,!PREAKQ
M)\38(ZVQ:3>A8G?"133H"?DDCE9H5NTZ!AI#H2,H4,EF@ZE?(37$'FG %0W4
M-:X<E06D;ZZ$49:>=5,2P3I*#N[/%]\+GV6J-!@_I[(6\U& . 7(A]32NJ[M
M\>7JBHI'0W8$J5A[IQ>/"2M*,B6_FM 2N2!=0)+/J3"=F:7E6%U2FM,<#<B9
M]ZQ'9HV+WXT,B[:#].AP]YF*!!CG!O,<RF*[C5 DP$N<L4W"'? )L?Q>JDWK
M>O>W]0Z%GPI$=T!/@85 ;5LQ UP#5 VU:&/Y/\SM 3-<!OTVFP8)!ZM%(!0
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MFN/$_(+[Z% (?SNA$$XHA#\:A7#:EO[X;>G8]J-?E)+I?YODRRE@.B;+/-*
M:5I6@5,X*"% ]#'P>0 ^'9MU69.TF*,30'0X0K[_S3[48:F<@7U&DRIL^"=%
M28;I!L"X^@RGJ/]DQ!\8]8?B'(?P4J,3I=$(EA/ZV8FH!4U9>P@%J#WI)<0>
M0J2'(N"P".:QA &>=C=R-.ZI;P?0UMRZ3P=RN.M3#%TI>2B'9!;_*[>[)R%S
MJ!UP5@^X"^1*"HY+H.)K?N+KTA_^J8$%>IC'21,]7$.&KE_<0P8(NK0TY%;M
M"@C1X+7]8NVAX-/N()<X=/2O75O5I?QC=55W+68+\#>8U>7A;-KFS-3034;!
MWSA\4/9]C>5N__,&@!/Q5XO -$F?XE[I+8QN#_:.]!?T8=FXWH\*/S?_JZ=I
M _8 O9<^J?WUMJYNH+?H_GUZD\&5I+Y]U?8[ "7PN-_ @UW5!'RI&_\+ZFE$
M^4+_C]X?T3;(XV/&FE$8WK?66S =K&WCBF%TT(FY\.0*[^H*31<&Z[< X@X<
MVO]O[UV;VT:N=>'O;]7['U"39)==1=&B;I8]>Z?*ENW$V9FQ8WF2_<T%$DT1
M,0AP<)',_/K3Z]:]&@!UL66;DK'KG(PED4!?5J]>EV<]RVH 0B+.(Y!>,3;C
M*;0\$.U)-[HK4X @P4<)$N!#V_D8!460I$1?8H"A3RCZV$JRG?_0>1W%LBWT
M.2.!7[I72B^)C>5T'F_CFH5NJ)EU =#S(H-X4"F '(P:0<&PR3#:*Y!!AZMK
M?0S_8<VF99.=H6+F=CFRNBJ_(IF@B[0R'L?FM+A&ATO581@P932D5_>>/!5[
M62-%!=%$_ZRLN^X"(AU"YR[@^^J+;IOP2O$?[9T( &T=  9[V"=IC4AMIE.:
M47&Y&\\=8+-\3GW,Y:A!R"BI%[Z,U:&&X*]Y7)9P@515Z <"UM)%P[EB*9Y#
M46\Y!7[2^#Q.,T8<8,A_5534BXP:%D-%6*=#C#? 77&KPEQY"A2RCZ#/%#+I
MEO@HAT]KI1"9246#;+GJ0=?G 0F6%7?[>#M')IS@M=@N,I27OM$1M\]RO8E;
MK8+]NMICQWVR*U$[*51:0"I%RMZT5E*L0RU(8AM-1M^U-D5A)Q\@ 1DM[@&'
M<XAD<IK:FEM!%M;3(]!;$JQ&GT+H "\"+O9HEVIXZ"^3*<2U5_A-I:E9=2];
M2:,%VKV;Y5>?2^)E?&:HP1;\AT'F4J-(.:ET%4M1B%*I6NX$(./OLEX@#5*.
M68.UR(FP*$#O@P+$[-TTX[[KK,2PBR6P :6XY,2*T.+Z*,I5P1B\VIPA+;7O
M:^M@ /Y7J'(KW%LX>_(^NU5@+<]:M*D]ZF/6@'&=R?/Q2FE H3-<*13;WA++
MWI9G/;#"#A_%QD;:X^@5T1"#TS WU"5<^L'#"&AW&-_._"D@SPC<M5;<#D4"
M!,Y =1?<1$I575#2(C>9[A>%W =@!8V01IAW*R[;;6RN,3)]'0L5E'P8I#]8
M$?X<(#ZAR^&=PE63$A&:=:VI:(_E3."=S& 7?3ZNR1;84PP6%,QR65A_PVR'
MB0Z537!V-=1>._PCK6OL.L_\L::$OCX/-V/,[>T).+JDP?R9O>Z).(*HS;Y[
M*_.KV@<F:;6R_MW3- =S>&>:%;./^@V0H H>KY)_$^?)X1S_990J-Z$BUVW;
MJ(,IX2X<K:#Q@C@2*1PI^U)I2RV;';Z5T.H=>Y&%&J?HW\ @V ,[EZ2L-%=%
MSD; 6^1X#2!U8(K(AR1D#!S[.PA?X")6K0?&B=5W:44-TC=[$%@"2C:Q![-!
M2>C1H;NF='-7*=*!*U*HL&"<H-[#T3$)E3M%E3;C+Q:%&F' 0CVV)U7S:G88
M$*$"*S['-#;/9]Y CT)GPKKB>N$][- B:KZL-.' = ^%%EDD0'B&$39D,U,\
MV$;UGX=?MYO.=TBJ-E-2D3MDY\D<GM"> @6E@];%V:'OW5B-)I?RQJG"<8,>
MVXG&"*5)@ ,B/9P2*P'+2O_;QVVR42K+F,;P JZ9A)U)XCIV-<!DPOMNO>P5
M8@/<I=4T"T9R_][813>E],.%CY[\<AJ64EC1A.H8IHT0 2*4\]WD-C@:4 4#
MJN#^<!L$1 ;(BQS0$/J:@U>%UO'DBZ#:"*@[?WGK]1U>W<)1@]Y*3&&1-,^+
M<VS3H^M#3?3<NB_66DQGQB=E&'%-&L/>N/ 1,@?4_0%.(O53 ",>ZR^@O*H<
M,3DT81@%S<@N(U"JV<TBBT%Q.(_ ^:*"=2ZN0,AC8*IPAK^?N8TZ48MJ%8\,
M:$?C;-:X<)KN8:XB E@71@E3W\N<E;<B&-(Q0"KZ+/(9<;M1A&8&KA$E<D-:
MR_95*0!RJ[NY/0>S3)SB2-Z&?.&GGNA;APGQ<FA="&-\9$-4E6F8Q&(_HZG;
M=-#/G8=1ZJXJR'5'7'IV"-$J:Y!/AX 24/AJ2E#==M@2$V$'/;Z(=0P')=SZ
M#\ 'C/:A=(I)01J1PME^&6OMK3=?&BHS)KP%]VM \X9Y !#7*]NJ(._Z7O4K
M#5^:"J$1/QXHAN 484N0%64(@=,:.>LBO!/8B,./<8LK2";B,)/&3OBMM=>@
M,:6B9ARYXXB81[MD\_2,2)C$D*;8$M)K0>/C2OBQ:%<NHRI]T4-5^CRJ[=#.
MQ'R]'E>I[)6XGB**@:1894VU7D&4"[?$%VW0PL)J4K*B)6MHE_1&JS9BP/WY
M<AYC4(:"W)J*2$MTXU;1>KSR&1Z?X&8VTS6G3=@Z4YZ9\\'I/D "MM!OJS=Q
MP;NLRD9.>.PHC\5U(/*A2\#M60+'H-Y$GK[1-6@))E70XGC<$/K]+9[*.]=I
M$Y[F3/YG_ V&\#NP\+M3AQ7F\"VO,]](0E%O]4=YYN/[*5*T4KY=O %7V9,7
M%'='#HU:AL]OY/)^.F,"<&C[4+0Z%PN3T]'&6TF[&Y6I:R1WHWIE?$%G'.Z.
MPHIL0R3FD*D#7\:WK,&4O#XR88F2D JU64CL7CAFGXT2-=+NK,^\4YK#?@0&
M!TX3, 26& JR(EHM8LI:6(MAAWUTGGBEY"%82:3R]3<TE7W%*A\#&L7^T16&
M5-Z/TLJ6/4(BK',BO,'A@TGIEP:N=,@WX@@<E/92_EX0(=$#R5('?R^93K%%
MY=NS%BI\AO1_?'_AO=']. HZ'(1>.X \</SSJJ%&$&C.+>%;O7(WID]#T@C"
M:T#0$:9%[+_CTI4#]ES /5.2F#D&EEQH8J/^[W360(D+:YD)GXGA1[BBH!DU
M'?+.00(QP#&YOA)X0-5$<6/\;"$ZH10.LM]4?#-71=8(20"2Q@J? @EF_U%&
M>BLP%#RK!<>R57HE;R>%4:VX>;5S?SK#)P%PH-<DZD18,"10<5VPB-2">Q12
M"Q*_6YU*:/)+W><[,\*$!W(8PQY?,@FMA<7$H/N)K6GC<\W2(J6C.M.\K3FW
MZ:)_+9<J7:%.RL12XIN8-8@+'J&]'][!5U^H%'_BRGF\/"6T&$1]Q(A"+6^0
MK_2R4"PW=.DQ-GX;GXY;7/'_!&YS"$P^FP,^U5/$_]/?Q6+[G#:8LCR=+0P4
ME+J/OCKU;/(M&T7'-/_Y++*?]-)Y$2I#^,BO1;XC;Q/GZ1<]M="'PH_KQDO]
M=S<K9_M^3)NR8MFTTAV+009TPDHP\*O#J\Y=8W9D$8QL\^4GYL(<LX1NFTO#
M8^5F+-T=>P'YMLJHOY\4L5W&O]B[@@GQW5_ZNPP]:'5;S!/ "X8?>N@O*Y:D
MM?-DBEP= "V]2[@=2?E+0A'C^0;@*!Q[\.VFWK][??+LW4MI.\42O?:B ]U,
M6RVW MW$YK,2*O1_*JV=V.D)/.R2\@XW]G]&'1/Z!F[0EBFY-FVT;NPH=/@Z
MWM\EBH;V)HY4F)-Q(<L>(BO:C .]1/YT3KDIP52\09\8>:;Z3&JN-Y/BA>:(
M*ZGU&;V;YH!RTN&U5+FPD'M*ST^2UHIEC2;<RNO7\<=N2Q'@NF,-4PJY\1PN
M63KH8^L;=7#4#ACDO87D'*-J>5$C=;9=M@R:LR7M]XV4Q1K^R?$]$_X0\<1N
M=9@TE6HC\?7JB2[Z%\4S.U:V]'#_]'%2/-MX[A@1 Z!#40Z"8&9T)2L[^AWR
MKC)='$^33&Z>SMA>.[ L:F?:C-:*5YSY(X!N0O>KH5?%72E"0[ZI%]:+_ \'
M$W65>I\U6XKQ)PX:-E-F<DP(;:65,@F[1B",&-J_@%Z"PQ%#<V9LIH1$-YA]
M-;5V0;3 ME!\*%8!&!(T(->S:OS!)HF_FZFCQT/J:$@=W=/4D<;;],(2\>;C
M,D:%2VX!=5R,MHVN"U3993IL] 5HGBVP=A1NZVU ^8JQ'!7I8+K0>%86516R
M>WH<)-D4H)H_\66"8;$:F@+YM<5"E148M-+*#>!M0<++<ZV",Q#>A60?62_=
MK[T]!I0N(59#@J\B-@5N$+X<Y6(()A7<HO;Y&;"L$&HV7]MK%^(=,&^ .CHZ
M!/J2?LZ(]]_9$VC5T16+]TLJCW6@V#;TEN8O!J!+C?9"V-QZY^T87J>Q!$1A
MV4>$E ]\F!O2M?O"^L =L4S9>YDC:_:$O>4P7;!XK5>C"Z0((W&CPIA8S3O6
M _O@EJHB6/[9.EICW;A-)@<#.XG))5% S*M]&-AJ\F.\D<3&5BNQ$Q)8C3:^
M!<LIK!Y(*Y=2=FAB*NY09LNST[?R),E,J<2=6R,:&Z7E(.S)3AO'/,$LVC 8
M\N6338&ZP(W7Z0+H1(+:,]A$2K,RF!=V7%)3A-GMZX#I@4^JO2YFYQT\36H]
M0'R@ACW(R[1B1$6WE^%5D"[TT[EK74P4[NNB\7E:G:+%/"6/@182FDW:.?<#
M2EU40K#PSC9E2Q7SKE];U8O!U0573H-W:ECO3W]^EU8?*^MD.9# &U=<:.42
M"'9/BJ4]:]%I7<P^6C-X>JO T:\--'Z_D IQ.=B"AL-)53@I#DXL["BLS)]C
M&4-F1D'4L:QZO^IT/DF0*Y:PCEZUG9S)UUH12 ]@([_6FG#S5/C\:VY:R:&S
M-T)")C''UV_?!$E*3(3DUJ=*H"$C CWH_2OPZ#%[!F\M"?* &;H_'HZ/=D$F
M_[A_/)[LJD_ZIM@"H< O_&I/)3JNV'QV<N#":*=F5=-?]G>I+RT'4;KX[@N(
MALVS!CMGHC8@?OR5_:<)F**EYEA*GTBI$;'2NN!Z!>[^Y:*8'%CP$"8$6E K
M1=^:A=<0#F?TBKXB:=?*<Z<AQN4?+O7USJ$F7T$QU&1WYQ_>?J@DR3&P- _E
MOI_%?' "@>*=R9,(DFA&.K/0=7B>TA5.?QCH- :ANH90B6?L2E>X.T=%O;*-
MXUT %TK^7=5- C2- TW!(&+7$+$<4EJZMG"*P6Y5Q 4Y:#O$0: &@;JF0%$+
M(4B)DT]LA_#ZUQ>CZ-<7ST;1\[_;_SEE&VW_</+@XT/XG?<<55#+NYRN^]W&
M+D042X/^>*PU52NQB)#$"'E+>C^ <2<P8A4&2R' VX$V3U51FO/4[CP:F]91
M_M)Y#J=L.&77-#=1H%?BZF 2T[@N7_!$2C%R1+?5+==%I5NG:)"_0?ZNPU88
MIQGGZ7T-?[8.^LU=IYG;(&Z#N%U#W+"5H&<E MH=*/6JJL:$Q-N;^X'[3MZ5
MX+>S]2!^@_C=3-MAA2(X2"!IYE-:U5Q0:.7L+)U%*!C30N@EJ*<-E[TC0BG\
MP"" @P#>0  1!A"Q)6=]$Y-7!7//;1!!!+KFPBM:%A5T/S C)<<.M($/!=Q!
M!MU'&DJB6R/3:EH$$PW".@CK=8254"88HT00A\>I$)K$>]7AA3W(UR!?7Q:R
M-+\W3 R$!F!%528MS[=E%U+653TML2Y- 2B<> ;N-<H=5=0-\CG(YS7D,TGG
M<VC7Q=6Z4N#8*AQ (-$BG2, #?/@G, 9*<=YI%#?*?5DE9AANTTQ^S31PIJD
M18F9H'DQ:[#&1OL^2&$$AB@;#"CSTR8%I%*4F9A:"D(U<;%3Y !ZMA^90]^F
M!8+" 6?$[;&QLRN]ESEV!2;!I,'^O0[.>=D9NG/@\>,!/#Z QX=N1L--\]WQ
M 2Z3E)A96@V1A4&$KBE"P@T@9HDJH@/@GM""@*%L9HL<VW38G_U=CSV(BG*0
MMT'>;AI*-083\\"I;Q)%VFOE[]^&"8&Y^,@585-F'CE+9H/(#2+W12*'K*B]
M8L<.FNH<Y!B6!JD;I.ZS$!J7-+X1MC/2:Y[$!]@!E=-?J3J!03 'P?S,\&E>
M-/F,RS2!P$#U;U#\#-CJ27)*DD5:I"O[>V)D!RH+I*\$]'&,''#< )4>S36K
M6#IV57+*E:8-]N0@S3<+MB(#FRI!5ZC.$!L"V4P@3,1294QH:D898+;"<G=@
MX3\3_C3LW>Y:JW1S#O0MW:%5L@W:71ID>9#E:X5S"'//A1Z@'$F_SJ./9AU5
M,ZC5Q2;4V*,MCZG!E>?(&N1LD+-KR!EDY9LT5'_3!DF3'(Q82'\ )@)9+"AE
MY20/%L NBBRAWJ]VTXJE:,G^ZYT*A95BG:<9/8O0+/2C[^,$$@WJ510W*=DT
MGT,2K-6YRS55JXC&?H"O#*?CBQTWNP% =E-)H[Z9%=W_&"O0W'"]\A(L'04K
M8SZRO+HNHH[GC:M)RN(<BO7F.C$Z@%\&Z;Q)O'X.]>U-Z>AV70C!V@/9&@AU
MD@(U.?,Z@S2:N(0^P](WKH(6DTT=-LLC;A0KJ(RK)K9CRB^!N9%6 @XH5E8S
M8QM:(7PF%P^:D U"/ CQC1""M2?;@%[%_B87_>CZ2 ^R-<C6-61+<% L5.@I
MS<K"S(J\6&( BIO@!>9OF5;$APG-)RIN=,-\\MP899"_0?ZN(7]$W--'&12
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M6GT6X.:M3\PSK#!>,FD2 PZ01 7N1:3:H-"(O<&+<E6H_>O]UG0-]/3H'%Q
MP-[^-P0"O+ *Y )B*O8_DJ>ZA!XG5DQF:QT':I@^63GZLZ)"TX(^0G#=$=[K
M8 0E"$"U1_V"@9A A5%W'7J$5BR+<W+2^1 HOW@;#_V;S]G$T64[B+_3>R4^
MM][.$+/L@ZH$.,WHB&*I*1I7Y%H27!\M+R%PF?-NMI#\>LT_:X;X29X/ PK;
MPW\:_>BUUP,/V,T[O4A83'S6:1;G'ZWXFME'=E1!YG4<)PP"3IV#O3'0B8X:
MT+SWT1@QM=+:'4HB[H'N1U;U)7R\7=C)!^DV) \'WM'A#-R4"\_>NY VBZQ1
M5E44.^V3X@7$4Y88RZNPRA;D)X9B!\3<E<;L8(( T[Z#[ VR=QV2[I4UQ.=K
MLC_P!V",-Z9&UZ,/NS2+@20P@G0:.$-YMO8]L,E<P A?2>WE=#8ZQI(KAFW$
M2;%B$ B@5_YM+X%Z[=R7CO0/XCR(\W6*"\MBD4[3UE5/_0BMI%V4@*O.J3XN
MKP>A&H3J&D(%_A%U$*).0)@BRZV9.$,?:&:2IF2$?X^!*35>4\2$U9+4\)@7
MUK9]RC9 L2*EHM680/22^_8PE)VD8 VF[14HKL>*D+JL. \>M(RM0S=%>C)*
M\/!75'ZE[V$05:!.M[4QFS\X'+3AH%U/>V,J&(T1+-)UDL9X20HGL=F!W"^$
M 2F=CT>_X,(9%XB:1T='!$7:>[3O4#K,T;HJ+BBQ'%/<,@]P.CXGIRE=!XD>
M)/JF$GT>SP V[DOR>S0JR_D\#:SKT$+VGT9AA1 ?$AIS@!;.P1D3)J">CZ/?
MFZ)LEH/,#C)[4Y<P#\F_J<R/JQ,!8M8L@; ?52EA0R"_X\R0P088I.^FQO:G
ME;UN$6#G0L,;="700!2)W921O;F1I0&+]@V U#;E."B%,30J&>3QFO+(O"-?
MT93$T!C(*L7?,/P;)GH_+[%L/LW,JG9)?/=(R!$C;K3VW$O"S=]_RJ@-[@T2
M-%?DM.] $Q8J0_/; "J&Z_$\'E"JTNT9'1'D7J5HK<38]T+%1?S10&,-+A'R
MB5F7M+TT7;MEX%;5FL:0KW4A#1M<_!>QY)+Q'LD'SF 1\DVL!J=D,O#)VMV7
M@^42YW]ARML3)>)_!^ #90,18E(%_2ZDO,<=W0LIY8"C0>UB)H>N8X<^J>WS
MB;PRU)EC.87:2@>RWJ;M 4R./^:?K3B*2^].^'. 9N .0M4EJ 4\&^4FT (=
M(]\?OJ]!6;"1=>& NS$<MV7:+$7/I>6E=4VN\!KK2E6?(2X>P30(,'?X@E&8
M)T":B"01,7!]K4SN*-QU;X"[#G#7.PIWO9&^[#$@PP,)"O5GT)UT?3Q=I(E]
M#%JFQ_9"^ODK8-7"H5U6L2:WW[NT^AB](NI'J&'[>J/IR(T>T+==IDNY1J[&
M:?8LYVO1[EQ.A76'L]IG5;#,7M6?D?32#6#R\[0L<C#/H.5#56#2'*X6,G'P
M"[JS7;J$S$U 5V%MPTJ@N_ W(I:&BJG2[O!7:=KR14OVW3<\.-A[W8/]'EG2
M4BZD<]T3YL7,+BTR84AUBKO91[J0W[6>U(68%=CN#OA0V'U%3+9".EA#8V5%
MAM=F)"X<%1M+$\7KRLP#:U:X@NZ_2)V6B-(X.FT9)DC^03]!7K*8Q;-U!+?U
MBN2N(31OY:412D\;"$A['D4[29C)64IT(I!R) MH%C/COF;RF"T*$%? DV-Q
M\#FU9Q-K: 7AOW1.Y%_2S@W/$K:)LZ_0!VG3,K(_$2=065UC^51:)CL$7.:0
M>LEE4AN>0(T?A?@-[$F,NOOFF8BS];0*0KAN5^^"G 1>U\0LX1E@\2WM1QNF
M(+WLW4IOL"N,G&V&\2WEF1W!?Z3!D:L,X*<+D9!NJ.E'#<8FU'Y;\;!#7J4S
MIC@AAE1'Y,L\;I7=P(KI;=&(3;"J'/G7H!(9.$W<6?"M1+%,WIZZNG$\G.Y3
M7J1DA3&[G<\60 F@1AH#PTHEM8(K(_XO$:? <#Q?G/4=LOCL#-8=_2I83RXP
M@XE2R1K8#D#'U#[%5#9.3*#LE:%H+D%0##X B RR E87O9>@KIC1G^@.('B>
M7;_$GF/V_,&Q@+\P;ZICI2TP*(1$UMS$JR=\$L^00P'K5$,*&<39ERD6^B(X
M!?W8$$C5EBPL+)P)GP/NKV'X*KI5(3;6T^:<(<2P[%QS/'9RY&GAL/87YPN7
M%,J"6WXL];#_K.;,2@P7ELQ!V(4P^B\: C03E!CD0CZQ\>L=35,PS-QE@YT.
M:0O)M?7(OXB@R6I#@_2NM!) ,! OF4D6G=ASQS5UQ78P^ /%"H,'6*O/!3>H
M4+#@U?T%&&BG:T?A"#@D.&<&TX*>BQD'&#9H!7N!KC&LZG=G!9809)SO+Q)-
MQ()\BNT'#<G9Z<L35SCN@"2S#$L]U?&(2JCXOV@)3W<@K).R%,^08X DR(N$
M?YBD&"K.OW:%]F;39NOMEAN)Y*72J,\IQ">P2!=_NE(>B;W<*?D0@I3%%Z 8
M\9],C&4^<13'\8.%DCQB8E#6]/[TQ[,%=7C-D>Y\18D6D%]D-:E M<?!%<XL
M9LH X-]SFR'@.8B@;]"E#\$<^N:'Z)B0EWOBG;-*2(?30I8#.I!V#Q(IQ[-O
MZEY1%XN"KJF,-18;3GB"Q73"W@=(0%[5)K:7\YN<F?[1AD7K9</62\MF8+\+
MS$-NGP17NQ##5%;A3N'2G<+U>)E[@DJDUSO!ZK]YG&:@,^A&Y:M<?CD%ZY,6
M,:VX1;=N51![B@O7PXQ#AV1,^K- $PD[DHPHR"<$1/W=/\O^W@8:5(>G(928
M=@4E]L1&]KS!U_XL7_L-[B;?%4@!(56(Y ]@?JV2UDJXK; !0 HA2'+/:.")
M\\%,QO05D\DCAYGJ \(-$H##ZIS(3);$/\2W>O!\5ZB\3"N\Q:Q@Q<R#QM<C
MF,O?U"O_[OM^U=7UW"> 2D.MK,*]M?O)1<O2P+X!1[3A'>[2&!*%IGW]"%&H
M$->4D][>+N(T6J+-5!GSD=@YBUH: M,>4A&"_>4B+[+BC%H@V=&!?@H)=*SB
M )(>9%Y$TS%H#=+A_O $/<!Z.0>_P'T!$H-99O5K26T4H'@:>T"$'T&J0,R)
M^%>Y^[1BSE'U-W59N*<7-)V<N"X3*S)A7*/-2N@96CRUF1N>EW7!&\L"ICDZ
M3$2'2JE1-;!ZO>* A\_A<'4<)_$Z8L&@33E:/"V_ _J-(_(5(,&D96!L3<QJ
ME=92L)S7X!P!H%HE%GDAN$G+15%^=(9S,":RDI&UUBFA4.+\;;IIG"WE!#<E
MYY-@^.'3F![^8UY<Y+Y\QK4P&CG/!; 5%!]HY5>924&)-EQ<,,!*G"ZGN+"Q
M345V^7E:9+KP/MC*<?27E""$<?<4220?+'VD)AO):1K)]0SSV5E $\<\:2MP
MK9N=+R+JV5V[X3*YXV M2,^?%@H/:!/R6*B7;VA/G1L_;O'UKV> ^ XY/XBZ
M_\)K_E]&Z/W"TXX=E:P!O"1RXI7A78"V-ZU.[H0-L,JH7EB'_:/F'\YC>VT@
M$V 55[4$DP)#C:FD47D#ZP5_$E+%)&)$\PWO1CH,C@H@SR+=&Q(ICL$O0 ==
M'K*=5_^=2S;O#\GF(=E\3Y/-C]LG^DT0K%E8EY[;>)'N8A.N*"E,F14S04YA
MP,ZNXZL2G%I[04;/K<YZ9@5=^-Y/BP:T8A[!+*P!DJ=Q]. DMJ^W;DSQ<"3!
M4;L"V5HL-GP#6D6<^R ?"OAG/>MJ8E7?N2'Z(:>%O>W34<-H?W-\:1:7I5;?
M$,EH8 YF'+V\GE*G" $- 9GBJ[)9M;O&T3W#Y(*;#6(<]LWN^M&FB,&FYHGV
MYL"%)C+=N#.CD2!"&^H*X>CT*9Q'/0:Y80[C!M' H7NH(>YXZE<5!W'85D-N
M+5TC>AS%#Q.,KV-W;&NJEG9094,>V -G56,#'G'-N+4D7#ZI!U'IT)F8VMJ?
M*ZN'WKF&&5X ,3YO7]#10;/?>WXBX$U5!(*2>EP& %6*$ 0=(]SE3P1'NG^#
M9UNEU@?O%Z;')D!:FQX+0EH[N;,";4L#(J_2TUIAC@_CG%GZ$>26?%&0/#8R
M6F'<>8^)@<%+]OKP8RY=07WQ]-S@O"+)/Q#'2L126,MY4"B*[HC<<.8<;VEE
M!=&)@M10[D"PWBNUZ_.12+2[YW]TH]#?_;:\O]#,?L_.KMTM[<9%%S&$\*/?
M/I; YLQ<VE9DRRF(GQPL#-^"6$.^X=N"3+Z[?W/Y;?VNL9HF=HYIFI_'$O:7
M-;7K]\I,RP:<8=<-%/FOLV)*#84A*&_: 6948ZELEATTMW%A'/1O.9[7TQH;
M>>@X0Y-CKVTY/<P30[D]V5G:T3GU5.YT=L4#9["-"*KA\![%&XQN2Z?5&5!P
MH74=W^^4/":(;E.CX8TA/LQU9\ZOUM=4>+#[;M%-4?IQ]%=[<YXS[6Z/A$/=
M>UIA&U#@QI<N*$B%".3?M#!"LDAJ'*,V6& AF8E_T*5I1_\.42(PU%?6-+5^
MP<X_>GK7.,3(&#[FDZPI%^\WJQ5>#K[="Z+&LS3'.U@O?JDO2&!Q!I@0CAZL
M,"<E2,UW7EBI]\ 3%@Q0R-@:DJ876DAD ML?%NF*6Q\I=<_464%7'AY+JYML
M0W;6;#V%I]=6R\OW:;#(2P@A559$!6>M($QF=5@=0A+:+G^[(:SKZPN+FR\H
M9P F'KQ>V@\YL(SK%Z1IN6#;<7%=J@O)$.<-[1_M.\.L-)Q2JEDJJD3X1NF>
M[ZX6O_ ^.BV$"HB7U-HIX(?DQE4'Q>C6R6'"9@$49VU%/3T)HE(A("E4W(<V
M1I-#+-6:.)B%]F 6L-R!/5^BEO^F<!+W*8$%& 4H%RH<#-(06+I34&&(/2L9
MM@RH)/_LFE3:T;#M\_7H*S?>4MLE.I>/]3V&IZTJO5PPL'1D:JQ-*2%J=$NA
M4[F]Y!KQ71+[3K9:70MK_JU+-0'Y.52$T'.E#QR%]'))WQ _"EX+,7<@:)#=
M!0+:A(VS,D>1>7 J7(<3ESJ!.B.4XG%T*G-R4AXG26"J8QH 1MWD;(21H@NO
MZNYST/#'NKN>@X(FO+OPTT+\AO[&8"CDZ<I [U3])S9?2@.8!3P;^NIF<;>#
ML<ON:MSF)N[1V?A)=9;HTE/'+9[:E]EU5QS&\/I'5%&UA 935K3^XRQ:ZR,4
MF57VF?FV%59W^L"])&.$^EIU!$I86Y^7 .Z)D<\7M-EXU+) Y0O'H]VC_='D
MF.S<X]'$_G1HK=X'7+>54;C^V?+,Y*XW#%DU)6E?SE'-&VXS8(\GPF*BE[FU
M'C- N$1_:^QIHS[VNZ,>>_C$BA7:%L]64-GM2:E?F83J =-RUJ2NVUCLD)L,
M"< V]X8,]0R#,3-XI$]!R<>;%4">Q&BW-G.:,!Z$TF2\+MA719QN3%AC$HN"
M$DF;J1L#FW\]W=G=FQQ$#[!YG-4, )=9U=$#6H>'^@B[\_EPD/P;736N>0VX
M$:IS9O<D4 [07DR!3<Q*$%%AN@TH:#Y/[^VU7@J' $V.N'?_?(XV%&C2EO<S
MMO%5LHJ2L&/O#<LJK$L+05#>4.ZYCAER]D6A9T&Y*AGPR-^ 0)0]JBOVH5=I
MJ2X<>ICHL24,XDIO)42W=&[![<P:?J]#^B\T/F GSZS3#4X 8[NA9D1*KLAT
M(T *62]Q'F=KKD21J,JT(8!YJZV$^/<SMZUM4:$;AF5@+J^;97&ZK"1]'0I&
M]PEPQ2'ZV=2&;:@"N?U&=DRH .!2F/J@VZ88!+8;Q!HP2D_38# HPRT&M<G*
MAG$W6A1/RR+F' )B+7G A+[W'6;EXNPUN#:TE>66%/^V7G>5I.07W[UKZ<[E
MR0^&//F0)_]1\N3OM4:. YU,'2UU*U.L[N2K/<A_8 \4#!,SQZ^"AV&'=*5>
M*>\-/^JB& @NXA,7*0#HU]0IH_]MSJ"02Z,[ 4Q(]BERCH,Y:\69'&#G0"=
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MBGJ=7%*3Z;P9>Y3F*9(KBH?N?>7JRJAG_^EG* D6T;GKL+.Y[P$()) /="<
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MC90619G]V-WG.MKN%2-Z7/(4?L!<:"*W)T7M=)"-DE5]'$=9IB!'?:O/!X$
M+PN[,EQ[[6J&1JYF[=*==<W5W=OL:\ E[@F/L>;+P(JSB\&U27@LJ?U%7U"M
MI\FTH!;PQ5T\/MNA(IR7"V;A<V4XI!J,OCE3,2)I XR"7MD_/!?"I_0?[0]W
M[.AVF-]4HJ*[1835+4YA<[$6QP^4$4MS87T/-TII-%V[[BII5PVNF)*?$M8$
MA,67E=K4,7@SE;U5,7EU585W3UJ2&WV+X:=08AUIW2P_A12#<SL_"FDAFL9#
M^8)']Q(6NJ8EP3K#%,. 9\-]_(*X:F=[0LIRS,GATOIDH%K93;%37R3J>K=#
MI]JRUO%[7PM8  ]Q"2/MDJ9W7CI""I96"HLS  $PC\$H5OZKN@3X3<QA_'ZY
M?T\DHGX;)'1J? ^-3OVKBO%>5@G,IU/)F"<JP)[( #=(35Z'8@=8-6DI;D!*
M!G*?FY'[^#(O:K0@Z4A(O.AF/65AC_P23X,(&E]2_LJZZMH0Q=TZA6#V4\$8
MH0^I.;OTT?$M)()&+O)W/EQ$U^\^RA?"/#X71D0-.=I0VG^3<O6P)< 26\74
MJAN0;_93U73T.]'WUN$@TY6SA$Z<@SK(H/%E.Q?$R^R*]<;16X=TK?H5P%5;
M,_(9C!+7T^?G!42I"Z8\XRRAQ*B%(;A"E*N ; ?_&@"PA)/$TTMKWH)!^(Y6
M]"JHY@V*XVIB)H=(N"'Q<X57!#9@]AGL) 1%6]FZI94Z)<SR0"1K96 QQ=-Q
M! 04[@(2XJJ"63)T5Y(VC6<PXZP0$+%++1/8%TU:>XQ."AC#V!%R&FY_I30G
M! T21.(16M5#/93:]%9"ADTFX,:W&S:._N+\9USBKA6%T$@4$9)<!VY2BX[7
M:Y"+RI$A7Y6K4Y)$#4)5A4,X;@;I*C$@8(V>H8]KAPEVAI:4EM!>JEZX/,U;
MNXXFRC6P4EP5(:JT+SCH<&K];Y5-D[O=EZC>3V?R]N.$?7Q%/21%#R"01M+W
ML$_??07:(K%IW""HZ0J\A93T$+;K <6$X)'>DFX?/G!Y\U#EMS.-BGU%DZ\$
M&<@6E0_HHR^FZ]%CJ-#J!%TQ"A'%Z"1(6T)'Q )_<3VDA= 8?812RYHBM)"F
M@P & STC?J.05;K@WD;RE[C=JEK\;F^/^,EIX >;)>Y!9CDMDM07\-R @,:I
M6XKG$^01OF$M.WNO+:ENF3>.+FCIG*WA@'<S*_QXR H/6>'[FA5F0P\\?(@G
M(BYX28:0=%;#7FU28(>E;UXQ%"TU@C8Q8 >UPL6(G%*T7K<&/3[U<Z%/'0>&
MPIZ (XAB7 !E+%?D;=19CG9#&&_07-T,VH?.[J *V-<M+KM-,""B7 1I'Y\;
MPK$QM[. 9OI'V$-,9NP_B[6AEHHY.%\Q7H)^]<"(32MDQIT6UD^P3@!DP.@+
MV" 1_Z8I#S/7R5DHU\Y-17 X=_ML+CRE5(V?ND^P&(XDX&)1/@X)DAR"E;'?
M_^(;W(N%L<)Z;IP!?H8M\_HN<&D.&]=QSSTX70<9Z-5B7:%4N2Y\SI$VR]01
M!<NG, 0/5W)96&'L?$F+DB\AEB &!>$("QFR7%&DM=,(T&>50??/%H#"#DTK
MF?M,XN880+<:)$T:A(@7Y9GU]_ZC0*QN,&I_BIXNA')_RZL[9&%4<B6NE/-$
M!6!!WZ-\^0WLE'K1R*N!/(1[EC$UH<[Y04@<T/$:9%E0:!#'LAZ B_UC?9:!
MVC[#7 )W/^6"ND";R-D2A<)1#0@04-A:!=F9=@7C.#V/:BDFT4;T^;Q=S@&E
MTR1;&%I2VM=9X&).CSKWBC]T+@M\A5X>M20(>1G"6AI'VK19KR4-YLV0*"^Y
M J^]*<(8G!(]73U)!.^RSI4;(W$>@SX@[I,^T7T6$X! +6LX& R2:7M=HADJ
ME@<3_;U)S^/,4*UL>)KQG@9NKU8SV3@/VHYY>B92%)2<\$M+H4)U(VY8$$TS
MWYG/902'$OCI56"XT:SY !B?5EAV8P?@1*W)XP::Y-B#F.B^#+U,G1T&I%Y0
MK.1^;MI1/.0&Y,["5LNO*M?87/6@[4H@]I4U5*(DZ^%"(=PK7J5;H-MZ ^/I
MQZ(C%5JP8%(4I=YZQ1%1J@-VVFB]1+! IY:<F&_,JCJ&@3 U.(Z><Y4#5W==
M5FN_,??K8K,O?V/VV$ P>F@(!)H(BZM[3];V6E[5&AZN4OR>F-</_SZ&FFX'
MHC+US!J@^RD(+S6"KH,Y+J75E(MTU:I1=U#5R[,_7Z/7O+Z[]R?CP_::1-MK
M:O0-5QL;+A7@"F A:^&Z0-Q\FX)37N !,<'G-A#A74@3&7P!1X-[988H15H:
M:-3RCUPV)M2#0CV'62?K/(4<.)W!NY):)\)2;G]%GAP RKE;)E*/._)CZQ(.
M=;I>6+UZ]C9;-:C;2K :.)U.G<]1CTZM#,C(YX$VEK&2&8=<Q40$BA%$E9K=
M5-;\=WN3G04!1 \51^0$I);5S1,V2N^1H8W31#8 ((SE%)P&6G$--#TN8!Z@
M..P:/K8L<BY_H;2<6UZT6:Q]U*"M<5F2RA&..U)&TY+BDCY))O953X6>RP22
M9.[%SV+'\ R=?&A5$7:X3KP+P5IE?@.OEQ &FPQ$#@,1O,++.(\Y+^XWUQW
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MR+#>TPRKK\?!FE>EW5LJ1#CW*<+C7?U02\ I#Y( K)H";:4=GK*'QP!+<E2
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MVV5@OG9L6\-+I;>)D%W [0$]W#7@GC$-!H$+6S+V;7Q5D2<&---/[X*$S6>
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M13^V;O#N_@]02P$"% ,4    " !;@&A5N8;&6O$5  !&Z0  $0
M    @ $     8VAR<RTR,#(R,#DS,"YX<V102P$"% ,4    " !;@&A5^#Z/
MM:$1   N]   %0              @ $@%@  8VAR<RTR,#(R,#DS,%]C86PN
M>&UL4$L! A0#%     @ 6X!H5?TKI8J8.   !L<# !4              ( !
M]"<  &-H<G,M,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( %N :%5/XVO@
MPVP  &+>!@ 5              "  ;]@  !C:')S+3(P,C(P.3,P7VQA8BYX
M;6Q02P$"% ,4    " !;@&A57R#5I!M1  !N\P4 %0              @ &U
MS0  8VAR<RTR,#(R,#DS,%]P<F4N>&UL4$L! A0#%     @ 6X!H58LI^*@#
MQ , I;PD !4              ( ! Q\! &-H<G,M,C R,C Y,S!X,3!Q+FAT
M;5!+ 0(4 Q0    ( %N :%6R_9R8,PD  ( V   8              "  3GC
M! !C:')S+3(P,C(P.3,P>&5X,S%D,2YH=&U02P$"% ,4    " !;@&A5G&,L
MG8D)    .@  &               @ &B[ 0 8VAR<RTR,#(R,#DS,'AE>#,Q
M9#(N:'1M4$L! A0#%     @ 6X!H58()FA+8!@  M"X  !@
M ( !8?8$ &-H<G,M,C R,C Y,S!X97@S,F0Q+FAT;5!+!08     "0 ) & "
(  !O_00    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
